<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:dikbD2R="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:domeoclient:uuid:190E7AE8-2ACF-42E2-AE00-E433EEA9737C">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:E69A980E-DFDE-46F6-BAC1-FFD29BDCB6F5"/>
    <permissions:permissions rdf:nodeID="N812443d2344e4773afdf14af64f54f2c"/>
    <pav:createdOn>2014-09-02 19:38:12 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-78.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:EC3A3861-9232-4673-B5DA-6BEA85FD20A7"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D9D9F4B7-9732-49A7-8862-FFF6D70C89DF</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:5C49E98B-9150-4558-BA6E-8A0528C6D9D6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F2A6F24F-0266-4E33-86F7-71BB9F9CD038"/>
    <pav:lastSavedOn>2014-09-02 19:38:39 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8164F866-D42E-492E-9290-5B0170C62867">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:60F0E01C-50AF-48FD-82F1-C840D5A8FDDD"/>
    <pav:lineageUri>urn:domeoserver:annotation:CB9D594C-4469-45CF-B5C6-3B8FFA5E53B2</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 15:04:06 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F10F658-B658-4FA9-8235-47BB00E1C0A0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:443354CF-9409-4015-81BA-17601E505BAB</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:A3482164-6D7D-4B99-A855-EA0193119654</pav:lineageUri>
    <pav:createdOn>2014-09-02 15:06:20 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:BD1FBEAA-B2D7-405D-8489-BDC578CFEAEB"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 15:06:18 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N8235f3e5c30c42d79a037df424a19edd"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94239CD6-2883-459B-A125-FF55B9791833">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D909BDC5-468E-434E-B3E5-632F1565E73C"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:4B9E6D9B-AF88-4692-9DEF-8B6FA5D8F2B7</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:11:25 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/200F7C4A-CD90-46C0-8779-AF63E291B5C6">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/84108</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>rosiglitazone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36443C46-71EF-4792-ADF2-D6E6E248EFAA">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-166.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:36443C46-71EF-4792-ADF2-D6E6E248EFAA"/>
    <ao:prefix>; increased serum concentrations of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> with concomitant hematologic and gastrointestinal toxicity have been observed with methotrexate. Use of methotrexate with penicillins should be carefully monitored.</ao:suffix>
    <ao:exact>methotrexate</ao:exact>
    <pav:createdOn>2014-07-28 17:02:33 -0400</pav:createdOn>
    <domeo:uuid>36443C46-71EF-4792-ADF2-D6E6E248EFAA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D16208CB-7392-415A-8487-52928A419F00">
    <ao:suffix> 100 mg was administered as a single oral dose alone and two hours after a single dose of cimetidine 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a </ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D16208CB-7392-415A-8487-52928A419F00</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D16208CB-7392-415A-8487-52928A419F00"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <ao:exact>Fluconazole</ao:exact>
    <pav:createdOn>2014-07-13 12:46:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:555D0A1F-632F-4953-A2D8-E08196E7CEB9">
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B0781B4-A013-4EA2-8F12-DEE15D23DD0E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:0019883E-5898-4EB5-BE4B-4192267B6B23</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:57:24 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0050ED6-BE4F-4871-9847-FC4493F22447">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <permissions:permissions rdf:nodeID="N636bd8627dcd413f9e91686dcc0475cf"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:lastSavedOn>2014-07-24 20:00:43 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:7CF400AE-CD72-49D9-9780-049736D11E6D"/>
    <pav:createdOn>2014-07-24 20:00:35 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1262FCE3-53B9-497A-AB5D-DA122BFC8786"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-135.txt.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:838A3F9E-0F12-46F7-B6B3-FFABDE022693"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:A11B8A91-953F-44CE-8F20-52A8EFBAA088</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC77541A-190C-4C62-930E-9CF52E6C4A67">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CC3DAA6B-4FED-42FC-B83D-E1EECF33E119"/>
    <pav:createdOn>2014-09-02 19:13:16 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8739072C-5D47-4302-BD43-4756B65DFB2B">
    <ao:suffix>), and protease inhibitors (e.g., ritonavir), may prolong opioid effects. If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibitors. Evaluate these patients at frequent interv</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>ketoconazole</ao:exact>
    <pav:createdOn>2014-09-02 19:09:23 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>8739072C-5D47-4302-BD43-4756B65DFB2B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8739072C-5D47-4302-BD43-4756B65DFB2B"/>
    <ao:prefix>), azole-antifungal agents (e.g., </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:404B1852-88F6-45BB-8C18-358B3A408485">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2014-07-21 21:50:34 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-07-21 21:50:30 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:3CA31561-312B-4AE9-A654-27502AE41947"/>
    <permissions:permissions rdf:nodeID="N87b8827c352f40e6a418b75b07265a70"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lineageUri>urn:domeoserver:annotationset:43084B54-D615-43F5-8037-82E9AB110383</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:A1184FE6-5357-43C5-BB6C-87EC586C8468"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-55.txt.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C02BE13-5688-4657-A7A7-6A459283AEB2">
    <pav:lineageUri>urn:domeoserver:annotation:A431D5CB-5994-440B-99C7-32C2F2EC8DE9</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 11:24:07 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:1554FCFD-7477-413C-879A-913DFFAB5886"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02AA319D-AB4A-42F1-B73D-EF0CC9D22427">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:02AA319D-AB4A-42F1-B73D-EF0CC9D22427"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> maleate tablets.</ao:suffix>
    <ao:prefix> maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended. No dosage adjustment is required for </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:exact>fluvoxamine</ao:exact>
    <domeo:uuid>02AA319D-AB4A-42F1-B73D-EF0CC9D22427</domeo:uuid>
    <pav:createdOn>2014-09-02 11:46:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D07F657-485E-493B-84FC-C20CA68F0295">
    <ao:suffix> in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA. No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days </ao:suffix>
    <ao:prefix>Single oral doses of </ao:prefix>
    <domeo:uuid>2D07F657-485E-493B-84FC-C20CA68F0295</domeo:uuid>
    <ao:exact>glimepiride</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:53:12 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2D07F657-485E-493B-84FC-C20CA68F0295"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74381157-1392-49DE-BD6B-8C71824715BF">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:74381157-1392-49DE-BD6B-8C71824715BF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>74381157-1392-49DE-BD6B-8C71824715BF</domeo:uuid>
    <pav:createdOn>2014-07-22 19:31:30 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:exact>AVANDIA</ao:exact>
    <ao:suffix> improved glycemic control in both males and females. In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.</ao:suffix>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:040380DC-30D6-454D-ACD7-489B2130A9CC">
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2014-07-22 18:36:37 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-57.txt.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N702f09942286480888b10c78231d8c59"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F5A32BEB-91E7-4E38-9495-09168C9EA7B8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:A1EB0824-DCE2-40B3-B3EE-D596E2049283</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:2C536245-38D8-4238-BA9C-5A2C84CD1E14"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2014-07-22 18:36:06 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7C69D717-13B9-4E6F-B20D-24925FA1E992"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:183649A8-AEE3-4F6E-9CCA-10E240E419C8">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:8E89967E-ADD7-495C-B4F3-72B05A30FE8E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:AAEABA6B-99EF-4FDC-8CA7-2C7B1FCF3FF0</pav:lineageUri>
    <pav:createdOn>2014-07-24 20:12:29 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A52F0287-AD68-4755-8E11-75217CD4FED8">
    <permissions:permissions rdf:nodeID="Nf64d48be91cd446286df97e81b3a67e2"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:833A5FDE-B0F0-4E66-B232-68839CFE44D9"/>
    <pav:lastSavedOn>2014-07-21 21:38:45 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-21 21:38:40 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-29.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA5DA7BD-C00F-4D3B-B057-830BB357C412"/>
    <pav:lineageUri>urn:domeoserver:annotationset:F3F491C1-68D8-4886-B2FC-D5550636F035</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:BBA25E8B-C9EC-4761-85B9-71DE456EB881"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:938EFE6C-8A23-4829-AFA7-544CDA08913A">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4BE7A024-EE88-4E7C-BCF8-571E06F8C6B1"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05CE82A3-E1C6-497A-B0B0-31DD508C02A1">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:223CD894-F008-4BE2-8498-33B3CB50DC37</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-165.txt.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N3d7ab3124abc45b8aa55c787d9f3d744"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:46461303-C78E-4E52-94D7-0AB13BC2A0A5"/>
    <pav:lastSavedOn>2014-07-28 17:01:38 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:7E9300CC-A667-49A8-AD8F-115AE6705100"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:346C2F84-FCE8-40ED-8A94-975E020C4F44"/>
    <pav:createdOn>2014-07-28 17:01:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62F73A2A-2D49-4A1C-B836-1F3280DE6ACE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-22 19:48:54 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:E6E87B62-FE76-4230-92AF-6FD2DBA966AD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA6549D1-9142-4B02-863B-C31046392662">
    <ao:context rdf:resource="urn:domeoclient:uuid:F442DD1F-67E3-41D3-92CB-9048022BDFCC"/>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:15:59 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:18BE6999-E03C-4FFF-8400-81AB658469AB">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4B76211E-8EB7-4844-9558-2AE555B3F201"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA">
    <ao:item rdf:resource="urn:domeoclient:uuid:8ABD9FDA-0F08-474A-A9C8-437A5346F2AC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E0DCF362-11F8-4FF3-8C3C-EDB9DD3D53A7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DE5C582E-1F4C-478C-9DDC-DAB4C0C1ABFF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:02D92735-6D44-4DFA-A2E9-75A5A3D4DCF9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BDA75ADA-742A-402B-AE97-4438F99C61FC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1C02BE13-5688-4657-A7A7-6A459283AEB2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2093FF56-689E-4246-AF69-F566860B27BF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:42423629-C409-4AD4-BBE6-7C86A696F03E"/>
    <pav:lastSavedOn>2014-07-07 11:37:25 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:55E300CE-2A8F-42F4-9877-A49DDE4F3360"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5D480921-AA61-499B-9C3F-3043269104B4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FB0C633B-9063-4FD0-91E9-2810CF1C157A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7D37CC60-618E-46B6-8C99-BA7D598E3762"/>
    <permissions:permissions rdf:nodeID="N38240924dd1e4d7c9794150119568b9b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2ABA1A35-6C77-4A0A-9EC5-109AA13136B6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:697C8F03-1543-4427-9D85-7967FCEA3100"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:32B1CD5D-3CD7-4D5E-BD76-57F6F0A9480A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2F71B86E-3B80-4813-9F00-A9E3E6B30C9E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:6588D45E-2F4C-40CF-8AF4-0CD621F484E1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8C5BA635-EF8B-4165-A2A6-5832D61A15BF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:16393981-08BF-477D-ACB9-8FB804E50D0C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DA7B78BE-B91C-4178-9AF1-7DC800EF5121"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D22E6FA-B90D-49C2-B42F-B8122D48D82A"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9E21C61-063D-4F80-8E08-85865B387669"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:08713DDF-0935-4B63-B281-AEE56A8D7628"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E010F58-AD7C-435C-B2DC-0F81F34B978E"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:54B9529D-9030-4194-B66A-D7ECCBABED1F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE16BF01-AD42-444E-9A68-FEF6AED26815"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:E7907DD5-4FA4-4B5A-99D9-9D24B76931C6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F3C4287B-36A9-48BF-8081-A39BEF5F3C51"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E76D782E-ADBF-42D0-9CCA-8944F07D22DA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E13140FE-59B4-45B2-A524-CAED051C4F9D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B8D94772-B85A-452F-91A5-C644F8298C08"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:57E98049-37B0-4F70-963B-F0D12C3B36C7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0B2918C2-A28D-40C3-8147-F19D09B7119C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C8D05CE4-8287-449A-8921-AFACBAEE2002"/>
    <pav:createdOn>2014-07-07 09:34:12 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:E5DE379E-8BB3-4609-BFC6-A0E275978ADC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6FD9D48D-F639-4F09-ABA6-F4B259681453"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:10BB95F9-1856-4D70-9976-235CE8AD3D39"/>
    <pav:previousVersion>urn:domeoserver:annotationset:22ED7220-C6F6-43C5-9DF9-89F62F0F8E27</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:222C9B55-A770-41C7-AF04-566E7C7A1DBC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:79293219-D172-4E27-A045-D16B4F539C60"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FA4C8A6E-17D4-47F8-A369-67AF061E9037"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EC416A29-1315-42C5-90FA-652412A6AD12"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1F12731E-6D41-4E27-83E3-C87822424FCA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DC9FB0B5-1564-4BF2-A4E4-4D05B0A1AB86"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3ED57AC4-296D-4C8D-9873-49C193F69BBA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3762570C-CF43-4DB9-B163-FAA6DAE60017"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:74FDA5BD-9C18-4F10-AC59-C5C75AA497C2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E76B5D64-7248-4EBD-A023-3820BFDEFD26"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:137A1951-AA86-4074-9581-B011801B955F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B85AE85-A07C-4614-91F5-52EF7A4737DF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FA428F64-D782-46F5-B866-2FBC24D3F4F8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B5E75366-F0BF-442F-852E-19C5EDDC84EE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F9FE917E-CAFF-4C8B-B16B-BB0606212145"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:735CA4BD-A16D-4729-BFC3-96D72BFE5B0B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9BD9047F-C1DA-4B64-92B7-4D031972C9CF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:2CF891F7-2E96-4382-8EDB-5C061E8E1AFA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CBB863B4-0141-4362-8357-0FD5A3909A10"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:17E64297-0A57-4C9B-94C4-18ED1956FCF7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8DA59D18-94D7-4239-958E-D00E6CCD30E7">
    <ao:suffix>or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see PRECAUTIONS- Drug Interactions).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>mercaptopurine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>. Subsequent adjustment of doses of </ao:prefix>
    <pav:createdOn>2014-09-01 16:12:30 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-42.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8DA59D18-94D7-4239-958E-D00E6CCD30E7"/>
    <domeo:uuid>8DA59D18-94D7-4239-958E-D00E6CCD30E7</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:67D24023-38AB-4DC8-B710-B1EC8B3A147D">
    <pav:lineageUri>urn:domeoserver:annotation:04FACAFC-E89E-4116-BE1F-60034A71727A</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-01 16:06:16 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-01 16:06:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:88D0CD7F-7AEE-47DB-9F13-A8F5D6A36CAB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:135F1FE6-83FC-4E58-95A7-4C08AED291BA">
    <ao:suffix> in subjects with liver disease were comparable to those in young healthy subjects, the mean free fraction of risperidone in plasma was increased by about 35% because of the diminished concentration of both albumin and α1-acid glycoprotein. Risperidone d</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:17:38 -0400</pav:createdOn>
    <ao:prefix>Hepatic Impairment: While the pharmacokinetics of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:135F1FE6-83FC-4E58-95A7-4C08AED291BA"/>
    <domeo:uuid>135F1FE6-83FC-4E58-95A7-4C08AED291BA</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E8B9127A-D513-4699-BEA0-07E095BADF5D">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:29BA1C64-71E4-4437-B3E3-C16FF494B3CA"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D6A30BCE-90A8-4548-B78C-7949C0F059D0">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 15:06:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:443354CF-9409-4015-81BA-17601E505BAB</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:16F3A6F5-5770-4762-81FE-B45C6811904F</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:D0CD8B93-AF6F-43D3-99AB-2252325772E9"/>
    <pav:createdOn>2014-09-02 15:05:52 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F63AE259-E4D8-48C8-9143-FADBBFAD548B">
    <ao:exact>serotonin</ao:exact>
    <domeo:uuid>F63AE259-E4D8-48C8-9143-FADBBFAD548B</domeo:uuid>
    <ao:suffix> 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-sensitive sigma site, and no affinity (when tested at concentrations &gt;10-5 M) for cholinergic muscarinic or β1 and β2 adrenergic receptors.</ao:suffix>
    <ao:prefix> has low to moderate affinity (Ki of 47 to 253 nM) for the </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F63AE259-E4D8-48C8-9143-FADBBFAD548B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:07:54 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BF9F224-82C0-470E-9645-8A6965E66A04">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2BF9F224-82C0-470E-9645-8A6965E66A04"/>
    <ao:exact>There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.</ao:exact>
    <ao:suffix> The mean increase in</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 12:45:35 -0400</pav:createdOn>
    <ao:prefix> 50 mg once daily for 10 days in 10 healthy women. </ao:prefix>
    <domeo:uuid>2BF9F224-82C0-470E-9645-8A6965E66A04</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D907D608-9F35-4208-BA27-EE0CA65B1AE3">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>quinidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EDE878E4-C5E0-46C3-B925-8B3825F4CA93">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EDE878E4-C5E0-46C3-B925-8B3825F4CA93"/>
    <domeo:uuid>EDE878E4-C5E0-46C3-B925-8B3825F4CA93</domeo:uuid>
    <ao:suffix> led to increased plasma concentrations of fexofenadine in healthy adult subjects. Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole. In two separate studies in healthy adult subjects, fexofenadine hydrochloride 12</ao:suffix>
    <ao:prefix> or </ao:prefix>
    <ao:exact>erythromycin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-24 20:07:21 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5701D17C-4067-47BA-ACBD-ED6053F1DE96">
    <domeo:uuid>5701D17C-4067-47BA-ACBD-ED6053F1DE96</domeo:uuid>
    <pav:createdOn>2014-07-24 20:10:51 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5701D17C-4067-47BA-ACBD-ED6053F1DE96"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3FEE8D2-9817-490A-AF14-CC53E5ADFBF2">
    <pav:createdOn>2014-07-13 12:35:54 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3FEE8D2-9817-490A-AF14-CC53E5ADFBF2"/>
    <domeo:uuid>F3FEE8D2-9817-490A-AF14-CC53E5ADFBF2</domeo:uuid>
    <ao:exact>fluconazole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> 300 mg to 21 normal females taking an oral contraceptive containing ethinyl estradiol and norethindrone. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, flucona</ao:suffix>
    <ao:prefix>A third study evaluated the potential interaction of once weekly dosing of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B61F1A9B-4696-4ED0-80AA-4FE2E9016966">
    <ao:item rdf:resource="urn:domeoclient:uuid:4A2643B5-4BD1-4161-8CBE-473EFB4DDFC8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7990829B-F65B-4D7A-B0B9-46A365009737"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:00F93F74-A2F5-4F4F-869B-19496B9D0B0C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DDADE3A5-763E-4A5F-A9E8-79A393BF0629"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:93DAC455-F057-464E-B0F5-494B00341776"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:F7650976-DBE7-4CD9-8158-46355CF2F821"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2C30455C-E476-4155-9E8E-67570BFAB396"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9FAFF1D3-9F76-4586-93FE-52B6168FFC14"/>
    <pav:lineageUri>urn:domeoserver:annotationset:EAC2701C-C88D-4DBC-A889-9FDEA7C97C40</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2014-07-21 21:35:09 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="Nec26fd5ce7aa49f289371fa49a428476"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:annotatesResource>
    <pav:createdOn>2014-07-21 21:33:41 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:3EE823B0-79E2-43AF-B47E-C72BE189895E"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:9C4009FB-5A17-4B3C-B5E0-D9CC8275A5D7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:254E1933-56AE-4110-9A6C-715CC58538B6">
    <domeo:uuid>254E1933-56AE-4110-9A6C-715CC58538B6</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>rosiglitazone</ao:exact>
    <pav:createdOn>2014-07-22 19:38:22 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:254E1933-56AE-4110-9A6C-715CC58538B6"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:85043124-E686-41BA-831E-AB868FA3D3B1">
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 19:09:50 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:77246EBF-67C1-4D2C-89E7-A85EBD42831E</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F7ED86B3-B970-41BF-B468-D38526646742"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1083CE4D-6393-4589-AC36-1DEC7BFE570A">
    <pav:createdOn>2014-07-22 18:54:08 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:302E5EA3-5D0F-4547-B3A1-1B63352BB1A5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lastSavedOn>2014-07-22 18:54:35 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N4c1c52171ba14679bcb3d901df1e8607"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:3D195979-3E82-427D-95B8-F50F48DB4AA7</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:30E22C75-24AF-4589-9D91-F93CB0D6E229</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:405F8748-3E22-452F-AC3B-86C4C931D36A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:26:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-21 21:27:51 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:B6F745E6-5734-4636-A383-683BA4C79E38</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:BE3E1AB1-3092-4849-B176-18D5F87FBCE0</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1488BDD9-0C63-45D6-A1E6-1AC89EE36E28"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B7476C3-D9FB-4C21-AF95-2B4CD2143061">
    <ao:prefix> is metabolized in part to </ao:prefix>
    <ao:suffix> via the cytochrome p450 isoenzyme CYP2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical significance with this agent. However, cli</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4B7476C3-D9FB-4C21-AF95-2B4CD2143061</domeo:uuid>
    <ao:exact>oxymorphone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4B7476C3-D9FB-4C21-AF95-2B4CD2143061"/>
    <pav:createdOn>2014-09-02 19:10:44 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C403ABF-BCD6-4923-946F-4AF2BAAB0800">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-21 21:31:54 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:2EB7D7E2-B15C-4936-A208-A041FD22D74F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40007BD9-0869-48CF-A8F2-BAD26AE3E6E1</domeo:belongsToSet>
    <pav:createdOn>2014-07-21 21:31:24 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:092451F5-B0C0-430C-8896-07F81D33F9E1</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC3DAA6B-4FED-42FC-B83D-E1EECF33E119">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CC3DAA6B-4FED-42FC-B83D-E1EECF33E119"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:suffix>, </ao:suffix>
    <pav:createdOn>2014-09-02 19:13:16 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>cyclosporine</ao:exact>
    <ao:prefix> was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., </ao:prefix>
    <domeo:uuid>CC3DAA6B-4FED-42FC-B83D-E1EECF33E119</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E4F0D688-0AAC-4069-A616-725458FCDC7B">
    <ao:exact>AVANDIA</ao:exact>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 20:18:17 -0400</pav:createdOn>
    <ao:prefix>A single administration of a moderate amount of alcohol did not increase the risk of acute hypoglycemia in type 2 diabetes mellitus patients treated with </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E4F0D688-0AAC-4069-A616-725458FCDC7B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E4F0D688-0AAC-4069-A616-725458FCDC7B</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C807E9A-52F6-4F5A-9553-5D4EB47525AC">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8C807E9A-52F6-4F5A-9553-5D4EB47525AC"/>
    <ao:prefix> can inhibit the metabolism of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-24 19:44:10 -0400</pav:createdOn>
    <domeo:uuid>8C807E9A-52F6-4F5A-9553-5D4EB47525AC</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-128.txt.html</ao:hasSource>
    <ao:exact>diazepam</ao:exact>
    <ao:suffix>, resulting in increased concentrations of diazepam and its metabolites. Diazepam does not alter the pharmacokinetics of propranolol.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28F8F8B3-4AAE-49BF-945F-3B91F3DE3958">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>28F8F8B3-4AAE-49BF-945F-3B91F3DE3958</domeo:uuid>
    <ao:exact>Ranitidine</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:28F8F8B3-4AAE-49BF-945F-3B91F3DE3958"/>
    <pav:createdOn>2014-07-22 19:55:24 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:914E70FC-7296-4025-B9C4-BDAD1F572CC6">
    <pav:createdOn>2014-09-01 15:57:31 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-01 15:57:39 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F87926C2-2747-4ED5-93E5-F7C25B2825BF"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:39B82E57-92E3-4322-A8E6-A3AFF215F02C</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:60449E8A-52B3-4A22-B766-56A345187A81</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC05ADFA-B5BA-4A4E-BAB0-61B3D424E8F2">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:C988D053-7CF3-4C50-BDB6-7C2B20B837B9</domeo:belongsToSet>
    <pav:createdOn>2014-07-21 21:54:13 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N478e4ebd309f415696c8b34512e393f2"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:D632D7ED-9F65-4CC8-992B-4A4753EEBBCC</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lastSavedOn>2014-07-21 21:55:00 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B6E0548D-97C5-4C24-A078-F69D2D16D9FE"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4BC86345-8DEB-4D78-A90E-121B217F37B6">
    <pav:createdOn>2014-09-02 12:03:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:46345058-661B-476F-9809-F885E60E0311"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B7BF8E5-F410-48B2-AF56-5421E6B7FF0B">
    <ao:suffix>, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolis</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5B7BF8E5-F410-48B2-AF56-5421E6B7FF0B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:15:50 -0400</pav:createdOn>
    <ao:exact>carbamazepine</ao:exact>
    <domeo:uuid>5B7BF8E5-F410-48B2-AF56-5421E6B7FF0B</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F80BB417-0183-4007-8F4C-0705AA0B529E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F80BB417-0183-4007-8F4C-0705AA0B529E"/>
    <ao:suffix> 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-137.txt.html</ao:hasSource>
    <ao:prefix> 400 mg/day with </ao:prefix>
    <ao:exact>trazodone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F80BB417-0183-4007-8F4C-0705AA0B529E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-24 20:03:45 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0124DF91-B793-47E7-9547-2BF080146FA7">
    <pav:createdOn>2014-07-13 11:12:20 -0400</pav:createdOn>
    <domeo:uuid>0124DF91-B793-47E7-9547-2BF080146FA7</domeo:uuid>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:prefix> by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0124DF91-B793-47E7-9547-2BF080146FA7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C75F6EFB-5E72-4CF2-9017-B3F8CA0EDE1F">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>C75F6EFB-5E72-4CF2-9017-B3F8CA0EDE1F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C75F6EFB-5E72-4CF2-9017-B3F8CA0EDE1F"/>
    <pav:createdOn>2014-07-22 20:17:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> AVANDIA</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Repeat oral dosing of</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B18CF78-48CD-4D32-B4F4-88F8072C8185">
    <pav:lineageUri>urn:domeoserver:annotation:A50036CB-D487-48AB-9CE3-45B6CA3540CD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:11:19 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:E0ECD29D-DAB1-4D63-85F1-1839E3B04BF6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:24143967-8568-40EB-838F-056E2F0B075C">
    <ao:context rdf:resource="urn:domeoclient:uuid:03FCDCDD-B854-48FC-9FD5-39AD4A15667C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-24 20:12:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:16F6FA5F-D1BC-4840-A4C5-5F4443E7706A</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F94384BA-7A08-4E0D-A89C-A73959BAA203">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:09:28 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:2D596385-5BFD-4D31-8E3A-AF1CD1B646BB</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:55C36B4E-CDCE-4B16-94D5-178014A48A7F"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29043652-5144-43F9-865A-114AECF87D36">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:76A6D4E8-CFC0-4AA9-B614-87128EB7486B</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 19:09:27 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C072F602-C93D-48EA-B6A2-EEDE4C49DC48"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39EB4A47-EAC7-4A2A-9B4F-05E57C8A10E3">
    <domeo:uuid>39EB4A47-EAC7-4A2A-9B4F-05E57C8A10E3</domeo:uuid>
    <ao:suffix> alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:39EB4A47-EAC7-4A2A-9B4F-05E57C8A10E3"/>
    <pav:createdOn>2014-09-02 11:42:08 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>tacrine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C08A8D30-A040-45EF-9873-91013299399D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C08A8D30-A040-45EF-9873-91013299399D"/>
    <ao:prefix> and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of </ao:prefix>
    <ao:exact>fluvoxamine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabo</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 11:30:17 -0400</pav:createdOn>
    <domeo:uuid>C08A8D30-A040-45EF-9873-91013299399D</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC">
    <ao:item rdf:resource="urn:domeoclient:uuid:2F010F0A-45BC-4132-A685-857F72A4DCEC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C6D1C88-D003-4F29-8AF2-F22A03983530"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E24CDAFA-738D-436F-8EA5-33584022000D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:26C8F2D4-9063-4B38-ABF2-AC4FA32AD27F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8786A121-1479-4E39-A0A4-280F6167DD01"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:41AFFAD3-B330-44BA-91A6-EFE69C07C0A2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:288BDA0B-5368-42DA-BCF5-4D9F229E72D5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:69354CBD-D372-4AD9-A6F1-93E07CA4D048"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:643EA9F8-ED1A-479B-9B59-6A63D55F43F7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B61CCD79-538E-42B4-8232-5A3A92F4AC3F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:06B4510C-85BF-4E4A-AA80-BA9BF3139105"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6EAB4BAE-C8C3-48B7-AC36-EFE4C7088448"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F7DD29E8-1783-4BA7-A529-9EF0B60D8F39"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5E25E6A4-046A-49AF-B686-005D1B9BE5EC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B837C05B-2090-4797-A3CF-E78BA29EF167"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:1D1D462E-3009-4EB1-A982-ED88FF1CE34A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:50C0FDF6-70A1-4B64-8F05-01088227E5AD"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:537EDFBD-E119-4A09-B40F-63E4648698FE"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:3EA9FD84-7972-4F14-ACAC-44E7B91CD0C2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CFB0CA51-827C-4CBB-9914-266A69F0AB0B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2D67B7C7-76F8-4FFD-A468-49E9E07064A4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:140EFF4D-9D91-427D-B48B-7B1FAFA2E5CF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EA587655-D235-49D2-9724-0AEBB3E5E13B"/>
    <pav:lastSavedOn>2014-09-02 11:54:50 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:A512929D-5410-4D52-AEA7-F2E68A62A9E8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1295B95D-9BC5-45F6-8E74-F4D1E052F64C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0DEE6C6F-A6F1-480F-B422-0E55E610EAAB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:70EB0C27-A6B8-49A5-94CD-7CCF2755C633"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:00D416DF-EC2B-4E10-8956-D09B3C52D5E6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:53FAB419-4FF7-440E-89DD-64411826800A"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:8EE2A094-F107-44EE-921E-0C729A88F5DB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E15B413C-BEDB-4A09-B61C-CC07F96666DD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6950FFA4-1583-4644-99BE-7BD0F0C06B95"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:04AF0456-B803-4275-972A-36BD0F6352B7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7B307336-ED36-40F6-8DED-B26488A43FD4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E2CEC4DC-B35C-4F1A-8ACA-017FE944131C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6793D5D8-D5E4-4015-B012-93740E224E6E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A3D1E36E-124A-4042-BB9B-6A358D1F3E3B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2BBB51CD-8D17-4DE2-B300-ED38485DEA33"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:581B1F88-8814-40C0-9F72-77FEA7E30122"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE03C8BC-514A-4589-B370-5BBCAFD1AFE7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F0A9334D-2A9F-4B70-AC7A-5A574EACCA65"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9A355239-7CF3-43F5-B979-1B59EE6C6121"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:393FB1C5-F66E-42C6-AA25-436EBF20214E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C8AD4F27-4001-4A0B-9D27-50063C65337E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4A624918-A90F-4845-8DFE-C35AFD8B0B68"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:43D41023-3393-411C-B3B2-FDFDACB25B35"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FB5478ED-0329-4EF5-88A8-06C125D68B2A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EAC57EB3-DF7D-46DD-AE24-159494F820F5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B664870-D5A4-43DD-8990-228B68AA60AA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:74C8573C-609D-4268-8133-F0B2749E0A1E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E4B6A541-B29F-419F-88B1-22F770341BFA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:82B09581-5976-41FA-8F72-66B1E36C8544"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0DC1E786-48C0-4894-B615-AFA91FDAC5BD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A3ECFEEE-C693-4117-91FB-027FB8CFC391"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:87135DB6-D4F3-4808-BE76-D891C704525E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:53C71D4E-A625-4012-ABC4-932105C30699"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2C5969D2-1348-44AF-8DA9-7B96D70B4770"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1236F221-49FC-4683-9E78-9A4C14E7DA9F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:00672751-8DEF-4963-8AA5-6205618296C1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B572D091-3712-43AD-B485-3E1311449FAA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:0F8D75BE-6E65-4B3E-AA75-B1FF492AC889"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:15142045-DA2F-4022-9FF7-3D0277BDC3FB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CAAFBBB8-299E-4407-AECC-19F6B511D24C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C6F74A83-2371-401E-B276-117735065820"/>
    <pav:createdOn>2014-09-02 11:30:03 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:B6024659-1A02-4A19-8ED3-F29F4A70681F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:08E3A94E-69BC-45F8-943D-0AE85FC3257B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA91EE4A-7D39-4CC0-A25E-E5ACA358E916"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:31254608-CDC4-4553-A278-115226EC9264"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8A033E70-6D84-4601-985E-2D559145926B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B427C906-5D72-43EE-85C9-4D7F3117059B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0BE2F54A-5A28-4297-82E1-2B83EE8D882C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7292F6B8-8DF2-4158-91E5-6FA4A069D796"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0D270EDF-E644-45EB-9C94-B02DA5C51002"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E45A71F-507C-47A7-A012-D482CF4059D6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:95D28FFB-FF92-495E-92BC-C2E25FBE02B1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CFBF6FAC-1B25-458D-A6E1-4DFEB8A3FAC9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B206386D-9F43-45A3-96CA-50B346B26C4D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8041B2EF-1040-472F-A3E7-DC65F8159B41"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:58271A45-7CE7-4B20-8F9F-82D4B6DD0D74"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8613E32B-563F-4611-BA22-4DC13243CFD4"/>
    <permissions:permissions rdf:nodeID="N3fc74516d9f647159b7dfadde465bfcd"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:44246EE4-6542-429C-AE56-DA84A2FDC57F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7DC48B58-6464-4FBE-B643-CA178DD552DB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F282170D-9AEA-4BD9-A758-9130391568F0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:59DF3B57-4013-45C3-9A3F-23E01D7020B8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DD921AA0-5FC8-4BE9-AAB8-13B1D92E1958"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:60DDCB17-0D44-46B0-8348-C078AAECFF80"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A3DAB1A6-C48D-422B-A0D0-776352B4CC3F"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:209C377C-FE31-4FA5-9168-BD0E96D0F448"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:85EED099-46E9-43C2-A412-DB4141880448"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D4CA3DCD-82EA-464C-8F9A-1D04DCECE7B6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1F561698-D9D5-496E-A7E9-97BDA5059FED"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:40AC1621-7CDD-45E4-98D3-4DE403F588CE"/>
    <pav:previousVersion>urn:domeoserver:annotationset:A5DD001D-C81A-4E2E-B5E0-7A866B35E26B</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:093D643B-E7AF-49BD-BBEA-F13CDCDAD6C4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DBA99B4F-F7DB-4460-981A-81817F4BFE98"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9BAD39B9-2A3E-47D0-84C7-BB409378B51D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0F702DA3-314E-4514-A96E-ADDF64264F59"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB533813-9EA9-4387-A0AA-5E6F4443AB02">
    <domeo:belongsToSet>urn:domeoclient:uuid:69C22FA1-8D50-4AA7-ACD8-8F71E69BB8AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:42:49 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:1C30AA73-C5EE-49D8-89F7-9E1BF28A2C37</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:E2D0AAC2-1961-4E4C-93E0-B707D321E662"/>
    <pav:createdOn>2014-09-02 19:42:27 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26FE0E4C-4C7A-4DDB-B49D-53B765A8B4E3">
    <ao:suffix> were 3.15 L/hr and 13.5 L, respectively. These estimates of CL/F and V/F were consistent with the typical parameter estimates from a prior adult population analysis.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:26FE0E4C-4C7A-4DDB-B49D-53B765A8B4E3"/>
    <domeo:uuid>26FE0E4C-4C7A-4DDB-B49D-53B765A8B4E3</domeo:uuid>
    <pav:createdOn>2014-07-22 19:35:50 -0400</pav:createdOn>
    <ao:prefix>tion pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging from 35 to 178.3 kg). Population mean CL/F and V/F of </ao:prefix>
    <ao:exact>rosiglitazone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0E3203A-2AD3-4045-BAB8-27B340F81B0E">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-28 17:02:28 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:4DAAB121-0E59-4A51-A71B-B8E4DB847D18"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdOn>2014-07-28 17:02:22 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N946c4c6932284cb08d053ef1b8becbda"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B57AA8FB-9DF0-47AD-B8F5-577E80B7511C</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F554D87-2148-4927-B2EE-B016ECABC1C6"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-166.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:A24D3202-33F3-42B7-9021-4CDA18CA2F7B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:90D65AEF-2F91-4982-9D2A-D9266BCF827E"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6BB6E4E-BC80-4ACC-A7B5-88D5847926E4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F6BB6E4E-BC80-4ACC-A7B5-88D5847926E4"/>
    <domeo:uuid>F6BB6E4E-BC80-4ACC-A7B5-88D5847926E4</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Acarbose</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-22 19:55:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B475492-95FE-4CDD-81AE-94DFEEB91E11">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:D6AADC58-2D29-4DC9-83E4-5252DDC68D2C</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:09:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:46780EA4-462F-4B55-AB22-23CB7FC82C80"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AAC67B06-289C-4EF8-9E7D-46A9BC438F20">
    <ao:prefix>, but </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AAC67B06-289C-4EF8-9E7D-46A9BC438F20</domeo:uuid>
    <ao:suffix>does not alter the kinetics of diltiazem.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>quinidine </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AAC67B06-289C-4EF8-9E7D-46A9BC438F20"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-54.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-21 21:47:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:393FB1C5-F66E-42C6-AA25-436EBF20214E">
    <ao:context rdf:resource="urn:domeoclient:uuid:07FAC59A-4DB3-40BE-8ADC-7231ECC711EF"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:30:33 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0733D8F-AF43-42E3-B473-28271029CCA5">
    <ao:prefix>In a controlled study, a single dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-78.txt.html</ao:hasSource>
    <ao:suffix> 2 mg coadministered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism </ao:suffix>
    <domeo:uuid>D0733D8F-AF43-42E3-B473-28271029CCA5</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D0733D8F-AF43-42E3-B473-28271029CCA5"/>
    <pav:createdOn>2014-09-02 19:38:12 -0400</pav:createdOn>
    <ao:exact>pimozide</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:205F8706-B144-4ED0-9F00-551E6481AD6D">
    <ao:suffix> AUC and Cmax by 46% and 35%, respectively. Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations.</ao:suffix>
    <ao:prefix>, a non-specific CYP450 inhibitor, increased </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>205F8706-B144-4ED0-9F00-551E6481AD6D</domeo:uuid>
    <pav:createdOn>2014-07-24 19:45:44 -0400</pav:createdOn>
    <ao:exact>propranolol</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:205F8706-B144-4ED0-9F00-551E6481AD6D"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-129.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:346C2F84-FCE8-40ED-8A94-975E020C4F44">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-28 17:01:27 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-28 17:01:39 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:05CE82A3-E1C6-497A-B0B0-31DD508C02A1</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:30A1784E-C043-4F5D-A6AA-4EA335E7F589</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:7956E8A3-C5E3-47AD-A166-8DD4306EBB1D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4C207F47-3585-4A4F-A5A4-245A1F19DF8E">
    <ao:item rdf:resource="urn:domeoclient:uuid:23CAE79F-92D8-407B-BE7A-4BCA038E20F4"/>
    <pav:lastSavedOn>2014-07-22 19:00:28 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:7672655E-EB53-498B-A4E1-8C8EF326B3C0</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-121.txt.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Ndc58ef98dfa545569fd00d795b381bfd"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2014-07-22 19:00:38 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E63ABC8A-4562-42F9-B5F4-6A27DEE50F44">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:DC83EF48-BF8E-4B34-9782-4DFBE01FA8AA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:12:10 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C241BBD6-7DDD-4B8E-BA29-A9A307595892">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 19:09:23 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:8739072C-5D47-4302-BD43-4756B65DFB2B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:A64B7936-C650-42B0-B7E7-C6585052410D</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94DCE217-B72B-4727-9783-98D7EFCB02E6">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:08D219B2-A0EC-49C7-A943-47EE7CE4B542"/>
    <pav:createdOn>2014-09-01 16:19:43 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-43.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:FF3A4E4B-56B2-47CF-B174-C006C3954623"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-01 16:20:01 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N9ee8aa4820bf401195da3129ee623636"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:549650A1-2BE0-4AAB-87A9-51EB33F5FE79</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E3F8352-2C14-46DC-9E50-892286D5905F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:CAEF4002-AC71-41B3-AB37-783C0F6D54AB"/>
    <pav:createdOn>2014-07-22 18:46:46 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0054F81-6A9B-4AF0-9DCB-962A6FC1C418</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 18:46:52 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:B18D3A3B-241A-4AC2-8C86-EE2E51490093</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:body rdf:nodeID="Na25c0f5fb806447eaf0b5fc018bec458"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1">
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:AF657FF8-3529-4A9B-9294-13C604834E0A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:11E26B74-9DE2-4B10-A8C9-A250D2747B3E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1836E85-2D43-46EF-848C-F6204E5A50A7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A5A1F4E1-991C-4D93-AC6A-4DEDDF392601"/>
    <pav:createdOn>2014-07-13 12:55:59 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:70919722-5B5F-4E86-A52F-8A64A1EFDA72"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:35685454-E730-4B12-A923-46EE9655234C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B4E5EBBF-965D-41F8-B54E-0CF48653C43C"/>
    <permissions:permissions rdf:nodeID="N592645e7c4f142778c042ef2dc9fae05"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:66EBA4F6-77AF-4AB4-A3E8-E0D406200FF6</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:962DC691-3D08-4224-8D22-C0DD8D9F24CA"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF2D2BC3-6C22-44A4-8021-D0C2308687B9">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-52.txt.html</ao:annotatesResource>
    <pav:createdOn>2014-07-21 21:44:28 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:A3FC309E-D0BF-44B0-9FA1-EE2A55F76369</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:AC96215A-123C-49AB-9A1D-9FE75BE48E10"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <permissions:permissions rdf:nodeID="N6b6f7ee80a86438c83cd8cf5e9d44d18"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lastSavedOn>2014-07-21 21:44:21 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/2E8E0C08-A9A5-4122-9C0E-4594641FBED5">
    <rdfs:label>nelfinavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/134527</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F97F910-5C88-42D5-BF36-6EFC8C9A3DD1">
    <pav:createdOn>2014-07-07 11:35:30 -0400</pav:createdOn>
    <ao:exact>When a single 100 mg dose of sildenafil was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC)</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>5F97F910-5C88-42D5-BF36-6EFC8C9A3DD1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5F97F910-5C88-42D5-BF36-6EFC8C9A3DD1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2ABA1A35-6C77-4A0A-9EC5-109AA13136B6">
    <pav:lineageUri>urn:domeoserver:annotation:6129321F-FF20-473A-89DA-A79D75F63074</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D3737933-330F-487F-B41C-CDB0FF5C6F1C"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-07 09:58:59 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8232EB8B-B7ED-4583-BE33-F0AD71DA4D1C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8232EB8B-B7ED-4583-BE33-F0AD71DA4D1C"/>
    <ao:suffix>is only about 10-fold as potent for PDE5 compared to PDE6, an enzyme found in the retina and involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision observed wit</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>terases (10-fold for PDE6, &gt; 80-fold for PDE1, &gt; 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The approximately 4,000-fold selectivity for PDE5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Sildenafil </ao:exact>
    <pav:createdOn>2014-07-07 09:36:49 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6024659-1A02-4A19-8ED3-F29F4A70681F">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:44:27 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:DFAAFFAE-4EF6-4FDF-9B79-9C8FCB23829E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69C094F7-F9EC-4E26-B0BB-5E321AD43538">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:69C094F7-F9EC-4E26-B0BB-5E321AD43538"/>
    <ao:suffix>did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapr</ao:suffix>
    <ao:prefix>under steady-state conditions. The results of these studies indicated that </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-01 15:57:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>sertraline </ao:exact>
    <domeo:uuid>69C094F7-F9EC-4E26-B0BB-5E321AD43538</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40AC1621-7CDD-45E4-98D3-4DE403F588CE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:0072DC69-60A4-45F2-9EA7-C1B1D9B53CA2"/>
    <pav:createdOn>2014-09-02 11:41:05 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1FE8E158-755A-4E57-81FB-928873E93B12">
    <pav:lastSavedOn>2014-07-21 21:49:33 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:A5DD6E78-70E1-4015-8485-53B5D56072C0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:B803E851-5AD5-4741-B1B9-1CBAED597E18</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-21 21:49:21 -0400</pav:createdOn>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nfdf7b4afdbfd41e8ad45338e2d77f07a"/>
    <pav:lineageUri>urn:domeoserver:annotation:9D336A52-427C-4D16-B0EB-4A52D6237761</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D618B8B-0DAF-414B-911B-81ED1815FD8C">
    <pav:lastSavedOn>2014-09-01 16:00:14 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:659ED9DF-77DA-41F2-B123-6E455B4F2385</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:E5909B1D-7622-4164-8773-34186D306235</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-01 15:59:50 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:DB79C29A-687E-46A8-AEEA-C0F67E49EB97"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D0D19A7-AA2E-4F5C-86E6-0B171A00A7B1">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:26FE0E4C-4C7A-4DDB-B49D-53B765A8B4E3"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2014-07-22 19:35:50 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EC8E075-F7E3-4259-A656-99D292E9F0A4">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:6A45E1E3-7270-4950-9185-AED9AF04A2E4</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:0124DF91-B793-47E7-9547-2BF080146FA7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:12:20 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AFC27E91-AC15-4700-A2C7-343191A7F13A">
    <domeo:uuid>AFC27E91-AC15-4700-A2C7-343191A7F13A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AFC27E91-AC15-4700-A2C7-343191A7F13A"/>
    <ao:exact>normeperidine</ao:exact>
    <pav:createdOn>2014-07-28 17:00:54 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-164.txt.html</ao:hasSource>
    <ao:suffix>, in healthy subjects and thus, caution should be used with concomitant administration.</ao:suffix>
    <ao:prefix> and also the formation of the metabolite, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A2B398FC-383E-4A71-A215-EA4AD0E5C9DA">
    <domeo:uuid>A2B398FC-383E-4A71-A215-EA4AD0E5C9DA</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:exact>theophylline</ao:exact>
    <ao:prefix>Although in normal subjects no interaction with </ao:prefix>
    <ao:suffix> or propranolol was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines). Patients should be monitored to determine if it is necessary to adju</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A2B398FC-383E-4A71-A215-EA4AD0E5C9DA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:13:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6EC654F2-7C5C-4C0B-9973-518245983B18">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:16:01 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:36129C88-CE12-4AF2-ABDA-B2DC6006FD29"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:2B0A8F16-94F6-4911-8E78-98C4225AC672</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E010F58-AD7C-435C-B2DC-0F81F34B978E">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:6AED9017-2775-4A23-915C-FCB7842E4D54</pav:lineageUri>
    <pav:createdOn>2014-07-07 11:37:21 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N91892f31a51041c8a93a7c8b14831bec"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:CF3DBDD7-1816-4E91-BF27-7D21BEF67A06"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-07 11:37:25 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/19778C35-B5B2-4C65-9F2A-49A170F2C3CF">
    <rdfs:label>AVANDIA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/261455</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32B1CD5D-3CD7-4D5E-BD76-57F6F0A9480A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:34:12 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5672F5D0-071A-4DE9-9A98-BD20431A00C2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25585F8F-7F91-467C-B8DE-9153331081D5">
    <pav:createdOn>2014-09-02 19:13:14 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:25585F8F-7F91-467C-B8DE-9153331081D5"/>
    <domeo:uuid>25585F8F-7F91-467C-B8DE-9153331081D5</domeo:uuid>
    <ao:prefix> was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:suffix>). Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with omeprazole delayed-release capsules USP.</ao:suffix>
    <ao:exact>benzodiazepines</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB9A9C70-7859-46AE-887F-B9F2CBDE39DB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:11:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>BB9A9C70-7859-46AE-887F-B9F2CBDE39DB</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BB9A9C70-7859-46AE-887F-B9F2CBDE39DB"/>
    <ao:exact>monoamine </ao:exact>
    <ao:suffix>oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B427C906-5D72-43EE-85C9-4D7F3117059B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 11:39:51 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1B45944E-9180-4FB2-9DC0-7DC156F7508B"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E77E45D-0BB8-4168-8CAF-9D1591E37A36">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A29DA787-54E3-4422-B166-2BA6676BC91D"/>
    <pav:createdOn>2014-07-13 11:11:50 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:A1D65D6C-6A4B-478F-8140-AA87C27DB44D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50AA7124-5304-4E5F-8D20-3405C75223FB">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:207BC1EC-ACF7-457D-B193-939C1AE9DD4B"/>
    <pav:createdOn>2014-09-02 19:17:45 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N87b8827c352f40e6a418b75b07265a70">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1488BDD9-0C63-45D6-A1E6-1AC89EE36E28">
    <ao:prefix>AUC. The mean ± SD increase in </ao:prefix>
    <domeo:uuid>1488BDD9-0C63-45D6-A1E6-1AC89EE36E28</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1488BDD9-0C63-45D6-A1E6-1AC89EE36E28"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of phenytoin. (See PRECAUTIONS.)</ao:suffix>
    <ao:exact>phenytoin </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-21 21:26:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36129C88-CE12-4AF2-ABDA-B2DC6006FD29">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>36129C88-CE12-4AF2-ABDA-B2DC6006FD29</domeo:uuid>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the enzyme suggests this is unlikely [see 7 DRUG </ao:suffix>
    <pav:createdOn>2014-07-13 11:16:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:36129C88-CE12-4AF2-ABDA-B2DC6006FD29"/>
    <ao:prefix> may cause a decrease in the combined plasma concentrations of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:109B3973-618F-4814-8D01-1C468E7A80F2">
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid>109B3973-618F-4814-8D01-1C468E7A80F2</domeo:uuid>
    <ao:prefix> with </ao:prefix>
    <ao:suffix>, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone conc</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 12:03:06 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:109B3973-618F-4814-8D01-1C468E7A80F2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B383ED3F-1A7B-49EF-9DAD-049AD0F927DE">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B383ED3F-1A7B-49EF-9DAD-049AD0F927DE"/>
    <ao:exact>The mean Cmax and AUC of nifedipine are increased by 64% and 79%, respectively, by co-administration of propranolol.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-126.txt.html</ao:hasSource>
    <domeo:uuid>B383ED3F-1A7B-49EF-9DAD-049AD0F927DE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-24 19:39:41 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0FDB999F-470E-431C-829C-F231318245D8">
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-22 19:53:20 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:7C414A6F-D97C-4DE2-83B7-8EA499CCDE11"/>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/314A940A-9CA5-4B7A-B433-2AECFF25EFA4">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>propranolol</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69C22FA1-8D50-4AA7-ACD8-8F71E69BB8AC">
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <permissions:permissions rdf:nodeID="N38dabe368b5e46468e3eacc4953f51b2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EB533813-9EA9-4387-A0AA-5E6F4443AB02"/>
    <pav:lastSavedOn>2014-09-02 19:42:49 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:41:34 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:194B637B-12E0-40F8-A961-33C50074CD18"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:BB14DC78-807E-4A6B-BCB8-D66CC1E0A2E7"/>
    <pav:lineageUri>urn:domeoserver:annotationset:6B16FDBC-E803-4786-93CA-6CA50C2701B9</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-117.txt.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2532730F-81C6-4CC5-93B2-FC3A19B98EC5">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:09:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:FA839309-7C8B-4446-A5C1-08694E7B8482"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:2080DF37-EAA6-443D-A391-2897A81CAD23</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9258e03bec2c4f3abb8b2cb3a8ba3554">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9FA29E53-6B1B-4856-B5BD-22A93164E58E">
    <ao:item rdf:resource="urn:domeoclient:uuid:D599C322-4D76-48B0-9A8D-27A82819F5D2"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:B3318C2E-550E-4881-B82E-0796C34E1F98</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-58.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:38CE57C6-582D-4AE5-90CF-F2966A431DF6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:856332C7-36D0-4788-B89D-FC8E3A9C55D9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-22 18:37:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-22 18:37:42 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <permissions:permissions rdf:nodeID="N77b8670d22b2476490296e0bca826d6f"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8AEAC215-292C-4E6F-9305-D62BECCA32B2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 11:56:00 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:B0F3FF3D-59BD-4B9F-B0DD-AC814D8A4A0C</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:4302BBE9-CEFD-4D9A-8509-E48CACB9AAC3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F9FE917E-CAFF-4C8B-B16B-BB0606212145">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:43:59 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C29885C9-C34F-446F-88D0-5C6DE9D91033"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3C076A6A-DF94-4E44-AAAE-9F07C1FE0946"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AB1F4800-7A8C-48DD-A103-ADE54191154D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:160236BC-C839-4CD6-8648-FE98F4F6BC3F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 12:05:00 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:379CD8C1-F4B4-42B7-8F87-70776866DB1F</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:E07974BC-9D8F-4D5E-A1B2-C28141CD86ED"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:17C13D4B-C4FD-4F4C-8B4F-969B0D63CD46"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:047EE665-B8C6-4153-96F1-5D2C3C08A276"/>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:64531818-53F3-4463-8017-8AD63F5904C3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E2FD166-718B-4FDB-8465-F19A84DE1BB4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4E7D289E-0E68-4A95-9CAF-BA6B4026295E"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:5CFC30D6-1C24-402D-845E-93F7BF5F0922"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N75cecc01b0984d4599e0e10e2ccb23f5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4BC86345-8DEB-4D78-A90E-121B217F37B6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4746991B-1E22-4518-B0DA-6C25E8605F5D"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1594E9A-1D6B-476C-8DD6-9BADB6C707A8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:04DF851F-404D-44D4-A74D-22017210AF9A"/>
    <pav:createdOn>2014-09-02 12:02:37 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:852CFA91-85F8-4EF7-A64F-D2A63BC3A6B5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C988D053-7CF3-4C50-BDB6-7C2B20B837B9">
    <ao:item rdf:resource="urn:domeoclient:uuid:3BF96FBC-622D-4EC3-80A1-339B20EFCD2C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:7E388D29-FA3D-451D-B685-893CF456C7E5</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N8896431255c64da18e8b19940edcf181"/>
    <pav:lastSavedOn>2014-07-21 21:55:00 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:CC05ADFA-B5BA-4A4E-BAB0-61B3D424E8F2"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FE7EF264-FC22-45A9-853D-E8804BE9EF1B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6FF44D67-C048-4D48-95BC-9CAC7BF5E54F"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:35E17DFA-B3B8-4521-B986-4AC98CC81C96"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-56.txt.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-21 21:51:30 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:64F7664B-0B75-443E-8A3F-3A145064071E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1D7C043D-E62F-4A5D-A912-AB586E95D811"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:D41F6EB4-7428-411F-9159-905789D6B7B0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9805A65-BB53-4315-AF92-EC703ABB5E61"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/C4007BE1-F417-40F4-9849-29EA38C247C5">
    <rdfs:label>lovastatin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6472</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0EEDF160-BB48-4F3A-8FC7-D52C908CAECC">
    <ao:context rdf:resource="urn:domeoclient:uuid:CD89FD03-D99F-41BD-9614-0F760DFF0EFC"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 20:07:14 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87FEE025-38F8-476B-BB04-19AD3D10B07C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:exact>For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15.</ao:exact>
    <pav:createdOn>2014-09-02 19:33:36 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>87FEE025-38F8-476B-BB04-19AD3D10B07C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87FEE025-38F8-476B-BB04-19AD3D10B07C"/>
    <ao:suffix> Dose reduction of</ao:suffix>
    <ao:prefix> is therefore not recommended. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90F5AA7B-F35E-4B00-A666-C6FE8F1B0324">
    <pav:lineageUri>urn:domeoserver:annotation:86034B03-551B-406A-BFE8-B44A1CB16857</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:10:35 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:FADFAA32-BB4A-4542-AEFD-2B7D80177234"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/513340A0-A222-4865-9DAF-1EDDCCCA86A0">
    <rdfs:label>omeprazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7646</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3699069-7DAD-4616-9500-2A16ADBA4010">
    <ao:exact>FLAGYL</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> (metronidazole) is prescribed for patients on this type of anticoagulant therapy.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D3699069-7DAD-4616-9500-2A16ADBA4010"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-120.txt.html</ao:hasSource>
    <domeo:uuid>D3699069-7DAD-4616-9500-2A16ADBA4010</domeo:uuid>
    <pav:createdOn>2014-07-22 18:58:36 -0400</pav:createdOn>
    <ao:prefix> and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70E63C27-77CA-4EFB-9B3F-9125C608F260">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:70E63C27-77CA-4EFB-9B3F-9125C608F260"/>
    <ao:suffix> and lorazepam did not produce larger mean decrements compared to lorazepam alone.</ao:suffix>
    <ao:prefix> produced substantial decrements in cognitive functioning; however, the coadministration of </ao:prefix>
    <ao:exact>fluvoxamine</ao:exact>
    <pav:createdOn>2014-09-02 11:38:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>70E63C27-77CA-4EFB-9B3F-9125C608F260</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DD4A9BB-16CD-4C46-9CE2-E74FD07B5626">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5DD4A9BB-16CD-4C46-9CE2-E74FD07B5626"/>
    <ao:prefix> may significantly inhibit the activity of this isozyme. In most patients (&gt;90%), this CYP2D6 isozyme is saturated early during </ao:prefix>
    <domeo:uuid>5DD4A9BB-16CD-4C46-9CE2-E74FD07B5626</domeo:uuid>
    <pav:createdOn>2014-09-02 11:56:15 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>paroxetine</ao:exact>
    <ao:suffix> dosing. In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. Concomitant </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16393981-08BF-477D-ACB9-8FB804E50D0C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:5D5E7705-CD13-417B-BE4C-010E6D19EB36</pav:lineageUri>
    <pav:createdOn>2014-07-07 09:57:03 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:49F8A244-9291-40F9-AE95-B64DDF5E624D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABF527C0-D635-49E4-BC45-911EBB72D2E8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:10:47 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> is rapidly distributed. The volume of distribution is 1 to 2 L/kg. In plasma, risperidone is bound to albumin and α1-acid glycoprotein. The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Nei</ao:suffix>
    <domeo:uuid>ABF527C0-D635-49E4-BC45-911EBB72D2E8</domeo:uuid>
    <ao:exact>Risperidone</ao:exact>
    <ao:prefix>Distribution: </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ABF527C0-D635-49E4-BC45-911EBB72D2E8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8">
    <ao:item rdf:resource="urn:domeoclient:uuid:F1AECF5B-0B80-4F34-AE54-273DA1B3D41A"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:C9DB2D07-ABDB-402C-AA6C-8EB7046415D4"/>
    <pav:createdOn>2014-09-02 19:08:19 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE8D9855-AB1B-4B9E-97B4-6A441B8254E8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:724EC70E-AD36-444C-A1EB-23C9873CB536"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:095C4B55-33C1-4413-83DF-963BC2158506"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:85043124-E686-41BA-831E-AB868FA3D3B1"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:18E928D8-1D25-4E2F-BBD0-E7B1E4E45799"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C241BBD6-7DDD-4B8E-BA29-A9A307595892"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:29043652-5144-43F9-865A-114AECF87D36"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8BA43995-3A5A-44A6-AEC6-73AB1675E1DE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4683A379-9BF3-47AD-B269-BF50998FE88B"/>
    <permissions:permissions rdf:nodeID="N0a93cde7037a4766b6ff21e60fdfe160"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A07FFEB8-13E6-4964-A170-13A6FA26AB90"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:5BCF5967-ADD0-4798-B754-B12D230BDBFA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:083AD66D-BAA3-4731-A45A-FB051CF3619F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9517CDA-E201-4D75-90EA-09D040EC5F9E"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:01CABF7B-5601-4091-B27B-BB36CCDE1151"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:35B0C843-6298-4494-92B8-CA2A60C766FB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:960E16A3-CF0E-48BD-8B23-ACD869DFB214"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:76ADDE4C-05F0-4C9D-B547-37B2AA813054"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FA208444-D170-43D4-B1EB-ED24016D3210"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D37B2D57-1801-4552-AFD9-6AE31E8DC5A5</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B40A6C2-C532-4FE1-9D1E-96A1576E7CC1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:55F0E65E-65B9-4FEF-9D48-18521D03D3DC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CB3BF401-6553-421E-A6DD-22B0C2F0BC44"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/8FE58707-AFDD-4F32-9EA8-03EC3BF4D67B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>sildenafil</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA6CCDE1-25E7-45C1-9526-49B0190E1EC2">
    <pav:lineageUri>urn:domeoserver:annotation:72BA026E-14B2-4E60-B7F7-DA440E8ED26F</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-07-24 19:53:59 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:nodeID="N9e5d3138851c4983b2cd0bd169a7bb7d"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-24 19:53:55 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F8AA6DCD-35A7-4319-9C3D-CFA5C6AE10EE"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0863579-8D19-4B30-ADD6-2A5BDBC2F482</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7CF400AE-CD72-49D9-9780-049736D11E6D">
    <pav:lastSavedOn>2014-07-24 20:00:43 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:9FD13A04-F6A6-4702-A660-AD94950EF574</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0050ED6-BE4F-4871-9847-FC4493F22447</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:74981A52-DA21-4061-9DF7-E2A73DB55601"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 20:00:56 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:326CE5A9-3567-4645-9375-940B32F01216">
    <pav:createdOn>2014-07-24 20:12:55 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4EED7C96-E04B-4187-8077-DF5C7020A789"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:64586693-F5DB-44D2-AF71-39671402DBA2</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5584BFA-AB83-49EE-A2F1-68159AD3AEAC">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D5584BFA-AB83-49EE-A2F1-68159AD3AEAC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and </ao:prefix>
    <pav:createdOn>2014-09-02 11:38:45 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>lorazepam</ao:exact>
    <ao:suffix> did not produce larger mean decrements compared to lorazepam alone.</ao:suffix>
    <domeo:uuid>D5584BFA-AB83-49EE-A2F1-68159AD3AEAC</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C3FBF61-A16E-4DBB-B539-F88F8B7E60B7">
    <ao:suffix>, dextromethorphan, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrat</ao:suffix>
    <ao:exact>debrisoquin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5C3FBF61-A16E-4DBB-B539-F88F8B7E60B7"/>
    <domeo:uuid>5C3FBF61-A16E-4DBB-B539-F88F8B7E60B7</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:32:39 -0400</pav:createdOn>
    <ao:prefix>Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6. Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/E74D3AEA-33B5-4A50-A977-87798E92D401">
    <rdfs:label>propranolol</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1836E85-2D43-46EF-848C-F6204E5A50A7">
    <pav:createdOn>2014-07-13 12:56:03 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:67C91220-39BA-4E36-AF83-B063DCBE7679</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:42DD4654-83AE-4111-86D8-574617EB3CAB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:034AD896-FB93-4F64-9796-CB98DF23644B">
    <ao:exact>paroxetine</ao:exact>
    <domeo:uuid>034AD896-FB93-4F64-9796-CB98DF23644B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:034AD896-FB93-4F64-9796-CB98DF23644B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> administered alone. The effect of </ao:suffix>
    <ao:prefix>xidative) enzymes. When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-45.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-01 16:22:02 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3D2A83E-9B62-495D-A7E7-A17FEF5E2561">
    <ao:prefix>The mechanism of action of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, as with other drugs used to treat schizophrenia, is unknown. However, it has been proposed that the drug’s therapeutic activity in schizophrenia is mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>F3D2A83E-9B62-495D-A7E7-A17FEF5E2561</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3D2A83E-9B62-495D-A7E7-A17FEF5E2561"/>
    <pav:createdOn>2014-07-13 11:04:07 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:189A8E0E-67D6-4C53-A96E-CB48A3B4B2E9">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:84B56A7B-030D-4746-A4B2-C5097E07099C"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-136.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:7EF07060-EF5D-42BC-87F0-3EFC38B56BAA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:40692CE2-57E3-4181-873F-BF7EE5E8B25B"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N03320dcbcf444f378f68cdf86d042a09"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:164A1C02-147C-4620-8927-26251560C2C2"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:F6D8B558-463C-428A-82F9-861E7A7AA7AC"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-24 20:01:20 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:2FF3133B-3C6A-4B14-A744-B8F141C65349"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3DCB5ACD-9F2E-46B4-98D0-F1D2BD3C8EE7"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9ADFC8FA-4A14-45BD-A695-CF6C015BEB43</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:34A39B5E-1BC8-4028-8390-448D67AF41F6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1BB855FB-FD90-4495-85CA-4D3634124298"/>
    <pav:lastSavedOn>2014-07-24 20:02:49 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC959F62-91AD-411B-AC17-FFBBEE22EAF0">
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdOn>2014-09-02 19:18:28 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A404FE8-4389-4D36-A815-EE09948F4613"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A22D7450-FC77-45A4-B835-3948870AD344">
    <ao:suffix> hydrochloride is supplied for oral administration as scored tablets containing sertraline hydrochloride equivalent to 25, 50, 100, 150 and 200 mg of sertraline and the following inactive ingredients: dibasic calcium phosphate dihydrate, hydroxypropyl ce</ao:suffix>
    <domeo:uuid>A22D7450-FC77-45A4-B835-3948870AD344</domeo:uuid>
    <ao:exact>Sertraline</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A22D7450-FC77-45A4-B835-3948870AD344"/>
    <pav:createdOn>2014-07-13 12:34:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5442793D-CF1E-40C2-8779-648AB7BD1967">
    <pav:lineageUri>urn:domeoserver:annotation:C512B0A7-104C-4F2C-A89E-7F1B583CDB00</pav:lineageUri>
    <pav:lastSavedOn>2014-09-01 16:06:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-01 16:05:56 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:0415BFC3-92B0-4B40-B23A-DCE512A51F26"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F41B0D87-B434-42EF-90F7-E87825A6741D">
    <domeo:uuid>F41B0D87-B434-42EF-90F7-E87825A6741D</domeo:uuid>
    <ao:prefix>AUC following the administration of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F41B0D87-B434-42EF-90F7-E87825A6741D"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-21 21:31:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6 ± 3.6 to 5.7 ± 2.2.</ao:suffix>
    <ao:exact>fluconazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5FD113AB-8FB6-4F29-B1BE-0A776992E0B0">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>TID sildenafil</ao:exact>
    <pav:createdOn>2014-07-07 09:39:42 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5FD113AB-8FB6-4F29-B1BE-0A776992E0B0"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E68B19A2-98CC-4D01-88C9-2BCC8709D27A">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 19:19:41 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:79F49E5C-6D04-4116-8E54-1C6470AEB616"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDDA5AD1-5495-41C1-821C-109A7D029580">
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 20:07:07 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A71C73E7-BDEF-430C-BE2B-73E35D00A542"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF177109-0D4D-4DEA-BD5C-F29B10621C02">
    <pav:lineageUri>urn:domeoserver:annotation:55B9C1C9-DA6A-4528-A411-28F4318BAEDF</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6DEBCD8F-80B7-4229-A275-28C4CFF1B5A0"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-22 20:18:04 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42248733-4719-42F4-8132-866191F8E708">
    <ao:item rdf:resource="urn:domeoclient:uuid:35E50D31-0B97-45CD-9519-3A5F2D6512D3"/>
    <pav:lastSavedOn>2014-07-21 21:43:59 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:0EA544B7-9EBE-419C-A57B-B74B8AC3FB29"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-51.txt.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D514E533-2EAF-4DD1-ADEB-209AF96F6E59</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N1e1e40a79b134732a76159a7264f0552"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2014-07-21 21:43:17 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:93AEC1F9-3191-4D73-8BB9-21EE50636AB5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B549CAF8-BA63-4493-B342-27702B9FC841"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9AE25ABB-CFC2-479D-B1B0-184576D49108"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0476DD8-15DF-4D2C-ADC4-C5C80BA1F15B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E0476DD8-15DF-4D2C-ADC4-C5C80BA1F15B"/>
    <pav:createdOn>2014-07-24 19:47:39 -0400</pav:createdOn>
    <ao:exact>cholestyramine</ao:exact>
    <ao:prefix>Co-administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E0476DD8-15DF-4D2C-ADC4-C5C80BA1F15B</domeo:uuid>
    <ao:suffix> or colestipol with propranolol resulted in up to 50% decrease in propranolol concentrations.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-131.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF6678E7-2ECF-462C-8BF0-34D8AD9D7A8B">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-117.txt.html</ao:hasSource>
    <ao:suffix> causes arterial vasodilation and decreased peripheral vascular resistance which results in reduced arterial blood pressure.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>BF6678E7-2ECF-462C-8BF0-34D8AD9D7A8B</domeo:uuid>
    <ao:prefix>lts in an inhibition of calcium influx through these channels. Stores of intracellular calcium in vascular smooth muscle are limited and thus dependent upon the influx of extracellular calcium for contraction to occur. The reduction in calcium influx by </ao:prefix>
    <ao:exact>nifedipine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BF6678E7-2ECF-462C-8BF0-34D8AD9D7A8B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:46:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:2B18F6B1-59F7-4EA0-9386-55A934108055">
    <ao:item rdf:resource="urn:domeoclient:uuid:525D9A2A-57D7-4B82-AAC2-92BA3D298032"/>
    <pav:previousVersion>urn:domeoclient:uuid:0819E6B8-B8E8-4EB2-9248-CA54623D1BB2</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N0024b5e9f27845f9b7061cfd742357bf"/>
    <pav:createdOn>2014-07-22 19:06:46 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:E5B69523-748D-4576-8C13-43546FFB2F5E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2FC7CD9D-9CBA-4723-8996-9E721AB52D4A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:605A1706-1C67-4FBD-9A42-21DF312E4339"/>
    <pav:lastSavedOn>2014-07-22 19:08:05 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:ACA8DFD4-1166-4984-97D0-E4E251EA94F3"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:32C325B9-09DD-4A0B-A270-BAA0C42956A1</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-122.txt.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED1540C5-0D63-4D37-A891-4B8F18792981">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:A84907A8-B9AD-4919-822F-3903218E78F8</pav:lineageUri>
    <pav:createdOn>2014-07-22 19:56:13 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:AA4737DB-0EF5-4431-A3C1-AB7A8F5E730A"/>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA838F12-E2BB-4B13-B633-B6F4480341B7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>DA838F12-E2BB-4B13-B633-B6F4480341B7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:12:29 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:exact>Omeprazole</ao:exact>
    <ao:suffix> can prolong the elimination of diazepam, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver. There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DA838F12-E2BB-4B13-B633-B6F4480341B7"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D860A1B6-8D5E-4FE4-9EDB-4E1397B29BBD">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sildenafil</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C29885C9-C34F-446F-88D0-5C6DE9D91033">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C29885C9-C34F-446F-88D0-5C6DE9D91033"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>sildenafil</ao:exact>
    <ao:suffix>, so that the metabolite accounts for about 20% of sildenafil's pharmacologic effects. In patients with pulmonary arterial hypertension, however, the ratio of the metabolite to sildenafil is higher. Both sildenafil and the active metabolite have terminal</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:43:59 -0400</pav:createdOn>
    <ao:prefix>s metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug. In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1DA34422-734D-46B1-AB2C-C1CABCA4C26C">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-01 16:07:12 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:75244705-D763-4A47-A23E-5C4CAE8A90B5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3B3D1AF0-4CC7-45F3-88F0-8C987CA69613</pav:lineageUri>
    <permissions:permissions rdf:nodeID="Ne432bd8751914067b2b0e8d76e54ca0b"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-40.txt.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:E854201F-10EB-4992-8353-B60276384931"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B0F0546-41D1-46D1-95BF-CB03118C9BB8"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:3347F4AE-F668-4910-8729-7775D7697AD7"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:lastSavedOn>2014-09-01 16:07:52 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6BC9135A-65A9-4BB2-A462-DD73D14C286B">
    <ao:context rdf:resource="urn:domeoclient:uuid:54953EDA-07BE-4F30-8DE9-32B9DFDAC13D"/>
    <ao:body rdf:nodeID="N31c86788d74e49c8aa01657fabf0f31c"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-21 21:47:00 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:DDF78D61-DEA7-475E-A81F-CC94BAF10D7B</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:876DAFB7-BB08-4119-BA16-59187031D7BB</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-21 21:46:47 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F9664F35-3DEE-47BF-95B4-E93F2BBC1965">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:AD7D1F18-857F-4502-9621-F93B88E936D2</domeo:belongsToSet>
    <pav:createdOn>2014-07-28 17:00:13 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:B79DF7F1-8FF8-4B3E-A461-BBAFAD29A77F</pav:lineageUri>
    <pav:lastSavedOn>2014-07-28 17:00:03 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:544DD6BF-DAEB-4EEF-86D9-2AD7760B51C5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38CE57C6-582D-4AE5-90CF-F2966A431DF6">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:5A027EDF-83FE-475F-9F74-63D2D35751F4</pav:lineageUri>
    <pav:createdOn>2014-07-22 18:37:22 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:9FA29E53-6B1B-4856-B5BD-22A93164E58E</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:8156B623-1ED5-4672-8474-3E892FC84DF5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-22 18:37:42 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B622988-60A1-49F1-966B-8460BBF1DD4D">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:18FCF895-E37C-47DC-9D3E-92CD602023DD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:04:27 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3967C16-EC04-423B-908A-CF2BC1EC4011"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:043FCC7B-7CBD-4BE5-9962-3F6CF2B132DB">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> oral solution is bioequivalent to risperidone tablets.</ao:suffix>
    <pav:createdOn>2014-07-13 11:09:21 -0400</pav:createdOn>
    <ao:prefix>Pharmacokinetic studies showed that </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:043FCC7B-7CBD-4BE5-9962-3F6CF2B132DB"/>
    <domeo:uuid>043FCC7B-7CBD-4BE5-9962-3F6CF2B132DB</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB3BF401-6553-421E-A6DD-22B0C2F0BC44">
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 19:10:58 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:1E8589E4-636D-44DF-8972-8217A9E8E1C6</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9C5170BD-B57E-4757-B143-AE7F2FE21CCC"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54A742F1-BC99-4080-8071-732BA171793D">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-24 20:07:04 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3357AB7A-4128-4D9D-8FEF-3908BC9E44F0"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1FF7E05-1C80-4A3F-9366-A074CA5EDF15">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <ao:body rdf:nodeID="N6db07ba76ff444be9d2ac66e28011bfe"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:33BB0EA3-00A7-4E9A-8406-1B489BED52FB"/>
    <pav:previousVersion>urn:domeoclient:uuid:CB83FFC2-EA71-44EA-8F11-DE80E389C84E</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:32:05 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 19:32:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F554D87-2148-4927-B2EE-B016ECABC1C6">
    <pav:createdOn>2014-07-28 17:02:30 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:BE32957F-9AE2-489B-96B6-1B02D0F5DB9A</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:A0E3203A-2AD3-4045-BAB8-27B340F81B0E</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:46ACA9D3-9DB9-4318-BFF9-15A57F3153D1"/>
    <pav:lastSavedOn>2014-07-28 17:02:28 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf25bdae03fc24acf881db3e866476767">
    <domeo:sets rdf:resource="urn:pddi:uuid:11C59DB6-9144-4BAA-B630-BA9A001B4C4A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0B2918C2-A28D-40C3-8147-F19D09B7119C">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-07 09:37:58 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A3612760-5AFD-415B-8269-F1483D859C5D"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D477356-49DE-4F65-97BE-07989E4A1B92">
    <domeo:belongsToSet>urn:domeoclient:uuid:E0054F81-6A9B-4AF0-9DCB-962A6FC1C418</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 18:44:54 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:7E943426-6E66-4EE6-89C5-B45CC35BD194</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 18:46:52 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:E19B0AE6-FB85-4E0D-AC07-7E22C589DC36"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EDEC592-2359-4661-BE34-B3BD50D59548">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:6F9E01FD-BC9F-4B86-8FFF-8A4DC8CD6CB5"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:4FC315CC-8F6D-4166-AEB6-FBF9CF2FA510</domeo:belongsToSet>
    <pav:createdOn>2014-07-28 17:00:51 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:60C5D726-2ED7-4694-AF41-71FA9512BAFC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-28 17:00:29 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C86F61CA-C8B8-45D2-86FA-DC4DB976D43B">
    <pav:lineageUri>urn:domeoserver:annotation:CF02237F-C859-48FC-9C3F-9401B806E6E6</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:F2788742-3226-4BFB-9D85-2FC7211066F7</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-22 18:58:19 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1FEAE882-CD22-4693-8DC0-495CC155160B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-22 18:59:41 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C9F22978-089A-4215-9421-19B4E3E4358A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C9F22978-089A-4215-9421-19B4E3E4358A"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-07-24 19:38:18 -0400</pav:createdOn>
    <ao:prefix>The metabolism of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-125.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>propranolol</ao:exact>
    <domeo:uuid>C9F22978-089A-4215-9421-19B4E3E4358A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0EE858B-D738-4E79-B01E-E50A3141586B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A0EE858B-D738-4E79-B01E-E50A3141586B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>quinidine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:15:01 -0400</pav:createdOn>
    <ao:prefix> [see 7 DRUG INTERACTIONS]. This occurs with </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A0EE858B-D738-4E79-B01E-E50A3141586B"/>
    <ao:suffix>, giving essentially all recipients a </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B549CAF8-BA63-4493-B342-27702B9FC841">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:42248733-4719-42F4-8132-866191F8E708</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:1C4D4CDE-899A-4154-909A-B83F015F7989"/>
    <pav:lineageUri>urn:domeoserver:annotation:CCF2824F-F8E6-41C2-9BA5-3EB9D1CDDB8A</pav:lineageUri>
    <pav:lastSavedOn>2014-07-21 21:44:00 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:43:17 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F895E903-9E93-41BD-BED1-2EA2CE628B45">
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:DC75BC49-9657-4DDD-BA6E-E382607C98F8"/>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 19:22:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:544DD6BF-DAEB-4EEF-86D9-2AD7760B51C5">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:544DD6BF-DAEB-4EEF-86D9-2AD7760B51C5"/>
    <pav:createdOn>2014-07-28 17:00:13 -0400</pav:createdOn>
    <domeo:uuid>544DD6BF-DAEB-4EEF-86D9-2AD7760B51C5</domeo:uuid>
    <ao:prefix>Plasma concentrations of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-163.txt.html</ao:hasSource>
    <ao:exact>meperidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> and its metabolite, normeperidine, may be increased by acyclovir, thus caution should be used with concomitant administration.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232">
    <ao:item rdf:resource="urn:domeoclient:uuid:9AF0B949-C133-4703-9F65-362D4B5B4494"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E8680340-7715-4656-A160-A6F608AD7CE9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:34472B29-EA4E-45E5-84B2-2EEE556610B6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:539264FC-F626-408A-BB71-03BC387083CB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:518CD4C6-1719-48AB-B300-84A10DEACB68"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0D7139F9-BDC3-437F-A5A1-D75EDAC972B0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1E597BBC-9857-4D08-953B-5CBE831F5884"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B18CF78-48CD-4D32-B4F4-88F8072C8185"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5BA6BC8B-1F30-4288-9D03-060F552BAA12"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0025BED1-B4CA-4D8F-9C43-B2F10841CCF4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA2C0A64-143A-46D5-A408-01FC3EC62525"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:420B9B73-0394-4975-8634-61202EA8F217"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6ECE2E9A-54C4-4507-95A6-2F4053719529"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8E221E79-602A-4812-8488-538D6506C879"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:90F5AA7B-F35E-4B00-A666-C6FE8F1B0324"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3805F006-2423-4B51-87AB-CAE85C6B4E21"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:72843AE3-90CC-43FD-BCEC-E83B4E3A7EDF"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23E5F3F5-E089-460E-A736-58E2FC44ADC6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CBE541BF-AED9-48E5-ACA0-9309C45B20F5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DFCBEAF2-DEEA-4C46-A167-B2B6F5C56C00"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA230F0A-406C-43AE-88DE-A7FD67CF4D61"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:64792593-BEAB-4B65-88FB-A2254663F469"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:99E97745-423E-4818-BFC6-3F67C8BF2A87"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4E77E45D-0BB8-4168-8CAF-9D1591E37A36"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EFBA3663-4C52-45BA-895B-7EB3C0A4DA3A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:92436D94-1FB4-49B2-B20D-385CA961A940"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5FF2B43E-5E15-4C21-BFDD-C97D4C18B3B1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9C5564E-F653-404D-B333-299E63141AF5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4019A76A-1D16-4F04-8CBF-FF855DD2A7A2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E73E8FF7-7FA2-47F3-B0B1-14D1640DDBF7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FE717566-90D0-4B59-B00F-B053CAE639C4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7AF3A49F-90C3-4D03-97CB-74AE03BF7C86"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:56F428F6-CAF7-4343-B57C-103B1BA935EB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:94239CD6-2883-459B-A125-FF55B9791833"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:05BFBD66-D24D-4F61-89C5-4EDDE7B6040C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2532730F-81C6-4CC5-93B2-FC3A19B98EC5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6EC654F2-7C5C-4C0B-9973-518245983B18"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E6A5356C-B181-4F61-AEF2-74464A340D7F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E2A93D3C-935C-417F-BE1B-282EDBEB8D85"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7CC41192-004E-44F9-8E3D-0FF7CECF1DC2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FD9D4BD5-A390-4CD6-8FF4-21ABE76D596A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EEC761C8-1050-4E1A-A450-D460F8514160"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 11:04:07 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:651C0626-4BF6-4B96-A66A-7385C6456D51"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B088F7FA-8870-4336-965B-4A558E3F08B0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B743E18-8323-4761-B0A4-3B200C16F9BE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C15235C1-3B10-4949-B8E4-1D7FCCD3AC4B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8EAC93E7-05D8-439B-86B4-7B47CB07E8D8"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:97C1D6A3-E462-4C1F-8DD6-513D5AD2268A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1C446162-FA92-4715-9095-A116DC12F4C8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E728D92E-FEA6-4EE6-9E40-E59051DEB8E3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E202AAE6-7DCA-486D-9C29-8CB3B82CFECF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:14556CC1-0C55-47A6-8175-973C292639CC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:A151EB77-7400-49F2-9673-BFAD2171D5CD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:420A77EC-3CAE-4EA3-B428-B635FA4A9F5D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:71E5047C-5690-4D45-9A6E-FB1384C14928"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9F3CA373-B79A-4B2D-8C96-BFB67CB4B175"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:97FF727B-70F7-4A8F-9355-6D53C2602A7E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5B622988-60A1-49F1-966B-8460BBF1DD4D"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:CAC294B3-5790-4488-B65C-CB3269F765C6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:934B866B-AFCB-4F4A-A5CA-1B312B3088E1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6B6560EB-DD3A-4FD9-ACE8-690CA260DD8B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:90C0A4CD-5288-4960-B31A-195D0159FE45</pav:lineageUri>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:A6F0B480-ABD4-436B-8A6F-A4BD34827F73"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:92DB5361-BE2B-4C69-B141-FB431E8EFC22"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6DDA4ED5-743F-4C12-93A8-37B2366FF364"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A46A827E-4936-4BBC-8078-913DD6DAA84E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:464ED203-77EC-4EFC-873A-7853A308DCA5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F94384BA-7A08-4E0D-A89C-A73959BAA203"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:04EFF21D-F5C9-468D-BFA5-057DD08ABD00"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B475492-95FE-4CDD-81AE-94DFEEB91E11"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:A361190A-A611-4162-AA47-4014AAEBA0B2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9BD1E279-39ED-4853-AF2E-BE56BEB4AF03"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5F8E4E79-C59A-410E-ACD6-41B9C532F968"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9011E52E-6FAE-42BF-913B-D3EF952E8A2B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C5594C9A-8B88-4CF6-B5AA-3F081580D92D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:017A9836-D985-4347-BFF0-9EBED8DB5CD1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2EC8E075-F7E3-4259-A656-99D292E9F0A4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F0AC105E-C659-4D3F-9F13-4104BCC29CDE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:89155DC0-3493-4590-8DD7-44717F141C27"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:95AEC430-A2F4-4B0D-B623-70050D7B891E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2537CEFB-4053-4AC9-8731-C65B1AC5D0F9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C4061A3-979D-486B-9CDA-1CFF771CCB5B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F46BEE2C-B82E-4386-96D7-C74221898C04"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:454E7688-A4B1-42BF-86B5-6E1A3C88986A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:72584FCC-E5F1-4130-993B-ED469AE3E810"/>
    <permissions:permissions rdf:nodeID="N54cec6e5108e43acbd7e1ffb67334648"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:689B7657-F3FC-48C0-A564-2904140C7D29">
    <ao:suffix>.</ao:suffix>
    <pav:createdOn>2014-09-02 19:16:36 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:689B7657-F3FC-48C0-A564-2904140C7D29"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>689B7657-F3FC-48C0-A564-2904140C7D29</domeo:uuid>
    <ao:exact>voriconazole</ao:exact>
    <ao:prefix> was given without </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29694BD5-41F2-4693-A623-AABDC826F754">
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:53:07 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:62CEF929-8FCC-4F3F-8B23-F0215966A438"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6BD06504-E85C-4ECF-9079-FE0363DD8508">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoclient:uuid:CB83FFC2-EA71-44EA-8F11-DE80E389C84E</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:0ED57E86-1291-4DDA-9436-EC8F43B4A452"/>
    <pav:createdOn>2014-09-02 19:28:25 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 19:32:13 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:88A57962-2A3E-4D94-8F54-0A13BDB6FAD9">
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 15:04:24 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:DEE6A881-BE96-44F5-B16E-077C84D64859</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:631995B6-520A-4B5F-B283-0557077A8B49"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C7DC9EA-F2B4-4F7F-BD05-8D844F135B91">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 19:46:05 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:4519FF07-AE90-4478-8B97-B4B2C84457DC</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:69FB098B-12F9-4F1C-AE30-F8B99226F270"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-24 19:45:39 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:A6C4359D-F4E7-4034-B791-FE7811C43403</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A0AE7AB-260B-4296-BC83-DB443FEE5161">
    <ao:prefix> AUC and Cmax. There was a mean ± SD decrease in </ao:prefix>
    <ao:suffix> AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of flucon</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A0AE7AB-260B-4296-BC83-DB443FEE5161"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <ao:exact>fluconazole</ao:exact>
    <domeo:uuid>6A0AE7AB-260B-4296-BC83-DB443FEE5161</domeo:uuid>
    <pav:createdOn>2014-07-13 12:46:24 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:079AA7B9-9BE4-4706-A20A-5848B50272B5">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-124.txt.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="Ncf7e0af81c5144a5ac15bdb615c11005"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 19:37:33 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:CF44A79E-F8B5-4F6D-B490-6D46E9586529</pav:lineageUri>
    <pav:createdOn>2014-07-24 19:36:31 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:CDCD9DD7-A54D-402A-8BEE-9FE5E515E7D4"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:E785934B-232B-456F-A0C7-F28959E09129"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:35B88B08-A82B-4D65-B565-57DA9528E578"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:463EFB94-13AD-4945-B3D3-4B953F099775">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:AE2B15F2-9CA8-49EC-B61F-0A38DD22AF0C"/>
    <pav:lineageUri>urn:domeoserver:annotation:BDB7A5F6-354B-467E-8723-23AEC5C9C146</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 20:17:49 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3077386C-E136-4431-9DB1-FC99BF18719B">
    <pav:previousVersion>urn:domeoserver:annotationset:7E80543E-BF76-4514-92A9-91458DCB802B</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:F652E827-5625-4F3B-BD53-6EF8860F2CDE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2014-07-22 19:35:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 19:35:16 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2FC7CD9D-9CBA-4723-8996-9E721AB52D4A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 19:07:10 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:9A8A293B-262D-43EF-8C00-7D4DBC75FC6D</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2B18F6B1-59F7-4EA0-9386-55A934108055</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:08:05 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2C00A54D-2DAC-4CE9-9A86-5591EF7E3323"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D9E07C8-AA4D-4D08-897A-996E5C499CF6">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:797E523C-94FC-4569-A544-1F1C2179E9C1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 19:49:34 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66A10386-3791-4236-BBA2-9E3AD59B847D">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:98363801-880A-4060-8919-70CE42916B17"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:514BA51B-D734-4003-A7C3-F03C0F95833A</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 19:44:46 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 19:42:09 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:98363801-880A-4060-8919-70CE42916B17">
    <ao:prefix> (4 mg once daily) for 7 days increased </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:42:09 -0400</pav:createdOn>
    <ao:suffix> AUC by 127%, compared to the administration of </ao:suffix>
    <domeo:uuid>98363801-880A-4060-8919-70CE42916B17</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>rosiglitazone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:98363801-880A-4060-8919-70CE42916B17"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDDC5F6F-E40F-4F4A-BB7A-C77A3A968B0B">
    <ao:exact>Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days).</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>CDDC5F6F-E40F-4F4A-BB7A-C77A3A968B0B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CDDC5F6F-E40F-4F4A-BB7A-C77A3A968B0B"/>
    <pav:createdOn>2014-07-22 18:36:48 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-57.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DFAAFFAE-4EF6-4FDF-9B79-9C8FCB23829E">
    <ao:suffix>(see WARNINGS AND PRECAUTIONS [5.3]).</ao:suffix>
    <ao:exact>tryptophan </ao:exact>
    <ao:prefix>and </ao:prefix>
    <domeo:uuid>DFAAFFAE-4EF6-4FDF-9B79-9C8FCB23829E</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DFAAFFAE-4EF6-4FDF-9B79-9C8FCB23829E"/>
    <pav:createdOn>2014-09-02 11:44:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC3A3861-9232-4673-B5DA-6BEA85FD20A7">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:190E7AE8-2ACF-42E2-AE00-E433EEA9737C</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:66762812-3E76-4815-AF5C-6E5A2D4739C3"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 19:38:25 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:AD590B0B-4C27-41DB-9A70-638C00DE9BDA</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 19:38:39 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82B114B4-DF8C-4358-AB9B-8EBA4957BC3F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:82B114B4-DF8C-4358-AB9B-8EBA4957BC3F"/>
    <ao:exact>AVANDIA</ao:exact>
    <ao:suffix>.</ao:suffix>
    <domeo:uuid>82B114B4-DF8C-4358-AB9B-8EBA4957BC3F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:50:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> AUC and Cmax slightly increased following coadministration of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB2B2DE0-2BB6-4F47-A9DF-A6326E16D770">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>DB2B2DE0-2BB6-4F47-A9DF-A6326E16D770</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DB2B2DE0-2BB6-4F47-A9DF-A6326E16D770"/>
    <pav:createdOn>2014-07-22 20:21:10 -0400</pav:createdOn>
    <ao:exact>Repeat oral dosing of AVANDIA (8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of digoxin (0.375 mg once daily) in healthy volunteers</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD3EF274-2E89-4A1A-9C95-5AE9F608E1E0">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:27:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:83944842-F662-4A59-B8BB-809D6D8471DC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-21 21:27:51 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:B6F745E6-5734-4636-A383-683BA4C79E38</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:CBD1F653-F7E2-49C1-AEF3-0CF16AA17649"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6EB60C9-CEEF-414F-8B0A-9C1AF0091872">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:985C3233-0D87-48CA-9DDA-A1D83B9FCA6D"/>
    <pav:lineageUri>urn:domeoserver:annotation:5FAF681B-8EF3-4A88-B5CE-244A3255305E</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 15:03:58 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BFB51383-F8CA-4B7D-AF51-8BC2302A8276">
    <domeo:uuid>BFB51383-F8CA-4B7D-AF51-8BC2302A8276</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BFB51383-F8CA-4B7D-AF51-8BC2302A8276"/>
    <ao:prefix>Many drugs, including most drugs effective in the treatment of major depressive disorder (</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>paroxetine</ao:exact>
    <ao:suffix>, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme. In most patients (&gt;90%), this CYP2D6 isozyme </ao:suffix>
    <pav:createdOn>2014-09-02 12:02:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52192391-30EB-46A9-93CB-47EC77CE40BC">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>After chronic dosing of 80 mg </ao:prefix>
    <pav:createdOn>2014-07-07 09:39:32 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:52192391-30EB-46A9-93CB-47EC77CE40BC"/>
    <ao:exact>TID </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA5DA7BD-C00F-4D3B-B057-830BB357C412">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B4B52B26-239D-47C5-8E82-702E109CC247"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:A52F0287-AD68-4755-8E11-75217CD4FED8</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:24FDF5F9-D6C5-4622-91F8-981D96C742C1</pav:lineageUri>
    <pav:lastSavedOn>2014-07-21 21:38:46 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-21 21:38:46 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AFAC33CD-2472-4FC2-BA17-FF7F45039527">
    <pav:createdOn>2014-09-02 19:11:02 -0400</pav:createdOn>
    <domeo:uuid>AFAC33CD-2472-4FC2-BA17-FF7F45039527</domeo:uuid>
    <ao:exact>oxidase </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AFAC33CD-2472-4FC2-BA17-FF7F45039527"/>
    <ao:suffix>inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BE2F54A-5A28-4297-82E1-2B83EE8D882C">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 11:43:53 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:143E0873-3AEC-4273-B2E8-23467A7C6978"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58271A45-7CE7-4B20-8F9F-82D4B6DD0D74">
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdOn>2014-09-02 11:44:35 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:62E0CEDC-0C94-4CC8-83F4-85DD741C49B6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E6C968E-32AF-45A2-96F3-10B3A640C99F">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>1E6C968E-32AF-45A2-96F3-10B3A640C99F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1E6C968E-32AF-45A2-96F3-10B3A640C99F"/>
    <ao:exact>Risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> could be subject to two kinds of drug-drug interactions. First, inhibitors of CYP 2D6 interfere with conversion of risperidone to 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a risperidone</ao:suffix>
    <pav:createdOn>2014-07-13 11:13:53 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F41B5CD-E2A4-46BE-9B88-1BCA05A1A5EE">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 15:04:25 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:EEE12379-F146-461E-9F7D-3F5DEEF5991C</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:2E73BB40-870E-4E49-B189-491A7CC6CA08"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0208A9D0-4889-4F9D-A5F0-C1CBBBE42EE0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-24 20:07:25 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:8301C100-8F47-4B2E-A908-FF663A864A1E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:40007BD9-0869-48CF-A8F2-BAD26AE3E6E1">
    <pav:lastSavedOn>2014-07-21 21:32:45 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:E2932281-71AF-4D8C-BFA1-44627891CD3C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C36C5E7A-30AD-4497-9348-913F96DD443E"/>
    <pav:createdOn>2014-07-21 21:31:06 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:5B3EE83F-83C7-4BA8-A892-C032BE699CFA</pav:previousVersion>
    <permissions:permissions rdf:nodeID="N6648e4d88e2c4eca88daa5e9118b3c3c"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:631B556D-C865-4327-8C15-D735A7315C3D"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:8C403ABF-BCD6-4923-946F-4AF2BAAB0800"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6CB1CEB5-788B-4E3B-9578-C8DF02D212D9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FC139E5E-6513-4B13-9FE1-980FD4117A68"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:01600057-F016-4A5A-AC67-3F30E5F3B4EA"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:092451F5-B0C0-430C-8896-07F81D33F9E1</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F01E73F-19F5-4FA0-A47A-6EC3310E264C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F01E73F-19F5-4FA0-A47A-6EC3310E264C"/>
    <pav:createdOn>2014-07-21 21:47:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>8F01E73F-19F5-4FA0-A47A-6EC3310E264C</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-54.txt.html</ao:hasSource>
    <ao:suffix>significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.</ao:suffix>
    <ao:exact>Diltiazem </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58F2142F-5F2A-4136-AB4F-944FA95FB01D">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:1285AF18-3541-4E0D-9BAA-DDBC5E9C152C</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 19:46:53 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 19:46:58 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:0B49CFF0-97DD-4E4F-B22A-E1301AFF9F67</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:BF6678E7-2ECF-462C-8BF0-34D8AD9D7A8B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C076A6A-DF94-4E44-AAAE-9F07C1FE0946">
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <pav:createdOn>2014-09-02 12:03:50 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:78651239-7677-4E29-8D57-C04613A83C19"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E692274-1B14-40DE-8BD6-F464FE52CF01">
    <pav:createdOn>2014-07-22 20:22:47 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:92352C6B-D275-4DA3-A8EC-F2963768C84F</pav:lineageUri>
    <ao:body rdf:nodeID="Nc0b0222e27024f76beee60eef89e69c2"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6F5EB55C-E7E1-447C-B54E-5F02D52FA3AE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F1DD8EF-72E2-425B-B98B-233F1591A13F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F1DD8EF-72E2-425B-B98B-233F1591A13F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:42:06 -0400</pav:createdOn>
    <ao:suffix>is 105 L, indicating distribution into the tissues. Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations.</ao:suffix>
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. The mean steady state volume of distribution (Vss) for </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A4B6F3D-5923-4FB1-A369-D9FE1BF7FD5C">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:8D86A4AC-54BD-4BB3-8B58-AB55DEC01A88</pav:previousVersion>
    <pav:createdOn>2014-07-24 20:08:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-24 20:10:48 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F941BEEC-394B-4F88-B13F-E8C0361B2C8D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DDADE3A5-763E-4A5F-A9E8-79A393BF0629">
    <pav:createdOn>2014-07-21 21:33:41 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-21 21:35:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:B8506D6D-BA0C-452E-BC7D-21D250B32240</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:B61F1A9B-4696-4ED0-80AA-4FE2E9016966</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:E0926D3D-98EA-4A7F-A9B4-EC238004514E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F4EA581-2F5C-4FF1-8DA3-D5101E760F69">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5F4EA581-2F5C-4FF1-8DA3-D5101E760F69"/>
    <domeo:uuid>5F4EA581-2F5C-4FF1-8DA3-D5101E760F69</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:28:14 -0400</pav:createdOn>
    <ao:prefix> and its major metabolite, </ao:prefix>
    <ao:suffix> [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5A4FF79-C22B-475D-8775-B7CA929DA67C">
    <ao:exact>ethinyl estradiol</ao:exact>
    <ao:prefix> treatment did not cause a decrease in the </ao:prefix>
    <ao:suffix> AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatment.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 12:38:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F5A4FF79-C22B-475D-8775-B7CA929DA67C"/>
    <domeo:uuid>F5A4FF79-C22B-475D-8775-B7CA929DA67C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64531818-53F3-4463-8017-8AD63F5904C3">
    <ao:context rdf:resource="urn:domeoclient:uuid:96A8BD35-396A-4A08-9E1C-55EB39E4B7D4"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 12:03:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70EB0C27-A6B8-49A5-94CD-7CCF2755C633">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:44:20 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:0FEC326D-6B98-40B2-8D49-7B4318AEB3B8"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:319A061D-1A35-4E08-859B-F39DA704D1B4">
    <pav:createdOn>2014-07-22 19:00:38 -0400</pav:createdOn>
    <ao:exact>metronidazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:319A061D-1A35-4E08-859B-F39DA704D1B4"/>
    <ao:suffix> at high doses for extended periods of time. A cause and effect relationship has not been established. Crohn's disease is not an approved indication for FLAGYL.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-121.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>319A061D-1A35-4E08-859B-F39DA704D1B4</domeo:uuid>
    <ao:prefix>s disease patients are known to have an increased incidence of gastrointestinal and certain extraintestinal cancers. There have been some reports in the medical literature of breast and colon cancer in Crohn's disease patients who have been treated with </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:489FB94C-2475-4EC7-BE20-CF92749745A7">
    <pav:lastSavedOn>2014-07-13 12:34:42 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:88C1F1C9-E75C-4A69-9BFF-84FAF6F2C2ED</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B0AC894E-27E2-43D9-BFEB-167E8117247A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:6A05795B-B1AB-4DB3-A12F-2765CBCC2FED</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 12:34:38 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF873305-5222-4D37-9C71-925D3C390B7A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CF873305-5222-4D37-9C71-925D3C390B7A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>hydroxyrisperidone</ao:exact>
    <ao:prefix>, its major metabolite, 9-</ao:prefix>
    <domeo:uuid>CF873305-5222-4D37-9C71-925D3C390B7A</domeo:uuid>
    <ao:suffix>, and </ao:suffix>
    <pav:createdOn>2014-07-13 11:09:51 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315">
    <permissions:permissions rdf:nodeID="Ndbad6df695d34433be47e84d6cd67d19"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7EA46EFB-1A94-409D-B432-24203EA5400F"/>
    <pav:createdOn>2014-07-13 12:35:54 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9174469-54E0-4FAB-8165-210C50F1F809"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:72594949-CA92-4CEF-8CB6-0072661759A0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DA8337B7-4497-4F34-93E8-291B9ED278CB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C0B517A8-DCD4-4740-A77D-8490A77113AE"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:3BEBBBC1-7503-4FA0-9B16-ED708F2AE108"/>
    <pav:lineageUri>urn:domeoserver:annotationset:7698170F-5CE1-49C4-9F55-5ED355B5BEA7</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:12FA04F1-54A6-4C48-9FDA-8E372C8A648A"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C7A86B1F-FEF9-4500-AC47-4A4949A51ABD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5E38DB7B-2B38-491B-8686-9C2D434ACD79"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:4EEAF739-3D04-465D-8AC0-35EAE4B00AE0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:76D2A20E-E18E-4676-958D-12D182D20430"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:167FB68A-5943-4F0E-8CC6-C6BAB7625E4F"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2014-07-13 12:41:09 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3CE3E7D7-79CE-4BA9-8CA0-7B7A05D77AFC"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:6BF180C6-926E-4F67-84B0-1DC9E664C663"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51F1BD01-1111-4CA2-BC77-65762E0E45AA">
    <pav:createdOn>2014-07-22 19:11:53 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:B94B65A7-B52E-41EB-9E72-C3F942808AFB"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-22 19:11:40 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD65EDB0-5E4A-430E-B9C2-3D953A7DE94C">
    <ao:prefix>ident. For a given body mass index (BMI), females tend to have a greater fat mass than males. Since the molecular target PPARγ is expressed in adipose tissues, this differentiating characteristic may account, at least in part, for the greater response to</ao:prefix>
    <ao:exact> AVANDIA</ao:exact>
    <domeo:uuid>BD65EDB0-5E4A-430E-B9C2-3D953A7DE94C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD65EDB0-5E4A-430E-B9C2-3D953A7DE94C"/>
    <pav:createdOn>2014-07-22 19:34:31 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:suffix> in females. Since therapy should be individualized, no dose adjustments are necessary based on gender alone.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CBCBF368-3CFC-48BC-94C0-C6E5CA87262D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:3D195979-3E82-427D-95B8-F50F48DB4AA7</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 18:52:17 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:56F09161-F30B-4E8B-B945-EBDA08D0D771</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 18:54:35 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:68293B6C-C124-4A8B-AD38-563F597E9486"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7CF0599-4EF7-4EA9-AA71-F3F0B7596EF6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>B7CF0599-4EF7-4EA9-AA71-F3F0B7596EF6</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:26:44 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B7CF0599-4EF7-4EA9-AA71-F3F0B7596EF6"/>
    <ao:exact>The mechanism of action of risperidone, as with other drugs used to treat schizophrenia, is unknown. However, it has been proposed that the drug’s therapeutic activity in schizophrenia is mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:D5B6732B-67A7-4A25-9BC2-70185A35217F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A30DCF7F-AD5F-403E-9FF6-A1CEC51B4252"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A05ABC03-57B2-463F-8733-BF02DB5FE3A7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0A3EAA6A-641B-48C1-A03F-CCA1FF890D64"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:94E71C50-311F-485B-9C5A-D703BD0E29D1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:62793798-1CBD-4B4E-97DB-09E6DED152F0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F5B0ED12-45EB-48BE-B664-DDC78E05AA4A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2FAF656F-18DD-448F-84DF-6CC1FD701820"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FF4B8408-EC34-4E9C-A970-D7F98CF2EEE1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0E2360A5-44FC-4633-8B3E-758DB777C4E6"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:EA6549D1-9142-4B02-863B-C31046392662"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:812A1777-BC32-4760-9024-CF9758CF804E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F64BA1C3-4615-428E-A209-D304847D4A08"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:807433B2-EB3F-4CEF-824C-1D71920A4C22"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:50AA7124-5304-4E5F-8D20-3405C75223FB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:50CB810E-E5CE-4D21-8703-B10F04053C7D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F989B861-2D11-4383-83FA-D6724A4DE400"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2DE3872D-3935-4824-AF9D-DBFF26D2588F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:31C3D8BC-BEE5-4732-B113-5F04341D26EC"/>
    <pav:previousVersion>urn:domeoserver:annotationset:392EE0FB-AC4F-4AF2-87A6-2E50A281F434</pav:previousVersion>
    <pav:createdOn>2014-09-02 19:12:09 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:00C24F6A-259C-4CD5-BB57-3231935B23AE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9BCE3E38-7FC6-48FE-A2E7-EB618F9B1F7F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F0FFC655-44BB-402B-B7C7-6EB6CD49035C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:883BB188-A483-4C32-85F5-63D2C4B33561"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:5EA1A12E-999D-4F07-B3EF-67CFE143F274"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:46890B26-242B-40DA-BF4E-E7B90E54E678"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:53200B7D-3B88-4C24-827A-DE552ED1B23F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0B3096F2-9B83-424A-BCB8-CF996BA224AC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B1D53EEF-8BCA-4B91-B107-30A073406F41"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:66EF0F25-8A90-4498-99B4-6985AB481B18"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:56E0618F-C2A8-4B2E-868E-D415AEE3E3EF"/>
    <permissions:permissions rdf:nodeID="N0a8d04ac97be4b7b9850f253c8187cc7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:968E2714-CEBF-4C37-913F-C2DF10947AB8"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:6BD06504-E85C-4ECF-9079-FE0363DD8508"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED46D326-5EE0-47F9-A0D2-97252A43CE9D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F45CCE04-9C17-4AB6-BF4A-23A94A70AB21"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F1FF7E05-1C80-4A3F-9366-A074CA5EDF15"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:19626855-8C17-4CB6-BD80-697B52F6ADC9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E68B19A2-98CC-4D01-88C9-2BCC8709D27A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:70CC18BE-600E-4B98-B2C6-E5920EB63D79"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:820A8921-32D8-4CA7-991C-5585C1088203"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8621DC71-D1C0-4E5B-97BA-B7275B47A413"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DC77541A-190C-4C62-930E-9CF52E6C4A67"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4B8A305B-D42C-40FD-B384-05FE89B4ACA4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0772E366-3DDD-4D99-A1E7-B6F12EFF65DC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F9653C29-A4D2-424D-A8FE-3DDBAC24C18C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:85752833-4F1F-4395-A378-9451755A600C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:16D91D82-D12B-41E8-A218-F336224CF507"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:25474B79-791D-49D5-B5D1-858E90C62BB2"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:95404334-796F-4A07-A18A-42601A802CDF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B188771E-D938-4A6E-AA65-8D511119CA92"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:42F3EB55-6A92-4EE6-9472-03CDC6E02D69"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DC959F62-91AD-411B-AC17-FFBBEE22EAF0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:939BD222-0159-44F2-9E01-3D674AEF5EFE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DC13A4FA-8B30-458B-9343-4B48CC945EBF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E63ABC8A-4562-42F9-B5F4-6A27DEE50F44"/>
    <pav:lastSavedOn>2014-09-02 19:33:40 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F87926C2-2747-4ED5-93E5-F7C25B2825BF">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F87926C2-2747-4ED5-93E5-F7C25B2825BF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-01 15:57:31 -0400</pav:createdOn>
    <ao:suffix>, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid>F87926C2-2747-4ED5-93E5-F7C25B2825BF</domeo:uuid>
    <ao:exact>carbamazepine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC7897DF-F240-4C01-A8E7-BD5189815B10">
    <pav:lineageUri>urn:domeoserver:annotation:8BE98D27-B14B-4326-9CC3-87A6DD3A1F8B</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-01 16:06:02 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4866C08-5431-4BCB-8D02-35C7E6408B74"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-01 16:06:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA2A0666-709F-4D11-B84E-C64B1709D0F9">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BA2A0666-709F-4D11-B84E-C64B1709D0F9"/>
    <pav:createdOn>2014-09-02 11:30:45 -0400</pav:createdOn>
    <domeo:uuid>BA2A0666-709F-4D11-B84E-C64B1709D0F9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>alprazolam</ao:exact>
    <ao:prefix>), CYP3A4 (e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>), and CYP2C19 (e.g., omeprazole).</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:373141E1-A5DA-4819-A876-BCB2CCE1144A">
    <pav:lineageUri>urn:domeoserver:annotation:341AD40F-1D77-4D32-94CA-1FAF53B56288</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-24 19:44:56 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:511EDFA9-5A42-4340-9D4A-CBF6EDD9185C</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 19:44:20 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:9C2BE5C7-01F4-4E29-A201-893A98F5268A"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/066DE754-7246-47EA-9F6B-DB99A3097E26">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/261455</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>AVANDIA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F68E59B2-9C61-4DC7-A6E2-B96F04B0D293">
    <rdfs:label>AVANDIA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/261455</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CB57EB2-8A93-411F-AFE4-75EE6C88177B">
    <ao:prefix>, </ao:prefix>
    <ao:exact>butorphanol </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3CB57EB2-8A93-411F-AFE4-75EE6C88177B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <domeo:uuid>3CB57EB2-8A93-411F-AFE4-75EE6C88177B</domeo:uuid>
    <ao:suffix>and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride. In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may </ao:suffix>
    <pav:createdOn>2014-09-02 19:08:36 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:507B5E29-9158-4374-B797-6175E792AA48">
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:983811FA-8F7B-417F-9FCB-1073412D65C7</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:05003F42-3401-4DB3-B275-544005230F77"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 15:04:30 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ACE53139-5B8B-4FB2-8940-338C5989D498">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ACE53139-5B8B-4FB2-8940-338C5989D498"/>
    <pav:createdOn>2014-09-02 11:53:56 -0400</pav:createdOn>
    <domeo:uuid>ACE53139-5B8B-4FB2-8940-338C5989D498</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix>: </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution. Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F557214F-193F-480C-8483-C59A8CFCD22E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid>F557214F-193F-480C-8483-C59A8CFCD22E</domeo:uuid>
    <ao:suffix> from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <pav:createdOn>2014-07-13 11:09:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> is 70% (CV=25%). The relative oral bioavailability of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F557214F-193F-480C-8483-C59A8CFCD22E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9A7BCFA2-0D97-4701-B6BB-99407F80BF4B">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:41533E80-E3DB-4B1A-BC74-31DB2EDCBDFA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C914763B-B8F8-41B8-8D18-F2B33883EA27">
    <pav:createdOn>2014-09-02 11:46:02 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C914763B-B8F8-41B8-8D18-F2B33883EA27"/>
    <ao:suffix> maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended. No dosage adjustment is required for fluvoxamine maleate tablets.</ao:suffix>
    <domeo:uuid>C914763B-B8F8-41B8-8D18-F2B33883EA27</domeo:uuid>
    <ao:prefix> is coadministered with </ao:prefix>
    <ao:exact>fluvoxamine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3E38D47-25A8-4196-B6ED-8D47D85B5D94">
    <ao:suffix> is contraindicated in these patients.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C3E38D47-25A8-4196-B6ED-8D47D85B5D94"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:exact>AVANDIA</ao:exact>
    <domeo:uuid>C3E38D47-25A8-4196-B6ED-8D47D85B5D94</domeo:uuid>
    <pav:createdOn>2014-07-22 19:37:28 -0400</pav:createdOn>
    <ao:prefix> with </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3357AB7A-4128-4D9D-8FEF-3908BC9E44F0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-24 20:07:04 -0400</pav:createdOn>
    <ao:prefix>1 </ao:prefix>
    <domeo:uuid>3357AB7A-4128-4D9D-8FEF-3908BC9E44F0</domeo:uuid>
    <ao:suffix> is a registered trademark of Novartis Consumer Healthcare.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3357AB7A-4128-4D9D-8FEF-3908BC9E44F0"/>
    <ao:exact>Maalox®</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE972F8D-C1AD-46A9-B34B-1D883FDAF1EC">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-07 09:40:14 -0400</pav:createdOn>
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CE972F8D-C1AD-46A9-B34B-1D883FDAF1EC"/>
    <ao:suffix>to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7CBD8092-1453-4994-9F29-22622E743A15">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/B7CB635F-4EBF-434B-9159-71DC46A33588"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/94DFD21D-D749-4F5E-AE57-CF5CE30BA0D9"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:874E727F-4FC5-466C-9B3D-C17154D3C2D1">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-201.txt.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>874E727F-4FC5-466C-9B3D-C17154D3C2D1</domeo:uuid>
    <ao:exact>In a pharmacokinetic study with patients on methadone maintenance therapy, phenytoin administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. Upon discontinuation of phenytoin, the incidence of withdrawal symptoms decreased and methadone exposure increased to a level comparable to that prior to phenytoin administration.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-28 17:07:56 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:874E727F-4FC5-466C-9B3D-C17154D3C2D1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:659ED9DF-77DA-41F2-B123-6E455B4F2385">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:3469EEA4-696B-455B-896A-1006CE93364D"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:createdOn>2014-09-01 15:59:50 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-01 16:00:14 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6586910C-89D6-48D4-A5C5-1E4D8CB29677"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:56AEEC1F-6F5E-4CAD-A96A-7EC09CB365C8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:7D618B8B-0DAF-414B-911B-81ED1815FD8C"/>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N6f93e46fc7af42179bb2a5e53ae7f08a"/>
    <pav:lineageUri>urn:domeoserver:annotationset:767CBD9B-B530-4930-AF7E-16533AEFF50A</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-17.txt.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6016855A-FC6C-4F50-BBD3-3126439782E9">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 19:44:46 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 19:41:41 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C8BC97FA-A136-4744-ADD4-4988FBBA6CCB"/>
    <pav:previousVersion>urn:domeoserver:annotationset:514BA51B-D734-4003-A7C3-F03C0F95833A</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20F62F72-784B-45A3-91FF-645FE13940A8">
    <ao:prefix>Plasma </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:20F62F72-784B-45A3-91FF-645FE13940A8"/>
    <domeo:uuid>20F62F72-784B-45A3-91FF-645FE13940A8</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <ao:suffix>concentrations were determined on two occasions (before and following fluconazole 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC </ao:suffix>
    <ao:exact>zidovudine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-21 21:31:06 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F07EC2D-B722-4E66-94F2-FC8B5EEAC608">
    <pav:createdOn>2014-07-24 19:53:38 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-132.txt.html</ao:hasSource>
    <domeo:uuid>9F07EC2D-B722-4E66-94F2-FC8B5EEAC608</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9F07EC2D-B722-4E66-94F2-FC8B5EEAC608"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. Propranolol did not have an effect on the pharmacokinetics of fluvastatin.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB5478ED-0329-4EF5-88A8-06C125D68B2A">
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:C08A8D30-A040-45EF-9873-91013299399D"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 11:30:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50C0FDF6-70A1-4B64-8F05-01088227E5AD">
    <pav:createdOn>2014-09-02 11:43:52 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:CFAB29CD-3C49-4713-BDAE-478181F5EB8F"/>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03276EA7-732F-4344-8706-3960852CCE36">
    <ao:context rdf:resource="urn:domeoclient:uuid:031F5AE1-D155-403C-AE7F-01A1DD9F84AC"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-21 21:30:23 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-21 21:28:25 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:41C8DF88-B17A-4B09-986C-ED152384BD07</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:B394B422-1AAF-4ED4-A3BB-3FB13E961EEA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60">
    <ao:item rdf:resource="urn:domeoclient:uuid:8AEAC215-292C-4E6F-9305-D62BECCA32B2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:02B52C58-6F51-4B2E-9D66-4E523227806E"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A676ABAB-01BC-4D19-9DA7-5CF8687711A8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA8C16C4-EEEA-4E22-BEA7-98D738176A08"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4599F40B-EE74-4C90-A4C8-716EBE52CAA7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1DCA5297-1C05-4654-AADE-90A7C81DD992"/>
    <pav:createdOn>2014-09-02 11:55:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:16C89EA1-7173-40AF-99E3-B5CF422C3FBB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE0574D5-7BB9-4BA6-A291-C37F1314832B"/>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:06439E07-6402-42CF-99AD-58333426FE52"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:28EC9E22-4FF4-4D9B-93F4-C03F41FBC1BB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6522F182-C5C2-4066-893C-355B3A906EBE"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:555D0A1F-632F-4953-A2D8-E08196E7CEB9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:95BF8C06-515D-4690-B616-64E06F6C0C8D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:657DCEFF-DA71-40A0-8E23-F90A79E8F3B2"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B915360D-1136-4865-9637-DFBCBDB0B73D</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:9D275C93-4567-4FDB-902A-6385CDBFA809"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:01B5F725-B643-43F6-B470-6409EC7AE08D"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1338CA36-AF29-4D2A-AAA6-13857E4D14F2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0A617D2E-816A-496B-B5FC-091514B75E33"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:F3272B85-6D67-4686-901C-B1617D8FE66B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BC0DA7A3-93CD-44F0-B862-95BDA351400D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:270BC940-6C4E-4F0E-91AB-DAC2FC78E847"/>
    <permissions:permissions rdf:nodeID="N4828a7615acd4c2cbe5689af36560e8e"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35718176-8B1F-491A-BA1E-B0A7887FDD76">
    <domeo:uuid>35718176-8B1F-491A-BA1E-B0A7887FDD76</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:35718176-8B1F-491A-BA1E-B0A7887FDD76"/>
    <ao:exact>norverapamil</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-127.txt.html</ao:hasSource>
    <ao:suffix>. Verapamil does not affect the pharmacokinetics of propranolol.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-24 19:42:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B206386D-9F43-45A3-96CA-50B346B26C4D">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 11:42:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:FC9F95A3-1FEE-4EEA-8C1A-39DFE96EBAB8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8cd98dbf60b94c1b8dea50213566da16">
    <domeo:sets rdf:resource="urn:pddi:uuid:EE9876CA-9D21-44C9-A6F5-8C0F13C4447C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FCDCF22B-9687-4394-9D96-2255CE012E2D">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1C14E39F-8619-4318-B524-D5D59AE2A868"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 20:17:43 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:84B7AD13-E987-4309-B765-FB5115098E4A</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:432A7650-30CD-4BF8-8B03-ECC3935769BA">
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-24 20:12:18 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:0236C5C5-A2FF-49E3-889E-80589B392E0C</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:04F1D04C-3FDE-4B85-A97A-D8EA12CEF79C"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23E5F3F5-E089-460E-A736-58E2FC44ADC6">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:11:55 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:8FDCFCF8-1579-4EA3-B0D9-73159007B108</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:C84DD53D-5B64-47C5-92EE-E2D0E78BD754"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BAA59CB-3862-4A98-8A6C-AA14E82983DC">
    <pav:lineageUri>urn:domeoserver:annotationset:8B64B96E-071B-44E9-B07F-4E24C15D39AF</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <permissions:permissions rdf:nodeID="Nb98092af08f84e3ab4f13089f993ad23"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:A59202ED-7ABE-4A45-97C0-8272FAD7DF90"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4D592D1B-7B6F-448B-9149-4BBF0B36A730"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-161.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:787692CD-0BB7-4EBC-B1EB-B839CB0674FF"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lastSavedOn>2014-07-24 20:14:42 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:4FEEF689-2803-4ABA-A0A9-56F6C3A923F0"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:5B604E28-4F1B-4B10-A878-DE6620893CDB"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:createdOn>2014-07-24 20:14:32 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:09CCA90F-F1D9-49A6-A47E-B693A373A03E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E785934B-232B-456F-A0C7-F28959E09129">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:5B787EC6-4A3E-44EC-8288-875426F19CB3"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-24 19:37:23 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-24 19:37:34 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:104DADA8-D487-4A8B-A0D8-CC6F4317C2AA</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:079AA7B9-9BE4-4706-A20A-5848B50272B5</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D41626C4-D21B-4872-9F5F-C3F819ACF1BB">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 19:42:53 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:A8A2A505-B5C3-4980-A24B-C5D9EBD9B482</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEB6848-E3C6-4761-8965-41F19EE5D781</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 19:43:34 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:35718176-8B1F-491A-BA1E-B0A7887FDD76"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D23F4554-62F9-4BD8-A750-B7F24EF0C57E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>rosiglitazone.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D23F4554-62F9-4BD8-A750-B7F24EF0C57E"/>
    <pav:createdOn>2014-07-22 19:38:36 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>D23F4554-62F9-4BD8-A750-B7F24EF0C57E</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0072DC69-60A4-45F2-9EA7-C1B1D9B53CA2">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 11:41:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Tacrine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0072DC69-60A4-45F2-9EA7-C1B1D9B53CA2"/>
    <domeo:uuid>0072DC69-60A4-45F2-9EA7-C1B1D9B53CA2</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>: In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administrat</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44EFF86D-2559-4F65-A1D1-E51A6BDD91CF">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:44EFF86D-2559-4F65-A1D1-E51A6BDD91CF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>44EFF86D-2559-4F65-A1D1-E51A6BDD91CF</domeo:uuid>
    <ao:suffix>, such as liver enzyme abnormalities and hearing impairment, is warranted (see ADVERSE REACTIONS).</ao:suffix>
    <ao:exact>azithromycin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-24 20:14:58 -0400</pav:createdOn>
    <ao:prefix>, close monitoring for known side effects of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-161.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/1FCFC8E7-95A0-4188-9582-891391C2CFE6">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluconazole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E74FD429-7BE1-4BBF-BDBE-DA9A73D330DA">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-24 20:07:33 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:25B50478-76B9-41F0-8556-A8AEB125E61E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2025A1F1-3A58-4E3E-A4B7-739A783D52BB">
    <domeo:uuid>2025A1F1-3A58-4E3E-A4B7-739A783D52BB</domeo:uuid>
    <ao:suffix> is therefore not recommended. For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg)</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2025A1F1-3A58-4E3E-A4B7-739A783D52BB"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:exact>nelfinavir</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 19:18:51 -0400</pav:createdOn>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C72F4C30-BFCD-4714-88DE-DBF33CE067AD">
    <ao:exact> lorazepam</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C72F4C30-BFCD-4714-88DE-DBF33CE067AD"/>
    <domeo:uuid>C72F4C30-BFCD-4714-88DE-DBF33CE067AD</domeo:uuid>
    <pav:createdOn>2014-09-02 11:38:17 -0400</pav:createdOn>
    <ao:suffix> alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:820A8921-32D8-4CA7-991C-5585C1088203">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:8AA02101-5E16-4D28-B719-8FAC66F7E101"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:13:15 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC">
    <ao:item rdf:resource="urn:domeoclient:uuid:CDDA5AD1-5495-41C1-821C-109A7D029580"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DDF76582-7387-4F32-A252-95E7B69F65AE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E74FD429-7BE1-4BBF-BDBE-DA9A73D330DA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6A4B6F3D-5923-4FB1-A369-D9FE1BF7FD5C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:875A1582-88A4-40A2-9290-112578B609F1"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:5846C0A3-8519-4160-91FD-DFD71E2DCC95"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B60D6EE8-97E8-426E-9A95-B877100EC48A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:97C469A7-A5FD-4636-8744-4240B805D2D0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1707DB4-5B7C-4588-BAE0-034F66A1800B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6DF7A5F7-A5AA-4B80-A495-D1E04A24A471"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1C538CF6-5CD8-48ED-96FC-B9B3546A66F8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0208A9D0-4889-4F9D-A5F0-C1CBBBE42EE0"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:DF3B3F8F-7CB0-4DA2-B24E-32B9E66603BF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BE69196D-B8BA-4576-AC08-BEA775939851"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7359157D-6F7C-43D2-9127-08D4CCFA7E1A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:432A7650-30CD-4BF8-8B03-ECC3935769BA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:183649A8-AEE3-4F6E-9CCA-10E240E419C8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:19746D22-D232-4FCB-B5B2-64CA519A479E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0EEDF160-BB48-4F3A-8FC7-D52C908CAECC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2D1425A6-04BE-4372-9798-B6059B7EFF83"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A9F0C45F-A9FD-47B4-BBF0-2D2F2CBAD8B9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:986D80D9-D47C-41ED-95FE-F55B1AE2AC9D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4AF71C9F-3EB8-4736-9C47-FEDEAC296DAB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <permissions:permissions rdf:nodeID="N0ae4bdc875a4416ab77028b72c909a79"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:236BB8FF-931E-44E4-8D12-9F1FB83D8082"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DE707944-9AAF-45E4-85A6-2EA10D365226"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:31F715F6-A269-43C4-9AA2-9270BCFEF7C0"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:DDEC112C-9331-4573-8A13-ED3D4798FE89"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:54A742F1-BC99-4080-8071-732BA171793D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3DC39945-7562-466B-9B45-B860249B5C62"/>
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:84BD0311-11DD-4CCD-B082-CEE1C8BAAD37"/>
    <pav:previousVersion>urn:domeoserver:annotationset:37B2514D-1A92-45B1-8A5C-610DA6DC935A</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:A533EC0D-DA36-41E1-8BF3-3650517EB300"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9273B7AD-9357-4702-9126-48471F347ED0"/>
    <pav:createdOn>2014-07-24 20:05:33 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:326CE5A9-3567-4645-9375-940B32F01216"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:24143967-8568-40EB-838F-056E2F0B075C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A05795B-B1AB-4DB3-A12F-2765CBCC2FED">
    <ao:item rdf:resource="urn:domeoclient:uuid:489FB94C-2475-4EC7-BE20-CF92749745A7"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:lineageUri>urn:domeoserver:annotationset:428337F8-4C91-47BA-A4E8-ABD1A86D1498</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N7eda72905af24be98d5f19cfeffe44b0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D3F1A48F-9525-4CA3-8022-C7885849CBC2"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:34:42 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:34:35 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:92530361-A562-40CE-942A-CC181EBE7AD7"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64F7664B-0B75-443E-8A3F-3A145064071E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:85A8E907-AEE7-43A2-A096-5391F5C529CB"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:C988D053-7CF3-4C50-BDB6-7C2B20B837B9</domeo:belongsToSet>
    <pav:createdOn>2014-07-21 21:53:36 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:E18BAA97-6DC8-4523-A6ED-EC1EB1A1FA99</pav:lineageUri>
    <pav:lastSavedOn>2014-07-21 21:55:00 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BBA25E8B-C9EC-4761-85B9-71DE456EB881">
    <pav:lastSavedOn>2014-07-21 21:38:46 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:53465311-823E-4CB3-9C24-4241F449E2C3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-21 21:38:52 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:1F0337A4-2EFA-48BC-A824-5EE6C6368FED</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:A52F0287-AD68-4755-8E11-75217CD4FED8</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59F56EF7-8899-4A8B-904D-B19516E60E30">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:59F56EF7-8899-4A8B-904D-B19516E60E30"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-132.txt.html</ao:hasSource>
    <ao:suffix> with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. Propranolol did not have an effect on the pharmacokinetics of fluvastatin.</ao:suffix>
    <ao:exact>propranolol</ao:exact>
    <ao:prefix>Co-administration of </ao:prefix>
    <pav:createdOn>2014-07-24 19:52:41 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>59F56EF7-8899-4A8B-904D-B19516E60E30</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42DD4654-83AE-4111-86D8-574617EB3CAB">
    <domeo:uuid>42DD4654-83AE-4111-86D8-574617EB3CAB</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:42DD4654-83AE-4111-86D8-574617EB3CAB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 12:56:03 -0400</pav:createdOn>
    <ao:exact>fluconazole</ao:exact>
    <ao:suffix> AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole hal</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/7C9742EE-BA6E-4470-AF96-757C3B8CF332">
    <rdfs:label>Fexofenadine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/87636</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05DDDFF9-6ACB-4806-8A4D-37A221046E18">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>.</ao:suffix>
    <pav:createdOn>2014-09-02 11:40:15 -0400</pav:createdOn>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>lithium</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:05DDDFF9-6ACB-4806-8A4D-37A221046E18"/>
    <domeo:uuid>05DDDFF9-6ACB-4806-8A4D-37A221046E18</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:636BB7C2-294D-452D-967D-461DEF7A510A">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>636BB7C2-294D-452D-967D-461DEF7A510A</domeo:uuid>
    <ao:exact>Risperidone</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:636BB7C2-294D-452D-967D-461DEF7A510A"/>
    <ao:suffix> is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), α1 and α2 adrenergic, and H1 histaminergic receptors. Risperidone acts as an antagonist at other receptors, but with</ao:suffix>
    <pav:createdOn>2014-07-13 11:07:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:808DC7C6-B4BD-432C-A6A2-0F47B3206319">
    <pav:createdOn>2014-09-02 19:10:00 -0400</pav:createdOn>
    <ao:exact>phenytoin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>808DC7C6-B4BD-432C-A6A2-0F47B3206319</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:808DC7C6-B4BD-432C-A6A2-0F47B3206319"/>
    <ao:prefix>, and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone. If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB138E02-5A43-4D20-A598-828A1F13AC26">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>CB138E02-5A43-4D20-A598-828A1F13AC26</domeo:uuid>
    <ao:exact>ketoconazole</ao:exact>
    <pav:createdOn>2014-07-24 20:07:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study). No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochloride alone or in combination with either</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CB138E02-5A43-4D20-A598-828A1F13AC26"/>
    <ao:prefix> 500 mg every 8 hours or </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09BC9686-C635-41F7-85A0-6560EB1B0E1B">
    <pav:lineageUri>urn:domeoserver:annotation:335F50B9-E22A-4E09-99C0-34C4EF941E22</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-01 16:12:36 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1E61DE2D-66C2-4CB4-9D74-6D8DC468ABA3"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:5D381360-05CD-407C-BAB9-6496A42C73E4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-01 16:12:00 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06439E07-6402-42CF-99AD-58333426FE52">
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:9784302E-E2D0-4C10-91A7-37F0E9D1996B</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:55:53 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:D5D8B7FB-8F69-439A-B1F3-0DC084AEDE1E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46345058-661B-476F-9809-F885E60E0311">
    <ao:exact>paroxetine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46345058-661B-476F-9809-F885E60E0311"/>
    <domeo:uuid>46345058-661B-476F-9809-F885E60E0311</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold. The effect of </ao:prefix>
    <pav:createdOn>2014-09-02 12:03:26 -0400</pav:createdOn>
    <ao:suffix> on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:125C14DB-1F35-4667-846F-F789D6D0AFCF">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E72D7D03-AAE5-42A5-A83A-3C68C2C2BCB6"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:85A8E907-AEE7-43A2-A096-5391F5C529CB">
    <ao:exact>valproate</ao:exact>
    <ao:suffix> </ao:suffix>
    <domeo:uuid>85A8E907-AEE7-43A2-A096-5391F5C529CB</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-21 21:53:36 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-56.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:85A8E907-AEE7-43A2-A096-5391F5C529CB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95E14AD2-785D-44CE-B25D-C8A915ADD717">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:88CAF2D5-BF6B-4F50-8663-F233B152EA66</pav:lineageUri>
    <pav:createdOn>2014-07-28 17:00:54 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AFC27E91-AC15-4700-A2C7-343191A7F13A"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:4FC315CC-8F6D-4166-AEB6-FBF9CF2FA510</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-28 17:00:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7C414A6F-D97C-4DE2-83B7-8EA499CCDE11">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7C414A6F-D97C-4DE2-83B7-8EA499CCDE11"/>
    <pav:createdOn>2014-07-22 19:53:20 -0400</pav:createdOn>
    <domeo:uuid>7C414A6F-D97C-4DE2-83B7-8EA499CCDE11</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>AVANDIA</ao:exact>
    <ao:suffix>. No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects.</ao:suffix>
    <ao:prefix> in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:745E9BC2-9930-4FE0-83A2-11668B70C40A">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-22 19:41:54 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 19:44:46 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0A0256F1-F31A-4A0C-BA59-EC817B22A85D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:514BA51B-D734-4003-A7C3-F03C0F95833A</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56E0618F-C2A8-4B2E-868E-D415AEE3E3EF">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 19:19:11 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:43D69C84-CE2E-4308-B875-6976981E58BC"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:545EC8BB-0B95-4E21-B88B-BE07F31247CE">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 19:55:19 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F6BB6E4E-BC80-4ACC-A7B5-88D5847926E4"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:0C65C382-D747-4535-B13B-98E69E9D4718</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F05ECB2E-0877-466E-936C-3A60595FD6B9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-17.txt.html</ao:hasSource>
    <ao:prefix> administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of </ao:prefix>
    <ao:suffix>, suggesting that the decreased clearance was due to a change in the metabolism of the drug. The clinical significance of this decrease in tolbutamide clearance is unknown.</ao:suffix>
    <ao:exact>tolbutamide</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>F05ECB2E-0877-466E-936C-3A60595FD6B9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-01 16:00:05 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F05ECB2E-0877-466E-936C-3A60595FD6B9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4EA9F290-CB9E-46F8-AF87-B09760F74365">
    <pav:createdOn>2014-07-22 20:19:49 -0400</pav:createdOn>
    <ao:exact>Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>4EA9F290-CB9E-46F8-AF87-B09760F74365</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4EA9F290-CB9E-46F8-AF87-B09760F74365"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A2D6969-9724-41E9-BCD8-E35100958761">
    <pav:lineageUri>urn:domeoserver:annotation:1D52E1DA-96E5-4844-867C-9D6C0FB89EA8</pav:lineageUri>
    <pav:createdOn>2014-09-01 16:06:05 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:55590627-6DCB-46F4-B196-1032E6ECA077"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-01 16:06:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ABA0AC7-182A-406C-840C-4443E197D138">
    <pav:lastSavedOn>2014-07-24 19:38:41 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-24 19:38:25 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:1CE9469B-7304-476E-AA93-EA94C2D2AB7C</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:8B0374C4-A360-43F1-A6B7-10442B0A8905"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:DBA2FBEC-FB21-4B1E-AFD1-05AF52CBAB09</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2DBC33BA-B5CF-487A-BE2E-5C3FB9F71111">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-22 19:55:20 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:E742E839-0D02-426E-A4C3-7F1867EC092E</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7B342FF2-047C-4302-8F5E-8EED89D8C32D"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E71F7227-79D2-4BF7-AAF2-F7F5CA5F1555">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E71F7227-79D2-4BF7-AAF2-F7F5CA5F1555"/>
    <ao:suffix> gastrointestinal absorption. This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decrea</ao:suffix>
    <ao:exact>fexofenadine</ao:exact>
    <ao:prefix> coadministration enhances </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E71F7227-79D2-4BF7-AAF2-F7F5CA5F1555</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 20:11:46 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF68257F-3ADB-4BA4-9BD1-247F8428319E">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-22 19:22:27 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:90498C00-BE72-46BA-94D5-04F8265DDA63"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA7B78BE-B91C-4178-9AF1-7DC800EF5121">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:5139C7C3-ACE5-4F03-BC84-8DD2AF187DDB"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-07 11:22:50 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:B08B644F-5630-4DD4-870A-83EE4BFF9279</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B12E6D2-E83F-42E5-821A-DFDAD994F783">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>perienced an event on at least one occasion. All events are included except those already listed in the previous table or discussed in WARNINGS or PRECAUTIONS, trivial events, those too general to be informative, and those not reasonably associated with </ao:prefix>
    <domeo:uuid>2B12E6D2-E83F-42E5-821A-DFDAD994F783</domeo:uuid>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 18:37:56 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B12E6D2-E83F-42E5-821A-DFDAD994F783"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-58.txt.html</ao:hasSource>
    <ao:exact>zonisamide</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1BB855FB-FD90-4495-85CA-4D3634124298">
    <pav:lastSavedOn>2014-07-24 20:02:49 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:189A8E0E-67D6-4C53-A96E-CB48A3B4B2E9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:42B2FE1C-E6AF-411B-A916-428E36F4B282"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-24 20:02:19 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:2A35646F-1DFD-4CD6-9FB4-83DC9A5AE3D6</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE5EBB85-C1D9-438F-B2E8-17B61D972F3D">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> volunteers</ao:suffix>
    <pav:createdOn>2014-07-13 12:48:08 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AE5EBB85-C1D9-438F-B2E8-17B61D972F3D"/>
    <ao:exact>However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male</ao:exact>
    <ao:prefix> </ao:prefix>
    <domeo:uuid>AE5EBB85-C1D9-438F-B2E8-17B61D972F3D</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N592645e7c4f142778c042ef2dc9fae05">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E8BEB68-80C9-4767-BEC0-5810B8C956C0">
    <ao:exact>desmethyl </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>metabolite equivalent to that of a 20 mg oral dose.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E8BEB68-80C9-4767-BEC0-5810B8C956C0"/>
    <pav:createdOn>2014-07-07 09:58:55 -0400</pav:createdOn>
    <ao:prefix>Injection is predicted to provide a pharmacological effect of sildenafil and its N-</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D381360-05CD-407C-BAB9-6496A42C73E4">
    <ao:item rdf:resource="urn:domeoclient:uuid:C3BD9C2A-EDB9-42C4-8D62-372034300BF1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:09BC9686-C635-41F7-85A0-6560EB1B0E1B"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:346B16C2-85FF-42F8-A3AB-6C7DEBB418C7"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-42.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:DCBFA6B2-22F1-4138-ABA7-CDA3F5A19FC6"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2014-09-01 16:11:59 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-01 16:12:35 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N0fda40d7ea8d49f094b68775ed4fba34"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B332456-24D5-452E-8A10-14D40375ED79"/>
    <pav:lineageUri>urn:domeoserver:annotationset:F5BDD98B-931D-46AD-978A-EF6B8EF58A83</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:A5437FEA-0356-41EE-AA7B-C75739F23B59"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7A41AFCF-E95D-4B06-B213-C3D7AC444FB8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40158315-C4E3-4EA7-89A6-6D4031E7590C">
    <ao:prefix>, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:40158315-C4E3-4EA7-89A6-6D4031E7590C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <domeo:uuid>40158315-C4E3-4EA7-89A6-6D4031E7590C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 12:02:39 -0400</pav:createdOn>
    <ao:exact>paroxetine </ao:exact>
    <ao:suffix>may significantly inhibit the activity of this isozyme. In most patients (&gt;90%), this CYP2D6 isozyme is saturated early during paroxetine dosing. In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions i</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B63FFC37-B751-48F0-8F6D-DC3232F9B394">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B63FFC37-B751-48F0-8F6D-DC3232F9B394"/>
    <ao:suffix> with propranolol resulted in up to 50% decrease in propranolol concentrations.</ao:suffix>
    <ao:prefix> or </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-131.txt.html</ao:hasSource>
    <domeo:uuid>B63FFC37-B751-48F0-8F6D-DC3232F9B394</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-24 19:47:46 -0400</pav:createdOn>
    <ao:exact>colestipol</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4AF71C9F-3EB8-4736-9C47-FEDEAC296DAB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:19A46F54-942B-4821-B4F0-DA4F98AAF594</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-24 20:13:04 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:12AC269E-4947-4540-A483-BE43615F8E88"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39B82E57-92E3-4322-A8E6-A3AFF215F02C">
    <ao:item rdf:resource="urn:domeoclient:uuid:0F6275ED-13B1-45BE-8276-90A65C4C4506"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:3E551BB3-088F-4A07-A523-A094DE08768F"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:annotatesResource>
    <pav:createdOn>2014-09-01 15:57:26 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nc3ab48c0a79645e6aa0f8644c9a84e00"/>
    <pav:lineageUri>urn:domeoserver:annotationset:39101FC3-67D7-4AD0-9EEA-6871F413979B</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:C44A8620-423F-46B3-A5AA-096744C9A1FF"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:59CE514A-8B1A-4DA2-92CC-4703FC7215B7"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-01 15:57:39 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:86BC1F50-DBC2-4291-BD23-23F4890101B8"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BEED566B-9689-4906-8331-FFFE92EBBEEE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:C93F0A9D-FE1B-4281-BB1F-58EBF1E21173"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3152AF8A-AAEB-4E0D-8A47-3405FA95E483"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:914E70FC-7296-4025-B9C4-BDAD1F572CC6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08556835-0438-4667-8B70-71388FA5E865">
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2014-07-22 19:36:20 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:38A0F3BF-9F6A-4A3D-89AB-BD75B2AC4CE8"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA8809D6-7C92-459E-B3FE-D31BB8203D90">
    <ao:prefix>(5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to </ao:prefix>
    <pav:createdOn>2014-07-21 21:42:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AA8809D6-7C92-459E-B3FE-D31BB8203D90"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:hasSource>
    <ao:exact>procyclidine </ao:exact>
    <domeo:uuid>AA8809D6-7C92-459E-B3FE-D31BB8203D90</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97DC09C5-358C-425D-918D-34D9317DC89F">
    <ao:suffix> concentrations.</ao:suffix>
    <domeo:uuid>97DC09C5-358C-425D-918D-34D9317DC89F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-131.txt.html</ao:hasSource>
    <ao:prefix> resulted in up to 50% decrease in </ao:prefix>
    <ao:exact>propranolol</ao:exact>
    <pav:createdOn>2014-07-24 19:51:31 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:97DC09C5-358C-425D-918D-34D9317DC89F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA96F07E-C088-44C7-AC16-D0EBD7DBD41D">
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D23F4554-62F9-4BD8-A750-B7F24EF0C57E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2014-07-22 19:38:36 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B307336-ED36-40F6-8DED-B26488A43FD4">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C0ABFAEB-5A08-4B49-A2D0-716AA915DFF2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 11:36:07 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F0C7C89-516F-4D00-BAAB-BA2950277705">
    <ao:prefix> is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses up to 240 mg/day, dose adjustment may be considered. When </ao:prefix>
    <domeo:uuid>2F0C7C89-516F-4D00-BAAB-BA2950277705</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% </ao:suffix>
    <ao:exact>voriconazole</ao:exact>
    <pav:createdOn>2014-09-02 19:16:07 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2F0C7C89-516F-4D00-BAAB-BA2950277705"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1920C60-E3BB-461B-89EC-34061357C4C7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F1920C60-E3BB-461B-89EC-34061357C4C7"/>
    <ao:exact>rosiglitazone</ao:exact>
    <pav:createdOn>2014-07-22 20:18:44 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> is not altered in conditions accompanied by increases in gastrointestinal pH.</ao:suffix>
    <domeo:uuid>F1920C60-E3BB-461B-89EC-34061357C4C7</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix> in healthy volunteers. These results suggest that the absorption of oral </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/089280DB-9E3B-46D1-9448-CA64307E1CBF">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:370F2AF6-A399-4830-9318-16C2CC56C4E5">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F9A7B706-7816-4689-A106-0C28124DEA2F"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/BB308B9B-CA39-4247-9128-9D19C4C28A67"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46461303-C78E-4E52-94D7-0AB13BC2A0A5">
    <pav:createdOn>2014-07-28 17:01:19 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-28 17:01:39 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:05CE82A3-E1C6-497A-B0B0-31DD508C02A1</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C3190341-7099-485B-A4E9-E9FFAB0E8032"/>
    <pav:lineageUri>urn:domeoserver:annotation:5F16508C-3D93-4DE2-A5F1-292B959915AB</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F3CA373-B79A-4B2D-8C96-BFB67CB4B175">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:612855C1-32AF-48C7-A341-A649DD897808"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:6784E1B8-4746-4B76-AE23-2ACB7CBA8ADF</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:16:05 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFE95BF7-1349-414E-B68F-6C5149A03072">
    <ao:exact>TID</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EFE95BF7-1349-414E-B68F-6C5149A03072"/>
    <pav:createdOn>2014-07-07 11:22:43 -0400</pav:createdOn>
    <ao:prefix>exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug interaction studies with CYP3A inhibitors (except for potent inhibitors such as ketoconazole, itraconazole, and ritonavir).</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1554FCFD-7477-413C-879A-913DFFAB5886">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1554FCFD-7477-413C-879A-913DFFAB5886"/>
    <ao:prefix>, a CYP3A inhibitor, at steady state (1200 mg TID) with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact>sildenafil </ao:exact>
    <ao:suffix>(100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 11:24:07 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A361190A-A611-4162-AA47-4014AAEBA0B2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:19172135-E2AA-4088-BCFD-164180C591A3</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:12:23 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E52164F-6FEF-4A1A-A55B-01314BCEB19B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3737933-330F-487F-B41C-CDB0FF5C6F1C">
    <ao:suffix>equivalent to that of a 20 mg oral dose.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:58:59 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D3737933-330F-487F-B41C-CDB0FF5C6F1C"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>metabolite </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97C1D6A3-E462-4C1F-8DD6-513D5AD2268A">
    <pav:lineageUri>urn:domeoserver:annotation:693FA6F8-074D-41A3-9AF3-2256D761F345</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F63AE259-E4D8-48C8-9143-FADBBFAD548B"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 11:07:54 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42F3EB55-6A92-4EE6-9472-03CDC6E02D69">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2CDE5DF-B4CC-4374-8C21-8821B6582DB8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:16:52 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83D060E5-70B4-4270-94D2-6FF812E77E78">
    <domeo:uuid>83D060E5-70B4-4270-94D2-6FF812E77E78</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83D060E5-70B4-4270-94D2-6FF812E77E78"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:12:03 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results fr</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A838F94E-4F5C-413B-9E9E-051199F7FC9F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A838F94E-4F5C-413B-9E9E-051199F7FC9F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-21 21:52:27 -0400</pav:createdOn>
    <ao:prefix>, </ao:prefix>
    <ao:exact>carbamazepine</ao:exact>
    <domeo:uuid>A838F94E-4F5C-413B-9E9E-051199F7FC9F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-56.txt.html</ao:hasSource>
    <ao:suffix>, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other d</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06B4510C-85BF-4E4A-AA80-BA9BF3139105">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:98C6E110-7293-43BC-967C-E828D967CC54"/>
    <pav:createdOn>2014-09-02 11:39:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE5AF44C-D211-4F33-A502-2B4C37E2ACFC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:6CBB0DBC-BDB3-472E-A2C0-B3E73E7BB10B</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N608089a516a345d4a44361d1b5bc39fd"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7F0238CB-D573-4236-AA09-42BC8251946C"/>
    <pav:lastSavedOn>2014-07-24 19:39:22 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-126.txt.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:39262D74-39DF-473E-A61D-3DBC89E74ACA"/>
    <pav:createdOn>2014-07-24 19:39:19 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:1CF0856D-0878-41B0-8A05-7007C19C91DB"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD1FBEAA-B2D7-405D-8489-BDC578CFEAEB">
    <pav:createdOn>2014-09-02 15:06:20 -0400</pav:createdOn>
    <ao:exact> Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of sotalol.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD1FBEAA-B2D7-405D-8489-BDC578CFEAEB"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>BD1FBEAA-B2D7-405D-8489-BDC578CFEAEB</domeo:uuid>
    <ao:prefix> hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-70.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4C303406-873F-442A-82D7-9FA28371D696">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:7CE724FC-6C82-4813-B4E1-392FDE649F66</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-24 19:52:52 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0863579-8D19-4B30-ADD6-2A5BDBC2F482</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 19:53:55 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B748A453-816C-4DEF-91A1-F20E7FC12F1A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D56C301-550F-4FAE-8357-941B7D128A4B">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <ao:exact>buprenorphine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 19:08:37 -0400</pav:createdOn>
    <ao:prefix>and </ao:prefix>
    <ao:suffix>) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride. In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withd</ao:suffix>
    <domeo:uuid>3D56C301-550F-4FAE-8357-941B7D128A4B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3D56C301-550F-4FAE-8357-941B7D128A4B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0AE7742B-EF74-477D-95CF-44A73986D022">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0AE7742B-EF74-477D-95CF-44A73986D022"/>
    <domeo:uuid>0AE7742B-EF74-477D-95CF-44A73986D022</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-122.txt.html</ao:hasSource>
    <ao:prefix>. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, changes in diabetes treatment may be needed based upon clinical response. [See Clinical Pharmacology (12.4).] </ao:suffix>
    <pav:createdOn>2014-07-22 19:06:58 -0400</pav:createdOn>
    <ao:exact>rosiglitazone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72584FCC-E5F1-4130-993B-ED469AE3E810">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:4F012046-527A-4412-B5FE-F766182124E4</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5B7BF8E5-F410-48B2-AF56-5421E6B7FF0B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:15:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:77415BA5-F65C-46BF-B1E8-F58D8F285BE2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:77415BA5-F65C-46BF-B1E8-F58D8F285BE2"/>
    <domeo:uuid>77415BA5-F65C-46BF-B1E8-F58D8F285BE2</domeo:uuid>
    <ao:prefix> (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in </ao:prefix>
    <ao:exact>glyburide</ao:exact>
    <ao:suffix> AUC and Cmax of approximately 30%. In Japanese subjects, </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:51:04 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60DE0286-3CA3-49E7-8170-0F036F3F13E2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-24 20:14:01 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:99DC39B5-C193-4FEC-922A-52F2BAF5AFA5</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:B866F0DD-7DF3-4E04-804F-9A346D40E738"/>
    <pav:createdOn>2014-07-24 20:14:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DCD6738-9404-46BB-A758-BDDEB41B4565</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04EFF21D-F5C9-468D-BFA5-057DD08ABD00">
    <pav:lineageUri>urn:domeoserver:annotation:9901869B-6CBE-4242-B8B1-1CE8B5D728FA</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:11:36 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E804A110-85A5-4650-B960-F11AB9FD25A2"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D62F417A-98ED-4008-ADC4-F7EBC73F9F68">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A332788B-8D94-435B-A2BD-5419224AC500"/>
    <pav:createdOn>2014-07-22 19:48:47 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E960F182-0178-48DA-9F6A-A1F40CDC1A1D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E960F182-0178-48DA-9F6A-A1F40CDC1A1D"/>
    <ao:prefix>, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:12:33 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>warfarin </ao:exact>
    <ao:suffix>and phenytoin, drugs that are metabolized by oxidation in the liver. There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly. Increases in INR and prothr</ao:suffix>
    <domeo:uuid>E960F182-0178-48DA-9F6A-A1F40CDC1A1D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56885854-DBBA-451C-B531-1D54B8C98A0B">
    <pav:lineageUri>urn:domeoserver:annotation:9427347D-3858-453E-8DD2-0BA570A34C9D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lastSavedOn>2014-07-24 19:38:41 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 19:38:56 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:DBA2FBEC-FB21-4B1E-AFD1-05AF52CBAB09</domeo:belongsToSet>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="N97cc11880a0f4d699e83bbe3398d069f"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:67E0B291-7BEC-4E9A-AE3A-91E5111086CD"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD975124-2202-48D6-98F2-6042E8AC8DF1">
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>AD975124-2202-48D6-98F2-6042E8AC8DF1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Oxycodone hydrochloride</ao:exact>
    <pav:createdOn>2014-09-02 19:08:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AD975124-2202-48D6-98F2-6042E8AC8DF1"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <ao:suffix> may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A9B35D2-1697-453D-A110-43EEC635AE7B">
    <ao:prefix> was reduced by 36%. Therefore, to maximize the effects of </ao:prefix>
    <ao:suffix>, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].</ao:suffix>
    <ao:exact>fexofenadine</ao:exact>
    <domeo:uuid>4A9B35D2-1697-453D-A110-43EEC635AE7B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4A9B35D2-1697-453D-A110-43EEC635AE7B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 20:13:00 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EDAAAA2E-DA5E-4DC5-9EDE-0B4E06286E7C">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-21 21:27:51 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:nodeID="Nf25bdae03fc24acf881db3e866476767"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:B6F745E6-5734-4636-A383-683BA4C79E38</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-21 21:28:04 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E36FB611-A4C3-4DBB-9B86-FD93883853AE"/>
    <pav:lineageUri>urn:domeoserver:annotation:6C5335E0-4F46-4772-AFE2-0838AAA48FEB</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B160A10-3999-44C9-A9E0-AB903EF4E9F4">
    <ao:prefix>inant manifestations have been hyper-excitability, convulsions, tachycardia, hyperpyrexia, and hypertension. Although it is not known that other narcotics are free of the risk of such reactions, virtually all of the reported reactions have occurred with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-28 17:01:58 -0400</pav:createdOn>
    <domeo:uuid>3B160A10-3999-44C9-A9E0-AB903EF4E9F4</domeo:uuid>
    <ao:exact>meperidine</ao:exact>
    <ao:suffix>. If a narcotic is needed in such patients, a sensitivity test should be performed in which repeated, small, incremental doses of morphine are administered over the course of several hours while the patient's condition and vital signs are under careful o</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-165.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3B160A10-3999-44C9-A9E0-AB903EF4E9F4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E71470A-E5FA-4B06-9981-E64925A42B90">
    <pav:lineageUri>urn:domeoserver:annotation:EEDCBBC3-C811-4145-B325-0617B41561BD</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:CF43541C-6D0C-436D-805F-CCE8AF9ED52C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 20:18:40 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:575F0CD0-2CEC-4594-9019-B1A6C8BA5D55">
    <ao:suffix> dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to </ao:suffix>
    <ao:prefix>. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, </ao:prefix>
    <pav:createdOn>2014-07-13 12:37:40 -0400</pav:createdOn>
    <domeo:uuid>575F0CD0-2CEC-4594-9019-B1A6C8BA5D55</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:575F0CD0-2CEC-4594-9019-B1A6C8BA5D55"/>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1A79F27D-249B-477A-8F23-ED3A357054B9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8EEB8C5F-684D-4C78-B063-32431C5FE74A"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3010354C-0396-4F68-8730-35FBE74BAACF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8D8724AE-D8FE-4EA2-BC2B-883652CC6520"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0054F81-6A9B-4AF0-9DCB-962A6FC1C418">
    <ao:item rdf:resource="urn:domeoclient:uuid:5D477356-49DE-4F65-97BE-07989E4A1B92"/>
    <pav:lastSavedOn>2014-07-22 18:46:51 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="N288c78171ffa435dbeb0b7195369c3e0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:170D0DFA-5641-4603-80E1-C79ED18CB7D8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FFD8A436-5516-4F50-8C7E-7512116C24BA"/>
    <pav:createdOn>2014-07-22 18:44:30 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:532BC8DC-5349-4E14-AC6A-60B992104491"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-118.txt.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B3FBAFB-BA3F-4404-86D8-EB3FEBC44D50"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:53D686B6-4D2E-4EA7-922E-FFE9A54F0AFC"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:1DBDA3FA-5F1C-4CC1-9712-91AF1D9421C6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9E3F8352-2C14-46DC-9E50-892286D5905F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:7BB31731-2995-4E32-A961-91EF24F0EEE7"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:lineageUri>urn:domeoserver:annotationset:BDA938F7-92DA-40E1-8207-1B5ED3889ECC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:65044E3B-BE66-455E-B576-1B8DF996B6B4">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix>, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower </ao:prefix>
    <ao:suffix> and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:65044E3B-BE66-455E-B576-1B8DF996B6B4"/>
    <domeo:uuid>65044E3B-BE66-455E-B576-1B8DF996B6B4</domeo:uuid>
    <pav:createdOn>2014-07-13 11:13:36 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D693BC09-DDB8-454B-A812-E73AB798F6FA">
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8FCF78FA-4364-4E1D-8DBE-DAD0065AD4F4"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:7E80543E-BF76-4514-92A9-91458DCB802B</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-22 19:35:16 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-22 19:34:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76A2A466-4D5D-4AA1-8114-FAD1FF0E6FC0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:exact>sildenafil </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>(100 mg single dose) resulted in a 140% increase in </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76A2A466-4D5D-4AA1-8114-FAD1FF0E6FC0"/>
    <ao:suffix>Cmax and a 210% increase in sildenafil AUC.</ao:suffix>
    <pav:createdOn>2014-07-07 11:24:12 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:697C8F03-1543-4427-9D85-7967FCEA3100">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D346F3FB-2896-495E-BF67-B2BC6E8F5714"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-07 09:41:30 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D96071F-E598-4A67-BE46-D1F8D7E04E18">
    <ao:exact>risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5D96071F-E598-4A67-BE46-D1F8D7E04E18"/>
    <pav:createdOn>2014-09-02 11:57:44 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <ao:prefix> (4 to 8 mg/day) increased mean plasma concentrations of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold. The effect of paroxetine on the pharmacok</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>5D96071F-E598-4A67-BE46-D1F8D7E04E18</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB0C633B-9063-4FD0-91E9-2810CF1C157A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdOn>2014-07-07 09:40:26 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3D2E5F5D-2D44-4EC9-93CD-D558EE6CAD75"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F888C6E8-7F16-450A-A3B5-0E20C026DA2A">
    <domeo:belongsToSet>urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-01 16:06:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:15C3232E-943A-416F-90D9-C0872C8EC1AA</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-01 16:06:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C13FD629-159C-4DA7-9B01-A5B3536DF254"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35B0C843-6298-4494-92B8-CA2A60C766FB">
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:FED7A6FE-8A79-472C-8B1D-4F49432D005D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1EB12059-BBA2-4D0D-8E36-2569CD51DC88"/>
    <pav:createdOn>2014-09-02 19:09:38 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14F32A7A-80E4-454D-A47D-8CEAFB294984">
    <ao:body rdf:nodeID="N7fb7b59d697b4b7184c9a03ef68ed812"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdOn>2014-07-24 20:04:30 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:F70AB841-7C14-48D1-B543-A45EA067C642</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:14E49F07-F26F-4932-B80D-AB20FFEFDB12"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-24 20:04:12 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:4D9D276D-5B47-405C-A464-29D3E3246BAC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:812A1777-BC32-4760-9024-CF9758CF804E">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 19:12:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CDE42D33-6312-4DF8-AF70-310C20268892"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F66BC8F5-49B9-4B6B-9972-D0A9AFB6AF18">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>quinidine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:560D7055-0BE0-4AE4-9912-39985A237181">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-01 16:04:28 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:70BA73C3-70D0-43D1-9E54-82E0AE865E17</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:93131511-B4E7-412F-AB5A-F8722D2FB55B</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:AE73B237-E7E7-49DE-9295-FF17AED8776B"/>
    <pav:createdOn>2014-09-01 16:04:28 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/25CF5D55-E18C-41A3-8548-34F37BD2A10A">
    <rdfs:label>fosamprenavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/358262</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9C5B173-AFE1-44E0-A146-6AEBE6A982AB">
    <pav:lineageUri>urn:domeoserver:annotation:AD6B5DF1-C69F-4C7D-A37D-3E0DBE84C47A</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:21C1BD16-9B1B-4BDA-B036-93523B41DFDF</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:20DF2C21-448E-4857-BAE0-83C2A6124710"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 19:47:04 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-24 19:46:59 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F8D75BE-6E65-4B3E-AA75-B1FF492AC889">
    <ao:context rdf:resource="urn:domeoclient:uuid:05DDDFF9-6ACB-4806-8A4D-37A221046E18"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 11:40:15 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53465311-823E-4CB3-9C24-4241F449E2C3">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:53465311-823E-4CB3-9C24-4241F449E2C3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>53465311-823E-4CB3-9C24-4241F449E2C3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Tolbutamide </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-29.txt.html</ao:hasSource>
    <ao:prefix>AUC of 26% ± 9% (range: 12 to 39%). </ao:prefix>
    <ao:suffix>Cmax increased 11% ± 9% (range: -6 to 27%). (See PRECAUTIONS.)</ao:suffix>
    <pav:createdOn>2014-07-21 21:38:52 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DDB0C59F-0568-4D74-A9AA-D0E0750F758C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:29E9C9FA-0648-4564-86E4-3E4F28AF69B7"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3272B85-6D67-4686-901C-B1617D8FE66B">
    <ao:context rdf:resource="urn:domeoclient:uuid:F57938E2-AD63-45EA-B996-C0C893D21182"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:170ACB73-F2AA-42BF-B064-7D7B43660DBF</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:58:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40692CE2-57E3-4181-873F-BF7EE5E8B25B">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:060B4AD5-C06D-4579-9AB3-F6932ED1425B"/>
    <pav:lastSavedOn>2014-07-24 20:02:49 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:F54F1F42-E29B-4BF2-B251-F0FD34444115</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:189A8E0E-67D6-4C53-A96E-CB48A3B4B2E9</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 20:01:38 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:964473A2-5981-4815-94A0-CEAF4A357060">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-24 20:05:09 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:71B5C396-7FC2-4A48-9DD6-D8F541D4B553</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:07539CCF-9ED2-4C02-AC53-CD1CF6713CB3</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 20:04:50 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:67B51F20-AA33-44F4-AC6E-1115C0BA7889"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31C3D8BC-BEE5-4732-B113-5F04341D26EC">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:D5BCCF61-F8EE-41B5-8F8E-D5A8F239ED7F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:12:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5D480921-AA61-499B-9C3F-3043269104B4">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:40:13 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:CFAD9029-E218-4465-9975-0A69DA967891"/>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E45A71F-507C-47A7-A012-D482CF4059D6">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:39:42 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:15CCD695-F33B-4A85-9FD0-BAFCB7975EAB"/>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4B52B26-239D-47C5-8E82-702E109CC247">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B4B52B26-239D-47C5-8E82-702E109CC247"/>
    <ao:exact>tolbutamide </ao:exact>
    <ao:prefix>(500 mg single dose) AUC and Cmax following the administration of fluconazole. There was a mean ± SD increase in </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-21 21:38:46 -0400</pav:createdOn>
    <domeo:uuid>B4B52B26-239D-47C5-8E82-702E109CC247</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>AUC of 26% ± 9% (range: 12 to 39%). Tolbutamide Cmax increased 11% ± 9% (range: -6 to 27%). (See PRECAUTIONS.)</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-29.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2FB03C2F-1973-4F66-AF66-7DEAA97D5719">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9C7097E9-595B-4F6E-9745-CA4FB4156079"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7FB9730F-B82C-4408-87AE-CE704E2BFD12">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>7FB9730F-B82C-4408-87AE-CE704E2BFD12</domeo:uuid>
    <ao:exact>rosiglitazone</ao:exact>
    <ao:prefix>The absolute bioavailability of </ao:prefix>
    <pav:createdOn>2014-07-22 19:24:47 -0400</pav:createdOn>
    <ao:suffix> is 99%. Peak plasma concentrations are observed about 1 hour after dosing. Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours). T</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7FB9730F-B82C-4408-87AE-CE704E2BFD12"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/DBD9B114-1A26-42A6-8975-25C258D84F84">
    <rdfs:label>propranolol</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4FEEF689-2803-4ABA-A0A9-56F6C3A923F0">
    <ao:context rdf:resource="urn:domeoclient:uuid:8BCB35DD-E167-44C4-BD7A-709DC2E39765"/>
    <pav:createdOn>2014-07-24 20:14:38 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:D22E3AF2-1E34-4DEC-8926-B89FE6678282</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-24 20:14:43 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:2BAA59CB-3862-4A98-8A6C-AA14E82983DC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4BBBCCF7-77AF-4B32-B246-8C1032EB3DF0">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0863579-8D19-4B30-ADD6-2A5BDBC2F482</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 19:52:41 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:5BA69179-4C83-4FF7-804C-115EDBEB0233</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-24 19:53:55 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:59F56EF7-8899-4A8B-904D-B19516E60E30"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08E3A94E-69BC-45F8-943D-0AE85FC3257B">
    <pav:createdOn>2014-09-02 11:34:59 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:A05276D6-1557-4F87-90F3-A0B48D17A341"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA7A671D-A8CF-4ED4-9A82-73178DBED757">
    <ao:exact>sertraline </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapr</ao:suffix>
    <pav:createdOn>2014-09-01 16:06:00 -0400</pav:createdOn>
    <domeo:uuid>FA7A671D-A8CF-4ED4-9A82-73178DBED757</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FA7A671D-A8CF-4ED4-9A82-73178DBED757"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <ao:prefix>under steady-state conditions. The results of these studies indicated that </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86DB27B2-C2AF-49CE-BCD7-E158388CE52E">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:A27E2049-1CFB-4276-BEE2-19C4F918601D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D98E97B5-BA28-4298-8921-05B56B7A1166"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 18:51:31 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-22 18:54:35 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:3D195979-3E82-427D-95B8-F50F48DB4AA7</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/15A5B0E0-F6E2-41DD-B290-4DFF5706433B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>propranolol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7015192E-CCA2-475B-8C8B-10870378056A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdOn>2014-07-22 19:49:22 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:693EEFEC-7BCC-4823-A86C-533B31687EFA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0B56F971-EB28-4859-ADD4-58040927A5DF">
    <ao:suffix> maleate.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>0B56F971-EB28-4859-ADD4-58040927A5DF</domeo:uuid>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:prefix>There are no clinical studies establishing the benefits or risks of combined use of ECT and </ao:prefix>
    <pav:createdOn>2014-09-02 11:49:22 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0B56F971-EB28-4859-ADD4-58040927A5DF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4AF93FFE-AF2A-4091-98AF-CE5D00B15BB0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4AF93FFE-AF2A-4091-98AF-CE5D00B15BB0"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
    <domeo:uuid>4AF93FFE-AF2A-4091-98AF-CE5D00B15BB0</domeo:uuid>
    <pav:createdOn>2014-09-02 15:04:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, and cyclosporine. Based on the assumption that the relationship between paroxetine’s in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, paroxetine’s extent of inhibition of CYP3A4 activ</ao:suffix>
    <ao:exact>triazolam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE7EF264-FC22-45A9-853D-E8804BE9EF1B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-07-21 21:54:37 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:78619284-035D-4B46-89AF-54BD7FF23461"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N75df271eb2e047ff9cf0bba6152be3f7"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:0F617270-F9F7-43F7-B46E-93AD726CB6E6</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:C988D053-7CF3-4C50-BDB6-7C2B20B837B9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-21 21:55:00 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59DF3B57-4013-45C3-9A3F-23E01D7020B8">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:52224847-1B69-4520-9514-0282DC403A76"/>
    <pav:createdOn>2014-09-02 11:46:37 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEA0DB9F-24A6-4283-B426-FDECA24BE603">
    <domeo:uuid>EEA0DB9F-24A6-4283-B426-FDECA24BE603</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EEA0DB9F-24A6-4283-B426-FDECA24BE603"/>
    <pav:createdOn>2014-07-13 11:12:34 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> plus </ao:prefix>
    <ao:suffix>.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:70094340-3BB3-42EB-8579-D2FEE274AB33">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/C8697DBE-189E-49C7-A34D-563280FA497C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/027E2EA7-BD8C-4E55-AE53-75289D2AB62C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5A32BB60-7D2B-448B-A3EB-21F28A75BB33">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/B6FF0814-E04F-4FA2-8963-BC913DC8898E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D0EF2EA1-1BE2-4B9B-8114-37709CA5774E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12FA04F1-54A6-4C48-9FDA-8E372C8A648A">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 12:38:23 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A810EBBA-9C6C-4A0D-9FD2-AFA2874096F5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:13CBA444-A83A-48E8-AC3C-79379FB9E6F7</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B0781B4-A013-4EA2-8F12-DEE15D23DD0E">
    <ao:prefix> (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. Concomitant use of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B0781B4-A013-4EA2-8F12-DEE15D23DD0E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydrox</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:57:24 -0400</pav:createdOn>
    <ao:exact>paroxetine</ao:exact>
    <domeo:uuid>2B0781B4-A013-4EA2-8F12-DEE15D23DD0E</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE897434-B9A6-4A1A-B7D2-C1748858051B">
    <pav:previousVersion>urn:domeoserver:annotationset:514BA51B-D734-4003-A7C3-F03C0F95833A</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 19:44:46 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:9E1B668B-C744-4EDA-8C35-67ED2D2886D7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 19:43:36 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E924DBB-A7DD-4939-9801-279C7188D87E">
    <ao:suffix> </ao:suffix>
    <ao:exact>AVANDIA</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6E924DBB-A7DD-4939-9801-279C7188D87E"/>
    <domeo:uuid>6E924DBB-A7DD-4939-9801-279C7188D87E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 20:17:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4989A785-0867-4672-982C-3FCFF8AB4F7A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4989A785-0867-4672-982C-3FCFF8AB4F7A"/>
    <domeo:uuid>4989A785-0867-4672-982C-3FCFF8AB4F7A</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-24 20:05:33 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Fexofenadine hydrochloride</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> should not be taken closely in time with aluminum and magnesium containing antacids. In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2342B6D8-C79F-4015-BB88-4C2608E0EBC6">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2342B6D8-C79F-4015-BB88-4C2608E0EBC6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.</ao:suffix>
    <domeo:uuid>2342B6D8-C79F-4015-BB88-4C2608E0EBC6</domeo:uuid>
    <pav:createdOn>2014-07-24 20:05:44 -0400</pav:createdOn>
    <ao:prefix> containing antacids. In healthy adult subjects, administration of 120 mg of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fexofenadine hydrochloride</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2F9FC4A6-CD86-434B-9237-24FD478F9ECA">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/49D3BE30-05A4-4698-AD40-671451F49C7C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F52690C8-04C0-4A9E-B719-C8C7578F5CA8"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:023B39C4-2A61-428E-9D4B-84E60C00EA1D">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-22 19:55:33 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:30CD6C3F-1B6D-4C66-B96F-A460B56D3480"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:403C1687-0E8E-4E45-B22A-85D8A976B2E9</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70CC18BE-600E-4B98-B2C6-E5920EB63D79">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:40918124-C290-4DAB-B23D-F9B3E387A308"/>
    <pav:createdOn>2014-09-02 19:12:24 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/B4FD0768-DC29-42AD-9E32-079005955FF6">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5846C0A3-8519-4160-91FD-DFD71E2DCC95">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-24 20:05:50 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:B4B8ACAF-EC72-42B7-8537-72C0706EA026"/>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C36C5E7A-30AD-4497-9348-913F96DD443E">
    <domeo:belongsToSet>urn:domeoserver:annotationset:40007BD9-0869-48CF-A8F2-BAD26AE3E6E1</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-21 21:31:54 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-21 21:31:17 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:092451F5-B0C0-430C-8896-07F81D33F9E1</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F41B0D87-B434-42EF-90F7-E87825A6741D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4441B5B-C18F-4F66-90A8-3A3306CD1C90">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C4441B5B-C18F-4F66-90A8-3A3306CD1C90"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>and its major circulating N-</ao:prefix>
    <ao:suffix>metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations.</ao:suffix>
    <ao:exact>desmethyl </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:42:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3123DE1C-E4E4-41E2-8666-474B2051A954">
    <ao:context rdf:resource="urn:domeoclient:uuid:2BF35833-2A3B-4AAC-BA24-329D7F891DC5"/>
    <pav:lastSavedOn>2014-07-21 21:30:24 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:53F885E2-F0AA-488B-A5A9-317542EA1C11</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:B394B422-1AAF-4ED4-A3BB-3FB13E961EEA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:28:42 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1FEAE882-CD22-4693-8DC0-495CC155160B">
    <ao:suffix> has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when FLAGYL (metronidazole) is prescribed f</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1FEAE882-CD22-4693-8DC0-495CC155160B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 18:58:19 -0400</pav:createdOn>
    <ao:exact>Metronidazole</ao:exact>
    <domeo:uuid>1FEAE882-CD22-4693-8DC0-495CC155160B</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-120.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:643EA9F8-ED1A-479B-9B59-6A63D55F43F7">
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:5DB19655-BFA0-4BCE-93AA-DD6B932E259B"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:43:51 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97C469A7-A5FD-4636-8744-4240B805D2D0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:47CAE4AD-FEB1-437D-9ADB-758C9BEBE377"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:createdOn>2014-07-24 20:07:48 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-24 20:10:48 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoclient:uuid:8D86A4AC-54BD-4BB3-8B58-AB55DEC01A88</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D390D1C1-F946-4B8E-A2EB-3CBC7637D30E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D390D1C1-F946-4B8E-A2EB-3CBC7637D30E"/>
    <domeo:uuid>D390D1C1-F946-4B8E-A2EB-3CBC7637D30E</domeo:uuid>
    <ao:exact>In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 12:01:08 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> has been evaluated when both drugs were at steady state. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9802981C-E3CC-427F-9464-29E20B17C0CD">
    <ao:prefix>, drugs that are metabolized by oxidation in the liver. There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including </ao:prefix>
    <pav:createdOn>2014-09-02 19:12:43 -0400</pav:createdOn>
    <ao:exact>omeprazole</ao:exact>
    <domeo:uuid>9802981C-E3CC-427F-9464-29E20B17C0CD</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:suffix>, and warfarin concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and prothrombin time.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9802981C-E3CC-427F-9464-29E20B17C0CD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:181AEA3C-635D-4DE0-8CD4-D795EB36DD79">
    <domeo:uuid>181AEA3C-635D-4DE0-8CD4-D795EB36DD79</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix>), CYP2C9 (e.g., </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:181AEA3C-635D-4DE0-8CD4-D795EB36DD79"/>
    <pav:createdOn>2014-09-02 11:30:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).</ao:suffix>
    <ao:exact>warfarin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EACE427F-1066-4C2C-B450-F3CF99633404">
    <ao:suffix> (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects. The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearan</ao:suffix>
    <ao:exact>ritonavir</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EACE427F-1066-4C2C-B450-F3CF99633404"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir. The effect of short-term administration of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-136.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 20:02:07 -0400</pav:createdOn>
    <domeo:uuid>EACE427F-1066-4C2C-B450-F3CF99633404</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A">
    <ao:item rdf:resource="urn:domeoclient:uuid:BB4AA59B-BD34-4506-A617-157D639949C4"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdOn>2014-07-13 12:41:59 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:010AF63D-C71E-4A93-9F41-8E5764F068ED"/>
    <pav:lineageUri>urn:domeoserver:annotationset:CE4C4228-2925-4DF5-84E2-5A5B519C5595</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:2EC3D9EC-E1A7-4DD1-A006-50B08564335E"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:1B6E9A08-C112-4656-8901-F8802CD64317"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:67CFE2D6-F2AA-4465-A433-B26BEA64FB5E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5A5707CC-D3AC-4807-9E98-6536CDC7AC55"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:F0E54D90-28C4-48FD-B72C-21011511DD58"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A0645479-B3CA-4505-B451-B003C3B19554"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="Ned262ffe895e4d349861bd05bb3f95c1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3190341-7099-485B-A4E9-E9FFAB0E8032">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-28 17:01:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Meperidine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-165.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C3190341-7099-485B-A4E9-E9FFAB0E8032"/>
    <ao:suffix> is contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitors or those who have recently received such agents. Therapeutic doses of meperidine have occasionally precipitated unpredictable, severe, and occasionally fatal reactions i</ao:suffix>
    <domeo:uuid>C3190341-7099-485B-A4E9-E9FFAB0E8032</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48D839E5-6B0A-4EC3-B64A-E3E20E06246A">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:06A101E3-2794-4554-92A9-5297495C183D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D6A80456-C24A-4B51-9FF1-54B2442E9245"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:70E66A8A-36A7-4A61-AFC4-4E0A6DF9B0BC"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B8794C27-AB48-4247-A5DC-F99E0DB48B2D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D0923EA-66A5-4F6E-A3E6-A3D09E9AA9FA"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:4FEA5923-D748-4E87-8041-D8BE9DFF7EAA"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Nb85c2d59ca0b43a7865e0923fbf55525"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C889EF0F-E8A2-4563-BA94-C8364D653756"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-201.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:2551E950-6EBC-471F-B165-F68320BB8C62"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2014-07-28 17:04:15 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:034D46EE-44D2-4CA1-8E4F-58992C64123C</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-28 17:08:37 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB9F8CF3-932C-4B62-8B9D-7E4C3E1A4FF6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydrox</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 12:03:00 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DB9F8CF3-932C-4B62-8B9D-7E4C3E1A4FF6"/>
    <domeo:uuid>DB9F8CF3-932C-4B62-8B9D-7E4C3E1A4FF6</domeo:uuid>
    <ao:exact>paroxetine</ao:exact>
    <ao:prefix> (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. Concomitant use of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C2BE5C7-01F4-4E29-A201-893A98F5268A">
    <ao:suffix> does not alter the pharmacokinetics of propranolol.</ao:suffix>
    <pav:createdOn>2014-07-24 19:44:20 -0400</pav:createdOn>
    <ao:exact>Diazepam</ao:exact>
    <ao:prefix> and its metabolites. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-128.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C2BE5C7-01F4-4E29-A201-893A98F5268A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>9C2BE5C7-01F4-4E29-A201-893A98F5268A</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90498C00-BE72-46BA-94D5-04F8265DDA63">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:22:27 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:90498C00-BE72-46BA-94D5-04F8265DDA63"/>
    <domeo:uuid>90498C00-BE72-46BA-94D5-04F8265DDA63</domeo:uuid>
    <ao:suffix> in combination with other hypoglycemic agents were generally similar to those seen with AVANDIA in monotherapy.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix>The pattern of LDL and HDL changes following therapy with </ao:prefix>
    <ao:exact>AVANDIA</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/CE1B6F16-57BD-40EB-AB83-B1A40576F8C0">
    <rdfs:label>rifampin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261">
    <ao:item rdf:resource="urn:domeoclient:uuid:FBE8BF3F-CF31-4746-AE08-52B8B70D3AA7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A75B59C8-60A9-4317-B506-9477A97901ED"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AA680547-50B2-43E1-8768-6007654CDEF9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:137CD66C-79A5-4DE2-BF83-E1E083B1F26F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:17DEFB36-51D5-4E3A-92CC-91E1F7EEAE4B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CF4B56FC-1048-4C85-AD05-E8D9C4F159CF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED9A4881-5A44-4C07-BAFB-529340D632F3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5C77DFAE-836C-475E-BE78-637BCFAAA992"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ECE7CA77-7E57-44B0-89AE-B78915FEC8C2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:82628688-78B9-45FB-8BED-8C81D7B2F03E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED1540C5-0D63-4D37-A891-4B8F18792981"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FCDCF22B-9687-4394-9D96-2255CE012E2D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:424F0823-B0B8-4327-8A43-69119A2195AC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:97BD942B-FE8A-49D9-A08D-AF25357CEE2D"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:669918DD-5E01-4F63-9C3C-FB4172F004FB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23AC6809-BABB-405A-80DE-630CA211B109"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BFE514C1-B428-49F6-A34E-88C9F7618ABF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:08556835-0438-4667-8B70-71388FA5E865"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D519A3CD-A32C-4057-9BB6-FB2AE41AF4A9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:398266C6-18B2-479E-8C00-4B3F67E7DB6D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8C53D58B-D2A3-4A8C-9924-E26E43A59105"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:73B577C5-182A-4914-B557-9A6594045898"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:93764486-40C1-4D42-A6D0-D1FF47D6EC82"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:446F532B-903F-4B10-9F56-9CC000DF6BDF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2D0A6C88-E510-4AF5-8DFB-C35B1F919461"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6667DCF7-AA10-4999-B062-38650C90AEA5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B6681C81-EA03-49F0-8187-EF5752C9D126"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:15E1712B-2693-4DB6-A2FE-D2F158D3A823"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3077386C-E136-4431-9DB1-FC99BF18719B"/>
    <pav:createdOn>2014-07-22 19:08:44 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:0DCFB2B8-8A03-443E-AC2D-8FA3EBDA0087"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D62F417A-98ED-4008-ADC4-F7EBC73F9F68"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:023B39C4-2A61-428E-9D4B-84E60C00EA1D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AF68257F-3ADB-4BA4-9BD1-247F8428319E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:44D9A897-A866-42BB-8DD9-A376BF8D1B3E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9D9E07C8-AA4D-4D08-897A-996E5C499CF6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:13D07A15-03D1-462A-AFD2-4B5FC8458177"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:37E9FF1C-D06E-42C3-944C-482813D8E38E"/>
    <pav:lastSavedOn>2014-07-22 20:22:37 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:545EC8BB-0B95-4E21-B88B-BE07F31247CE"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:9F788EEC-77F0-4E60-8480-F71299529EB7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:585BED0D-5182-4D39-912D-F355B5BEA6BA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2506F4F5-773E-4CCD-8303-CC244D5848D1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6981279A-8AEC-4DEB-BDFB-296A4FDF471C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AF177109-0D4D-4DEA-BD5C-F29B10621C02"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:745E9BC2-9930-4FE0-83A2-11668B70C40A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:503397EF-2F88-4CC5-9295-97542C30A8DC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EF32B76C-C252-4DA7-9AC6-7FCD32EE9F83"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5C47D157-D8A4-4053-B2C7-7ECD1B16B721"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B1EDC65E-7D2E-4E9E-9D08-0D72BD366C29"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:0FDB999F-470E-431C-829C-F231318245D8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5E8A53CD-1A4A-4A56-ABAA-82D073884595"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F895E903-9E93-41BD-BED1-2EA2CE628B45"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:544614C5-3057-4129-841C-95DBCD1340A4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:851EB41C-687B-464B-9105-16513BFE3A24"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9C9FE015-E10A-4124-9250-BA73B7E52470"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE897434-B9A6-4A1A-B7D2-C1748858051B"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:513FF3F1-4FCE-4790-A5C9-F75162D3687B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:292BF8EC-0E65-4E33-A331-3D217DD6B134"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BD61A2B7-5272-4F6D-A4A5-94082E805ED6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D7B822C5-ED4F-4553-B7A4-E4C2A921922B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4E71470A-E5FA-4B06-9981-E64925A42B90"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:37752019-6AF8-406B-9C87-6BCEF8ED7AAE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7015192E-CCA2-475B-8C8B-10870378056A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23D9C242-E097-43FB-88F0-20E20588FBFC"/>
    <permissions:permissions rdf:nodeID="N6062d078326342bea09692e19a8080f2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E50BE5A6-0C68-4839-AB64-4D7AED50EDAC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:84AD1907-FCD9-44ED-A2B9-CE7DA4A1A9AA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7086D655-845E-4135-B24F-75B4FFD47BD0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:C4558C3C-CC16-4A44-85EC-2AB4969F8A0D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2AE98FC9-CA39-4A5E-9A97-02182489F1DE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E2D1A706-CE7E-4379-97CF-4EE9CA384DB2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3E692274-1B14-40DE-8BD6-F464FE52CF01"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:15050075-436C-4668-9987-03D689AE2236"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:796FE422-C147-4AA7-A57F-067429194AA4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BFF65D4B-C4C0-4D4B-82C1-14B60D53FB1D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4411E759-9248-468B-B2F6-E5A5A8657C4C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:66A10386-3791-4236-BBA2-9E3AD59B847D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F2F7D256-D331-45B3-9459-089EEB530262"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FF1FC131-57E9-4A89-8FBF-B786D1543F24"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:78A5F631-80CE-4FB1-974D-F82BE8D8E584"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:463EFB94-13AD-4945-B3D3-4B953F099775"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:62F73A2A-2D49-4A1C-B836-1F3280DE6ACE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:51F1BD01-1111-4CA2-BC77-65762E0E45AA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2DBC33BA-B5CF-487A-BE2E-5C3FB9F71111"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:414AB21B-E61F-45BC-90CC-D10C8E784BF6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3E33C30E-6EC7-463F-A8C1-B699338A149B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D1F55052-16DF-4B25-AC16-7645C8E4AD77"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7616318E-C362-4BC0-B027-F84CBEA6207C"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2914A3FD-DF43-4F78-999C-77CE7A028B19</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:BD929BB0-93FC-4E77-9CA8-72C96F88EBB3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:29694BD5-41F2-4693-A623-AABDC826F754"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2BB40EDC-DE0E-4B5E-AEE3-DCE89148115F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D693BC09-DDB8-454B-A812-E73AB798F6FA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:52B64BE2-7636-4E5D-B162-D84F2D892E3D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E3C70535-C49A-4807-84DF-3951A0E27152"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:71244950-C950-47EB-A32B-D2748E51EF60"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D0D19A7-AA2E-4F5C-86E6-0B171A00A7B1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA9B3930-3D00-45F4-81DF-D789FB3565E3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D555EE88-9218-4AF9-81CC-40D543746D77"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FA96F07E-C088-44C7-AC16-D0EBD7DBD41D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B28EDC18-743D-4015-956F-B084F96B3589"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0A960BCB-9A9F-4998-9418-33D622C35F7C"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:6A67B256-CA48-48CA-B584-DB13E0D52B58"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:6016855A-FC6C-4F50-BBD3-3126439782E9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5CE56B1D-ACF0-4124-B31E-62EF1E11FED8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A68BF389-96D4-4F16-BF9D-C1BF35E3CE01"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F8EAE386-C8C4-4874-BD9D-09F2FAF602D8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09CCA90F-F1D9-49A6-A47E-B693A373A03E">
    <pav:createdOn>2014-07-24 20:14:49 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-24 20:14:43 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:13221C48-455C-448D-963D-B21F34F136A4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1A2265F0-B7D6-4A47-834F-F540E39BE257"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:2BAA59CB-3862-4A98-8A6C-AA14E82983DC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ACDCB5F4-8A15-444E-AB50-018A46C6500F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ACDCB5F4-8A15-444E-AB50-018A46C6500F"/>
    <ao:suffix>, and iron salts). In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-09-02 19:12:11 -0400</pav:createdOn>
    <ao:exact>esters</ao:exact>
    <domeo:uuid>ACDCB5F4-8A15-444E-AB50-018A46C6500F</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23EBC507-A336-4506-9D28-78F1ECDFDF8B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:23EBC507-A336-4506-9D28-78F1ECDFDF8B"/>
    <ao:exact>tomoxetine</ao:exact>
    <ao:suffix> has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state a</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 12:03:29 -0400</pav:createdOn>
    <domeo:uuid>23EBC507-A336-4506-9D28-78F1ECDFDF8B</domeo:uuid>
    <ao:prefix> on the pharmacokinetics of a</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:511EDFA9-5A42-4340-9D4A-CBF6EDD9185C">
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-24 19:44:56 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:864B2878-F3F7-49DF-B591-E0E101E10F02"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:3F0937C0-5C7C-49F4-A929-655D47825AE9"/>
    <pav:createdOn>2014-07-24 19:44:04 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Ncfb145fdb974485997b36d898fb1f287"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B16948AC-DC5A-471F-B39F-849EE793A353"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-128.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:E456854E-5580-4BC4-A878-DCBA76DC28FA"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:87027A0D-796C-443F-ADD9-9F9890FD40ED"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CEF578D1-19C2-4C11-9689-C713DB6D19A6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:373141E1-A5DA-4819-A876-BCB2CCE1144A"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:33F0F3E1-6662-4AD7-B2E4-3F73AF120086</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:752D3341-6554-481E-A205-06C244A6CD0A">
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:632B82EF-22AD-4B0E-97DC-A03C1CE546AB</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:AFC067D9-3DC4-4FB0-B028-1D222EE28907"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 15:04:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4ADFA01-70C2-42CC-87CC-869B81E3104E">
    <pav:lineageUri>urn:domeoserver:annotation:56FD27A9-9A20-480B-9750-E65B79E50EDB</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 12:46:24 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A0AE7AB-260B-4296-BC83-DB443FEE5161"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F87D2273-7E05-4F58-B46E-DA5B9D8816DE">
    <pav:lastSavedOn>2014-07-24 19:54:44 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:450319D6-0B1D-4008-A222-CF6FE648CCD6</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-134.txt.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N9d6a07932077407f97f12ca451cf8c5c"/>
    <pav:createdOn>2014-07-24 19:55:03 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:BB5170BC-470C-4927-94E9-76D8F5299B74"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:18F9EC5C-6A37-4A41-85DF-87BCEB900110"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:120B172A-5B0A-4411-BB16-2CE6618D971C">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:26:52 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-21 21:27:51 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:B6F745E6-5734-4636-A383-683BA4C79E38</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:4D5053F3-2E7B-45B1-9C0B-62DBD3C8B27C</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:8CCC8C43-B443-46E4-8630-042448CA24F6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DCEF4B50-19DE-4DDE-ADB0-22E897CE8FC1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DCEF4B50-19DE-4DDE-ADB0-22E897CE8FC1"/>
    <ao:exact>metformin</ao:exact>
    <ao:suffix>, AVANDIA improved glycemic control in both males and females. In metformin combination studies, efficacy was demonstrated with no gender differences in glycemic response.</ao:suffix>
    <ao:prefix>As monotherapy and in combination with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:31:27 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>DCEF4B50-19DE-4DDE-ADB0-22E897CE8FC1</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46890B26-242B-40DA-BF4E-E7B90E54E678">
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 19:18:02 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B237E79-AEFA-4271-8E72-C8B5A1D78190"/>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28368420-4E42-4D08-91FB-67DAADA661EC">
    <ao:suffix>, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15. Dose red</ao:suffix>
    <ao:prefix> is therefore not recommended. For other antiretroviral drugs, such as </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:exact>saquinavir</ao:exact>
    <domeo:uuid>28368420-4E42-4D08-91FB-67DAADA661EC</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:28368420-4E42-4D08-91FB-67DAADA661EC"/>
    <pav:createdOn>2014-09-02 19:18:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0991F050-6152-45E8-8D40-DC901E368C9E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0991F050-6152-45E8-8D40-DC901E368C9E"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <domeo:uuid>0991F050-6152-45E8-8D40-DC901E368C9E</domeo:uuid>
    <ao:prefix>Renal Impairment: In patients with moderate to severe renal disease, clearance of the sum of </ao:prefix>
    <pav:createdOn>2014-07-13 11:17:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> and its active metabolite decreased by 60% compared to young healthy subjects. Risperidone doses should be reduced in patients with renal disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8786A121-1479-4E39-A0A4-280F6167DD01">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 11:43:18 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E65733E-5455-4115-AFE9-BA2E1EB6BB2F"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC0A22A6-E91A-4E15-A935-E1021555864A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EC0A22A6-E91A-4E15-A935-E1021555864A"/>
    <pav:createdOn>2014-07-22 19:55:11 -0400</pav:createdOn>
    <ao:prefix>therapy. </ao:prefix>
    <ao:exact>Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%. In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>EC0A22A6-E91A-4E15-A935-E1021555864A</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B866F0DD-7DF3-4E04-804F-9A346D40E738">
    <pav:createdOn>2014-07-24 20:14:10 -0400</pav:createdOn>
    <ao:exact>mexiletine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B866F0DD-7DF3-4E04-804F-9A346D40E738"/>
    <ao:prefix>ted reports of drowsiness, nystagmus, ataxia, dyspepsia, hypersensitivity reaction, and exacerbation of congestive heart failure in patients with pre-existing compromised ventricular function. There have been rare reports of pancreatitis associated with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> treatment.</ao:suffix>
    <domeo:uuid>B866F0DD-7DF3-4E04-804F-9A346D40E738</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-160.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6BFB4F6-55F6-4660-A8CF-B7A01D2650C1">
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEB6848-E3C6-4761-8965-41F19EE5D781</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 19:43:34 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:794FFC2B-AC60-4181-8773-B24EE98EB4EB</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:D0643518-055A-42DE-BA98-B5C01760828C"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-24 19:42:43 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:420A77EC-3CAE-4EA3-B428-B635FA4A9F5D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:1734C6CD-F7E3-40D2-B440-4C5D8B428556</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 11:11:13 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:804C4BF7-B45B-4CC2-BD44-707AAD50F219"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9C5564E-F653-404D-B333-299E63141AF5">
    <pav:createdOn>2014-07-13 11:15:52 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D78CEABF-EE24-4AFF-81A9-B148050EFE16"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:228452B8-64FE-4746-AB80-952A986140F5</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C37E9D5-F4A3-4CDB-AE4B-E46CCA6F2A60">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:exact>AVANDIA</ao:exact>
    <ao:prefix>Increases in LDL occurred primarily during the first 1 to 2 months of therapy with </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6C37E9D5-F4A3-4CDB-AE4B-E46CCA6F2A60"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 19:16:20 -0400</pav:createdOn>
    <domeo:uuid>6C37E9D5-F4A3-4CDB-AE4B-E46CCA6F2A60</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> and LDL levels remained elevated above baseline throughout the trials. In contrast, HDL continued to rise over time. As a result, the LDL/HDL ratio peaked after 2 months of therapy and then appeared to decrease over time. Because of the temporal nature </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A221420-4081-46A9-839D-6DA46028DA4B">
    <pav:createdOn>2014-07-22 19:25:31 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:exact>AVANDIA</ao:exact>
    <domeo:uuid>5A221420-4081-46A9-839D-6DA46028DA4B</domeo:uuid>
    <ao:suffix> may be administered with or without food.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5A221420-4081-46A9-839D-6DA46028DA4B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours). These changes are not likely to be clinically significant; therefore, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F95BD67-87EE-4AA9-A33E-A0BCF7921FF0">
    <pav:createdOn>2014-07-13 12:56:00 -0400</pav:createdOn>
    <ao:prefix> after 15 days of </ao:prefix>
    <ao:exact>rifampin</ao:exact>
    <ao:suffix> administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (ran</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0F95BD67-87EE-4AA9-A33E-A0BCF7921FF0"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>0F95BD67-87EE-4AA9-A33E-A0BCF7921FF0</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3BF96FBC-622D-4EC3-80A1-339B20EFCD2C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:16E9C8A9-8DAA-4EB9-8859-7C353FD7C273"/>
    <pav:createdOn>2014-07-21 21:53:44 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-21 21:55:00 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:98C00EB4-0531-430D-AC33-58A40A3AE2BB</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:C988D053-7CF3-4C50-BDB6-7C2B20B837B9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE4E1848-BBFA-4DA4-8738-800749B0AAF2">
    <ao:exact>Daily oral dosing of immediate-release paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.</ao:exact>
    <pav:createdOn>2014-07-21 21:42:56 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>AE4E1848-BBFA-4DA4-8738-800749B0AAF2</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AE4E1848-BBFA-4DA4-8738-800749B0AAF2"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:215CE713-9F50-45C2-808D-0725CC11DF6D">
    <ao:item rdf:resource="urn:domeoclient:uuid:79E9E9CE-1D2A-473E-9AED-36041863A42E"/>
    <permissions:permissions rdf:nodeID="Ne5ca1c7ee16f4e439b69a0df4c61c0b6"/>
    <pav:lastSavedOn>2014-09-01 16:22:41 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:AD52F407-3F2E-43FA-A8DA-659510309A62"/>
    <pav:lineageUri>urn:domeoserver:annotationset:28689965-00D7-4FD6-A246-BDFF4DFC6794</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-45.txt.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FB09B648-AD4B-44C2-AE1F-42FAB75A314E"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:A8053299-E5E9-402F-B927-AC23DB68E0B9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2014-09-01 16:21:59 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8BCB35DD-E167-44C4-BD7A-709DC2E39765">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8BCB35DD-E167-44C4-BD7A-709DC2E39765"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>8BCB35DD-E167-44C4-BD7A-709DC2E39765</domeo:uuid>
    <ao:prefix> at steady-state with a single oral dose of </ao:prefix>
    <pav:createdOn>2014-07-24 20:14:38 -0400</pav:createdOn>
    <ao:exact>azithromycin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnorm</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-161.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:056787DE-BFEB-4038-A418-CB53FF7030DC">
    <pav:createdOn>2014-07-21 21:43:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>significantly decreased plasma levels of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>paroxetine</ao:exact>
    <domeo:uuid>056787DE-BFEB-4038-A418-CB53FF7030DC</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:056787DE-BFEB-4038-A418-CB53FF7030DC"/>
    <ao:suffix>. Any dose adjustment should be guided by clinical effect (tolerability and efficacy). </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-51.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7562C75C-08B1-4D26-BA5E-2C77FA08B4F0">
    <ao:exact>tacrine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7562C75C-08B1-4D26-BA5E-2C77FA08B4F0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7562C75C-08B1-4D26-BA5E-2C77FA08B4F0</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix>: In a study of 13 healthy, male volunteers, a single 40 mg dose of </ao:prefix>
    <pav:createdOn>2014-09-02 11:41:11 -0400</pav:createdOn>
    <ao:suffix> added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating,</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0EA544B7-9EBE-419C-A57B-B74B8AC3FB29">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-07-21 21:44:10 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:body rdf:nodeID="Nd764c18144dd46df889c525e535f67cd"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:7873FB6D-C7A1-42FA-A154-13822B5AA213</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F9EAA1C1-5B83-488C-8314-2E971233350A"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:42248733-4719-42F4-8132-866191F8E708</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-21 21:44:00 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3F0937C0-5C7C-49F4-A929-655D47825AE9">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:03305D4D-6511-4CBA-867A-2D6364F265B8</pav:lineageUri>
    <pav:createdOn>2014-07-24 19:44:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:511EDFA9-5A42-4340-9D4A-CBF6EDD9185C</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 19:44:56 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F8116D96-F5B7-4381-AFCF-C48903001E05"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD7D1F18-857F-4502-9621-F93B88E936D2">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:812F20EC-B150-4CC7-8C67-07A45894D904"/>
    <pav:lastSavedOn>2014-07-28 17:00:02 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="Ne96f1d6348cf4c8da6ada02b64bf08dd"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F9664F35-3DEE-47BF-95B4-E93F2BBC1965"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-163.txt.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:createdOn>2014-07-28 17:00:13 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C1303ECA-74F2-4ED6-A92B-92FD35350359</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:62E1503B-EE9D-40BF-B77B-6779195F8F1F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E15B413C-BEDB-4A09-B61C-CC07F96666DD">
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 11:46:29 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C91687BB-8074-4878-8273-7F14FC861404"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A057858-10CF-4E79-9283-5F1644D9BB0A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-21 21:30:23 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:3CBAF7C7-97EE-4740-8EC9-BC03D8839AB8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:82CD11C4-7E04-4E14-81A6-7D8B8CBC98F0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:B394B422-1AAF-4ED4-A3BB-3FB13E961EEA</domeo:belongsToSet>
    <pav:createdOn>2014-07-21 21:28:29 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B748A453-816C-4DEF-91A1-F20E7FC12F1A">
    <domeo:uuid>B748A453-816C-4DEF-91A1-F20E7FC12F1A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-132.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B748A453-816C-4DEF-91A1-F20E7FC12F1A"/>
    <ao:prefix>, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Propranolol</ao:exact>
    <pav:createdOn>2014-07-24 19:52:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> did not have an effect on the pharmacokinetics of fluvastatin.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A05ABC03-57B2-463F-8733-BF02DB5FE3A7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:35CDD6FE-B2DA-45B7-836A-B05452D0DAB8"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:13:49 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35C90981-123B-4326-86DF-489A6FE9CBFD">
    <domeo:uuid>35C90981-123B-4326-86DF-489A6FE9CBFD</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluvastatin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:35C90981-123B-4326-86DF-489A6FE9CBFD"/>
    <ao:prefix> did not have an effect on the pharmacokinetics of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-132.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 19:52:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D67B7C7-76F8-4FFD-A468-49E9E07064A4">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:39EB4A47-EAC7-4A2A-9B4F-05E57C8A10E3"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:42:08 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3DC39945-7562-466B-9B45-B860249B5C62">
    <pav:lastSavedOn>2014-07-24 20:10:48 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:8D86A4AC-54BD-4BB3-8B58-AB55DEC01A88</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F34547B1-36EF-43A2-81A9-922401A6E906"/>
    <pav:createdOn>2014-07-24 20:07:44 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A46A827E-4936-4BBC-8078-913DD6DAA84E">
    <pav:createdOn>2014-07-13 11:14:00 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:5B70F474-288C-4C1B-AF18-E0EF9B5EE27B</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:CC8C2FEA-C8BE-4A4F-98E3-3E4C44B65C83"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26C8F2D4-9063-4B38-ABF2-AC4FA32AD27F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:89F35E49-064B-44B8-B2CE-6FDE26A34AC7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:44:17 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5A1F4E1-991C-4D93-AC6A-4DEDDF392601">
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:4CEC1749-9AA0-4FDA-B649-6B3CDED4298A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:7920C548-5100-46DE-B19C-AFACF431A0C2</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:56:07 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08713DDF-0935-4B63-B281-AEE56A8D7628">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:6BF6E19B-3833-4401-A589-B16E9522C485"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:A6C1D994-FD1E-4778-8CFC-8AF61A3DA42E</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-07 09:58:53 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:19626855-8C17-4CB6-BD80-697B52F6ADC9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-09-02 19:27:52 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:CB83FFC2-EA71-44EA-8F11-DE80E389C84E</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:4F5662D1-C03B-40DB-AB83-59D0D62748A6"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:32:13 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1827DDD2-0D88-43CF-B4E7-833420181887">
    <ao:suffix> (4 mg b.i.d.) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine.</ao:suffix>
    <ao:exact> rosiglitazone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:40:45 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-116.txt.html</ao:hasSource>
    <domeo:uuid>1827DDD2-0D88-43CF-B4E7-833420181887</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1827DDD2-0D88-43CF-B4E7-833420181887"/>
    <ao:prefix>:  Coadministration of</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A59202ED-7ABE-4A45-97C0-8272FAD7DF90">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-24 20:14:43 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-24 20:14:54 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E6FE6875-950C-46F9-801E-FB47AB83A2ED"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:2BAA59CB-3862-4A98-8A6C-AA14E82983DC</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:C8BC9320-3D21-4D57-81E6-481EA29CFBC0</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:905FFDFF-C273-410A-BE8E-A56C8BC94629">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:B803E851-5AD5-4741-B1B9-1CBAED597E18</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:8F01E73F-19F5-4FA0-A47A-6EC3310E264C"/>
    <pav:createdOn>2014-07-21 21:47:18 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-21 21:49:33 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:FDD961B0-A5E5-4FCF-A847-3D4424A756CF</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0546F8AF-C9DB-4EB6-A2C6-2FB5CABD510D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-29.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>In 13 normal male volunteers, there was significant increase in </ao:prefix>
    <ao:exact>tolbutamide </ao:exact>
    <domeo:uuid>0546F8AF-C9DB-4EB6-A2C6-2FB5CABD510D</domeo:uuid>
    <ao:suffix>(500 mg single dose) AUC and Cmax following the administration of fluconazole. There was a mean ± SD increase in tolbutamide AUC of 26% ± 9% (range: 12 to 39%). Tolbutamide Cmax increased 11% ± 9% (range: -6 to 27%). (See PRECAUTIONS.)</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0546F8AF-C9DB-4EB6-A2C6-2FB5CABD510D"/>
    <pav:createdOn>2014-07-21 21:38:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C49E98B-9150-4558-BA6E-8A0528C6D9D6">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:E3F63B46-8EC1-4286-BFE3-5437DCC1DD99</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 19:38:39 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:190E7AE8-2ACF-42E2-AE00-E433EEA9737C</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:87659984-6B68-48C3-9D52-19757F705CEB"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:38:16 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C538CF6-5CD8-48ED-96FC-B9B3546A66F8">
    <pav:createdOn>2014-07-24 20:08:18 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:lastSavedOn>2014-07-24 20:10:48 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:E80C09FF-4092-4C04-9821-CFC8593DEFD7"/>
    <pav:previousVersion>urn:domeoclient:uuid:8D86A4AC-54BD-4BB3-8B58-AB55DEC01A88</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13D07A15-03D1-462A-AFD2-4B5FC8458177">
    <ao:body rdf:nodeID="N387d00726f3647acbb3945436b2a12c3"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:B65D7AE8-6335-4BF0-A6DD-B4D7C6287875</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:DB2B2DE0-2BB6-4F47-A9DF-A6326E16D770"/>
    <pav:createdOn>2014-07-22 20:21:10 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B06BD29E-2481-4EA0-885B-420749EBE703">
    <ao:suffix> AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900 mg intravenously over a four-hour period (from o</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:46:20 -0400</pav:createdOn>
    <ao:prefix>, there was a significant decrease in </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B06BD29E-2481-4EA0-885B-420749EBE703"/>
    <domeo:uuid>B06BD29E-2481-4EA0-885B-420749EBE703</domeo:uuid>
    <ao:exact>fluconazole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97FF727B-70F7-4A8F-9355-6D53C2602A7E">
    <pav:lineageUri>urn:domeoserver:annotation:7226510B-6369-4D4F-859D-276E6199315C</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:A31AAC0C-4709-458E-B722-42176D2F7E8D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:13:47 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A250DA9B-BB28-425B-B634-A002C82007BD">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/7C9742EE-BA6E-4470-AF96-757C3B8CF332"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/2B0C5D0C-3721-4FB9-8865-41008B332960"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8AC4DB85-84A2-4639-9224-724D4B50FC4B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8AC4DB85-84A2-4639-9224-724D4B50FC4B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>ithium</ao:exact>
    <pav:createdOn>2014-09-02 11:39:59 -0400</pav:createdOn>
    <ao:prefix>: As with other serotonergic drugs, l</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>8AC4DB85-84A2-4639-9224-724D4B50FC4B</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:suffix> may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution. Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA2C0A64-143A-46D5-A408-01FC3EC62525">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:A65B00D7-6AC0-4BC7-B831-3E6D23520F80</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5F4EA581-2F5C-4FF1-8DA3-D5101E760F69"/>
    <pav:createdOn>2014-07-13 11:28:14 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6BF180C6-926E-4F67-84B0-1DC9E664C663">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 12:38:39 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:B86B4616-9A36-459A-BD9A-3E75A70DBB8E</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E2C79BAB-965C-479E-824A-F2884B348419"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2CE66065-C68D-4E90-911C-F8B5E04B3813">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>2CE66065-C68D-4E90-911C-F8B5E04B3813</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:suffix>. In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2CE66065-C68D-4E90-911C-F8B5E04B3813"/>
    <ao:prefix> and </ao:prefix>
    <pav:createdOn>2014-07-13 12:37:33 -0400</pav:createdOn>
    <ao:exact>norethindrone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28F0EB50-7D95-4C50-8040-47E337110AC7">
    <pav:createdOn>2014-09-02 19:08:35 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <domeo:uuid>28F0EB50-7D95-4C50-8040-47E337110AC7</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:28F0EB50-7D95-4C50-8040-47E337110AC7"/>
    <ao:exact>pentazocine</ao:exact>
    <ao:prefix>Do not administer mixed agonist/antagonist analgesics (i.e., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, nalbuphine, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride. In these patients, mixed agonist/antagonist analgesics may reduce the an</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5DE379E-8BB3-4609-BFC6-A0E275978ADC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 11:23:45 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:C1698FA2-C1AE-4B3D-9950-C56ECC1CFB3C</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1A7382E8-45D1-4872-98EA-20455089A06B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB09B648-AD4B-44C2-AE1F-42FAB75A314E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:215CE713-9F50-45C2-808D-0725CC11DF6D</domeo:belongsToSet>
    <pav:createdOn>2014-09-01 16:22:02 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:034AD896-FB93-4F64-9796-CB98DF23644B"/>
    <pav:lineageUri>urn:domeoserver:annotation:2E93B705-88F1-45AA-8E94-53BE72B4DA55</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-01 16:22:41 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CEF578D1-19C2-4C11-9689-C713DB6D19A6">
    <ao:context rdf:resource="urn:domeoclient:uuid:BAF53035-A41C-4F81-96B6-41B0D9633025"/>
    <pav:lineageUri>urn:domeoserver:annotation:F859E2F6-DC05-424F-ACDA-CB07A73C778A</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lastSavedOn>2014-07-24 19:44:56 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 19:45:14 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:511EDFA9-5A42-4340-9D4A-CBF6EDD9185C</domeo:belongsToSet>
    <ao:body rdf:nodeID="N13d88b318b684685be021a49551b2eb2"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14E49F07-F26F-4932-B80D-AB20FFEFDB12">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:14E49F07-F26F-4932-B80D-AB20FFEFDB12"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-24 20:04:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-137.txt.html</ao:hasSource>
    <ao:exact>Carbamazepine induces CYP3A4. Following coadministration of carbamazepine 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.</ao:exact>
    <domeo:uuid>14E49F07-F26F-4932-B80D-AB20FFEFDB12</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EC3D9EC-E1A7-4DD1-A006-50B08564335E">
    <pav:lineageUri>urn:domeoserver:annotation:01F5BBDB-E20A-4996-9E0A-81199182C6B7</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 12:44:35 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E17F3ACA-8486-4702-886B-6FA2562FDEFF"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F8116D96-F5B7-4381-AFCF-C48903001E05">
    <pav:createdOn>2014-07-24 19:44:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites. Diazepam does not alter the pharmacokinetics of propranolol.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-128.txt.html</ao:hasSource>
    <domeo:uuid>F8116D96-F5B7-4381-AFCF-C48903001E05</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F8116D96-F5B7-4381-AFCF-C48903001E05"/>
    <ao:exact>Propranolol</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:29BA1C64-71E4-4437-B3E3-C16FF494B3CA">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/5AC4FDB3-99BB-4CC2-9A03-87893DB04756"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F4851EA8-C391-4F16-B8F8-81A3F2688015"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/83E9958D-5BAA-415C-B14A-C204CC3ED68C">
    <rdfs:label>risperidone</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99D19A33-63BB-4F24-96F1-57FE6B759A48">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:99D19A33-63BB-4F24-96F1-57FE6B759A48"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Ethanol</ao:exact>
    <pav:createdOn>2014-07-22 19:55:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>99D19A33-63BB-4F24-96F1-57FE6B759A48</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3152AF8A-AAEB-4E0D-8A47-3405FA95E483">
    <pav:createdOn>2014-09-01 15:57:27 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:36B5198A-3542-4C86-BF30-6375D3BC2CDB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:39B82E57-92E3-4322-A8E6-A3AFF215F02C</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:8E2AFF27-C876-4683-AE00-8DBC41A95E70</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-01 15:57:39 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBDA4EF3-E793-47E4-9F6F-74592DE48307">
    <pav:createdOn>2014-07-13 12:44:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EBDA4EF3-E793-47E4-9F6F-74592DE48307"/>
    <domeo:uuid>EBDA4EF3-E793-47E4-9F6F-74592DE48307</domeo:uuid>
    <ao:exact>ethinyl estradiol</ao:exact>
    <ao:prefix>. The mean increase in </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <ao:suffix> AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28EC9E22-4FF4-4D9B-93F4-C03F41FBC1BB">
    <pav:lineageUri>urn:domeoserver:annotation:2D98FBF3-6C37-4A7C-8FC6-315ACC460D3B</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5D96071F-E598-4A67-BE46-D1F8D7E04E18"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:57:44 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C889EF0F-E8A2-4563-BA94-C8364D653756">
    <pav:lastSavedOn>2014-07-28 17:08:37 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-28 17:04:48 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D888862A-48F7-478F-BD96-42A7D5B21693"/>
    <pav:lineageUri>urn:domeoserver:annotation:B51D6A91-C630-44CC-96EE-901F0B00549B</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:48D839E5-6B0A-4EC3-B64A-E3E20E06246A</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8D94772-B85A-452F-91A5-C644F8298C08">
    <pav:createdOn>2014-07-07 09:58:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E8BEB68-80C9-4767-BEC0-5810B8C956C0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:34C83714-44E7-4047-8688-163A67040E44</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2CD22D95-BDF9-4FBD-98F2-9CC6023043DD">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/C731F1F0-68ED-49B4-A9BF-768B903AF43C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/6AF445DF-7377-4547-8BE8-05F45AE821E0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA4C8A6E-17D4-47F8-A369-67AF061E9037">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:44:07 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A412DBFC-2FE0-43FA-A538-B84D822A5BFD"/>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:031F5AE1-D155-403C-AE7F-01A1DD9F84AC">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:031F5AE1-D155-403C-AE7F-01A1DD9F84AC"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>031F5AE1-D155-403C-AE7F-01A1DD9F84AC</domeo:uuid>
    <ao:suffix>AUC and Cmax were determined before and after the administration of fluconazole 200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks.</ao:suffix>
    <pav:createdOn>2014-07-21 21:28:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Cyclosporine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf8f3e9d6900445f29e6382be7baffd32">
    <domeo:sets rdf:resource="urn:pddi:uuid:EF55F74E-B5B2-4F66-9B6B-11C22CD3DDC4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:724EC70E-AD36-444C-A1EB-23C9873CB536">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:DE725ECB-6E8C-4D1C-9EE0-A969014D8035"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 19:09:57 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:84923C44-9D21-46C3-9B14-82EC8E46C8A7</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C74E3FF-0F23-47DF-BFE0-C6FFA3577DFE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5C74E3FF-0F23-47DF-BFE0-C6FFA3577DFE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:35:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>rosiglitazone</ao:exact>
    <ao:suffix> was about 2 hours longer in patients with liver disease, compared to healthy subjects.</ao:suffix>
    <ao:prefix> was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects. As a result, unbound Cmax and AUC0-inf were increased 2- and 3-fold, respectively. Elimination half-life for </ao:prefix>
    <domeo:uuid>5C74E3FF-0F23-47DF-BFE0-C6FFA3577DFE</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:544614C5-3057-4129-841C-95DBCD1340A4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:7E80543E-BF76-4514-92A9-91458DCB802B</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 19:35:16 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 19:31:19 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:EB4F72BF-4A36-4030-AF78-3FD9D5E4FE15"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/78B277CF-FACC-42EA-9594-CD77F7E3193A">
    <rdfs:label>erythromycin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4053</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8156B623-1ED5-4672-8474-3E892FC84DF5">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8156B623-1ED5-4672-8474-3E892FC84DF5"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-58.txt.html</ao:hasSource>
    <ao:exact>Zonisamide</ao:exact>
    <pav:createdOn>2014-07-22 18:37:22 -0400</pav:createdOn>
    <ao:suffix> has been administered to 1,598 individuals during all clinical trials, only some of which were placebo-controlled. During these trials, all events were recorded by the investigators using their own terms. To provide a useful estimate of the proportion o</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>8156B623-1ED5-4672-8474-3E892FC84DF5</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:424F0823-B0B8-4327-8A43-69119A2195AC">
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6C2A60D1-56A3-4C14-A2B0-4A75D2CDBF72"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-22 19:39:49 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:207BC1EC-ACF7-457D-B193-939C1AE9DD4B">
    <ao:exact>omeprazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19. For some antiretroviral drugs, such as atazanavir and nelfinavir, decreased serum levels have been reported when given together with o</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:prefix> has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during </ao:prefix>
    <domeo:uuid>207BC1EC-ACF7-457D-B193-939C1AE9DD4B</domeo:uuid>
    <pav:createdOn>2014-09-02 19:17:45 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:207BC1EC-ACF7-457D-B193-939C1AE9DD4B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB1F4800-7A8C-48DD-A103-ADE54191154D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <pav:createdOn>2014-09-02 12:03:45 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4F8ED859-2391-4F15-8FA4-EA14374BCE11"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2093FF56-689E-4246-AF69-F566860B27BF">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E766D1AC-45BC-4579-89AD-BE0DEC69FC35"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:42:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1285AF18-3541-4E0D-9BAA-DDBC5E9C152C">
    <pav:lineageUri>urn:domeoserver:annotationset:76C3B05B-36AE-4506-907E-7AB96328F926</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lastSavedOn>2014-09-02 19:46:58 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:0D11B975-10D6-42DD-93CA-9D9026AA5279"/>
    <pav:createdOn>2014-09-02 19:46:24 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N7bc5dd59ff134e17b222c394bd75c488"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2632D1DD-2AAF-40EA-9A99-DCA6352518F5"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-117.txt.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:58F2142F-5F2A-4136-AB4F-944FA95FB01D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00F93F74-A2F5-4F4F-869B-19496B9D0B0C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:44426881-7EDB-4E11-9DB3-EB4EEC0315EF</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:BD767394-A523-4383-85E2-F42A0A94276D"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-21 21:35:10 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:B61F1A9B-4696-4ED0-80AA-4FE2E9016966</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-21 21:33:43 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8A5F802-A216-476E-AB1E-621B048A27EA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E8A5F802-A216-476E-AB1E-621B048A27EA</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:39:46 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E8A5F802-A216-476E-AB1E-621B048A27EA"/>
    <ao:exact>carbamazepine</ao:exact>
    <ao:suffix> levels and symptoms of toxicity have been reported with the coadministration of </ao:suffix>
    <ao:prefix>: Elevated </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D22E6FA-B90D-49C2-B42F-B8122D48D82A">
    <pav:lineageUri>urn:domeoserver:annotation:462DD4AC-A4D5-481B-AE25-173C924C4620</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:62F3C932-C305-4581-AA4E-BB34C6D0F7D4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-07 11:22:45 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04F1D04C-3FDE-4B85-A97A-D8EA12CEF79C">
    <domeo:uuid>04F1D04C-3FDE-4B85-A97A-D8EA12CEF79C</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> decreases </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 20:12:18 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:04F1D04C-3FDE-4B85-A97A-D8EA12CEF79C"/>
    <ao:exact>fexofenadine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82CD11C4-7E04-4E14-81A6-7D8B8CBC98F0">
    <ao:prefix>AUC and Cmax were determined before and after the administration of </ao:prefix>
    <pav:createdOn>2014-07-21 21:28:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:82CD11C4-7E04-4E14-81A6-7D8B8CBC98F0"/>
    <domeo:uuid>82CD11C4-7E04-4E14-81A6-7D8B8CBC98F0</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluconazole </ao:exact>
    <ao:suffix>200 mg daily for 14 days in eight renal transplant patients who had been on cyclosporine therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks. There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour conce</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA91EE4A-7D39-4CC0-A25E-E5ACA358E916">
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:70E63C27-77CA-4EFB-9B3F-9125C608F260"/>
    <pav:createdOn>2014-09-02 11:38:37 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5034993F-95BA-483B-9B77-F3B8E9E3CFC5">
    <ao:suffix>(100 mg) when administered to 10 healthy male subjects had no effect on the beta-adrenergic blocking ability of atenolol.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5034993F-95BA-483B-9B77-F3B8E9E3CFC5"/>
    <ao:exact>Sertraline </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-18.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>5034993F-95BA-483B-9B77-F3B8E9E3CFC5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-01 16:02:32 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9FBD505E-822F-4348-AFE5-73B2A9104B24">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9FBD505E-822F-4348-AFE5-73B2A9104B24"/>
    <ao:exact>phenytoin </ao:exact>
    <domeo:uuid>9FBD505E-822F-4348-AFE5-73B2A9104B24</domeo:uuid>
    <ao:suffix>dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in p</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-21 21:26:48 -0400</pav:createdOn>
    <ao:prefix>AUC was determined after 4 days of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49838230-189C-4414-9619-31B8A0459B9E">
    <ao:prefix> alone or in combination with either </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-24 20:08:15 -0400</pav:createdOn>
    <ao:suffix> or ketoconazole. The findings of these studies are summarized in the following table:</ao:suffix>
    <domeo:uuid>49838230-189C-4414-9619-31B8A0459B9E</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:exact>erythromycin</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:49838230-189C-4414-9619-31B8A0459B9E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N91892f31a51041c8a93a7c8b14831bec">
    <domeo:sets rdf:resource="urn:pddi:uuid:FC76D7A1-BCF3-4AF0-92CC-E5D2F09F6BD7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:605A1706-1C67-4FBD-9A42-21DF312E4339">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0AE7742B-EF74-477D-95CF-44A73986D022"/>
    <pav:lastSavedOn>2014-07-22 19:06:48 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-22 19:06:58 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:32C325B9-09DD-4A0B-A270-BAA0C42956A1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2B18F6B1-59F7-4EA0-9386-55A934108055</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4BDD5E48-B9CE-48CF-BD41-105B25B3F7D2">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:2D709EC1-24A5-4D2C-9DB0-06873CF173A6</pav:lineageUri>
    <pav:createdOn>2014-09-02 19:40:45 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:1827DDD2-0D88-43CF-B4E7-833420181887"/>
    <pav:lastSavedOn>2014-09-02 19:40:44 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:C9195181-C772-4ED4-ADD8-56970C72AD38</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62793798-1CBD-4B4E-97DB-09E6DED152F0">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 19:12:43 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9802981C-E3CC-427F-9464-29E20B17C0CD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F561698-D9D5-496E-A7E9-97BDA5059FED">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:BA2A0666-709F-4D11-B84E-C64B1709D0F9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 11:30:45 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E2FD166-718B-4FDB-8465-F19A84DE1BB4">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 12:02:51 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5A444D2E-FB37-4D42-8D22-19CAC1F671D0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59E51D24-193D-4075-8FE6-4129F350FD59">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 18:58:24 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6F412DAA-5D4B-4581-AA6A-DB01672CE4BB"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:F2788742-3226-4BFB-9D85-2FC7211066F7</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 18:59:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:481FD8E2-4FE1-48EC-822F-EBE0190A2F47</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE17741D-F10F-4662-94F4-BB9A69F3D7F4">
    <pav:createdOn>2014-07-21 21:47:28 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-21 21:49:33 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A119113-824F-4EAE-B66E-B060687F0A7E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:B803E851-5AD5-4741-B1B9-1CBAED597E18</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:8EFE25C9-2600-4A54-BE26-4485EA6A3DFC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0461B0A0-7D13-480F-A86F-F2496AAA8BE6">
    <ao:exact>atomoxetine</ao:exact>
    <domeo:uuid>0461B0A0-7D13-480F-A86F-F2496AAA8BE6</domeo:uuid>
    <ao:prefix> was given alone. Dosage adjustment of </ao:prefix>
    <pav:createdOn>2014-09-02 11:58:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0461B0A0-7D13-480F-A86F-F2496AAA8BE6"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4866C08-5431-4BCB-8D02-35C7E6408B74">
    <ao:prefix>, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4866C08-5431-4BCB-8D02-35C7E6408B74"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>carbamazepine</ao:exact>
    <domeo:uuid>D4866C08-5431-4BCB-8D02-35C7E6408B74</domeo:uuid>
    <pav:createdOn>2014-09-01 16:06:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC139E5E-6513-4B13-9FE1-980FD4117A68">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-21 21:31:13 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-21 21:31:54 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:092451F5-B0C0-430C-8896-07F81D33F9E1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40007BD9-0869-48CF-A8F2-BAD26AE3E6E1</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:B097095F-835A-459A-BD2D-9F8F332DBE40"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94E71C50-311F-485B-9C5A-D703BD0E29D1">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 19:13:48 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:0BD5228B-2C30-4C04-8347-5E28492ED531"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42423629-C409-4AD4-BBE6-7C86A696F03E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6791DC23-BC40-4E62-815B-0DA5CCA7BD4F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:41:41 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D526C276-CAAE-4E9B-8038-08BB2FB8FBBD">
    <ao:exact>phenobarbital</ao:exact>
    <domeo:uuid>D526C276-CAAE-4E9B-8038-08BB2FB8FBBD</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D526C276-CAAE-4E9B-8038-08BB2FB8FBBD"/>
    <pav:createdOn>2014-07-13 11:15:55 -0400</pav:createdOn>
    <ao:prefix>, and </ao:prefix>
    <ao:suffix>) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54B9529D-9030-4194-B66A-D7ECCBABED1F">
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:DBBBE91C-3E2F-469A-9254-58328E372FEA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:37:41 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0A9334D-2A9F-4B70-AC7A-5A574EACCA65">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:FC36AAD8-731B-4089-8CD4-237A818B35C9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 11:35:32 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07EE36EA-171A-4057-95BE-E666C69DD2C3">
    <domeo:uuid>07EE36EA-171A-4057-95BE-E666C69DD2C3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>methotrexate</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-166.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-28 17:02:39 -0400</pav:createdOn>
    <ao:suffix>. Use of methotrexate with penicillins should be carefully monitored.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:07EE36EA-171A-4057-95BE-E666C69DD2C3"/>
    <ao:prefix> with concomitant hematologic and gastrointestinal toxicity have been observed with </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2D0AAC2-1961-4E4C-93E0-B707D321E662">
    <domeo:uuid>E2D0AAC2-1961-4E4C-93E0-B707D321E662</domeo:uuid>
    <pav:createdOn>2014-09-02 19:42:27 -0400</pav:createdOn>
    <ao:suffix> to voltage-dependent and possibly receptor-operated channels in vascular smooth muscle results in an inhibition of calcium influx through these channels. Stores of intracellular calcium in vascular smooth muscle are limited and thus dependent upon the i</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E2D0AAC2-1961-4E4C-93E0-B707D321E662"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>nifedipine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-117.txt.html</ao:hasSource>
    <ao:prefix> which acts directly on vascular smooth muscle. The binding of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A788721A-520C-402D-95A4-65EC994B3F25">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A788721A-520C-402D-95A4-65EC994B3F25"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>A788721A-520C-402D-95A4-65EC994B3F25</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> does not inhibit any of the major P450 enzymes at clinically relevant concentrations. </ao:prefix>
    <ao:exact>In vitro data demonstrate that rosiglitazone is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9. AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.</ao:exact>
    <pav:createdOn>2014-07-22 19:40:41 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611">
    <pav:createdOn>2014-07-13 12:46:12 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:0569E8E5-928F-4D8D-93AE-056F350503EF"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <permissions:permissions rdf:nodeID="Na7e3c681a1ac497892fc55d801d39f0d"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:190DDFDA-8456-4B27-972C-5E815FA29EBD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DE4A37C3-330E-406A-8B07-E596729011D4"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:5F230A2C-E15E-41D9-8781-4AF5CA3E381E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D2F70BCB-D9EC-44EA-93E7-C33A22842BF2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1B6D964C-5C7B-4A8B-91D1-71E48BED6297"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:60E67B22-5DBF-4F42-9120-BC7E0F398FA0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:37727E88-1331-4D52-A885-1D4C9745A521</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:B4ADFA01-70C2-42CC-87CC-869B81E3104E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EB66F52A-826A-4B19-9DAB-4F305456531E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8F4C5D67-B302-4D5E-86D3-E308EE0C607E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D195979-3E82-427D-95B8-F50F48DB4AA7">
    <ao:item rdf:resource="urn:domeoclient:uuid:86DB27B2-C2AF-49CE-BCD7-E158388CE52E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:264C22B2-F825-4CBC-9FA7-11B3154B2F50</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N7b38eabe4079490a9efa449a8187eb8e"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:996C494E-48A6-41DB-B582-CC68851B64C1"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:CBCBF368-3CFC-48BC-94C0-C6E5CA87262D"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-119.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:B7059CDB-FD5F-4D07-9802-7905CA2F92BA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2014-07-22 18:51:22 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:EAE18A28-D547-4A0F-951B-598FF59A2D26"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9AD8A1AA-8615-46DA-AE55-BBCBAC221CBF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1083CE4D-6393-4589-AC36-1DEC7BFE570A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 18:54:34 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:86768360-42DE-4CD0-A167-0F5E6C6CAE55"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B342FF2-047C-4302-8F5E-8EED89D8C32D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7B342FF2-047C-4302-8F5E-8EED89D8C32D"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>7B342FF2-047C-4302-8F5E-8EED89D8C32D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:55:20 -0400</pav:createdOn>
    <ao:exact>Digoxin</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C2A60D1-56A3-4C14-A2B0-4A75D2CDBF72">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6C2A60D1-56A3-4C14-A2B0-4A75D2CDBF72"/>
    <domeo:uuid>6C2A60D1-56A3-4C14-A2B0-4A75D2CDBF72</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.</ao:suffix>
    <pav:createdOn>2014-07-22 19:39:49 -0400</pav:createdOn>
    <ao:exact>AVANDIA</ao:exact>
    <ao:prefix> is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:812F20EC-B150-4CC7-8C67-07A45894D904">
    <ao:context rdf:resource="urn:domeoclient:uuid:CB40975A-75D0-432E-9BC4-38AE8661FBF6"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-28 17:00:25 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:AD7D1F18-857F-4502-9621-F93B88E936D2</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:B4AAADEA-D177-4862-AE55-20365549BFDE</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-28 17:00:03 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A8053299-E5E9-402F-B927-AC23DB68E0B9">
    <pav:lineageUri>urn:domeoserver:annotation:6245E059-3512-4EE8-B021-453F0EC2955B</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:215CE713-9F50-45C2-808D-0725CC11DF6D</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A2D6105B-A1D5-4610-94EC-C0CB40BB9E6D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-01 16:22:12 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-01 16:22:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1BF82CCC-CD60-4AB5-8C1B-4176DC1A85F3">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1BF82CCC-CD60-4AB5-8C1B-4176DC1A85F3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>The apparent half-life of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>1BF82CCC-CD60-4AB5-8C1B-4176DC1A85F3</domeo:uuid>
    <ao:suffix> was 3 hours (CV=30%) in extensive metabolizers and 20 hours (CV=40%) in poor metabolizers. The apparent half-life of 9-hydroxyrisperidone was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinet</ao:suffix>
    <pav:createdOn>2014-07-13 11:16:53 -0400</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53D686B6-4D2E-4EA7-922E-FFE9A54F0AFC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:6619A95A-D5DA-440A-ACEE-7F01BBD64327</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 18:46:52 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 18:46:07 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N9654ce6ec937425aabbae3e102b05aa9"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:EC4F7D99-8435-471D-98FA-12D2364884E1"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0054F81-6A9B-4AF0-9DCB-962A6FC1C418</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0FFC655-44BB-402B-B7C7-6EB6CD49035C">
    <pav:createdOn>2014-09-02 19:18:12 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:0A177F5C-EB12-4EE0-B135-C40638451C00"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7d4061094731431a80cc23850725f7bf">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:302E5EA3-5D0F-4547-B3A1-1B63352BB1A5">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-119.txt.html</ao:hasSource>
    <ao:suffix>.</ao:suffix>
    <domeo:uuid>302E5EA3-5D0F-4547-B3A1-1B63352BB1A5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Two randomized, open-label, controlled clinical trials of Synercid (7.5 mg/kg q12h intravenously [iv]) in the treatment of complicated skin and skin structure infections were performed. The comparator drug was oxacillin (2g q6h iv) in the first study (JRV 304) and cefazolin (1g q8h iv) in the second study (JRV 305); however, in both studies vancomycin (1g q12h iv) could be substituted for the specified comparator if the causative pathogen was suspected or confirmed methicillin-resistant staphylococcus or if the patient was allergic to penicillins, cephalosporins or carbapenems. Study JRV 304 enrolled 450 patients (n = 229 Synercid; n= 221 Comparator) and Study JRV 305 enrolled 443 patients (n = 221 Synercid; n = 222 Comparator)</ao:exact>
    <pav:createdOn>2014-07-22 18:54:08 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:302E5EA3-5D0F-4547-B3A1-1B63352BB1A5"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:19746D22-D232-4FCB-B5B2-64CA519A479E">
    <pav:createdOn>2014-07-24 20:06:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D344866F-87DE-4A61-99C8-1624A36AC49E"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:body rdf:nodeID="N8458402d605d4d6c8592ab33c692a49d"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5B69523-748D-4576-8C13-43546FFB2F5E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:B5EDCB4C-88FB-4DBE-B359-830C5B6FE5A7</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-22 19:08:05 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 19:08:18 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2B18F6B1-59F7-4EA0-9386-55A934108055</domeo:belongsToSet>
    <ao:body rdf:nodeID="N49b0b28cd9b847a1923f1141acef8370"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CEE8C6E7-92B6-4611-A8A6-213D50A907B1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0772E366-3DDD-4D99-A1E7-B6F12EFF65DC">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 19:16:24 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5F9DA591-B9E4-4841-9D52-F5DDC170AE85"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C901133-925A-4BA8-947F-0FE9FB6D60DB">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5C901133-925A-4BA8-947F-0FE9FB6D60DB"/>
    <ao:exact>ethinyl estradiol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>5C901133-925A-4BA8-947F-0FE9FB6D60DB</domeo:uuid>
    <pav:createdOn>2014-07-13 12:38:04 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:631B556D-C865-4327-8C15-D735A7315C3D">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:20F62F72-784B-45A3-91FF-645FE13940A8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:092451F5-B0C0-430C-8896-07F81D33F9E1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40007BD9-0869-48CF-A8F2-BAD26AE3E6E1</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-21 21:31:06 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-21 21:31:54 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5A5F8C7B-9705-4277-87C9-38037CFFC534">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/EF2D99E6-548C-4F7E-82EC-A1FF35F17CB0"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/43BF860F-DF76-4336-A687-956DE41661F4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C89B51C-E5B9-4048-B277-4FA66AA36C16">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>8C89B51C-E5B9-4048-B277-4FA66AA36C16</domeo:uuid>
    <ao:suffix> (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam,</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-118.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 18:44:33 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8C89B51C-E5B9-4048-B277-4FA66AA36C16"/>
    <ao:prefix> and </ao:prefix>
    <ao:exact>nifedipine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8FCF78FA-4364-4E1D-8DBE-DAD0065AD4F4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8FCF78FA-4364-4E1D-8DBE-DAD0065AD4F4"/>
    <ao:prefix>Unbound oral clearance of </ao:prefix>
    <domeo:uuid>8FCF78FA-4364-4E1D-8DBE-DAD0065AD4F4</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> was significantly lower in patients with moderate to severe liver disease (Child-Pugh Class B/C) compared to healthy subjects. As a result, unbound Cmax and AUC0-inf were increased 2- and 3-fold, respectively. Elimination half-life for rosiglitazone was</ao:suffix>
    <ao:exact>rosiglitazone</ao:exact>
    <pav:createdOn>2014-07-22 19:34:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78B644A0-98B2-496A-9F5D-B3073007740E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:78B644A0-98B2-496A-9F5D-B3073007740E"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Co-administration of propranolol with cimetidine, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively.</ao:exact>
    <pav:createdOn>2014-07-24 19:46:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>78B644A0-98B2-496A-9F5D-B3073007740E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-129.txt.html</ao:hasSource>
    <ao:suffix> Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD61A2B7-5272-4F6D-A4A5-94082E805ED6">
    <ao:context rdf:resource="urn:domeoclient:uuid:E4F0D688-0AAC-4069-A616-725458FCDC7B"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:B014F564-C05F-47C1-8A49-6B6A1D8E64BF</pav:lineageUri>
    <pav:createdOn>2014-07-22 20:18:17 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:98937C65-C245-4875-B071-CCFF5209C083">
    <ao:exact>omeprazole </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:98937C65-C245-4875-B071-CCFF5209C083"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>98937C65-C245-4875-B071-CCFF5209C083</domeo:uuid>
    <ao:prefix>Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 19:12:16 -0400</pav:createdOn>
    <ao:suffix>may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB14DC78-807E-4A6B-BCB8-D66CC1E0A2E7">
    <pav:lineageUri>urn:domeoserver:annotation:46D58FBB-E984-4FAD-AA55-BA245F35E096</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:69C22FA1-8D50-4AA7-ACD8-8F71E69BB8AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:42:49 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:42:42 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D704B671-5676-476E-BB75-84893439C054"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N946c4c6932284cb08d053ef1b8becbda">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4C7B2841-F48B-46C2-A7DF-E954EDF0385C">
    <pav:createdOn>2014-07-22 19:54:59 -0400</pav:createdOn>
    <ao:exact>Glimepiride\n\nSingle oral doses of glimepiride in 14 healthy adult subjects had no clinically significant effect on the steady-state pharmacokinetics of AVANDIA. No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult subjects</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>4C7B2841-F48B-46C2-A7DF-E954EDF0385C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4C7B2841-F48B-46C2-A7DF-E954EDF0385C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0ABFAEB-5A08-4B49-A2D0-716AA915DFF2">
    <domeo:uuid>C0ABFAEB-5A08-4B49-A2D0-716AA915DFF2</domeo:uuid>
    <ao:prefix>, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:suffix>, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacody</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>warfarin</ao:exact>
    <pav:createdOn>2014-09-02 11:36:07 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C0ABFAEB-5A08-4B49-A2D0-716AA915DFF2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndbad6df695d34433be47e84d6cd67d19">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C2EEFE36-AE7E-4BF4-943E-03D2760C673E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C2EEFE36-AE7E-4BF4-943E-03D2760C673E</domeo:uuid>
    <pav:createdOn>2014-07-13 11:08:45 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C2EEFE36-AE7E-4BF4-943E-03D2760C673E"/>
    <ao:suffix> results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of</ao:suffix>
    <ao:prefix>The clinical effect from </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3654752-C204-49F0-B3F7-87C2EE277992">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3654752-C204-49F0-B3F7-87C2EE277992"/>
    <ao:exact>serotonin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the </ao:prefix>
    <ao:suffix> Type 2 (5HT2), dopamine Type 2 (D2), α1 and α2 adrenergic, and H1 histaminergic receptors. Risperidone acts as an antagonist at other receptors, but with lower potency. Risperidone has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:07:24 -0400</pav:createdOn>
    <domeo:uuid>A3654752-C204-49F0-B3F7-87C2EE277992</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2EC2236-F4B5-4F35-8112-88B3BB4A33EA">
    <pav:lastSavedOn>2014-07-24 19:51:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:6C727003-BB8F-45A8-BBAC-ACBE1D4D132E</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 19:51:31 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:97DC09C5-358C-425D-918D-34D9317DC89F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:CD8D2B2B-6FC9-4E6A-AD9D-9F49C2EE67EE</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69FB098B-12F9-4F1C-AE30-F8B99226F270">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:69FB098B-12F9-4F1C-AE30-F8B99226F270"/>
    <pav:createdOn>2014-07-24 19:45:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> with </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-129.txt.html</ao:hasSource>
    <domeo:uuid>69FB098B-12F9-4F1C-AE30-F8B99226F270</domeo:uuid>
    <ao:exact>propranolol</ao:exact>
    <ao:prefix>Co-administration of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:446F532B-903F-4B10-9F56-9CC000DF6BDF">
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:4C7B2841-F48B-46C2-A7DF-E954EDF0385C"/>
    <ao:body rdf:nodeID="N9dcbdc73f84a423cbd2ef2b7012dbfc1"/>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:54:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D9DD245-350D-4E6C-84D1-AA5D144E689A">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D3699069-7DAD-4616-9500-2A16ADBA4010"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-22 18:58:36 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 18:59:41 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:748E0C00-F076-4688-9F44-CC6A5D99FDF4</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:F2788742-3226-4BFB-9D85-2FC7211066F7</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:96647834-C481-4294-B866-A481E00D4F42">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C20ADD05-5DFA-4D15-B8F8-1DD1BE6A5E76"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BC114E92-ED59-4D14-B788-57030FC75EBC">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AB3B0778-C37A-4D38-B2AC-7049DC5E2EE9"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1504073B-965A-43C5-A889-0D6EA22F08A0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>In vitro drug metabolism studies suggest that </ao:prefix>
    <ao:exact>rosiglitazone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1504073B-965A-43C5-A889-0D6EA22F08A0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 19:39:28 -0400</pav:createdOn>
    <domeo:uuid>1504073B-965A-43C5-A889-0D6EA22F08A0</domeo:uuid>
    <ao:suffix> does not inhibit any of the major P450 enzymes at clinically relevant concentrations. In vitro data demonst</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6522F182-C5C2-4066-893C-355B3A906EBE">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:D374971E-30F6-426D-8ED6-7C54E217A624</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:BE2369F6-B30D-45B8-9655-5079A35C9D6D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:58:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F70AB841-7C14-48D1-B543-A45EA067C642">
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-137.txt.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B8E504B5-222C-4BAE-88E1-E79A32308174"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:74CD19CE-F47D-46AD-8DBC-B02B6A6F0D87"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 20:03:38 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:14F32A7A-80E4-454D-A47D-8CEAFB294984"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:0FC34074-15F7-4C00-87F2-8D4B6F9B8889"/>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N4544b76dc7af44d4b5b4c8ef4c82e633"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:2CC86AAA-D8FA-4C97-8FBA-1AFD74F6813F</pav:lineageUri>
    <pav:lastSavedOn>2014-07-24 20:04:12 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:12ACDF1A-FCDF-42E9-A413-FB39FC095FFC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87027A0D-796C-443F-ADD9-9F9890FD40ED">
    <domeo:belongsToSet>urn:domeoclient:uuid:511EDFA9-5A42-4340-9D4A-CBF6EDD9185C</domeo:belongsToSet>
    <ao:body rdf:nodeID="Ne32486d1080a4562b59a22aef1c63dd1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdOn>2014-07-24 19:44:48 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:67F5D7F3-4C61-454A-8DC4-5AF1F8E00A9D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:48081C9F-3CDC-436C-888F-B763536ACD92"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-24 19:44:56 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3B66F49-9D04-482E-BF7F-722441E81595">
    <ao:prefix>, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <domeo:uuid>F3B66F49-9D04-482E-BF7F-722441E81595</domeo:uuid>
    <ao:exact>propranolol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3B66F49-9D04-482E-BF7F-722441E81595"/>
    <ao:suffix>, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).</ao:suffix>
    <pav:createdOn>2014-09-02 11:30:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4A07D2A-59AD-4845-9180-9D26F251F26E">
    <pav:createdOn>2014-09-02 11:58:55 -0400</pav:createdOn>
    <ao:prefix> be initiated at a reduced dose when given with</ao:prefix>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> paroxetine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B4A07D2A-59AD-4845-9180-9D26F251F26E"/>
    <domeo:uuid>B4A07D2A-59AD-4845-9180-9D26F251F26E</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D344866F-87DE-4A61-99C8-1624A36AC49E">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D344866F-87DE-4A61-99C8-1624A36AC49E"/>
    <pav:createdOn>2014-07-24 20:06:55 -0400</pav:createdOn>
    <domeo:uuid>D344866F-87DE-4A61-99C8-1624A36AC49E</domeo:uuid>
    <ao:prefix> containing antacids. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In healthy adult subjects, administration of 120 mg of fexofenadine hydrochloride (2 × 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8041B2EF-1040-472F-A3E7-DC65F8159B41">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B94664D-D507-4349-822D-1C47F7304469"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 11:36:31 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FC76D7A1-BCF3-4AF0-92CC-E5D2F09F6BD7">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7FE9AC63-C53E-4EF9-AEF0-CC1F82EDA7C3"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:366925ED-C6A8-41CA-97EB-602399B8DB72">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>366925ED-C6A8-41CA-97EB-602399B8DB72</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:366925ED-C6A8-41CA-97EB-602399B8DB72"/>
    <ao:suffix> and its metabolites are eliminated via the urine and, to a much lesser extent, via the feces. As illustrated by a mass balance study of a single 1 mg oral dose of 14C-risperidone administered as solution to three healthy male volunteers, total recovery </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Risperidone</ao:exact>
    <ao:prefix>Excretion: </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:16:30 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D37CC60-618E-46B6-8C99-BA7D598E3762">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:ECF8E578-9A91-41E0-91AC-502E097E5A11"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-07 11:23:40 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:DDCCCF49-E95D-4DE0-8F83-128C04E4F1DB</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CBE541BF-AED9-48E5-ACA0-9309C45B20F5">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:12:09 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:133A11F3-97FE-4A36-97AB-CF474CA6CAA0</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:78BBB6BD-543C-42F3-B5F5-431ADE5F4D72"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BCA04010-E0E5-4D69-A2B7-6AB2C8D2081F">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:6C727003-BB8F-45A8-BBAC-ACBE1D4D132E</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-24 19:51:13 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-24 19:47:39 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E0476DD8-15DF-4D2C-ADC4-C5C80BA1F15B"/>
    <pav:lineageUri>urn:domeoserver:annotation:90C2BA9F-2F4E-451B-B00D-D47BECA00268</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CAAFBBB8-299E-4407-AECC-19F6B511D24C">
    <pav:createdOn>2014-09-02 11:42:13 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:76579336-5224-465A-A966-852EF8B65F10"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6CB1CEB5-788B-4E3B-9578-C8DF02D212D9">
    <domeo:belongsToSet>urn:domeoserver:annotationset:40007BD9-0869-48CF-A8F2-BAD26AE3E6E1</domeo:belongsToSet>
    <ao:body rdf:nodeID="Ne52db7e2fde342bf9390f7684d47b628"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:0A3416DB-DA64-4D76-8C16-2E801A8153AF</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F79885A8-4CEA-4ACB-9EC1-9EB939A385DE"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-21 21:32:58 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-21 21:32:45 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE7787BA-2717-4D64-BE0B-A188784B75CE">
    <ao:suffix>and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of fluconazole</ao:suffix>
    <domeo:uuid>BE7787BA-2717-4D64-BE0B-A188784B75CE</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BE7787BA-2717-4D64-BE0B-A188784B75CE"/>
    <ao:prefix>A potential interaction between oral </ao:prefix>
    <ao:exact>miconazole </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-40.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-01 16:07:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D1425A6-04BE-4372-9798-B6059B7EFF83">
    <ao:context rdf:resource="urn:domeoclient:uuid:3E13A2A1-DB0E-49CA-8B2D-2D7FD2760FEC"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-24 20:06:30 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:137A1951-AA86-4074-9581-B011801B955F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-07 09:39:42 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5FD113AB-8FB6-4F29-B1BE-0A776992E0B0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3D401FD-5D13-4E47-A4E2-A367B34A8F2B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D3D401FD-5D13-4E47-A4E2-A367B34A8F2B"/>
    <ao:suffix>, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or </ao:suffix>
    <ao:prefix> interaction is possible with drugs having a narrow therapeutic ratio such as </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 11:36:01 -0400</pav:createdOn>
    <domeo:uuid>D3D401FD-5D13-4E47-A4E2-A367B34A8F2B</domeo:uuid>
    <ao:exact>pimozide</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE82B7F1-A555-4EA6-BB43-259D94DCEA76">
    <domeo:belongsToSet>urn:domeoclient:uuid:E0863579-8D19-4B30-ADD6-2A5BDBC2F482</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 19:53:55 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdOn>2014-07-24 19:53:38 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:207A3707-CA29-4402-95C8-5CD7687B2868</pav:lineageUri>
    <ao:body rdf:nodeID="Nf8f3e9d6900445f29e6382be7baffd32"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9F07EC2D-B722-4E66-94F2-FC8B5EEAC608"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5818A7A-2ACD-4500-9EFD-114B559AE626">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F5818A7A-2ACD-4500-9EFD-114B559AE626"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:prefix> can prolong the elimination of </ao:prefix>
    <ao:suffix>, warfarin and phenytoin, drugs that are metabolized by oxidation in the liver. There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly. Increases in INR</ao:suffix>
    <pav:createdOn>2014-09-02 19:12:32 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>diazepam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>F5818A7A-2ACD-4500-9EFD-114B559AE626</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E578ADE6-9B8F-4EBF-937E-7BA566587314">
    <domeo:uuid>E578ADE6-9B8F-4EBF-937E-7BA566587314</domeo:uuid>
    <pav:createdOn>2014-07-22 19:06:46 -0400</pav:createdOn>
    <ao:prefix>An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E578ADE6-9B8F-4EBF-937E-7BA566587314"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-122.txt.html</ao:hasSource>
    <ao:suffix> and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinica</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>rosiglitazone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3ECFEEE-C693-4117-91FB-027FB8CFC391">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D3D401FD-5D13-4E47-A4E2-A367B34A8F2B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 11:36:01 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8EE2A094-F107-44EE-921E-0C729A88F5DB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 11:46:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:02AA319D-AB4A-42F1-B73D-EF0CC9D22427"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2506F4F5-773E-4CCD-8303-CC244D5848D1">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-22 19:22:07 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:72BE2161-391C-488C-B44D-F6CF16588EAC"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC96215A-123C-49AB-9A1D-9FE75BE48E10">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:96E66F0D-E214-4562-BC8C-77A59132E471"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:38876558-6B16-4ACF-B7B6-2CCFB80241BA</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-21 21:44:21 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-21 21:44:28 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:BF2D2BC3-6C22-44A4-8021-D0C2308687B9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A2CCEA97-69CF-4E75-83A2-17A2D250C5C4">
    <pav:lineageUri>urn:domeoserver:annotation:2D276657-76B1-4CE2-91A8-A5540BFC39D1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:DCC80BE8-931B-476D-BAB4-F949DB49D489"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:443354CF-9409-4015-81BA-17601E505BAB</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 15:05:39 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-02 15:06:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1594E9A-1D6B-476C-8DD6-9BADB6C707A8">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:FC8952F2-7F31-41D0-BEDA-AC57C009870A"/>
    <pav:lastSavedOn>2014-09-02 12:05:00 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="Naadb8920debf48c0ba644812ae753575"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 12:04:40 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:A28BF2BE-2291-4744-A54F-D02559667C47</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF">
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N60eb8cfb63db4e8e95ba2286d666db5e"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:67D24023-38AB-4DC8-B710-B1EC8B3A147D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:0C1C2EB5-51AF-456E-A1C2-1ED9CDDC6C3B</pav:lineageUri>
    <pav:lastSavedOn>2014-09-01 16:06:17 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:EC7897DF-F240-4C01-A8E7-BD5189815B10"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:15F23356-1BF5-4C1D-B511-6EA6E4D8AC0E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:1B768EBB-3E7D-4144-B911-6362101E6343"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:03ABEF2C-055A-4C30-91E7-3717F41B4C84"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F888C6E8-7F16-450A-A3B5-0E20C026DA2A"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:DC193B15-53DF-4479-BA9B-BCE880C4232C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:01D05C1E-36FA-4699-B134-4F8E31F1B1CA"/>
    <pav:createdOn>2014-09-01 16:05:52 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0A2D6969-9724-41E9-BCD8-E35100958761"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:5442793D-CF1E-40C2-8779-648AB7BD1967"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:019F3E7A-E338-4B52-B537-D71474689AD1"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD767394-A523-4383-85E2-F42A0A94276D">
    <ao:suffix>(6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD t</ao:suffix>
    <ao:exact>aminophylline </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD767394-A523-4383-85E2-F42A0A94276D"/>
    <ao:prefix>were determined from a single intravenous dose of </ao:prefix>
    <domeo:uuid>BD767394-A523-4383-85E2-F42A0A94276D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-21 21:33:43 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75244705-D763-4A47-A23E-5C4CAE8A90B5">
    <ao:context rdf:resource="urn:domeoclient:uuid:5B31DBDC-7235-4CB3-937C-37BEC560A1C4"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:1DA34422-734D-46B1-AB2C-C1CABCA4C26C</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-01 16:07:52 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:2B6ECB24-F92D-4CD5-ABD6-C88B1D218116</pav:lineageUri>
    <pav:createdOn>2014-09-01 16:07:25 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6EF1F67B-32D0-48C5-BEB7-6F545D96A5AA">
    <ao:prefix>increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%. Adverse effects including nausea, hypotension, and syncope were observed when </ao:prefix>
    <domeo:uuid>6EF1F67B-32D0-48C5-BEB7-6F545D96A5AA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>ritonavir</ao:exact>
    <ao:suffix> and trazodone were coadministered.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-136.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 20:02:30 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6EF1F67B-32D0-48C5-BEB7-6F545D96A5AA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2FAF656F-18DD-448F-84DF-6CC1FD701820">
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A374628-9340-4980-A329-4E957642EBA7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 19:19:46 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:590B6F13-4CF1-42FD-BA01-FB622D059EBD">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:8CAB1CDF-9254-4D75-B7E1-3EC7187FF089</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:AF3F948A-978C-448B-972C-FC7423B8770D"/>
    <pav:createdOn>2014-07-24 19:51:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-24 19:51:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:6C727003-BB8F-45A8-BBAC-ACBE1D4D132E</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93550871-2475-42C7-82BF-66ECE7117537">
    <ao:exact>Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:93550871-2475-42C7-82BF-66ECE7117537"/>
    <domeo:uuid>93550871-2475-42C7-82BF-66ECE7117537</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-56.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-07-21 21:55:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8844F882-4F5A-460C-9215-039DEB9CB5A2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1E16FBF3-81EA-402D-80A2-67FDDDC020EA"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB311B8D-11CB-4B44-BDC1-9641D482BE0D">
    <domeo:uuid>AB311B8D-11CB-4B44-BDC1-9641D482BE0D</domeo:uuid>
    <ao:prefix> and α1-acid glycoprotein. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> doses should be reduced in patients with liver disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB311B8D-11CB-4B44-BDC1-9641D482BE0D"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>Risperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:18:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B1D53EEF-8BCA-4B91-B107-30A073406F41">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:50E47850-992D-44A2-BE5F-681487D5414C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 19:12:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2AE98FC9-CA39-4A5E-9A97-02182489F1DE">
    <pav:createdOn>2014-07-22 20:18:32 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:C674FD8E-5A17-4043-9DFE-245B0F493B69</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B1C7E3B-0E62-4AAE-9A68-874D098352C2"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F71B86E-3B80-4813-9F00-A9E3E6B30C9E">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:39:26 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EAE26632-A8D8-4E80-ADE1-8902853460F6"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A98AC7AB-8326-46FF-A484-D9D3774E511A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-07-21 21:42:56 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N13a46c5561874dfa93e3ff5c30a6c4da"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-21 21:42:43 -0400</pav:lastSavedOn>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:BD4B7475-BD13-46C4-932F-139564A0063D</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:F1F5B076-CA43-4BBF-AD5E-46855A01FCB5</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:AE4E1848-BBFA-4DA4-8738-800749B0AAF2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/A36E11B0-6726-4AD1-ACC7-4E8E59A350EB">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>levonorgestrel</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6373</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B837C05B-2090-4797-A3CF-E78BA29EF167">
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:46:02 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C914763B-B8F8-41B8-8D18-F2B33883EA27"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DFCBEAF2-DEEA-4C46-A167-B2B6F5C56C00">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:49F82F74-6EDD-4994-8052-10CB1FCA4BA0"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:09:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:AB8C215A-FA3F-4A34-A334-0F1287CE0DA8</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4FCA7E7B-CC82-4455-94C0-73C09ED070C1">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4FCA7E7B-CC82-4455-94C0-73C09ED070C1"/>
    <domeo:uuid>4FCA7E7B-CC82-4455-94C0-73C09ED070C1</domeo:uuid>
    <ao:suffix> and the following inactive ingredients: dibasic calcium phosphate dihydrate, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate, talc, and titanium dioxide.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:hasSource>
    <ao:prefix> hydrochloride equivalent to 25, 50, 100, 150 and 200 mg of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 12:34:41 -0400</pav:createdOn>
    <ao:exact>sertraline</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17C13D4B-C4FD-4F4C-8B4F-969B0D63CD46">
    <pav:createdOn>2014-09-02 12:03:06 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:109B3973-618F-4814-8D01-1C468E7A80F2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:19AF6A28-5E1F-4E38-963D-A9F4633CDDE9">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:19AF6A28-5E1F-4E38-963D-A9F4633CDDE9"/>
    <ao:exact>saquinavir</ao:exact>
    <ao:suffix>/ritonavir (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15. Dose reduction of saquinavir should be considered from the safety perspective for individual patients. There are also some antiretroviral drugs of which unch</ao:suffix>
    <ao:prefix>, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>19AF6A28-5E1F-4E38-963D-A9F4633CDDE9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:19:04 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E7448AD-8A84-4C38-A84C-AA12E07DD681">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6E7448AD-8A84-4C38-A84C-AA12E07DD681"/>
    <ao:suffix> does not affect the pharmacokinetics of propranolol.</ao:suffix>
    <pav:createdOn>2014-07-24 19:42:58 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-127.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>. </ao:prefix>
    <domeo:uuid>6E7448AD-8A84-4C38-A84C-AA12E07DD681</domeo:uuid>
    <ao:exact>Verapamil</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52AE2649-A143-4E37-A21D-82019096A697">
    <ao:prefix>, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:08:35 -0400</pav:createdOn>
    <ao:exact>nalbuphine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:52AE2649-A143-4E37-A21D-82019096A697"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>52AE2649-A143-4E37-A21D-82019096A697</domeo:uuid>
    <ao:suffix>, butorphanol and buprenorphine) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone hydrochloride. In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effe</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA9BE1F2-854A-4E7D-8C64-DCE1158C5D96">
    <ao:exact>N</ao:exact>
    <ao:suffix>-</ao:suffix>
    <ao:prefix>Injection is predicted to provide a pharmacological effect of sildenafil and its </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AA9BE1F2-854A-4E7D-8C64-DCE1158C5D96"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:58:57 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:804C4BF7-B45B-4CC2-BD44-707AAD50F219">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidon</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>804C4BF7-B45B-4CC2-BD44-707AAD50F219</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:804C4BF7-B45B-4CC2-BD44-707AAD50F219"/>
    <ao:prefix>, is 77%. Neither </ao:prefix>
    <pav:createdOn>2014-07-13 11:11:13 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5577FA82-F64B-40B7-8542-3CEE5BC9380E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>5577FA82-F64B-40B7-8542-3CEE5BC9380E</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5577FA82-F64B-40B7-8542-3CEE5BC9380E"/>
    <ao:prefix> 40 mg qd co-administered days 11 to 15. Dose reduction of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> should be considered from the safety perspective for individual patients. There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with omeprazole.</ao:suffix>
    <ao:exact>saquinavir</ao:exact>
    <pav:createdOn>2014-09-02 19:19:18 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60E67B22-5DBF-4F42-9120-BC7E0F398FA0">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nc1174d054689408ea7ac24af4942a624"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:AE5EBB85-C1D9-438F-B2E8-17B61D972F3D"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-07-13 12:48:08 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:B4D55559-EA4E-4B39-A156-D764B9CB8614</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:236BB8FF-931E-44E4-8D12-9F1FB83D8082">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:49838230-189C-4414-9619-31B8A0459B9E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:createdOn>2014-07-24 20:08:15 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-24 20:10:48 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:8D86A4AC-54BD-4BB3-8B58-AB55DEC01A88</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6B93EB2B-A516-48C4-A750-602CF9462A88">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8AF7E41C-63B6-4042-8707-4622E9BC98AA"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3BD9C2A-EDB9-42C4-8D62-372034300BF1">
    <pav:lastSavedOn>2014-09-01 16:12:36 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:A7B6F069-112F-4FDC-9A7B-D22FEB0AF9DB</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:5D381360-05CD-407C-BAB9-6496A42C73E4</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-01 16:12:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E3B6522F-F16C-4872-B4B8-C142D6BC0D2D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4519FF07-AE90-4478-8B97-B4B2C84457DC">
    <pav:lastSavedOn>2014-07-24 19:46:04 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:0F69928C-A74C-43BB-99CF-5CCE1F577586"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:EE072CDD-1278-4505-A3C0-39DABDD38987"/>
    <pav:createdOn>2014-07-24 19:45:35 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-129.txt.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N4bf70699bcb44141aeccce0f4da06ddd"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:436A0572-7B45-4903-B1A7-9FA513872756"/>
    <pav:lineageUri>urn:domeoserver:annotationset:FC19467B-77EB-4025-99ED-15D0CC1ED7F6</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C7DC9EA-F2B4-4F7F-BD05-8D844F135B91"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:160236BC-C839-4CD6-8648-FE98F4F6BC3F">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <pav:createdOn>2014-09-02 12:03:11 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:3E22917C-B2E2-46E9-8A17-EDAAF200AA66"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7DD29E8-1783-4BA7-A529-9EF0B60D8F39">
    <pav:createdOn>2014-09-02 11:35:30 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:34A4FD4A-1057-41A3-B555-92B00D0BD0D1"/>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B60D6EE8-97E8-426E-9A95-B877100EC48A">
    <pav:createdOn>2014-07-24 20:05:48 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:06311B02-CE01-4B2E-9D8E-7EAC3FBB8602"/>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49F82F74-6EDD-4994-8052-10CB1FCA4BA0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:49F82F74-6EDD-4994-8052-10CB1FCA4BA0"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>Absorption: </ao:prefix>
    <pav:createdOn>2014-07-13 11:09:11 -0400</pav:createdOn>
    <ao:suffix> is well absorbed. The absolute oral bioavailability of risperidone is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <domeo:uuid>49F82F74-6EDD-4994-8052-10CB1FCA4BA0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:537EDFBD-E119-4A09-B40F-63E4648698FE">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:65F441ED-AF61-4AE3-8365-8ABE9FA557A2"/>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 11:35:56 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/692FB180-95F1-4EAA-88D0-82BF4B541921">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6960</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>midazolam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82B09581-5976-41FA-8F72-66B1E36C8544">
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F0919B6C-E254-4D92-89B8-6C9E487C9A1E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:30:48 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DD921AA0-5FC8-4BE9-AAB8-13B1D92E1958">
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:39:08 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:83CCA675-BEDD-43C9-AB17-7E503848F851"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:67E0B291-7BEC-4E9A-AE3A-91E5111086CD">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:67E0B291-7BEC-4E9A-AE3A-91E5111086CD"/>
    <ao:exact>The metabolism of propranolol is reduced by co-administration of quinidine, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-125.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>67E0B291-7BEC-4E9A-AE3A-91E5111086CD</domeo:uuid>
    <pav:createdOn>2014-07-24 19:38:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E728D92E-FEA6-4EE6-9E40-E59051DEB8E3">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:DDCD9620-FC48-419B-ACE3-537915C7889C</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:09:21 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:043FCC7B-7CBD-4BE5-9962-3F6CF2B132DB"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0129AA9B-FCF1-4926-ABF4-20D80C13A55D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0129AA9B-FCF1-4926-ABF4-20D80C13A55D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:10:32 -0400</pav:createdOn>
    <ao:exact>Oxycodone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>0129AA9B-FCF1-4926-ABF4-20D80C13A55D</domeo:uuid>
    <ao:suffix> is metabolized in part to oxymorphone via the cytochrome p450 isoenzyme CYP2D6. While this pathway may be blocked by a variety of drugs (e.g., certain cardiovascular drugs and antidepressants), such blockade has not yet been shown to be of clinical sign</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E61B11CA-1C13-4025-B813-17930363237F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E61B11CA-1C13-4025-B813-17930363237F"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-201.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-28 17:04:20 -0400</pav:createdOn>
    <ao:suffix> maintenance therapy, phenytoin administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. Upon discontinuation </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>methadone</ao:exact>
    <domeo:uuid>E61B11CA-1C13-4025-B813-17930363237F</domeo:uuid>
    <ao:prefix>In a pharmacokinetic study with patients on </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EAC57EB3-DF7D-46DD-AE24-159494F820F5">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:5C3FBF61-A16E-4DBB-B539-F88F8B7E60B7"/>
    <pav:createdOn>2014-09-02 11:32:39 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96A8BD35-396A-4A08-9E1C-55EB39E4B7D4">
    <pav:createdOn>2014-09-02 12:03:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <ao:suffix> (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidon</ao:suffix>
    <ao:prefix> 20 mg in patients stabilized on</ao:prefix>
    <domeo:uuid>96A8BD35-396A-4A08-9E1C-55EB39E4B7D4</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:96A8BD35-396A-4A08-9E1C-55EB39E4B7D4"/>
    <ao:exact> risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8613E32B-563F-4611-BA22-4DC13243CFD4">
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 11:43:24 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C624C116-E8F0-4A10-B8B2-BC8AA88D6B11"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0919B6C-E254-4D92-89B8-6C9E487C9A1E">
    <ao:exact>omeprazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F0919B6C-E254-4D92-89B8-6C9E487C9A1E"/>
    <ao:suffix>).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:30:48 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>), and CYP2C19 (e.g., </ao:prefix>
    <domeo:uuid>F0919B6C-E254-4D92-89B8-6C9E487C9A1E</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:612855C1-32AF-48C7-A341-A649DD897808">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:612855C1-32AF-48C7-A341-A649DD897808"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>612855C1-32AF-48C7-A341-A649DD897808</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and </ao:prefix>
    <ao:suffix> [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the enzyme suggests this is unlikely [see 7 DRUG INTERACTIONS].</ao:suffix>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:16:05 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E61DE2D-66C2-4CB4-9D74-6D8DC468ABA3">
    <ao:prefix>or </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1E61DE2D-66C2-4CB4-9D74-6D8DC468ABA3</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1E61DE2D-66C2-4CB4-9D74-6D8DC468ABA3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustment of doses of</ao:suffix>
    <pav:createdOn>2014-09-01 16:12:00 -0400</pav:createdOn>
    <ao:exact>azathioprine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-42.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8CCC8C43-B443-46E4-8630-042448CA24F6">
    <ao:exact>fluconazole </ao:exact>
    <pav:createdOn>2014-07-21 21:26:52 -0400</pav:createdOn>
    <domeo:uuid>8CCC8C43-B443-46E4-8630-042448CA24F6</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8CCC8C43-B443-46E4-8630-042448CA24F6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>(oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in phenytoin AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown </ao:suffix>
    <ao:prefix>dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06416843-5F84-4886-A5D4-559FA1082541">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Warfarin</ao:exact>
    <pav:createdOn>2014-07-22 19:55:21 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:06416843-5F84-4886-A5D4-559FA1082541"/>
    <domeo:uuid>06416843-5F84-4886-A5D4-559FA1082541</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A533EC0D-DA36-41E1-8BF3-3650517EB300">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:4A9B35D2-1697-453D-A110-43EEC635AE7B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:0D02D3C9-3B10-4061-87CA-3B4D5940C940</pav:lineageUri>
    <pav:createdOn>2014-07-24 20:13:00 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE03C8BC-514A-4589-B370-5BBCAFD1AFE7">
    <pav:createdOn>2014-09-02 11:49:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 11:49:28 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0B56F971-EB28-4859-ADD4-58040927A5DF"/>
    <pav:previousVersion>urn:domeoserver:annotationset:3F546823-204F-4F9B-9006-3DC526C56931</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14556CC1-0C55-47A6-8175-973C292639CC">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:71D2AAB3-67A2-451B-BC9A-B33DCA934E67</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:86692ABC-62BE-4895-A4EF-50FCB21327B2"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:16:08 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:532294F2-A52D-4732-85C4-0F955156A615">
    <pav:createdOn>2014-07-13 11:10:06 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>532294F2-A52D-4732-85C4-0F955156A615</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> plus </ao:prefix>
    <ao:suffix> are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour. Peak concentrations of 9-hydroxyrisp</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:532294F2-A52D-4732-85C4-0F955156A615"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6BF6E19B-3833-4401-A589-B16E9522C485">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6BF6E19B-3833-4401-A589-B16E9522C485"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose.</ao:suffix>
    <ao:prefix>Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration. A 10 mg dose of </ao:prefix>
    <ao:exact>REVATIO </ao:exact>
    <pav:createdOn>2014-07-07 09:58:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3B6522F-F16C-4872-B4B8-C142D6BC0D2D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see PRECAUTIONS- Drug Interactions).</ao:suffix>
    <domeo:uuid>E3B6522F-F16C-4872-B4B8-C142D6BC0D2D</domeo:uuid>
    <ao:exact>azathioprine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-42.txt.html</ao:hasSource>
    <ao:prefix>or </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E3B6522F-F16C-4872-B4B8-C142D6BC0D2D"/>
    <pav:createdOn>2014-09-01 16:12:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/964F2661-87EF-4D00-87C8-D1C5E12C0ECB">
    <rdfs:label>fluconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE072CDD-1278-4505-A3C0-39DABDD38987">
    <pav:lineageUri>urn:domeoserver:annotation:B21366EB-B88D-4F1E-AD23-59BC46AC5171</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:4519FF07-AE90-4478-8B97-B4B2C84457DC</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 19:45:44 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 19:46:05 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:205F8706-B144-4ED0-9F00-551E6481AD6D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D275C93-4567-4FDB-902A-6385CDBFA809">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:0461B0A0-7D13-480F-A86F-F2496AAA8BE6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 11:58:47 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:58A85B09-BFE3-4349-8AAB-C9D3F4CFA818</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C4009FB-5A17-4B3C-B5E0-D9CC8275A5D7">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:B61F1A9B-4696-4ED0-80AA-4FE2E9016966</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:2849471A-11C0-4F9B-B7D7-4D948F848B33</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:FF9C19C8-A145-4276-833C-C3641196A24F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-21 21:35:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-21 21:35:21 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Nc3612987d6444ddc97bbdd3f2b74b82e"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A2D6105B-A1D5-4610-94EC-C0CB40BB9E6D">
    <ao:prefix>Phenobarbital induces many cytochrome P450 (oxidative) enzymes. When a single oral 30-mg dose of immediate-release paroxetine  was administered at phenobarbital steady state (100 mg once daily for 14 days), </ao:prefix>
    <ao:suffix> AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A2D6105B-A1D5-4610-94EC-C0CB40BB9E6D"/>
    <ao:exact>paroxetine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-01 16:22:12 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-45.txt.html</ao:hasSource>
    <domeo:uuid>A2D6105B-A1D5-4610-94EC-C0CB40BB9E6D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F409D487-F7F1-4F27-B967-0469F9A468A8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F409D487-F7F1-4F27-B967-0469F9A468A8"/>
    <ao:prefix> and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of </ao:prefix>
    <ao:suffix>. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response. [See Clinical Pharmacology (12.4).] </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:06:51 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-122.txt.html</ao:hasSource>
    <domeo:uuid>F409D487-F7F1-4F27-B967-0469F9A468A8</domeo:uuid>
    <ao:exact>rosiglitazone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/ED3BCC98-B0FE-4421-B54B-7B2414CF4328">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>norethindrone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7514</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/FE87FAA2-1979-46D4-90FE-4C8F260790F0">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/84108</dailymed:activeMoietyRxCUI>
    <rdfs:label>rosiglitazone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0E54D90-28C4-48FD-B72C-21011511DD58">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:58C4B9F6-E8BB-4567-9FF2-3D87C6E9284C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <ao:body rdf:nodeID="N2a95958eddb848db99f23a766ddc95db"/>
    <pav:lineageUri>urn:domeoserver:annotation:CC36BBDD-6E14-44E8-9E21-FE419782FE72</pav:lineageUri>
    <pav:createdOn>2014-07-13 12:45:51 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BFF92609-A328-4612-927E-6F35023B6FC8">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BFF92609-A328-4612-927E-6F35023B6FC8"/>
    <ao:suffix> with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).</ao:suffix>
    <pav:createdOn>2014-09-02 11:43:30 -0400</pav:createdOn>
    <ao:exact>fluvoxamine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>BFF92609-A328-4612-927E-6F35023B6FC8</domeo:uuid>
    <ao:prefix>. If concomitant treatment of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C9195181-C772-4ED4-ADD8-56970C72AD38">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:4BDD5E48-B9CE-48CF-BD41-105B25B3F7D2"/>
    <pav:createdOn>2014-09-02 19:40:30 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 19:40:44 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N7d4061094731431a80cc23850725f7bf"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:0B03E269-DEFB-43D7-8E21-1473D883F9E1</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:BD57075E-3889-44CB-8FF4-EC5663C33AC0"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-116.txt.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E65F5A7D-A02D-468C-B1BF-DA59E8B655C9">
    <domeo:uuid>E65F5A7D-A02D-468C-B1BF-DA59E8B655C9</domeo:uuid>
    <pav:createdOn>2014-07-24 20:14:15 -0400</pav:createdOn>
    <ao:exact>mexiletine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-160.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>In post-marketing experience, there have been isolated, spontaneous reports of pulmonary changes including pulmonary infiltration and pulmonary fibrosis during </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E65F5A7D-A02D-468C-B1BF-DA59E8B655C9"/>
    <ao:suffix> therapy with or without other drugs or diseases that are known to produce pulmonary toxicity. A causal relationship to </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1707DB4-5B7C-4588-BAE0-034F66A1800B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:EFB91CD1-48E1-4F2E-9E33-D718A3D8D087"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-24 20:07:29 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:996C494E-48A6-41DB-B582-CC68851B64C1">
    <pav:createdOn>2014-07-22 18:51:41 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:EB4D6CAD-8800-44E1-9856-C0585E6A6B61"/>
    <pav:lastSavedOn>2014-07-22 18:54:35 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:E5528993-F0D4-4378-B175-B901EA18D750</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:3D195979-3E82-427D-95B8-F50F48DB4AA7</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9ED864DE-C2BC-4B14-881F-AFD561FC58D1">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9ED864DE-C2BC-4B14-881F-AFD561FC58D1"/>
    <ao:suffix> was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues. Pharmacological studies in animal models indicate that rosiglitazone inhibits hepatic gluconeogenesis. The expression of the insulin-regulat</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>In animal models, the antidiabetic activity of </ao:prefix>
    <domeo:uuid>9ED864DE-C2BC-4B14-881F-AFD561FC58D1</domeo:uuid>
    <ao:exact>rosiglitazone</ao:exact>
    <pav:createdOn>2014-07-22 19:11:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D47C4E1D-3FAD-4BB4-842A-3B71726A722C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D47C4E1D-3FAD-4BB4-842A-3B71726A722C"/>
    <pav:createdOn>2014-09-02 11:30:03 -0400</pav:createdOn>
    <domeo:uuid>D47C4E1D-3FAD-4BB4-842A-3B71726A722C</domeo:uuid>
    <ao:prefix>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxam</ao:suffix>
    <ao:exact>fluvoxamine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA230F0A-406C-43AE-88DE-A7FD67CF4D61">
    <pav:lineageUri>urn:domeoserver:annotation:814003AB-50EC-489D-967C-53D890293957</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 11:12:34 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EEA0DB9F-24A6-4283-B426-FDECA24BE603"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49F8A244-9291-40F9-AE95-B64DDF5E624D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:49F8A244-9291-40F9-AE95-B64DDF5E624D"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-07 09:57:03 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>metabolite</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC75BC49-9657-4DDD-BA6E-E382607C98F8">
    <pav:createdOn>2014-07-22 19:22:19 -0400</pav:createdOn>
    <domeo:uuid>DC75BC49-9657-4DDD-BA6E-E382607C98F8</domeo:uuid>
    <ao:prefix> over time. Because of the temporal nature of lipid changes, the 52-week glyburide-controlled study is most pertinent to assess long-term effects on lipids. At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DC75BC49-9657-4DDD-BA6E-E382607C98F8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:exact>AVANDIA</ao:exact>
    <ao:suffix> 4 mg twice daily. The corresponding values for glyburide were 3.2, 3.1, and 2.9. The differences in change from baseline between </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2363FCF8-4364-4BDB-BB21-5EDBFD6F753B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2363FCF8-4364-4BDB-BB21-5EDBFD6F753B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Rosiglitazone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:11:19 -0400</pav:createdOn>
    <ao:suffix> reduces blood glucose concentrations and reduces hyperinsulinemia in the ob/ob obese mouse, db/db diabetic mouse, and fa/fa fatty Zucker rat.</ao:suffix>
    <ao:prefix> the pathogenesis of type 2 diabetes. The antidiabetic activity of rosiglitazone has been demonstrated in animal models of type 2 diabetes in which hyperglycemia and/or impaired glucose tolerance is a consequence of insulin resistance in target tissues. </ao:prefix>
    <domeo:uuid>2363FCF8-4364-4BDB-BB21-5EDBFD6F753B</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFB0CA51-827C-4CBB-9914-266A69F0AB0B">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C3406496-29A1-41A2-B195-BAD281E72E4B"/>
    <pav:createdOn>2014-09-02 11:40:04 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7AF3A49F-90C3-4D03-97CB-74AE03BF7C86">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:0C24008F-78E2-49EE-9161-71EEB60D2ECD</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:09:17 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:F557214F-193F-480C-8483-C59A8CFCD22E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B088F7FA-8870-4336-965B-4A558E3F08B0">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 11:17:32 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:0D1F3FB5-E327-4ED5-A129-940CBC83C151</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:ABB70710-CA87-4445-8EB3-1BFDDC4636FE"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ECB23C3B-E835-480F-B541-EB5CBBAB2855">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ECB23C3B-E835-480F-B541-EB5CBBAB2855"/>
    <domeo:uuid>ECB23C3B-E835-480F-B541-EB5CBBAB2855</domeo:uuid>
    <ao:suffix> 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.</ao:suffix>
    <pav:createdOn>2014-07-13 12:46:33 -0400</pav:createdOn>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:211F5FD6-FC29-4AC5-96E1-14E088108ABB">
    <ao:suffix> (See PRECAUTIONS.</ao:suffix>
    <pav:createdOn>2014-07-13 12:56:54 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Administration of a single oral 200 mg dose of fluconazole after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:211F5FD6-FC29-4AC5-96E1-14E088108ABB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>211F5FD6-FC29-4AC5-96E1-14E088108ABB</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C93F0A9D-FE1B-4281-BB1F-58EBF1E21173">
    <ao:context rdf:resource="urn:domeoclient:uuid:89138321-17A8-4CAE-B03E-6A7C0F8B6AC5"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:39B82E57-92E3-4322-A8E6-A3AFF215F02C</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-01 15:57:39 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:212DE3D9-8C0B-4C3D-9FCD-B82D6F9CF98E</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-01 15:57:31 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5EA1A12E-999D-4F07-B3EF-67CFE143F274">
    <ao:context rdf:resource="urn:domeoclient:uuid:57427A36-AF04-4B9A-A5C2-85D0AE5CA845"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:12:09 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0AC105E-C659-4D3F-9F13-4104BCC29CDE">
    <pav:createdOn>2014-07-13 11:13:36 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:6A3A3F06-7277-4FF9-9E27-EBB7510D87E7</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:65044E3B-BE66-455E-B576-1B8DF996B6B4"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2FF3133B-3C6A-4B14-A744-B8F141C65349">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6EF1F67B-32D0-48C5-BEB7-6F545D96A5AA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:189A8E0E-67D6-4C53-A96E-CB48A3B4B2E9</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 20:02:30 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-24 20:02:49 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:2D15DC95-96C2-4349-A95D-53D48B48C4C8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95D28FFB-FF92-495E-92BC-C2E25FBE02B1">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:39C2E9DA-729E-466D-9F16-3F254B23A03C"/>
    <pav:createdOn>2014-09-02 11:44:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9C7097E9-595B-4F6E-9745-CA4FB4156079">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/C98F4F9C-3452-4547-9D59-858A821616E1"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/A3E00879-812C-4400-97F2-AF59166DF8BB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3C4287B-36A9-48BF-8081-A39BEF5F3C51">
    <ao:context rdf:resource="urn:domeoclient:uuid:BB359BC3-6C0F-427E-B961-0838B54690D5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:38:27 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40519342-F06B-41D2-A39A-795BA218AF7B">
    <ao:exact>cimetidine</ao:exact>
    <ao:prefix> 400 mg to six healthy male volunteers. After the administration of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:46:18 -0400</pav:createdOn>
    <domeo:uuid>40519342-F06B-41D2-A39A-795BA218AF7B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:40519342-F06B-41D2-A39A-795BA218AF7B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of cimetidine 600 mg to 900</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc3ab48c0a79645e6aa0f8644c9a84e00">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A4B6E36-A9AC-4581-A4CD-969904241345">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0A4B6E36-A9AC-4581-A4CD-969904241345"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:42:05 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>0A4B6E36-A9AC-4581-A4CD-969904241345</domeo:uuid>
    <ao:exact>Thioridazine</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.4).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C9DB2D07-ABDB-402C-AA6C-8EB7046415D4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:7206074C-7221-4AA1-8796-9AD7DCD6C411</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 19:10:13 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:B30D95E2-6A9C-41B9-A6BC-823FD4639E01"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B097095F-835A-459A-BD2D-9F8F332DBE40">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B097095F-835A-459A-BD2D-9F8F332DBE40"/>
    <domeo:uuid>B097095F-835A-459A-BD2D-9F8F332DBE40</domeo:uuid>
    <ao:suffix>dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decrea</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-21 21:31:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable </ao:prefix>
    <ao:exact>zidovudine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D0A6C88-E510-4AF5-8DFB-C35B1F919461">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:9E86ADEB-E76E-4255-8364-3D0CF7C52E24"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 19:39:44 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CBD1F653-F7E2-49C1-AEF3-0CF16AA17649">
    <domeo:uuid>CBD1F653-F7E2-49C1-AEF3-0CF16AA17649</domeo:uuid>
    <ao:prefix>AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of </ao:prefix>
    <ao:suffix>. (See PRECAUTIONS.)</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CBD1F653-F7E2-49C1-AEF3-0CF16AA17649"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>phenytoin</ao:exact>
    <pav:createdOn>2014-07-21 21:27:02 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D630E295-F643-4F99-AB1E-8DA3F1178740">
    <domeo:uuid>D630E295-F643-4F99-AB1E-8DA3F1178740</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D630E295-F643-4F99-AB1E-8DA3F1178740"/>
    <pav:createdOn>2014-07-24 19:43:26 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-127.txt.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Propranolol does not affect the pharmacokinetics of verapamil and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A1E742B-4ABE-40BF-84E5-2A5F57F232F2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:09:15 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0A1E742B-4ABE-40BF-84E5-2A5F57F232F2"/>
    <ao:prefix> is well absorbed. The absolute oral bioavailability of </ao:prefix>
    <ao:suffix> is 70% (CV=25%). The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.</ao:suffix>
    <domeo:uuid>0A1E742B-4ABE-40BF-84E5-2A5F57F232F2</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BEED566B-9689-4906-8331-FFFE92EBBEEE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:B28E83A5-C85B-4EA5-8EDD-9A0A637268F6</pav:lineageUri>
    <pav:createdOn>2014-09-01 15:57:33 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AD70C5DB-2834-4A85-B530-F776A208FB2C"/>
    <pav:lastSavedOn>2014-09-01 15:57:39 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:39B82E57-92E3-4322-A8E6-A3AFF215F02C</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0e0f5b43049940cf8df3247a0853edc7">
    <domeo:sets rdf:resource="urn:pddi:uuid:1E635F35-7B6C-49A8-AD29-C3853F8DC576"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1DBDA3FA-5F1C-4CC1-9712-91AF1D9421C6">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:B268E8D2-7CCD-4C59-B9AD-152E8C225A69</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8C89B51C-E5B9-4048-B277-4FA66AA36C16"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0054F81-6A9B-4AF0-9DCB-962A6FC1C418</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 18:46:52 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-22 18:44:33 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81F0286A-7D44-49B2-9EF8-817CDCC20940">
    <pav:lineageUri>urn:domeoserver:annotation:D08D7947-3BE2-495E-AE50-1F65AAFC0B91</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E65F5A7D-A02D-468C-B1BF-DA59E8B655C9"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-24 20:14:15 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-24 20:14:01 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DCD6738-9404-46BB-A758-BDDEB41B4565</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2a95958eddb848db99f23a766ddc95db">
    <domeo:sets rdf:resource="urn:pddi:uuid:114406CD-55D0-459D-A4F0-CEDB09E201C6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:11C59DB6-9144-4BAA-B630-BA9A001B4C4A">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:639E5CAD-4CBF-4CC5-8D9F-6103AC373BA4"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E33C30E-6EC7-463F-A8C1-B699338A149B">
    <pav:createdOn>2014-07-22 19:40:41 -0400</pav:createdOn>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:A788721A-520C-402D-95A4-65EC994B3F25"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:nodeID="N65c4633ac4b24dbeb67a22ad3f7e5572"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:04DB6C49-D431-40EA-98E8-D720E8A6787D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:11BCB02F-AC6F-47D4-98D8-4B72C6ED08A2"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E8A53CD-1A4A-4A56-ABAA-82D073884595">
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:EB06C7B2-447E-44A6-9D7B-F5BB28ED6AB3"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-22 19:36:30 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E4DD9DD-ACD7-4BE1-99C4-C10C579DD83A">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:BD4B7475-BD13-46C4-932F-139564A0063D</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:AA8809D6-7C92-459E-B3FE-D31BB8203D90"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:5DCE6B18-109F-4776-930D-EF11FAF93A80</pav:lineageUri>
    <pav:lastSavedOn>2014-07-21 21:42:43 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-21 21:42:13 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:024DA998-8A48-48B5-83FB-3E3328F234D5">
    <ao:prefix>. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:024DA998-8A48-48B5-83FB-3E3328F234D5"/>
    <ao:exact>sertraline </ao:exact>
    <domeo:uuid>024DA998-8A48-48B5-83FB-3E3328F234D5</domeo:uuid>
    <ao:suffix>200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-01 15:57:37 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/20398182-F09D-4166-8536-A74DA8BDB5D5">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7417</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nifedipine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:414AB21B-E61F-45BC-90CC-D10C8E784BF6">
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8C5CCA78-2E90-4B2A-961F-DADE6196F08B"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:39:54 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:222C9B55-A770-41C7-AF04-566E7C7A1DBC">
    <ao:context rdf:resource="urn:domeoclient:uuid:B9D56D7C-5C37-4BCA-B9C4-0605E9E54998"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:43:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/5224D32E-E4DE-4A9C-B197-4A0F7E4F982D">
    <rdfs:label>ritonavir</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6F745E6-5734-4636-A383-683BA4C79E38">
    <ao:item rdf:resource="urn:domeoclient:uuid:AD3EF274-2E89-4A1A-9C95-5AE9F608E1E0"/>
    <pav:lastSavedOn>2014-07-21 21:27:51 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1956FA88-0DCF-4091-9E82-114782E551B6"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:405F8748-3E22-452F-AC3B-86C4C931D36A"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:D3B6634D-5A1F-4C6F-AF5E-421854DA709D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EDAAAA2E-DA5E-4DC5-9EDE-0B4E06286E7C"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-21 21:26:46 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:E4954BA3-FA9C-4983-8CA9-D8BA258D2881"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:120B172A-5B0A-4411-BB16-2CE6618D971C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:63218495-2D5D-4BAA-9325-6B514214E40A</pav:lineageUri>
    <permissions:permissions rdf:nodeID="Nd3042ece2bc14cb4961fbfbe9c2906bd"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2551E950-6EBC-471F-B165-F68320BB8C62">
    <ao:context rdf:resource="urn:domeoclient:uuid:79016A6C-CD48-4680-8D24-28567975EAC5"/>
    <pav:createdOn>2014-07-28 17:04:42 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:F9987B02-0E12-4725-ACBA-F5330BAA49CB</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:48D839E5-6B0A-4EC3-B64A-E3E20E06246A</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-28 17:08:37 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/C8697DBE-189E-49C7-A34D-563280FA497C">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fexofenadine hydrochloride</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/236474</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1AD84D60-1A25-43EF-A981-A873C4F1D40E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1AD84D60-1A25-43EF-A981-A873C4F1D40E"/>
    <domeo:uuid>1AD84D60-1A25-43EF-A981-A873C4F1D40E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>: Bradycardia has been reported with the coadministration of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:suffix> maleate and diltiazem.</ao:suffix>
    <pav:createdOn>2014-09-02 11:44:48 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6791DC23-BC40-4E62-815B-0DA5CCA7BD4F">
    <domeo:uuid></domeo:uuid>
    <ao:exact>REVATIO </ao:exact>
    <pav:createdOn>2014-07-07 09:41:41 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6791DC23-BC40-4E62-815B-0DA5CCA7BD4F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in Tmax of 60 minutes and a mean reduction in Cmax of 29%. The mean steady state volume of distribution (Vss) for sildenafil is 105 L, indicating distribution into the ti</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (25–63%). Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8680340-7715-4656-A160-A6F608AD7CE9">
    <pav:lineageUri>urn:domeoserver:annotation:9F72602C-A51D-443A-8FED-EF0310ADB89F</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:08:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F31EE1EC-A22F-4FE9-8763-7C623AD7B0BE"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25C05DA7-D004-4C59-A96C-F35D5BEB9B3F">
    <ao:exact>Phenytoin</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:25C05DA7-D004-4C59-A96C-F35D5BEB9B3F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-28 17:04:15 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>25C05DA7-D004-4C59-A96C-F35D5BEB9B3F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-201.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4e32b3d76ea240d8910f3c379dd2c9df">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A151EB77-7400-49F2-9673-BFAD2171D5CD">
    <ao:context rdf:resource="urn:domeoclient:uuid:A3654752-C204-49F0-B3F7-87C2EE277992"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:17F49268-30E8-4066-B9B1-4521C34B09E9</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:07:24 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2F70BCB-D9EC-44EA-93E7-C33A22842BF2">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:57242808-9748-4ED3-908E-E0054E0C8BBE"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:F4CD88A4-5CEC-433F-9DFF-C429C94CCEA2</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:46:37 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N31c86788d74e49c8aa01657fabf0f31c">
    <domeo:sets rdf:resource="urn:pddi:uuid:8BAAA01E-8AC9-466E-B388-3972354A4BAB"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F027CB1D-7D5A-4ADC-8E54-303492562FCA">
    <rdfs:label>warfarin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D7139F9-BDC3-437F-A5A1-D75EDAC972B0">
    <pav:createdOn>2014-07-13 11:07:46 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:18699EA6-5F06-460B-B2AD-992A44EC2FCD</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:B3435A02-DBAF-4D33-9A80-3B78037721AE"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6A356B7-0DEE-4744-8B2D-DDF0B281AC9B">
    <ao:exact>Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>C6A356B7-0DEE-4744-8B2D-DDF0B281AC9B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-118.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 18:46:29 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C6A356B7-0DEE-4744-8B2D-DDF0B281AC9B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B0F0546-41D1-46D1-95BF-CB03118C9BB8">
    <pav:createdOn>2014-09-01 16:07:44 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:A0AB1C1B-6261-4216-AAA4-093882220EF2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A08092E7-4D52-4833-B9FF-4EFA3BA6D2E4"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-01 16:07:52 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:1DA34422-734D-46B1-AB2C-C1CABCA4C26C</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E13140FE-59B4-45B2-A524-CAED051C4F9D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:42:08 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:68010F53-B903-4110-B73F-5CE843CA2E18"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3D1E36E-124A-4042-BB9B-6A358D1F3E3B">
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E8A5F802-A216-476E-AB1E-621B048A27EA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 11:39:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B57AEEF2-0F0B-4E76-9F59-DBC483D6322C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B57AEEF2-0F0B-4E76-9F59-DBC483D6322C"/>
    <domeo:uuid>B57AEEF2-0F0B-4E76-9F59-DBC483D6322C</domeo:uuid>
    <ao:suffix> at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known s</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-161.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>nelfinavir</ao:exact>
    <pav:createdOn>2014-07-24 20:14:32 -0400</pav:createdOn>
    <ao:prefix>Coadministration of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6FD6D5D-B7A2-423B-8A6B-8CCFD72983C1">
    <ao:context rdf:resource="urn:domeoclient:uuid:E2DFE50C-520B-4A09-83FE-8498F429017C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-24 20:13:52 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:D8F80F0D-199C-4FA6-8689-BEE04574348B</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DCD6738-9404-46BB-A758-BDDEB41B4565</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-24 20:14:01 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C0CF158-24A6-445D-B09F-EA2C2052959E">
    <ao:context rdf:resource="urn:domeoclient:uuid:2F209001-62CD-42DB-94B6-8505E0EB8F2E"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:BD4B7475-BD13-46C4-932F-139564A0063D</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-21 21:42:03 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-21 21:42:43 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:8FCA782E-F02D-491B-9589-8C28B1C29F7E</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4E518E3-AA88-46AF-85A6-8C02ABD7AB1D">
    <pav:createdOn>2014-09-02 15:08:17 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:lastSavedOn>2014-09-02 15:08:18 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:D6127232-F0FF-46A9-830F-67E3832E779A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:EEDB7AD0-3CC8-4CAE-AB61-BF30A626BE96</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <permissions:permissions rdf:nodeID="N9764c9bb5c364872a521284c7e9117e4"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-71.txt.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DCBFA6B2-22F1-4138-ABA7-CDA3F5A19FC6">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-01 16:12:26 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F55B6524-A848-4FBC-99DB-A1B22E5FCA28"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:5D381360-05CD-407C-BAB9-6496A42C73E4</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:AEC461AF-3F72-4CEA-BAB7-FFD36B18B42E</pav:lineageUri>
    <pav:lastSavedOn>2014-09-01 16:12:36 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3DFC0290-B79C-492E-A5DB-32EF23C9B433">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>.</ao:suffix>
    <domeo:uuid>3DFC0290-B79C-492E-A5DB-32EF23C9B433</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3DFC0290-B79C-492E-A5DB-32EF23C9B433"/>
    <ao:prefix> does not affect the pharmacokinetics of </ao:prefix>
    <ao:exact>propranolol</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-127.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 19:43:03 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3C70535-C49A-4807-84DF-3951A0E27152">
    <ao:context rdf:resource="urn:domeoclient:uuid:2D07F657-485E-493B-84FC-C20CA68F0295"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:53:12 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D599C322-4D76-48B0-9A8D-27A82819F5D2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:2FC590A9-4A32-43E3-8740-436A834AADD1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:1DC02DA4-9C12-4D4D-BD0C-036E8049CF14</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:9FA29E53-6B1B-4856-B5BD-22A93164E58E</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 18:37:42 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 18:37:42 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D96F23AA-C203-4EA6-BA78-F8249D904C85">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D96F23AA-C203-4EA6-BA78-F8249D904C85"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Cimetidine</ao:exact>
    <domeo:uuid>D96F23AA-C203-4EA6-BA78-F8249D904C85</domeo:uuid>
    <ao:suffix> reduced the clearance and volume of distribution of meperidine and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.</ao:suffix>
    <pav:createdOn>2014-07-28 17:00:48 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-164.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32AF5202-FB01-4507-AD10-D10F0C16E37A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>therapy for at least 6 months and on a stable cyclosporine dose for at least 6 weeks. There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administr</ao:suffix>
    <domeo:uuid>32AF5202-FB01-4507-AD10-D10F0C16E37A</domeo:uuid>
    <ao:prefix>200 mg daily for 14 days in eight renal transplant patients who had been on </ao:prefix>
    <ao:exact>cyclosporine </ao:exact>
    <pav:createdOn>2014-07-21 21:28:32 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:32AF5202-FB01-4507-AD10-D10F0C16E37A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DCC80BE8-931B-476D-BAB4-F949DB49D489">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DCC80BE8-931B-476D-BAB4-F949DB49D489"/>
    <ao:prefix> within 2 hours of antacids containing aluminum oxide and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 15:05:39 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-70.txt.html</ao:hasSource>
    <domeo:uuid>DCC80BE8-931B-476D-BAB4-F949DB49D489</domeo:uuid>
    <ao:exact>magnesium</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the antacid two hours after sotalol has no effect on t</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E73E8FF7-7FA2-47F3-B0B1-14D1640DDBF7">
    <pav:lineageUri>urn:domeoserver:annotation:469138F3-F092-499E-AF0F-B2CB920DF026</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:10:54 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:789A1E1D-CA44-4410-B654-F6392AB94EDC"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93C83EDE-36D5-4436-B242-D2D391BA499C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:93C83EDE-36D5-4436-B242-D2D391BA499C"/>
    <ao:suffix>was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <domeo:uuid>93C83EDE-36D5-4436-B242-D2D391BA499C</domeo:uuid>
    <pav:createdOn>2014-09-01 16:05:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>sertraline </ao:exact>
    <ao:prefix>In three separate in vivo interaction studies, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:114406CD-55D0-459D-A4F0-CEDB09E201C6">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7CBD8092-1453-4994-9F29-22622E743A15"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9654ce6ec937425aabbae3e102b05aa9">
    <domeo:sets rdf:resource="urn:pddi:uuid:0D94D28F-90BB-4AF1-9CBD-EC4DB10359AA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DE4A37C3-330E-406A-8B07-E596729011D4">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 12:46:33 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:8631DCC5-B27D-47B4-B621-CA41E8FF2E7A</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:ECB23C3B-E835-480F-B541-EB5CBBAB2855"/>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15F23356-1BF5-4C1D-B511-6EA6E4D8AC0E">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-01 16:06:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4EA61C9-E628-4806-856F-9D86959C5B20"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:E80212C3-3917-4EEB-A788-72AC214F830F</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-01 16:05:58 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60DDCB17-0D44-46B0-8348-C078AAECFF80">
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5C335096-224E-43D5-B91F-473E8217B098"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:41:14 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55E300CE-2A8F-42F4-9877-A49DDE4F3360">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:76A2A466-4D5D-4AA1-8114-FAD1FF0E6FC0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-07 11:24:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:7897E8BB-DD46-4B51-BE6D-8D92A1B57431</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4EED7C96-E04B-4187-8077-DF5C7020A789">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <domeo:uuid>4EED7C96-E04B-4187-8077-DF5C7020A789</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4EED7C96-E04B-4187-8077-DF5C7020A789"/>
    <ao:suffix> was reduced by 36%. Therefore, to maximize the effects of fexofenadine, it is recommended that fexofenadine hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-24 20:12:55 -0400</pav:createdOn>
    <ao:exact>fexofenadine</ao:exact>
    <ao:prefix>. The clinical significance of these observations is unknown. In addition, based on the population pharmacokinetics analysis of the combined data from grapefruit and orange juices studies with the data from a bioequivalence study, the bioavailability of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BBB51CD-8D17-4DE2-B300-ED38485DEA33">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:18A94768-B77C-45AF-843F-894BD40CD040"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:35:13 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFB91CD1-48E1-4F2E-9E33-D718A3D8D087">
    <ao:suffix> had no effect on the pharmacokinetics of either erythromycin or ketoconazole. In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg e</ao:suffix>
    <pav:createdOn>2014-07-24 20:07:29 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EFB91CD1-48E1-4F2E-9E33-D718A3D8D087"/>
    <domeo:uuid>EFB91CD1-48E1-4F2E-9E33-D718A3D8D087</domeo:uuid>
    <ao:prefix> in healthy adult subjects. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Fexofenadine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:939BD222-0159-44F2-9E01-3D674AEF5EFE">
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 19:19:18 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5577FA82-F64B-40B7-8542-3CEE5BC9380E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54953EDA-07BE-4F30-8DE9-32B9DFDAC13D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:54953EDA-07BE-4F30-8DE9-32B9DFDAC13D"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-21 21:47:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>54953EDA-07BE-4F30-8DE9-32B9DFDAC13D</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Perhaps because of competition for the P450 3A4metabolic pathway, quinidine levels rise when ketoconazole is coadministered.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-53.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:30AC56DD-1608-4DFA-90FC-CCBC462BCAEF">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/EAC1688B-D768-4B56-8D0E-B9D5F8FC7164"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/DF818BD4-17A0-4731-84D5-207257326816"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B94B65A7-B52E-41EB-9E72-C3F942808AFB">
    <ao:suffix> did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.</ao:suffix>
    <domeo:uuid>B94B65A7-B52E-41EB-9E72-C3F942808AFB</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Rosiglitazone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B94B65A7-B52E-41EB-9E72-C3F942808AFB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:11:53 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix> inhibits hepatic gluconeogenesis. The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7CC41192-004E-44F9-8E3D-0FF7CECF1DC2">
    <pav:lineageUri>urn:domeoserver:annotation:2E085178-1D00-47D7-8B18-1A094C6C93A7</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:13:30 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3F94F7A-3299-4ECD-8A0C-54D9B0E17A6D"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4E5EBBF-965D-41F8-B54E-0CF48653C43C">
    <pav:createdOn>2014-07-13 12:56:09 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:76B68D47-1D9C-4B2A-B9A6-CFE359C93E64"/>
    <pav:lineageUri>urn:domeoserver:annotation:F61FAB34-A2B1-45CE-B6A6-123A03AAD69D</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D867112-B5D9-4FEA-A8A5-D8FC72239EAE">
    <pav:createdOn>2014-09-02 11:57:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> dosing. In 1 study, daily dosing of immediate-release </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7D867112-B5D9-4FEA-A8A5-D8FC72239EAE"/>
    <domeo:uuid>7D867112-B5D9-4FEA-A8A5-D8FC72239EAE</domeo:uuid>
    <ao:exact>paroxetine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <ao:suffix>  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also b</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BDA75ADA-742A-402B-AE97-4438F99C61FC">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:3EBDA2ED-165F-4B57-B4BE-CFA63CD5C5A6"/>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:36:02 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC8952F2-7F31-41D0-BEDA-AC57C009870A">
    <pav:createdOn>2014-09-02 12:04:40 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FC8952F2-7F31-41D0-BEDA-AC57C009870A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>may significantly inhibit the activity of this isozyme. In most patients (&gt;90%), this CYP2D6 isozyme is saturated early during paroxetine dosing.</ao:prefix>
    <domeo:uuid>FC8952F2-7F31-41D0-BEDA-AC57C009870A</domeo:uuid>
    <ao:exact> In 1 study, daily dosing of immediate-release paroxetine (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. </ao:exact>
    <ao:suffix> Concomitant use of</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:288BDA0B-5368-42DA-BCF5-4D9F229E72D5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:53840DD5-460C-4E7F-BA1C-65662E771309"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:44:26 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6E0548D-97C5-4C24-A078-F69D2D16D9FE">
    <ao:exact>Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-56.txt.html</ao:hasSource>
    <domeo:uuid>B6E0548D-97C5-4C24-A078-F69D2D16D9FE</domeo:uuid>
    <pav:createdOn>2014-07-21 21:54:13 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B6E0548D-97C5-4C24-A078-F69D2D16D9FE"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E597BBC-9857-4D08-953B-5CBE831F5884">
    <pav:createdOn>2014-07-13 11:26:45 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B7CF0599-4EF7-4EA9-AA71-F3F0B7596EF6"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="N480f14c0cdc94b5d9e1c8fe57da8db31"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:DE221D8D-564A-4ED6-8FA2-FEACF6BADD9F</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A5707CC-D3AC-4807-9E98-6536CDC7AC55">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:41:59 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:0DDFAFFA-5DE6-4D3B-BC30-6421E6531AD8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:645C5A96-70FA-4A0B-86EC-B070C4FE123F</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A0FA947-246E-4008-87C0-91C5CA96E875">
    <domeo:uuid>8A0FA947-246E-4008-87C0-91C5CA96E875</domeo:uuid>
    <ao:prefix> and, therefore, the combination should be used with caution. Seizures have been reported with the coadministration of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A0FA947-246E-4008-87C0-91C5CA96E875"/>
    <pav:createdOn>2014-09-02 11:40:09 -0400</pav:createdOn>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:suffix> maleate and lithium.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F8AA6DCD-35A7-4319-9C3D-CFA5C6AE10EE">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Co-administration of propranolol with lovastatin or pravastatin, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. Propranolol did not have an effect on the pharmacokinetics of fluvastatin.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>F8AA6DCD-35A7-4319-9C3D-CFA5C6AE10EE</domeo:uuid>
    <pav:createdOn>2014-07-24 19:53:59 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F8AA6DCD-35A7-4319-9C3D-CFA5C6AE10EE"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-132.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95BF8C06-515D-4690-B616-64E06F6C0C8D">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:B5956029-7918-4124-9821-CDB625D5FA25</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5DD4A9BB-16CD-4C46-9CE2-E74FD07B5626"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 11:56:15 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8AD4F27-4001-4A0B-9D27-50063C65337E">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:A5711142-9ABC-4A8E-A6A1-D585CB7190C4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:46:58 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4DAAB121-0E59-4A51-A71B-B8E4DB847D18">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:A0E3203A-2AD3-4045-BAB8-27B340F81B0E</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-28 17:02:28 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-28 17:02:33 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:C503BECC-F67A-4BAE-BF4C-6F8F7B0511DA</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:36443C46-71EF-4792-ADF2-D6E6E248EFAA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8AA46BC0-EA66-4E73-81A9-6463BB4DE15B">
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D05E9B7E-AE50-4FCD-BC2D-B3A39CEF8396"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lastSavedOn>2014-07-24 19:54:28 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="Nce246f50d23749a28b4722f4dc20cb1b"/>
    <pav:createdOn>2014-07-24 19:54:37 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-133.txt.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:441C478A-130C-4F95-BEAE-9053E4BC0B6B</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:5B9978DD-BF7E-4B48-BA74-826CB1EA9750"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE5B91CD-CF9E-4980-B001-64C0D34FB3CE">
    <domeo:uuid>BE5B91CD-CF9E-4980-B001-64C0D34FB3CE</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BE5B91CD-CF9E-4980-B001-64C0D34FB3CE"/>
    <pav:createdOn>2014-09-02 12:03:19 -0400</pav:createdOn>
    <ao:suffix> approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold. The effect of paroxetine on the pharmacok</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> (4 to 8 mg/day) increased mean plasma concentrations of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE8D9855-AB1B-4B9E-97B4-6A441B8254E8">
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:6845B377-D6ED-489F-AEA2-ACDD60E3B922</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 19:08:23 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AD975124-2202-48D6-98F2-6042E8AC8DF1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1BC59DC6-C39B-4F32-9DCC-98000370046A">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/E74D3AEA-33B5-4A50-A977-87798E92D401"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/7C90A079-6EB4-494B-B58B-CC7428475342"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:43D69C84-CE2E-4308-B875-6976981E58BC">
    <ao:suffix> 40 mg qd co-administered days 11 to 15. Dose reduction of saquinavir should be considered from the safety perspective for individual patients. There are also some antiretroviral drugs of which unchanged serum levels have been reported when given with om</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:43D69C84-CE2E-4308-B875-6976981E58BC"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:19:11 -0400</pav:createdOn>
    <ao:prefix> (1000/100 mg) bid for 15 days with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>43D69C84-CE2E-4308-B875-6976981E58BC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>omeprazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74CD19CE-F47D-46AD-8DBC-B02B6A6F0D87">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F80BB417-0183-4007-8F4C-0705AA0B529E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:F70AB841-7C14-48D1-B543-A45EA067C642</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:C95F2443-78FA-4BF4-A1AB-C2328E73A175</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-24 20:04:12 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-24 20:03:45 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FFD8A436-5516-4F50-8C7E-7512116C24BA">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:DA6D10CF-A8C7-4652-89DC-12243324D61B</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0054F81-6A9B-4AF0-9DCB-962A6FC1C418</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 18:44:30 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 18:46:52 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:75348A1F-6A84-4B07-BE23-172E91593A8D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95404334-796F-4A07-A18A-42601A802CDF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:F5818A7A-2ACD-4500-9EFD-114B559AE626"/>
    <pav:createdOn>2014-09-02 19:12:32 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5CE56B1D-ACF0-4124-B31E-62EF1E11FED8">
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <pav:createdOn>2014-07-22 19:25:31 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5A221420-4081-46A9-839D-6DA46028DA4B"/>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA8337B7-4497-4F34-93E8-291B9ED278CB">
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 12:37:44 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8214D15C-5AF1-47D0-A63C-30543353403D"/>
    <pav:lineageUri>urn:domeoserver:annotation:6D41F524-FA45-4B72-94A7-36317513638D</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8214D15C-5AF1-47D0-A63C-30543353403D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>8214D15C-5AF1-47D0-A63C-30543353403D</domeo:uuid>
    <ao:exact>ethinyl estradiol</ao:exact>
    <ao:suffix> and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cau</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8214D15C-5AF1-47D0-A63C-30543353403D"/>
    <pav:createdOn>2014-07-13 12:37:44 -0400</pav:createdOn>
    <ao:prefix> dosing resulted in small increases in the mean AUCs of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34A4FD4A-1057-41A3-B555-92B00D0BD0D1">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:suffix>e has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.</ao:suffix>
    <ao:prefix>The metabolism of </ao:prefix>
    <pav:createdOn>2014-09-02 11:35:30 -0400</pav:createdOn>
    <ao:exact>fluvoxamin</ao:exact>
    <domeo:uuid>34A4FD4A-1057-41A3-B555-92B00D0BD0D1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:34A4FD4A-1057-41A3-B555-92B00D0BD0D1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97B4DA35-A3A0-41E4-9927-06388A15995F">
    <ao:suffix> is extensively metabolized with no unchanged drug excreted in the urine. The major routes of metabolism were N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid. All the circulating metabolites are considerably le</ao:suffix>
    <pav:createdOn>2014-07-22 19:26:15 -0400</pav:createdOn>
    <ao:exact>Rosiglitazone</ao:exact>
    <domeo:uuid>97B4DA35-A3A0-41E4-9927-06388A15995F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:97B4DA35-A3A0-41E4-9927-06388A15995F"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ED57E86-1291-4DDA-9436-EC8F43B4A452">
    <ao:prefix>. Following multiple doses of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0ED57E86-1291-4DDA-9436-EC8F43B4A452"/>
    <pav:createdOn>2014-09-02 19:28:25 -0400</pav:createdOn>
    <ao:exact>nelfinavir</ao:exact>
    <ao:suffix> (1250 mg, bid) and </ao:suffix>
    <domeo:uuid>0ED57E86-1291-4DDA-9436-EC8F43B4A452</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62E1503B-EE9D-40BF-B77B-6779195F8F1F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:6A93619D-217A-4394-B947-CAB50B0721D6</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:AD7D1F18-857F-4502-9621-F93B88E936D2</domeo:belongsToSet>
    <pav:createdOn>2014-07-28 17:00:22 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AC6949EC-26AB-43DC-8B1B-1401086A35B0"/>
    <pav:lastSavedOn>2014-07-28 17:00:03 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:852CFA91-85F8-4EF7-A64F-D2A63BC3A6B5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 12:03:19 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BE5B91CD-CF9E-4980-B001-64C0D34FB3CE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ACA8DFD4-1166-4984-97D0-E4E251EA94F3">
    <domeo:belongsToSet>urn:domeoserver:annotationset:2B18F6B1-59F7-4EA0-9386-55A934108055</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-22 19:06:48 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 19:06:46 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E578ADE6-9B8F-4EBF-937E-7BA566587314"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:32C325B9-09DD-4A0B-A270-BAA0C42956A1</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C5CCA78-2E90-4B2A-961F-DADE6196F08B">
    <pav:createdOn>2014-07-22 19:39:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:suffix> and oral contraceptives (ethinyl estradiol and norethindrone), which are predominantly metabolized by CYP3A4.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>8C5CCA78-2E90-4B2A-961F-DADE6196F08B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8C5CCA78-2E90-4B2A-961F-DADE6196F08B"/>
    <ao:exact>nifedipine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6F74A83-2371-401E-B276-117735065820">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:30:30 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:CA1AC920-C96A-453E-A808-BB6D8038B11E"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C5974F18-7052-426D-A45F-D129E2BC7FB8">
    <pav:lastSavedOn>2014-07-21 21:46:47 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6EE25330-67E2-4BE9-AB27-EB9F40763AA3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-21 21:46:40 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:876DAFB7-BB08-4119-BA16-59187031D7BB</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:2727C185-A674-4921-8C56-55CC92FEF648</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15142045-DA2F-4022-9FF7-3D0277BDC3FB">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:44:09 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:D19C185B-AB58-4956-9871-777E207AC825"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4588D04A-4EE6-4AEB-8E31-47ECEB3BF1E4">
    <ao:exact>rosiglitazone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4588D04A-4EE6-4AEB-8E31-47ECEB3BF1E4"/>
    <ao:prefix>Pharmacokinetic parameters of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:suffix> in pediatric patients were established using a population pharmacokinetic analysis with sparse data from 96 pediatric patients in a single pediatric clinical trial including 33 males and 63 females with ages ranging from 10 to 17 years (weights ranging </ao:suffix>
    <domeo:uuid>4588D04A-4EE6-4AEB-8E31-47ECEB3BF1E4</domeo:uuid>
    <pav:createdOn>2014-07-22 19:35:38 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD4B7475-BD13-46C4-932F-139564A0063D">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C0CF158-24A6-445D-B09F-EA2C2052959E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EB317DCF-ED84-480E-92AF-867EFA3D6E76"/>
    <pav:lastSavedOn>2014-07-21 21:42:43 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="Na2864cc8733f48488c44334d82ebb2b4"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:A98AC7AB-8326-46FF-A484-D9D3774E511A"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:createdOn>2014-07-21 21:42:03 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:F0BD5D38-FA1E-4B14-9F0A-76765ADF5FEE"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:6BA39DFC-7B82-4E59-8309-2C37AF881D40</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:3E4DD9DD-ACD7-4BE1-99C4-C10C579DD83A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F1D81A6A-D89D-4D44-96EB-35FB50C7D732">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2E7AB2E6-7FEA-4A78-80FB-CE3FA7ABBCCB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56F428F6-CAF7-4343-B57C-103B1BA935EB">
    <ao:context rdf:resource="urn:domeoclient:uuid:532294F2-A52D-4732-85C4-0F955156A615"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 11:10:06 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:679C48F0-BCFA-4F3B-93B6-03B171A529E1</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BFD55E1-3ADE-4DD6-8289-76C7DC405DE3">
    <domeo:uuid>9BFD55E1-3ADE-4DD6-8289-76C7DC405DE3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:exact>theophylline</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9BFD55E1-3ADE-4DD6-8289-76C7DC405DE3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, </ao:prefix>
    <pav:createdOn>2014-09-02 11:36:10 -0400</pav:createdOn>
    <ao:suffix>, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3652583-DA12-4711-86A1-59DC39EC9239">
    <ao:suffix> and Other Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, etc.): See WARNINGS AND PRECAUTIONS [5.8 and 5.10].</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Warfarin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 11:46:50 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E3652583-DA12-4711-86A1-59DC39EC9239"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <domeo:uuid>E3652583-DA12-4711-86A1-59DC39EC9239</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E551BB3-088F-4A07-A523-A094DE08768F">
    <pav:createdOn>2014-09-01 15:57:26 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:39B82E57-92E3-4322-A8E6-A3AFF215F02C</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:E8908FB6-439F-4C11-8D19-36DEDFABC4CC</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:92F50FB9-2DDF-4D9E-B8BE-97306CD17D51"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-01 15:57:39 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6189C7ED-8284-4BC1-8C1D-995A1B9E9199">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:991B1A28-CCE6-4672-8304-2C2413DEA09C"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DC1E786-48C0-4894-B615-AFA91FDAC5BD">
    <pav:createdOn>2014-09-02 11:30:42 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:181AEA3C-635D-4DE0-8CD4-D795EB36DD79"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06311B02-CE01-4B2E-9D8E-7EAC3FBB8602">
    <domeo:uuid>06311B02-CE01-4B2E-9D8E-7EAC3FBB8602</domeo:uuid>
    <ao:prefix> (2 × 60 mg capsule) within 15 minutes of an </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:06311B02-CE01-4B2E-9D8E-7EAC3FBB8602"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> and magnesium containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.</ao:suffix>
    <ao:exact>aluminum</ao:exact>
    <pav:createdOn>2014-07-24 20:05:48 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4EC67EE-50D3-4156-87D9-A45D936232F9">
    <pav:lineageUri>urn:domeoserver:annotation:513F1D38-9F2A-48A2-A22D-9F19EE14C73C</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:3E595AA2-A52D-41DE-BC69-4125AE10A552"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 15:04:34 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F788EEC-77F0-4E60-8480-F71299529EB7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:F77DAE8C-2F42-4FBF-A88C-549AE7ECC4C0</pav:lineageUri>
    <pav:createdOn>2014-07-22 20:21:31 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:176AA3EF-BFBB-48D5-8C72-B5138286D455"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nf230019cb2214378be9f7692c09ea932"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0DCF362-11F8-4FF3-8C3C-EDB9DD3D53A7">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-07 11:22:54 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:206422C6-3F3C-47E8-AC4D-3CADF0982F38</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3A07EF3E-A1DF-4E0E-952B-5422EC6E9B3D"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46ACA9D3-9DB9-4318-BFF9-15A57F3153D1">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-166.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>; increased serum concentrations of methotrexate with concomitant hematologic and gastrointestinal toxicity have been observed with methotrexate. Use of methotrexate with penicillins should be carefully monitored.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46ACA9D3-9DB9-4318-BFF9-15A57F3153D1"/>
    <ao:prefix> may reduce the renal clearance of </ao:prefix>
    <ao:exact>methotrexate</ao:exact>
    <pav:createdOn>2014-07-28 17:02:30 -0400</pav:createdOn>
    <domeo:uuid>46ACA9D3-9DB9-4318-BFF9-15A57F3153D1</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D519A3CD-A32C-4057-9BB6-FB2AE41AF4A9">
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EC0A22A6-E91A-4E15-A935-E1021555864A"/>
    <pav:createdOn>2014-07-22 19:53:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:body rdf:nodeID="N94709a13b615484785459852c2a23bcc"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00D416DF-EC2B-4E10-8956-D09B3C52D5E6">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:40:59 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:58576832-5E8D-41C1-98BF-9612C4FEA54D"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E19B0AE6-FB85-4E0D-AC07-7E22C589DC36">
    <ao:prefix> and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-118.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E19B0AE6-FB85-4E0D-AC07-7E22C589DC36</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 18:44:54 -0400</pav:createdOn>
    <ao:suffix>, respectively.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E19B0AE6-FB85-4E0D-AC07-7E22C589DC36"/>
    <ao:exact>midazolam</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE9D00B3-F511-4E8E-BFBF-A30D7A5C5F82">
    <pav:createdOn>2014-07-28 17:04:52 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EE9D00B3-F511-4E8E-BFBF-A30D7A5C5F82"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> administration.</ao:suffix>
    <ao:prefix> exposure increased to a level comparable to that prior to </ao:prefix>
    <domeo:uuid>EE9D00B3-F511-4E8E-BFBF-A30D7A5C5F82</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-201.txt.html</ao:hasSource>
    <ao:exact>phenytoin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0271A3E-BA13-45E3-87AB-B8C1F9BB72CC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 19:41:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Nifedipine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F0271A3E-BA13-45E3-87AB-B8C1F9BB72CC"/>
    <domeo:uuid>F0271A3E-BA13-45E3-87AB-B8C1F9BB72CC</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> is a peripheral arterial </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-117.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/8AB4378A-0391-4B0C-86C1-A8941D0249CB">
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C536245-38D8-4238-BA9C-5A2C84CD1E14">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:412C39E0-3B4C-49D9-82A9-AE16507E8B5F"/>
    <pav:lineageUri>urn:domeoserver:annotation:87D7D751-E4FB-4247-993D-C93391BD1998</pav:lineageUri>
    <pav:createdOn>2014-07-22 18:36:29 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 18:36:37 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:040380DC-30D6-454D-ACD7-489B2130A9CC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B188771E-D938-4A6E-AA65-8D511119CA92">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C3024DC6-4D5D-4ED8-8896-E6A281746675"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdOn>2014-09-02 19:19:06 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/6FA2E5AB-9D75-44CD-B064-73797C92A684">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>aminophylline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/689</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59CE514A-8B1A-4DA2-92CC-4703FC7215B7">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-01 15:57:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:69C094F7-F9EC-4E26-B0BB-5E321AD43538"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:39B82E57-92E3-4322-A8E6-A3AFF215F02C</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-01 15:57:39 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:37F743F9-CC64-4CE3-85B6-3B8B882E4367</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1F55052-16DF-4B25-AC16-7645C8E4AD77">
    <pav:createdOn>2014-07-22 19:22:42 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:BFE9EAEF-FFFF-446F-B84E-D50E1FB72CA0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9F3E7CF-7FCB-472F-9AC5-B1BE53CD842F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A9F3E7CF-7FCB-472F-9AC5-B1BE53CD842F"/>
    <ao:exact>rosiglitazone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis. Rosiglitazone is approximately 99.8% bound to plasma proteins, primarily albumin.</ao:suffix>
    <pav:createdOn>2014-07-22 19:26:02 -0400</pav:createdOn>
    <ao:prefix>The mean (CV%) oral volume of distribution (Vss/F) of </ao:prefix>
    <domeo:uuid>A9F3E7CF-7FCB-472F-9AC5-B1BE53CD842F</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57E98049-37B0-4F70-963B-F0D12C3B36C7">
    <ao:context rdf:resource="urn:domeoclient:uuid:EFE95BF7-1349-414E-B68F-6C5149A03072"/>
    <pav:lineageUri>urn:domeoserver:annotation:996E26F9-829E-4D62-867F-4975211CECA5</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-07 11:22:43 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E72D7D03-AAE5-42A5-A83A-3C68C2C2BCB6">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/C9B2FC03-3B32-472D-B469-B9F86400F4C6"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/5A962BFF-E73B-4290-B642-C49A7EBCD1B8"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4FC315CC-8F6D-4166-AEB6-FBF9CF2FA510">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <permissions:permissions rdf:nodeID="N8f4a6a3ce5904118aebc294ee0564492"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:95E14AD2-785D-44CE-B25D-C8A915ADD717"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7EDEC592-2359-4661-BE34-B3BD50D59548"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:364EB4BF-76FF-46DE-8F92-5E5F5D0222E7"/>
    <pav:createdOn>2014-07-28 17:00:46 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2014-07-28 17:00:28 -0400</pav:lastSavedOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-164.txt.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:8C6600A6-A090-4115-A07E-5151544DB3F1</pav:lineageUri>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:F9B083BB-350D-424C-ABD3-5F63B771A9A9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58C4B9F6-E8BB-4567-9FF2-3D87C6E9284C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:45:51 -0400</pav:createdOn>
    <ao:exact>There was no significant difference in ethinyl estradiol or levonorgestrel AUC after the administration of 50 mg of fluconazole.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>58C4B9F6-E8BB-4567-9FF2-3D87C6E9284C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:58C4B9F6-E8BB-4567-9FF2-3D87C6E9284C"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74C12A9B-7A11-44EB-A829-30F93AA6ADCF">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:74C12A9B-7A11-44EB-A829-30F93AA6ADCF"/>
    <ao:prefix> maintenance therapy,</ao:prefix>
    <pav:createdOn>2014-07-28 17:04:24 -0400</pav:createdOn>
    <ao:exact> phenytoin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in methadone exposure and withdrawal symptoms occurred concurrently. Upon discontinuation of phenytoin, the incidence of </ao:suffix>
    <domeo:uuid>74C12A9B-7A11-44EB-A829-30F93AA6ADCF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-201.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D888862A-48F7-478F-BD96-42A7D5B21693">
    <ao:prefix>, the incidence of withdrawal symptoms decreased and </ao:prefix>
    <ao:exact>methadone</ao:exact>
    <ao:suffix> exposure increased to a level comparable to that prior to phenytoin administration.</ao:suffix>
    <domeo:uuid>D888862A-48F7-478F-BD96-42A7D5B21693</domeo:uuid>
    <pav:createdOn>2014-07-28 17:04:48 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-201.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D888862A-48F7-478F-BD96-42A7D5B21693"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1338CA36-AF29-4D2A-AAA6-13857E4D14F2">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:5D62F542-8672-4D61-9EF9-E4202E2BA8EB</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E415356D-7B99-400C-A966-58BF2ADC3FC9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 11:57:35 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87659984-6B68-48C3-9D52-19757F705CEB">
    <domeo:uuid>87659984-6B68-48C3-9D52-19757F705CEB</domeo:uuid>
    <ao:suffix> 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:38:16 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-78.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87659984-6B68-48C3-9D52-19757F705CEB"/>
    <ao:prefix> 2 mg coadministered with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>citalopram</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E80C09FF-4092-4C04-9821-CFC8593DEFD7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E80C09FF-4092-4C04-9821-CFC8593DEFD7"/>
    <ao:prefix> or </ao:prefix>
    <ao:exact>ketoconazole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 20:08:18 -0400</pav:createdOn>
    <ao:suffix>. The findings of these studies are summarized in the following table:</ao:suffix>
    <domeo:uuid>E80C09FF-4092-4C04-9821-CFC8593DEFD7</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A24D3202-33F3-42B7-9021-4CDA18CA2F7B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:A0E3203A-2AD3-4045-BAB8-27B340F81B0E</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-28 17:02:39 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:07EE36EA-171A-4057-95BE-E666C69DD2C3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-28 17:02:28 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:693F959A-5877-43E5-95BB-063A7AB42D5D</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5FF2B43E-5E15-4C21-BFDD-C97D4C18B3B1">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:28D6D7F6-0FFB-41F2-BC7C-A9F0E4ED53AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C2EEFE36-AE7E-4BF4-943E-03D2760C673E"/>
    <pav:createdOn>2014-07-13 11:08:45 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06A101E3-2794-4554-92A9-5297495C183D">
    <pav:lastSavedOn>2014-07-28 17:08:37 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-28 17:04:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:48D839E5-6B0A-4EC3-B64A-E3E20E06246A</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:25C05DA7-D004-4C59-A96C-F35D5BEB9B3F"/>
    <pav:lineageUri>urn:domeoserver:annotation:D66FE462-CC41-4C42-83B4-1BDD6C8E54A7</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB4F72BF-4A36-4030-AF78-3FD9D5E4FE15">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EB4F72BF-4A36-4030-AF78-3FD9D5E4FE15"/>
    <pav:createdOn>2014-07-22 19:31:19 -0400</pav:createdOn>
    <ao:exact>rosiglitazone</ao:exact>
    <domeo:uuid>EB4F72BF-4A36-4030-AF78-3FD9D5E4FE15</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> in female patients (n = 405) was approximately 6% lower compared to male patients of the same body weight (n = 642).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Results of the population pharmacokinetics analysis showed that the mean oral clearance of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3BEBBBC1-7503-4FA0-9B16-ED708F2AE108">
    <pav:createdOn>2014-07-13 12:38:53 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:371BCC12-3242-4854-9882-2DB2B2EE1A70"/>
    <pav:lineageUri>urn:domeoserver:annotation:2A576179-7248-4360-B213-E95632A0489F</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E25E6A4-046A-49AF-B686-005D1B9BE5EC">
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 11:35:42 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:09E68084-B057-4315-B5D2-BAB13980BCAE"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D356370B-E2E4-45FD-AA2A-DBBBC15D7668">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4719</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>gemfibrozil</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D6C4080C-5AC3-402F-9359-F2135366B16E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D6C4080C-5AC3-402F-9359-F2135366B16E"/>
    <pav:createdOn>2014-07-24 20:00:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Propranolol</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-135.txt.html</ao:hasSource>
    <domeo:uuid>D6C4080C-5AC3-402F-9359-F2135366B16E</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> is extensively metabolized with most metabolites appearing in the urine. Propranolol is metabolized through three primary routes: aromatic hydroxylation (mainly 4-hydroxylation), N-dealkylation followed by further side-chain oxidation, and direct glucur</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:907AD9A7-E55A-480A-BC73-7429BC2CE1DE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:30:39 -0400</pav:createdOn>
    <ao:exact>tizanidine</ao:exact>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid>907AD9A7-E55A-480A-BC73-7429BC2CE1DE</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:907AD9A7-E55A-480A-BC73-7429BC2CE1DE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1BD555DB-DE08-478A-98FE-8A631606CA83">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1BD555DB-DE08-478A-98FE-8A631606CA83"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 19:49:08 -0400</pav:createdOn>
    <domeo:uuid>1BD555DB-DE08-478A-98FE-8A631606CA83</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Gemfibrozil</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A5A79F0-6C01-40CE-B775-CC68C1268935">
    <pav:lineageUri>urn:domeoserver:annotation:AFC65757-0E22-4DF6-AF98-3F2A9DAE6482</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:DFF0F114-795C-4A7F-B8CF-1A970C7B1D1A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:443354CF-9409-4015-81BA-17601E505BAB</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 15:05:19 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 15:06:18 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15050075-436C-4668-9987-03D689AE2236">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-22 19:28:40 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 19:35:16 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:7E80543E-BF76-4514-92A9-91458DCB802B</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:62CFF353-D9DB-4975-A77C-87D5AE3C0CCA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0B517A8-DCD4-4740-A77D-8490A77113AE">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <ao:body rdf:nodeID="N69100cd2a5414f258f6511d2eefdaf0a"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-07-13 12:40:40 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:CAB91F57-2F70-4DDB-9BF8-A50167C8BBCE"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:8D387F71-D7EF-42BB-8B40-0EBCAFF64A75</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8CBD941C-1C97-4CE2-A53E-A70EEF76055C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8CBD941C-1C97-4CE2-A53E-A70EEF76055C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 19:09:08 -0400</pav:createdOn>
    <ao:exact>voriconazole</ao:exact>
    <ao:suffix>, a CYP3A4 inhibitor, significantly increased the plasma concentrations of oxycodone. Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibito</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>8CBD941C-1C97-4CE2-A53E-A70EEF76055C</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <ao:prefix>A published study showed that the co-administration with </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:420B9B73-0394-4975-8634-61202EA8F217">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:83D060E5-70B4-4270-94D2-6FF812E77E78"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:F0B97FA3-5873-4BED-A500-3F99EF51951C</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:12:03 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70BA73C3-70D0-43D1-9E54-82E0AE865E17">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-09-01 16:04:28 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:560D7055-0BE0-4AE4-9912-39985A237181"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="Nae46eb0195924ed0be40a050e70705a9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:8E378B8C-A732-4AF9-8539-558B03C369A1</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-19.txt.html</ao:annotatesResource>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-01 16:04:28 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A31AAC0C-4709-458E-B722-42176D2F7E8D">
    <pav:createdOn>2014-07-13 11:13:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A31AAC0C-4709-458E-B722-42176D2F7E8D"/>
    <ao:prefix> concentrations than poor metabolizers, the pharmacokinetics of </ao:prefix>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
    <domeo:uuid>A31AAC0C-4709-458E-B722-42176D2F7E8D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76579336-5224-465A-A966-852EF8B65F10">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76579336-5224-465A-A966-852EF8B65F10"/>
    <domeo:uuid>76579336-5224-465A-A966-852EF8B65F10</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.5).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 11:42:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:exact>Tizanidine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EE9876CA-9D21-44C9-A6F5-8C0F13C4447C">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2C22B081-DC6C-4519-BC58-778F31A66BDB"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B94664D-D507-4349-822D-1C47F7304469">
    <domeo:uuid>2B94664D-D507-4349-822D-1C47F7304469</domeo:uuid>
    <ao:exact>omeprazole</ao:exact>
    <pav:createdOn>2014-09-02 11:36:31 -0400</pav:createdOn>
    <ao:prefix>, certain benzodiazepines, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B94664D-D507-4349-822D-1C47F7304469"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:85752833-4F1F-4395-A378-9451755A600C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 19:16:07 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:2F0C7C89-516F-4D00-BAAB-BA2950277705"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DF3B3F8F-7CB0-4DA2-B24E-32B9E66603BF">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-24 20:05:33 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:4989A785-0867-4672-982C-3FCFF8AB4F7A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A08092E7-4D52-4833-B9FF-4EFA3BA6D2E4">
    <pav:createdOn>2014-09-01 16:07:44 -0400</pav:createdOn>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> as a single daily oral dose for 7 days. The mean percentage increase in the glipizide AUC after fluconazole administration was 56.9% (range: 35 to 81).</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-40.txt.html</ao:hasSource>
    <domeo:uuid>A08092E7-4D52-4833-B9FF-4EFA3BA6D2E4</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A08092E7-4D52-4833-B9FF-4EFA3BA6D2E4"/>
    <ao:prefix>and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers. All subjects received glipizide alone and following treatment with 100 mg of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C5594C9A-8B88-4CF6-B5AA-3F081580D92D">
    <pav:lineageUri>urn:domeoserver:annotation:3F11C6A1-A35B-4B78-8E4B-F4E54C9EB08B</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8543469A-E725-45C1-A0A3-93FAB55D1DD5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:13:40 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39262D74-39DF-473E-A61D-3DBC89E74ACA">
    <domeo:belongsToSet>urn:domeoclient:uuid:CE5AF44C-D211-4F33-A502-2B4C37E2ACFC</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 19:39:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:8067DF3E-2917-42D8-A222-AC1982EBCC5F"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:EF749290-86B8-450E-A199-18D1E647CA0B</pav:lineageUri>
    <pav:lastSavedOn>2014-07-24 19:39:23 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:209C377C-FE31-4FA5-9168-BD0E96D0F448">
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:84F2753B-0F8B-4975-8EFA-3A99E0B82A50"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:44:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E817E52-FC9C-4090-86D7-ADDBC13CA122">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:28:50 -0400</pav:createdOn>
    <ao:exact>rosiglitazone</ao:exact>
    <ao:suffix> CL/F was shown to be influenced by both weight and gender, being lower (about 15%) in female patients.</ao:suffix>
    <ao:prefix>me of distribution (Vss/F) were shown to increase with increases in body weight. Over the weight range observed in these analyses (50 to 150 kg), the range of predicted CL/F and Vss/F values varied by &lt;1.7-fold and &lt;2.3-fold, respectively. Additionally, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6E817E52-FC9C-4090-86D7-ADDBC13CA122"/>
    <domeo:uuid>6E817E52-FC9C-4090-86D7-ADDBC13CA122</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6DDA4ED5-743F-4C12-93A8-37B2366FF364">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:17:38 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:341C8689-0903-4B8F-836F-B52DFF733FFD</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:135F1FE6-83FC-4E58-95A7-4C08AED291BA"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:539264FC-F626-408A-BB71-03BC387083CB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 11:18:02 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB311B8D-11CB-4B44-BDC1-9641D482BE0D"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:88B8196E-4906-4695-9420-CEEF74F91F98</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:934B866B-AFCB-4F4A-A5CA-1B312B3088E1">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:15:01 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A0EE858B-D738-4E79-B01E-E50A3141586B"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:AD145E05-D965-40D9-8AB9-4C610AF8A665</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0DCB0F4-61CC-48CE-8688-567F2327B321">
    <pav:createdOn>2014-07-13 12:46:27 -0400</pav:createdOn>
    <ao:suffix> 600 mg to 900 mg intravenously over a four-hour period (from one hour before to 3 hours after a single oral dose of fluconazole 200 mg) did not affect the bioavailability or pharmacokinetics of fluconazole in 24 healthy male volunteers.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C0DCB0F4-61CC-48CE-8688-567F2327B321"/>
    <ao:prefix> AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%). However, the administration of </ao:prefix>
    <ao:exact>cimetidine</ao:exact>
    <domeo:uuid>C0DCB0F4-61CC-48CE-8688-567F2327B321</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/4BCB725A-6FD9-45A7-A5BE-7BB7C488437E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <rdfs:label>quinidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:195005D8-3CE9-43AD-A3D8-56739DB440A4">
    <ao:suffix>. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:195005D8-3CE9-43AD-A3D8-56739DB440A4"/>
    <pav:createdOn>2014-07-13 12:44:25 -0400</pav:createdOn>
    <domeo:uuid>195005D8-3CE9-43AD-A3D8-56739DB440A4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> AUC after the administration of 50 mg of </ao:prefix>
    <ao:exact>fluconazole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E07974BC-9D8F-4D5E-A1B2-C28141CD86ED">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <pav:createdOn>2014-09-02 12:03:40 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:DD1327AF-4B75-4BEA-B917-539687934A1F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3805F006-2423-4B51-87AB-CAE85C6B4E21">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:4E13C50F-B8D6-4676-A219-AD5C04FF7CDB</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A95EA236-59E2-47FB-878A-81116D82930F"/>
    <pav:createdOn>2014-07-13 11:10:15 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D09BF05F-7BD7-4E57-A285-8CF1F5BA4395">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>(5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.</ao:suffix>
    <ao:prefix>(30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D09BF05F-7BD7-4E57-A285-8CF1F5BA4395"/>
    <ao:exact>procyclidine </ao:exact>
    <domeo:uuid>D09BF05F-7BD7-4E57-A285-8CF1F5BA4395</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-21 21:42:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E38DB7B-2B38-491B-8686-9C2D434ACD79">
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <ao:body rdf:nodeID="Nef31c47169944e18a0a65df627ee2d9f"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:B018D6F2-5667-4118-9A44-AD32984915AA</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 12:40:24 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:ED359A65-2894-4EE7-9430-453B2C8C6D26"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87135DB6-D4F3-4808-BE76-D891C704525E">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:ABD16F80-DE85-4E62-8A97-6477F60FC07D"/>
    <pav:createdOn>2014-09-02 11:30:22 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CA31561-312B-4AE9-A654-27502AE41947">
    <pav:lastSavedOn>2014-07-21 21:50:30 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:07D0E09D-1B95-4EA5-944E-2F63A43629C1</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:50:40 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:404B1852-88F6-45BB-8C18-358B3A408485</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E8450D63-C063-4E83-BCD1-4BE5A8F6FF5C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30044970-A8CB-42F8-A59C-789340FE24AC">
    <ao:exact> trazodone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>30044970-A8CB-42F8-A59C-789340FE24AC</domeo:uuid>
    <pav:createdOn>2014-07-24 20:01:45 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:30044970-A8CB-42F8-A59C-789340FE24AC"/>
    <ao:prefix>is a substrate of the cytochrome P450 3A4 (CYP3A4) enzyme and</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-136.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3EBDA2ED-165F-4B57-B4BE-CFA63CD5C5A6">
    <ao:suffix>, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with pulmonary hypertension, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, vasodilatation in the systemi</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3EBDA2ED-165F-4B57-B4BE-CFA63CD5C5A6"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Sildenafil</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 09:36:02 -0400</pav:createdOn>
    <ao:prefix>(PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92F50FB9-2DDF-4D9E-B8BE-97306CD17D51">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:92F50FB9-2DDF-4D9E-B8BE-97306CD17D51"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibi</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>92F50FB9-2DDF-4D9E-B8BE-97306CD17D51</domeo:uuid>
    <ao:exact>terfenadine</ao:exact>
    <ao:prefix>In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-01 15:57:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D0923EA-66A5-4F6E-A3E6-A3D09E9AA9FA">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:nodeID="Nc9aeff62f6cd48a09527e42e3bd3c5ea"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:A52D638C-2F1C-425C-BFAB-A6120EDEA665</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lastSavedOn>2014-07-28 17:08:37 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:48D839E5-6B0A-4EC3-B64A-E3E20E06246A</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-07-28 17:07:56 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:874E727F-4FC5-466C-9B3D-C17154D3C2D1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A177F5C-EB12-4EE0-B135-C40638451C00">
    <pav:createdOn>2014-09-02 19:18:12 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:suffix> (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 9</ao:suffix>
    <ao:exact>omeprazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>. Following multiple doses of nelfinavir (1250 mg, bid) and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0A177F5C-EB12-4EE0-B135-C40638451C00"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>0A177F5C-EB12-4EE0-B135-C40638451C00</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:436A0572-7B45-4903-B1A7-9FA513872756">
    <domeo:belongsToSet>urn:domeoclient:uuid:4519FF07-AE90-4478-8B97-B4B2C84457DC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:0E6FAD46-DBE8-4B45-9895-373A8D9E0281</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 19:46:05 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 19:45:35 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C48F039A-1F94-471B-9DF9-0D4E6B99DA14"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC8C2FEA-C8BE-4A4F-98E3-3E4C44B65C83">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CC8C2FEA-C8BE-4A4F-98E3-3E4C44B65C83"/>
    <domeo:uuid>CC8C2FEA-C8BE-4A4F-98E3-3E4C44B65C83</domeo:uuid>
    <ao:prefix> could be subject to two kinds of drug-drug interactions. First, inhibitors of CYP 2D6 interfere with conversion of </ao:prefix>
    <pav:createdOn>2014-07-13 11:14:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> to 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/AA628DF4-FFD3-40B4-AF7F-28CD7B682042">
    <rdfs:label>digoxin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E1B668B-C744-4EDA-8C35-67ED2D2886D7">
    <pav:createdOn>2014-07-22 19:43:36 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Rifampin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:suffix> administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9E1B668B-C744-4EDA-8C35-67ED2D2886D7"/>
    <domeo:uuid>9E1B668B-C744-4EDA-8C35-67ED2D2886D7</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:513FF3F1-4FCE-4790-A5C9-F75162D3687B">
    <pav:lastSavedOn>2014-07-22 19:11:40 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:DAB2122F-CA41-44C2-9EB5-3469E45FCF04"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-22 19:08:44 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DAB2122F-CA41-44C2-9EB5-3469E45FCF04">
    <ao:exact>Rosiglitazone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DAB2122F-CA41-44C2-9EB5-3469E45FCF04"/>
    <pav:createdOn>2014-07-22 19:08:44 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. Rosiglitazone is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ). In huma</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>DAB2122F-CA41-44C2-9EB5-3469E45FCF04</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F53CA93-4A9A-47DB-B928-A643C66C9223">
    <pav:createdOn>2014-07-28 17:02:45 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5F53CA93-4A9A-47DB-B928-A643C66C9223"/>
    <ao:prefix>. Use of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-166.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> with penicillins should be carefully monitored.</ao:suffix>
    <domeo:uuid>5F53CA93-4A9A-47DB-B928-A643C66C9223</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>methotrexate</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0645479-B3CA-4505-B451-B003C3B19554">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 12:44:25 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:195005D8-3CE9-43AD-A3D8-56739DB440A4"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:EABDAFD6-3CCF-4D2C-BD80-C1DB3A591C0B</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC861D6D-4076-4F69-B134-B404C685F91A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CC861D6D-4076-4F69-B134-B404C685F91A"/>
    <domeo:uuid>CC861D6D-4076-4F69-B134-B404C685F91A</domeo:uuid>
    <pav:createdOn>2014-07-13 11:18:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> was decreased, and elimination half-lives were prolonged compared to young healthy subjects. Dosing should be modified accordingly in the elderly patients [see 2 DOSAGE AND ADMINISTRATION].</ao:suffix>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F263AADA-7E42-4AA1-B33C-9D0E2B21A723">
    <domeo:uuid>F263AADA-7E42-4AA1-B33C-9D0E2B21A723</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 11:54:18 -0400</pav:createdOn>
    <ao:exact>In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.</ao:exact>
    <ao:prefix>: </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F263AADA-7E42-4AA1-B33C-9D0E2B21A723"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D7C043D-E62F-4A5D-A912-AB586E95D811">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nd4361df8c29b49b2b7fef99f73cb3033"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-21 21:55:12 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:C988D053-7CF3-4C50-BDB6-7C2B20B837B9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-21 21:55:00 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:F4651B13-0AD9-4F9A-BF93-E7DE774DF9D5</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:93550871-2475-42C7-82BF-66ECE7117537"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8301C100-8F47-4B2E-A908-FF663A864A1E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8301C100-8F47-4B2E-A908-FF663A864A1E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>8301C100-8F47-4B2E-A908-FF663A864A1E</domeo:uuid>
    <ao:suffix> in healthy adult subjects. Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole. In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadmini</ao:suffix>
    <ao:prefix> led to increased plasma concentrations of </ao:prefix>
    <ao:exact>fexofenadine</ao:exact>
    <pav:createdOn>2014-07-24 20:07:25 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9207210A-6F7A-4F79-BDF9-A1A2BE0D055E">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:06D43679-56C3-4F36-AF63-D6FFEE09CD2D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0863579-8D19-4B30-ADD6-2A5BDBC2F482</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 19:52:46 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-24 19:53:55 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:001ECFA6-B086-4B2B-977E-41F4C9DE054B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F353BFC5-D6B5-4819-8EA8-0A44F2223E3B">
    <ao:suffix>may be the basis for the enhanced platelet anti-aggregatory activity of nitric oxide observed in vitro, and the mild peripheral arterial-venous dilatation in vivo.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:37:19 -0400</pav:createdOn>
    <ao:exact>sildenafil </ao:exact>
    <ao:prefix>In addition to pulmonary vascular smooth muscle and the corpus cavernosum, PDE5 is also found in other tissues including vascular and visceral smooth muscle and in platelets. The inhibition of PDE5 in these tissues by </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F353BFC5-D6B5-4819-8EA8-0A44F2223E3B"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05AFE2BC-8117-40BD-BC72-6B1AA0443A12">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>:  Coadministration of rosiglitazone (4 mg b.i.d.) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine.</ao:suffix>
    <pav:createdOn>2014-09-02 19:40:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Rosiglitazone</ao:exact>
    <domeo:uuid>05AFE2BC-8117-40BD-BC72-6B1AA0443A12</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:05AFE2BC-8117-40BD-BC72-6B1AA0443A12"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-116.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBCFB082-4C3F-4C27-B1B4-7DE7E01178ED">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EBCFB082-4C3F-4C27-B1B4-7DE7E01178ED"/>
    <pav:createdOn>2014-07-13 12:55:59 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:prefix>Administration of a single oral 200 mg dose of </ao:prefix>
    <ao:suffix> after 15 days of rifampin administered as 600 mg daily in eight healthy male volunteers resulted in a significant decrease in fluconazole AUC and a significant increase in apparent oral clearance of fluconazole. There was a mean ± SD reduction in flucon</ao:suffix>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>EBCFB082-4C3F-4C27-B1B4-7DE7E01178ED</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54E3B0B5-2096-41BF-BC0D-256928923869">
    <pav:createdOn>2014-09-02 11:32:43 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:54E3B0B5-2096-41BF-BC0D-256928923869"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmac</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, </ao:prefix>
    <ao:exact>dextromethorphan</ao:exact>
    <domeo:uuid>54E3B0B5-2096-41BF-BC0D-256928923869</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/60730FAE-AD66-492F-8E58-7FE659B7159F">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <rdfs:label>Propranolol</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89138321-17A8-4CAE-B03E-6A7C0F8B6AC5">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:89138321-17A8-4CAE-B03E-6A7C0F8B6AC5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces th</ao:suffix>
    <pav:createdOn>2014-09-01 15:57:31 -0400</pav:createdOn>
    <ao:exact>terfenadine</ao:exact>
    <domeo:uuid>89138321-17A8-4CAE-B03E-6A7C0F8B6AC5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <ao:prefix>did not increase plasma concentrations of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74FDA5BD-9C18-4F10-AC59-C5C75AA497C2">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:5CD942C6-D369-4ED6-B77B-FB216085FF48</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F0CCA954-EB0E-4D16-9B00-C1E4BE4A989D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-07 11:24:14 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4ABC712B-B1B6-46E9-80C3-428EA00FAEEF">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/B92741C4-FB91-4395-8B40-7C9F2438DDA0"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F0EB30BB-0A91-4488-BC91-DB2E42B74BC6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9904E394-CEF0-416A-8F6B-42179BE2B9C6">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 19:43:26 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N1e475d5884324bb6bae01eb347432295"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:D630E295-F643-4F99-AB1E-8DA3F1178740"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEB6848-E3C6-4761-8965-41F19EE5D781</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 19:43:34 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:F9534CDE-E0E1-4B2C-8EB0-477EA628D436</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A0236F4-5119-432D-9B94-B00A5EEC35E7">
    <domeo:uuid>3A0236F4-5119-432D-9B94-B00A5EEC35E7</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3A0236F4-5119-432D-9B94-B00A5EEC35E7"/>
    <ao:exact>Metformin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-07-22 19:55:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:805A260D-8C6D-4764-98FF-7A828A5A8A65">
    <pav:createdOn>2014-07-21 21:47:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>significantly decreases the clearance and increases the t1/2 of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>quinidine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-54.txt.html</ao:hasSource>
    <ao:suffix>, but quinidine does not alter the kinetics of diltiazem.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:805A260D-8C6D-4764-98FF-7A828A5A8A65"/>
    <domeo:uuid>805A260D-8C6D-4764-98FF-7A828A5A8A65</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E51D112-F22F-4792-B99B-6D615797BAEB">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E51D112-F22F-4792-B99B-6D615797BAEB"/>
    <pav:createdOn>2014-09-02 19:09:15 -0400</pav:createdOn>
    <ao:prefix>, a CYP3A4 inhibitor, significantly increased the plasma concentrations of </ao:prefix>
    <ao:exact>oxycodone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects. If co-administration is necessary,</ao:suffix>
    <domeo:uuid>7E51D112-F22F-4792-B99B-6D615797BAEB</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DDF76582-7387-4F32-A252-95E7B69F65AE">
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7FD7602A-D05F-4BEA-AC56-67DE4BF0AB32"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 20:11:57 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:59EB0B7E-46DA-479E-89E3-A19A0E7DD3A2</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6864EB3-C97B-4F46-976B-E976F8C03348">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F6864EB3-C97B-4F46-976B-E976F8C03348"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak b</ao:suffix>
    <pav:createdOn>2014-07-13 11:15:56 -0400</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix>) with </ao:prefix>
    <domeo:uuid>F6864EB3-C97B-4F46-976B-E976F8C03348</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:73B577C5-182A-4914-B557-9A6594045898">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 19:55:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:28F8F8B3-4AAE-49BF-945F-3B91F3DE3958"/>
    <pav:lineageUri>urn:domeoserver:annotation:85C9C895-421F-49CC-9306-FD55486F21E9</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:271B21A2-D2A2-4C95-8E2C-A3C373B06A45">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-24 19:46:59 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-130.txt.html</ao:hasSource>
    <ao:prefix>Co-administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:271B21A2-D2A2-4C95-8E2C-A3C373B06A45"/>
    <ao:suffix> with the long-acting propranolol did not have a significant effect on propranolol’s pharmacokinetics.</ao:suffix>
    <ao:exact>metoclopramide</ao:exact>
    <domeo:uuid>271B21A2-D2A2-4C95-8E2C-A3C373B06A45</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74C8573C-609D-4268-8133-F0B2749E0A1E">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:E3652583-DA12-4711-86A1-59DC39EC9239"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 11:46:50 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7DEB6848-E3C6-4761-8965-41F19EE5D781">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9904E394-CEF0-416A-8F6B-42179BE2B9C6"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:0CD4EB6E-420B-4F8E-802C-4BC8BDD384E4"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-127.txt.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 19:42:43 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:3FDC3F96-3CFF-46A2-ABE6-20195EB336B0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A6BFB4F6-55F6-4660-A8CF-B7A01D2650C1"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:340175F1-825F-4D60-A67E-F61F27C225F8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D41626C4-D21B-4872-9F5F-C3F819ACF1BB"/>
    <pav:lastSavedOn>2014-07-24 19:43:34 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E72B2B0D-2578-4768-AC75-E12D6E7F84A9</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N4e32b3d76ea240d8910f3c379dd2c9df"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:224F94C2-6E6D-4C8D-9B6C-9E8B442425A3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2BC4367-94B2-4BA7-AAA4-DA34C58B02C3">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F2BC4367-94B2-4BA7-AAA4-DA34C58B02C3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-21 21:28:35 -0400</pav:createdOn>
    <domeo:uuid>F2BC4367-94B2-4BA7-AAA4-DA34C58B02C3</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
    <ao:exact>cyclosporine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>therapy for at least 6 months and on a stable </ao:prefix>
    <ao:suffix>dose for at least 6 weeks. There was a significant increase in cyclosporine AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of fluconazole. The mean ± SD increase in AUC was 92%</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C474000-EB80-4F4E-8C99-0066BDF22196">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C474000-EB80-4F4E-8C99-0066BDF22196"/>
    <ao:prefix> (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> and midazolam, respectively.</ao:suffix>
    <domeo:uuid>9C474000-EB80-4F4E-8C99-0066BDF22196</domeo:uuid>
    <pav:createdOn>2014-07-22 18:44:50 -0400</pav:createdOn>
    <ao:exact>nifedipine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-118.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8ABD9FDA-0F08-474A-A9C8-437A5346F2AC">
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:40:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:20B4F69C-E14E-46A0-8FCE-6AAC4D5EF0B0"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:601A10D5-2B9E-4942-8107-15DFA9C70ACF">
    <ao:prefix> or </ao:prefix>
    <domeo:uuid>601A10D5-2B9E-4942-8107-15DFA9C70ACF</domeo:uuid>
    <ao:suffix> was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram, benzodiazepines). Patients should be monitored to determine if it is necessary to adjust the dosage o</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:exact>propranolol</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:601A10D5-2B9E-4942-8107-15DFA9C70ACF"/>
    <pav:createdOn>2014-09-02 19:13:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F282170D-9AEA-4BD9-A758-9130391568F0">
    <pav:createdOn>2014-09-02 11:39:30 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:99838144-4399-4843-860D-C565071F0347"/>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A75B59C8-60A9-4317-B506-9477A97901ED">
    <pav:previousVersion>urn:domeoserver:annotationset:514BA51B-D734-4003-A7C3-F03C0F95833A</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-22 19:44:46 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:CC6345F2-574E-4300-B936-8ED1CC3E2DBC"/>
    <pav:createdOn>2014-07-22 19:42:13 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/1D5C7B20-628D-4819-8BB5-5D5207989917">
    <rdfs:label>propranolol</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C4D4CDE-899A-4154-909A-B83F015F7989">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1C4D4CDE-899A-4154-909A-B83F015F7989"/>
    <ao:suffix>/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy). </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1C4D4CDE-899A-4154-909A-B83F015F7989</domeo:uuid>
    <ao:exact>fosamprenavir</ao:exact>
    <ao:prefix>Co-administration of </ao:prefix>
    <pav:createdOn>2014-07-21 21:43:17 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-51.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D6AEBDD-929E-4D65-B956-E7E552F5D014">
    <ao:prefix>/</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy). </ao:suffix>
    <pav:createdOn>2014-07-21 21:43:18 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0D6AEBDD-929E-4D65-B956-E7E552F5D014"/>
    <domeo:uuid>0D6AEBDD-929E-4D65-B956-E7E552F5D014</domeo:uuid>
    <ao:exact>ritonavir </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-51.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4B8ACAF-EC72-42B7-8537-72C0706EA026">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B4B8ACAF-EC72-42B7-8537-72C0706EA026"/>
    <ao:exact>magnesium</ao:exact>
    <ao:suffix> containing antacid (Maalox®1) decreased fexofenadine AUC by 41% and Cmax by 43%.</ao:suffix>
    <ao:prefix> and </ao:prefix>
    <pav:createdOn>2014-07-24 20:05:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>B4B8ACAF-EC72-42B7-8537-72C0706EA026</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA1C9791-9797-4F15-A767-767B900E9B87">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>-</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:58:58 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EA1C9791-9797-4F15-A767-767B900E9B87"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92DB5361-BE2B-4C69-B141-FB431E8EFC22">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:BF0C3C69-52C2-4462-9A48-708B80A1A097</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:17:24 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:0991F050-6152-45E8-8D40-DC901E368C9E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A07EF3E-A1DF-4E0E-952B-5422EC6E9B3D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3A07EF3E-A1DF-4E0E-952B-5422EC6E9B3D"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:exact>sildenafil </ao:exact>
    <ao:suffix>concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>(800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma </ao:prefix>
    <pav:createdOn>2014-07-07 11:22:54 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4D592D1B-7B6F-448B-9149-4BBF0B36A730">
    <pav:lastSavedOn>2014-07-24 20:14:43 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:2BAA59CB-3862-4A98-8A6C-AA14E82983DC</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:44EFF86D-2559-4F65-A1D1-E51A6BDD91CF"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:A96839AB-F43F-41B5-BAE4-0A2BE8F8A144</pav:lineageUri>
    <pav:createdOn>2014-07-24 20:14:58 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DCFB2B8-8A03-443E-AC2D-8FA3EBDA0087">
    <ao:body rdf:nodeID="N170f06b4eb99445f825536b64dc09b0c"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4EA9F290-CB9E-46F8-AF87-B09760F74365"/>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 20:19:49 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:BA098515-4096-4EFB-BF90-5970404842E1</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D909BDC5-468E-434E-B3E5-632F1565E73C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D909BDC5-468E-434E-B3E5-632F1565E73C"/>
    <ao:exact>ulfamethazine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> displaces each other from plasma binding sites. High therapeutic concentrations of s</ao:prefix>
    <domeo:uuid>D909BDC5-468E-434E-B3E5-632F1565E73C</domeo:uuid>
    <pav:createdOn>2014-07-13 11:11:25 -0400</pav:createdOn>
    <ao:suffix> (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0415BFC3-92B0-4B40-B23A-DCE512A51F26">
    <domeo:uuid>0415BFC3-92B0-4B40-B23A-DCE512A51F26</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0415BFC3-92B0-4B40-B23A-DCE512A51F26"/>
    <ao:prefix>was co-administered with cytochrome P450 3A4 substrates, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>terfenadine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-01 16:05:56 -0400</pav:createdOn>
    <ao:suffix>, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibi</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86692ABC-62BE-4895-A4EF-50FCB21327B2">
    <ao:exact>risperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:16:08 -0400</pav:createdOn>
    <domeo:uuid>86692ABC-62BE-4895-A4EF-50FCB21327B2</domeo:uuid>
    <ao:suffix> to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of risperidone to the enzyme suggests this is unlikely [see 7 DRUG INTERACTIONS].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> [see 7 DRUG INTERACTIONS]. It would also be possible for </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:86692ABC-62BE-4895-A4EF-50FCB21327B2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D11B975-10D6-42DD-93CA-9D9026AA5279">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:6E17111B-43FD-450F-81B0-BB4156153427</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:EC569F9C-8D7B-414A-9059-EDFAE9A86040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 19:46:58 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:46:24 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:1285AF18-3541-4E0D-9BAA-DDBC5E9C152C</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:007F6835-1CAF-4F0B-8BFD-311D8BFD8926">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:007F6835-1CAF-4F0B-8BFD-311D8BFD8926"/>
    <ao:suffix>was co-administered with erythromycin, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).</ao:suffix>
    <ao:exact>sildenafil </ao:exact>
    <ao:prefix>When a single 100 mg dose of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-07 11:23:01 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:017A9836-D985-4347-BFF0-9EBED8DB5CD1">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:17:02 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:489A8473-952A-4034-A912-302A2847F038</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:55E92945-9B4A-406D-8BFF-54471B2E432E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8D05CE4-8287-449A-8921-AFACBAEE2002">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:39:32 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:52192391-30EB-46A9-93CB-47EC77CE40BC"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9E21C61-063D-4F80-8E08-85865B387669">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:8232EB8B-B7ED-4583-BE33-F0AD71DA4D1C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-07 09:36:49 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A3DCC3AB-4469-4227-B682-6E7F65CD2A7A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9D2EDEBD-1223-4650-A96C-6AA36F00C854"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/FE6B22BB-D261-488B-A15D-2B75123912F4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdfs:label>carbamazepine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E415356D-7B99-400C-A966-58BF2ADC3FC9">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E415356D-7B99-400C-A966-58BF2ADC3FC9"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:57:35 -0400</pav:createdOn>
    <ao:suffix> (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidon</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E415356D-7B99-400C-A966-58BF2ADC3FC9</domeo:uuid>
    <ao:prefix> 20 mg in patients stabilized on </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:507B5E29-9158-4374-B797-6175E792AA48"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:8164F866-D42E-492E-9290-5B0170C62867"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D4EC67EE-50D3-4156-87D9-A45D936232F9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7ACE5CBD-6F8F-4F53-8756-2657011A4A35"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N5c71be82559b46e99fc4e32dcaefb89c"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1F41B5CD-E2A4-46BE-9B88-1BCA05A1A5EE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D32DB27C-3D8E-46AF-87F9-8A3307B5D13B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3B6AC179-753D-43FC-9F87-1511C2E4BFA1</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:F6EB60C9-CEEF-414F-8B0A-9C1AF0091872"/>
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 15:03:58 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:C8425744-9F63-4970-8237-27D021CAD666"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:BE7465D0-1375-484E-9391-EFB42F00FC99"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7B017829-D9F5-484A-8F49-2CBAD935419D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:88A57962-2A3E-4D94-8F54-0A13BDB6FAD9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:752D3341-6554-481E-A205-06C244A6CD0A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3AA77CCF-FE2A-48F6-9346-1114AFD695DA">
    <ao:prefix>clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3AA77CCF-FE2A-48F6-9346-1114AFD695DA"/>
    <ao:suffix>increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours. (See PRECAUTIONS.)</ao:suffix>
    <ao:exact>theophylline </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-21 21:34:02 -0400</pav:createdOn>
    <domeo:uuid>3AA77CCF-FE2A-48F6-9346-1114AFD695DA</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4CCAADB-C549-4258-8D06-8971C53D94D8">
    <ao:prefix> on phenobarbital pharmacokinetics was not studied. Since </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A4CCAADB-C549-4258-8D06-8971C53D94D8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>paroxetine</ao:exact>
    <pav:createdOn>2014-09-01 16:22:20 -0400</pav:createdOn>
    <domeo:uuid>A4CCAADB-C549-4258-8D06-8971C53D94D8</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-45.txt.html</ao:hasSource>
    <ao:suffix> exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustment with Paroxetine Hydrochloride Controlled-Release Tablets is considered necessary whe</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F1504F1A-B189-4B6A-9973-4A17775240C5">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>9-hydroxyrisperidone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/679314</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28EA3105-DAE4-4248-8C5A-EACDF44B4680">
    <ao:exact>ECG </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:28EA3105-DAE4-4248-8C5A-EACDF44B4680"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-07 09:39:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>were reported.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>to patients with pulmonary arterial hypertension, no clinically relevant effects on </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7990829B-F65B-4D7A-B0B9-46A365009737">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:34:02 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:B1BFEACD-2C0F-411A-ABC8-BA247A926C11</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3AA77CCF-FE2A-48F6-9346-1114AFD695DA"/>
    <pav:lastSavedOn>2014-07-21 21:35:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:B61F1A9B-4696-4ED0-80AA-4FE2E9016966</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B6D964C-5C7B-4A8B-91D1-71E48BED6297">
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D16208CB-7392-415A-8487-52928A419F00"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 12:46:12 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:A5674909-9644-497C-B284-D55E831FC413</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB01A892-8D67-4A38-8CA4-2D230875A1F6">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CB01A892-8D67-4A38-8CA4-2D230875A1F6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> and 9-hydroxyrisperidone combined, after single and multiple doses, were similar in extensive and poor metabolizers, with an overall mean elimination half-life of about 20 hours.</ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>CB01A892-8D67-4A38-8CA4-2D230875A1F6</domeo:uuid>
    <pav:createdOn>2014-07-13 11:17:12 -0400</pav:createdOn>
    <ao:prefix> was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinetics of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6341241A-9991-4CE8-B771-4A2513B1FF21">
    <ao:suffix>following an intravenous 1000 mg dose. Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabol</ao:suffix>
    <pav:createdOn>2014-09-01 15:59:54 -0400</pav:createdOn>
    <domeo:uuid>6341241A-9991-4CE8-B771-4A2513B1FF21</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6341241A-9991-4CE8-B771-4A2513B1FF21"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>tolbutamide </ao:exact>
    <ao:prefix>for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-17.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8BAAA01E-8AC9-466E-B388-3972354A4BAB">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3CF71FFB-73DC-483D-B743-8D191F63D01D"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:412C39E0-3B4C-49D9-82A9-AE16507E8B5F">
    <domeo:uuid>412C39E0-3B4C-49D9-82A9-AE16507E8B5F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-57.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
    <pav:createdOn>2014-07-22 18:36:29 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:412C39E0-3B4C-49D9-82A9-AE16507E8B5F"/>
    <ao:exact>Zonisamide</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6DF7A5F7-A5AA-4B80-A495-D1E04A24A471">
    <ao:context rdf:resource="urn:domeoclient:uuid:E71F7227-79D2-4BF7-AAF2-F7F5CA5F1555"/>
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:7F45168A-D602-4AE9-97E4-CBD63E9FE38D</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-24 20:11:46 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:585BED0D-5182-4D39-912D-F355B5BEA6BA">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 19:11:40 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:11:19 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:2363FCF8-4364-4BDB-BB21-5EDBFD6F753B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/7C90A079-6EB4-494B-B58B-CC7428475342">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>quinidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:651C0626-4BF6-4B96-A66A-7385C6456D51">
    <ao:context rdf:resource="urn:domeoclient:uuid:DD06894B-6765-494F-98ED-9B2C217D26FD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:13:26 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:298F93DA-79DF-482C-B367-9A29F14FB3D6</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8450D63-C063-4E83-BCD1-4BE5A8F6FF5C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E8450D63-C063-4E83-BCD1-4BE5A8F6FF5C"/>
    <pav:createdOn>2014-07-21 21:50:40 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-55.txt.html</ao:hasSource>
    <domeo:uuid>E8450D63-C063-4E83-BCD1-4BE5A8F6FF5C</domeo:uuid>
    <ao:exact>quinidine sulfate</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyethylene glycol, povidone, triacetin and titanium dioxide.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> Extended-release Tablet contains 300 mg of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB4D6CAD-8800-44E1-9856-C0585E6A6B61">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EB4D6CAD-8800-44E1-9856-C0585E6A6B61"/>
    <ao:suffix> (1g q12h iv) could be substituted for the specified comparator if the causative pathogen was suspected or confirmed methicillin-resistant staphylococcus or if the patient was allergic to penicillins, cephalosporins or carbapenems. Study JRV 304 enrolled</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-119.txt.html</ao:hasSource>
    <ao:prefix> (1g q8h iv) in the second study (JRV 305); however, in both studies </ao:prefix>
    <ao:exact>vancomycin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>EB4D6CAD-8800-44E1-9856-C0585E6A6B61</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 18:51:41 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B394B422-1AAF-4ED4-A3BB-3FB13E961EEA">
    <pav:lineageUri>urn:domeoserver:annotationset:DA4FB434-928A-4C10-A856-79B90E224B6F</pav:lineageUri>
    <pav:lastSavedOn>2014-07-21 21:30:23 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B0CDA62F-9ACD-470D-B0EC-F331BF018B09"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:FF969EAD-2CD7-4039-AD45-C2D98B79E3B0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:03276EA7-732F-4344-8706-3960852CCE36"/>
    <pav:createdOn>2014-07-21 21:28:25 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:3123DE1C-E4E4-41E2-8666-474B2051A954"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <permissions:permissions rdf:nodeID="N933161c3cfb9468e9ad8163dadd666cf"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:9A057858-10CF-4E79-9283-5F1644D9BB0A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4C6E4A21-6D29-4DFC-BCC7-71D10F66BA88"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C970223A-AA7A-4283-8B0C-B1F7B0A1261F">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C970223A-AA7A-4283-8B0C-B1F7B0A1261F"/>
    <ao:exact>Diltiazem</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:44:36 -0400</pav:createdOn>
    <domeo:uuid>C970223A-AA7A-4283-8B0C-B1F7B0A1261F</domeo:uuid>
    <ao:suffix>: Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DFEFC5E6-CD9E-430A-AB17-673B60C626A3">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F04829AF-C604-411D-8F92-B9DB45D4050E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/6C885934-8872-486F-BCF1-97D398581817"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F9E01FD-BC9F-4B86-8FFF-8A4DC8CD6CB5">
    <ao:exact>meperidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> and also the formation of the metabolite, normeperidine, in healthy subjects and thus, caution should be used with concomitant administration.</ao:suffix>
    <domeo:uuid>6F9E01FD-BC9F-4B86-8FFF-8A4DC8CD6CB5</domeo:uuid>
    <pav:createdOn>2014-07-28 17:00:51 -0400</pav:createdOn>
    <ao:prefix> reduced the clearance and volume of distribution of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6F9E01FD-BC9F-4B86-8FFF-8A4DC8CD6CB5"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-164.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17DEFB36-51D5-4E3A-92CC-91E1F7EEAE4B">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:77415BA5-F65C-46BF-B1E8-F58D8F285BE2"/>
    <pav:createdOn>2014-07-22 19:51:04 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2788742-3226-4BFB-9D85-2FC7211066F7">
    <pav:lineageUri>urn:domeoserver:annotationset:C838220C-7EBC-4E05-B48B-8211CA4F259C</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 18:59:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-120.txt.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N4d33327ccf1341f4b3d3ef1545fcbc12"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:59E51D24-193D-4075-8FE6-4129F350FD59"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:F47F11AD-A4E0-4F3C-B00C-4BAD618B41C3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D9DD245-350D-4E6C-84D1-AA5D144E689A"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:C86F61CA-C8B8-45D2-86FA-DC4DB976D43B"/>
    <pav:createdOn>2014-07-22 18:58:19 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9D56D7C-5C37-4BCA-B9C4-0605E9E54998">
    <pav:createdOn>2014-07-07 09:43:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, and is, itself, further metabolized. This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an in vitro potency for PDE5 approximately 50% of the parent drug. In healthy volunteers, plasma concentrations of this metabolit</ao:suffix>
    <ao:prefix>of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B9D56D7C-5C37-4BCA-B9C4-0605E9E54998"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>sildenafil</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04B30485-E368-4D5D-ABB9-17EBA8B817CD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>04B30485-E368-4D5D-ABB9-17EBA8B817CD</domeo:uuid>
    <ao:suffix>.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:04B30485-E368-4D5D-ABB9-17EBA8B817CD"/>
    <ao:prefix>Results of the population pharmacokinetic analysis (n = 716 &lt;65 years; n = 331 ≥65 years) showed that age does not significantly affect the pharmacokinetics of </ao:prefix>
    <pav:createdOn>2014-07-22 19:31:11 -0400</pav:createdOn>
    <ao:exact>rosiglitazone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED46D326-5EE0-47F9-A0D2-97252A43CE9D">
    <pav:createdOn>2014-09-02 19:12:11 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:ACDCB5F4-8A15-444E-AB50-018A46C6500F"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F209001-62CD-42DB-94B6-8505E0EB8F2E">
    <ao:prefix>Daily oral dosing of immediate-release </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2F209001-62CD-42DB-94B6-8505E0EB8F2E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>2F209001-62CD-42DB-94B6-8505E0EB8F2E</domeo:uuid>
    <ao:suffix>(30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclid</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-21 21:42:03 -0400</pav:createdOn>
    <ao:exact>paroxetine </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F049BA4A-8DAF-49C1-ABA1-6E76A2F6DA6B">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/1FCFC8E7-95A0-4188-9582-891391C2CFE6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/A36E11B0-6726-4AD1-ACC7-4E8E59A350EB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE2B15F2-9CA8-49EC-B61F-0A38DD22AF0C">
    <ao:suffix> </ao:suffix>
    <ao:exact>AVANDIA</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AE2B15F2-9CA8-49EC-B61F-0A38DD22AF0C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AE2B15F2-9CA8-49EC-B61F-0A38DD22AF0C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 20:17:49 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/A52FAC94-0446-462D-9EE8-53E67CFDFC2E">
    <rdfs:label>Metronidazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6922</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A0A9901-A1C2-4230-8BC1-B758AADE7F4C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A0A9901-A1C2-4230-8BC1-B758AADE7F4C"/>
    <ao:suffix> (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> (repeated oral doses) and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-118.txt.html</ao:hasSource>
    <domeo:uuid>8A0A9901-A1C2-4230-8BC1-B758AADE7F4C</domeo:uuid>
    <pav:createdOn>2014-07-22 18:44:37 -0400</pav:createdOn>
    <ao:exact>midazolam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8067DF3E-2917-42D8-A222-AC1982EBCC5F">
    <ao:prefix>The mean Cmax and AUC of </ao:prefix>
    <domeo:uuid>8067DF3E-2917-42D8-A222-AC1982EBCC5F</domeo:uuid>
    <ao:suffix> are increased by 64% and 79%, respectively, by co-administration of propranolol.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-126.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>nifedipine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8067DF3E-2917-42D8-A222-AC1982EBCC5F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-24 19:39:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:984E4D2D-A998-4068-9BF7-F709348DD1B2">
    <domeo:uuid>984E4D2D-A998-4068-9BF7-F709348DD1B2</domeo:uuid>
    <pav:createdOn>2014-07-13 11:18:21 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix>Elderly: In healthy elderly subjects, renal clearance of both </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:984E4D2D-A998-4068-9BF7-F709348DD1B2"/>
    <ao:suffix> and 9-hydroxyrisperidone was decreased, and elimination half-lives were prolonged compared to young healthy subjects. Dosing should be modified accordingly in the elderly patients [see 2 DOSAGE AND ADMINISTRATION].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:01600057-F016-4A5A-AC67-3F30E5F3B4EA">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6EB0C05E-6581-4241-B07F-CF48B6405DC1"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:31:10 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-21 21:31:54 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40007BD9-0869-48CF-A8F2-BAD26AE3E6E1</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:092451F5-B0C0-430C-8896-07F81D33F9E1</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:643A5ED0-8507-40E4-BF8F-798721470D41">
    <ao:prefix>e N-demethylation and hydroxylation, followed by conjugation with sulfate and glucuronic acid. All the circulating metabolites are considerably less potent than parent and, therefore, are not expected to contribute to the insulin-sensitizing activity of </ao:prefix>
    <pav:createdOn>2014-07-22 19:28:08 -0400</pav:createdOn>
    <ao:exact>rosiglitazone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:643A5ED0-8507-40E4-BF8F-798721470D41"/>
    <ao:suffix>.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>643A5ED0-8507-40E4-BF8F-798721470D41</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18A94768-B77C-45AF-843F-894BD40CD040">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:18A94768-B77C-45AF-843F-894BD40CD040"/>
    <ao:suffix> is metabolized, at least in part, by CYP2D6. Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).</ao:suffix>
    <ao:exact>fluvoxamine</ao:exact>
    <domeo:uuid>18A94768-B77C-45AF-843F-894BD40CD040</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:35:13 -0400</pav:createdOn>
    <ao:prefix>tics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BB046B1-5949-4043-9525-70D01EC3816C">
    <ao:suffix> is bound to albumin and α1-acid glycoprotein. The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9BB046B1-5949-4043-9525-70D01EC3816C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> is rapidly distributed. The volume of distribution is 1 to 2 L/kg. In plasma, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:10:51 -0400</pav:createdOn>
    <domeo:uuid>9BB046B1-5949-4043-9525-70D01EC3816C</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A404FE8-4389-4D36-A815-EE09948F4613">
    <domeo:uuid>6A404FE8-4389-4D36-A815-EE09948F4613</domeo:uuid>
    <ao:prefix> (400 mg, qd) and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A404FE8-4389-4D36-A815-EE09948F4613"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:18:28 -0400</pav:createdOn>
    <ao:suffix> (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%. Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended. For other antiretroviral drugs, such as saq</ao:suffix>
    <ao:exact>omeprazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:704A238F-4D41-41C0-AEE2-EF49045B60D6">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:D94A3BF4-A374-449F-9330-5C3F983FC929</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5034993F-95BA-483B-9B77-F3B8E9E3CFC5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-01 16:02:32 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-01 16:02:34 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:A7D6B2F9-CA80-489F-A2EE-AF66905E962F</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8425744-9F63-4970-8237-27D021CAD666">
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:04931205-C053-487C-8E10-4A1A8F38120C"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:E384B2C0-0834-482B-812C-73024B30202C</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 15:04:22 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A512929D-5410-4D52-AEA7-F2E68A62A9E8">
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:0DC4E7B3-91DD-45B9-9175-1936730AC49F"/>
    <pav:createdOn>2014-09-02 11:43:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F9271EC-A8D0-45D0-9412-2C40F45D0D4B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F9271EC-A8D0-45D0-9412-2C40F45D0D4B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-118.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 18:47:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>7F9271EC-A8D0-45D0-9412-2C40F45D0D4B</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:525D9A2A-57D7-4B82-AAC2-92BA3D298032">
    <ao:context rdf:resource="urn:domeoclient:uuid:F409D487-F7F1-4F27-B967-0469F9A468A8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:32C325B9-09DD-4A0B-A270-BAA0C42956A1</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2B18F6B1-59F7-4EA0-9386-55A934108055</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:06:51 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 19:06:48 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16FE2F0D-3BF4-4708-9147-BD5159B47059">
    <pav:createdOn>2014-07-13 11:14:31 -0400</pav:createdOn>
    <ao:prefix>r drugs. CYP 2D6 is subject to genetic polymorphism (about 6% to 8% of Caucasians, and a very low percentage of Asians, have little or no activity and are “poor metabolizers”) and to inhibition by a variety of substrates and some non-substrates, notably </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>16FE2F0D-3BF4-4708-9147-BD5159B47059</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16FE2F0D-3BF4-4708-9147-BD5159B47059"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. Extensive CYP 2D6 metabolizers convert </ao:suffix>
    <ao:exact>quinidine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED9A4881-5A44-4C07-BAFB-529340D632F3">
    <ao:context rdf:resource="urn:domeoclient:uuid:47492213-15E8-4498-83DF-D443A77CE0C4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-22 19:11:40 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 19:08:55 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:776765AF-5295-4800-809B-C7978354CB7E">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:370F2AF6-A399-4830-9318-16C2CC56C4E5"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F64BA1C3-4615-428E-A209-D304847D4A08">
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C00C0C31-D3ED-43CE-8CB0-398EA275616B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdOn>2014-09-02 19:18:20 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N387d00726f3647acbb3945436b2a12c3">
    <domeo:sets rdf:resource="urn:pddi:uuid:B3F6AB4E-3B37-4465-8CFC-119F30A661AA"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/506F49B8-922C-4813-A6D3-3A7CFAA9C474">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>valproate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/40254</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:159DCA30-3727-4241-9440-301E40381956">
    <ao:suffix> (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:159DCA30-3727-4241-9440-301E40381956"/>
    <ao:prefix> (100 mcg/mL), </ao:prefix>
    <domeo:uuid>159DCA30-3727-4241-9440-301E40381956</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>warfarin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:11:31 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/093D1F2A-587E-4B3C-AAF4-10347561D8A9">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sildenafil</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78651239-7677-4E29-8D57-C04613A83C19">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 12:03:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:78651239-7677-4E29-8D57-C04613A83C19"/>
    <ao:exact>paroxetine</ao:exact>
    <ao:suffix>.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <domeo:uuid>78651239-7677-4E29-8D57-C04613A83C19</domeo:uuid>
    <ao:prefix> be initiated at a reduced dose when given with </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2FC590A9-4A32-43E3-8740-436A834AADD1">
    <ao:suffix> who experienced an event on at least one occasion. All events are included except those already listed in the previous table or discussed in WARNINGS or PRECAUTIONS, trivial events, those too general to be informative, and those not reasonably associate</ao:suffix>
    <ao:exact>zonisamide</ao:exact>
    <ao:prefix>e of the proportion of individuals having adverse events, similar events have been grouped into a smaller number of standardized categories using a modified COSTART dictionary. The frequencies represent the proportion of the 1,598 individuals exposed to </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2FC590A9-4A32-43E3-8740-436A834AADD1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 18:37:42 -0400</pav:createdOn>
    <domeo:uuid>2FC590A9-4A32-43E3-8740-436A834AADD1</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-58.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5D8B7FB-8F69-439A-B1F3-0DC084AEDE1E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme. In most patients (&gt;90%), this CYP2D6 isozyme </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D5D8B7FB-8F69-439A-B1F3-0DC084AEDE1E"/>
    <ao:prefix>Many drugs, including most drugs effective in the treatment of major depressive disorder (</ao:prefix>
    <ao:exact>paroxetine</ao:exact>
    <domeo:uuid>D5D8B7FB-8F69-439A-B1F3-0DC084AEDE1E</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:55:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E52164F-6FEF-4A1A-A55B-01314BCEB19B">
    <ao:suffix>. Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.</ao:suffix>
    <ao:prefix>, has similar pharmacological activity as </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E52164F-6FEF-4A1A-A55B-01314BCEB19B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:12:23 -0400</pav:createdOn>
    <domeo:uuid>7E52164F-6FEF-4A1A-A55B-01314BCEB19B</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DC4E7B3-91DD-45B9-9175-1936730AC49F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <domeo:uuid>0DC4E7B3-91DD-45B9-9175-1936730AC49F</domeo:uuid>
    <ao:suffix>: There have been rare postmarketing reports of </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0DC4E7B3-91DD-45B9-9175-1936730AC49F"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-09-02 11:43:26 -0400</pav:createdOn>
    <ao:exact>Triptans</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A07FFEB8-13E6-4964-A170-13A6FA26AB90">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:09:08 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:8CBD941C-1C97-4CE2-A53E-A70EEF76055C"/>
    <pav:lineageUri>urn:domeoserver:annotation:12709F63-2474-4857-8883-0FFFA8BD82EB</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25474B79-791D-49D5-B5D1-858E90C62BB2">
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5F397631-58CE-4AAD-85E7-C4D90E5C8F78"/>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 19:12:34 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5B0ED12-45EB-48BE-B664-DDC78E05AA4A">
    <pav:createdOn>2014-09-02 19:17:02 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F7832F9-F40E-4E9B-917C-25342C417D3F"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EAE26632-A8D8-4E80-ADE1-8902853460F6">
    <domeo:uuid></domeo:uuid>
    <ao:exact>TID </ao:exact>
    <ao:prefix>After chronic dosing of 80 mg </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EAE26632-A8D8-4E80-ADE1-8902853460F6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 09:39:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC36AAD8-731B-4089-8CD4-237A818B35C9">
    <ao:prefix>fluvoxami</ao:prefix>
    <pav:createdOn>2014-09-02 11:35:32 -0400</pav:createdOn>
    <ao:suffix> has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>ne</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FC36AAD8-731B-4089-8CD4-237A818B35C9"/>
    <domeo:uuid>FC36AAD8-731B-4089-8CD4-237A818B35C9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3024DC6-4D5D-4ED8-8896-E6A281746675">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (1000/100 mg) bid for 15 days with omeprazole 40 mg qd co-administered days 11 to 15. Dose reduction of saquinavir should be considered from the safety perspective for individual patients. There are also some antiretroviral drugs of which unchanged seru</ao:suffix>
    <pav:createdOn>2014-09-02 19:19:06 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C3024DC6-4D5D-4ED8-8896-E6A281746675"/>
    <domeo:uuid>C3024DC6-4D5D-4ED8-8896-E6A281746675</domeo:uuid>
    <ao:exact>ritonavir</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:prefix>/</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EDF86F62-D99C-4656-9677-171A5B522535">
    <ao:body rdf:nodeID="N2ea9c4b38a204fb0a2f7f4b68240f2ef"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:BD2F8285-34FA-4CD1-8607-8FE20DF34F40</pav:lineageUri>
    <pav:createdOn>2014-07-21 21:49:45 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5DCEC7D7-75CA-429F-BCD4-2381663B0506"/>
    <pav:lastSavedOn>2014-07-21 21:49:33 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:B803E851-5AD5-4741-B1B9-1CBAED597E18</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/B7481A86-7883-4807-96C3-AE9B411B847B">
    <rdfs:label>AVANDIA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/261455</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DCEC7D7-75CA-429F-BCD4-2381663B0506">
    <domeo:uuid>5DCEC7D7-75CA-429F-BCD4-2381663B0506</domeo:uuid>
    <pav:createdOn>2014-07-21 21:49:45 -0400</pav:createdOn>
    <ao:exact>Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-54.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5DCEC7D7-75CA-429F-BCD4-2381663B0506"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F57938E2-AD63-45EA-B996-C0C893D21182">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F57938E2-AD63-45EA-B996-C0C893D21182"/>
    <pav:createdOn>2014-09-02 11:58:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F57938E2-AD63-45EA-B996-C0C893D21182</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <ao:prefix> may be necessary and it is recommended that </ao:prefix>
    <ao:suffix> be initiated at a reduced dose when given with paroxetine.</ao:suffix>
    <ao:exact>atomoxetine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D92FA7B-3CB7-4C89-9E21-9980B649BC2E">
    <ao:prefix>Population data from patients in clinical trials indicated a reduction in </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1D92FA7B-3CB7-4C89-9E21-9980B649BC2E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>clearance when it was co-administered with CYP3A inhibitors. Sildenafil exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg TID. This concentration range covers the same </ao:suffix>
    <pav:createdOn>2014-07-07 11:22:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:962DC691-3D08-4224-8D22-C0DD8D9F24CA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:0F95BD67-87EE-4AA9-A33E-A0BCF7921FF0"/>
    <pav:lineageUri>urn:domeoserver:annotation:4EAFAB1D-1E62-4401-9065-8F44961694A1</pav:lineageUri>
    <pav:createdOn>2014-07-13 12:56:00 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B8303DC-666E-48AC-A169-56BEAEB6610A">
    <ao:exact>metoprolol</ao:exact>
    <ao:suffix> is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended. No dosage adjustment is required for fluvoxamine maleate tablets.</ao:suffix>
    <domeo:uuid>3B8303DC-666E-48AC-A169-56BEAEB6610A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3B8303DC-666E-48AC-A169-56BEAEB6610A"/>
    <pav:createdOn>2014-09-02 11:45:59 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E6E80C9-FE56-4016-839A-ADB4FEFC8C55">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9E6E80C9-FE56-4016-839A-ADB4FEFC8C55"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>9E6E80C9-FE56-4016-839A-ADB4FEFC8C55</domeo:uuid>
    <pav:createdOn>2014-09-02 11:38:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix> with </ao:prefix>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:suffix> produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02B52C58-6F51-4B2E-9D66-4E523227806E">
    <pav:createdOn>2014-09-02 11:57:13 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:91866B43-056C-4732-918F-F1A8DB5C81CC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:7D867112-B5D9-4FEA-A8A5-D8FC72239EAE"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D04CBBE-379A-4D9F-BDD4-AA3663CD4669">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2D04CBBE-379A-4D9F-BDD4-AA3663CD4669"/>
    <domeo:uuid>2D04CBBE-379A-4D9F-BDD4-AA3663CD4669</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-07 11:36:13 -0400</pav:createdOn>
    <ao:exact>Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56C7D107-DA52-4259-9BBA-41DB4C5FB13D">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>56C7D107-DA52-4259-9BBA-41DB4C5FB13D</domeo:uuid>
    <ao:exact>rosiglitazone</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:56C7D107-DA52-4259-9BBA-41DB4C5FB13D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 19:38:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F397631-58CE-4AAD-85E7-C4D90E5C8F78">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5F397631-58CE-4AAD-85E7-C4D90E5C8F78"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:12:34 -0400</pav:createdOn>
    <ao:exact>phenytoin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, drugs that are metabolized by oxidation in the liver. There have been reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including omeprazole, and warfarin concomitantly. Increases in INR and prothrombin time ma</ao:suffix>
    <ao:prefix>and </ao:prefix>
    <domeo:uuid>5F397631-58CE-4AAD-85E7-C4D90E5C8F78</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2E73BB40-870E-4E49-B189-491A7CC6CA08">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2E73BB40-870E-4E49-B189-491A7CC6CA08"/>
    <pav:createdOn>2014-09-02 15:04:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>2E73BB40-870E-4E49-B189-491A7CC6CA08</domeo:uuid>
    <ao:suffix>. Based on the assumption that the relationship between paroxetine’s in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, paroxetine’s extent of inhibition of CYP3A4 activity is not likely </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
    <ao:exact>cyclosporine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/C731F1F0-68ED-49B4-A9BF-768B903AF43C">
    <rdfs:label>propranolol</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C727003-BB8F-45A8-BBAC-ACBE1D4D132E">
    <ao:item rdf:resource="urn:domeoclient:uuid:590B6F13-4CF1-42FD-BA01-FB622D059EBD"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <permissions:permissions rdf:nodeID="Nedafe03b7c9b4388b0c59e9c8aa32636"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1584C65E-C32D-42F5-A725-32DCDF671F11"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:6E55DAE1-1B74-4DEB-88DF-468C3C50E4E0</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E2EC2236-F4B5-4F35-8112-88B3BB4A33EA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-24 19:47:39 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-131.txt.html</ao:annotatesResource>
    <pav:lastSavedOn>2014-07-24 19:51:12 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BCA04010-E0E5-4D69-A2B7-6AB2C8D2081F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EA46EFB-1A94-409D-B432-24203EA5400F">
    <ao:context rdf:resource="urn:domeoclient:uuid:8A7AE105-ADC2-416B-AD5B-0B0B1DB2A2E2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 12:38:56 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:0DE5D981-90C9-4EFB-8436-D8AEB6978507</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C072F602-C93D-48EA-B6A2-EEDE4C49DC48">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C072F602-C93D-48EA-B6A2-EEDE4C49DC48"/>
    <ao:exact>ritonavir</ao:exact>
    <ao:suffix>), may prolong opioid effects. If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibitors. Evaluate these patients at frequent intervals and consider dose adjustments until sta</ao:suffix>
    <ao:prefix>), and protease inhibitors (e.g., </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>C072F602-C93D-48EA-B6A2-EEDE4C49DC48</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:09:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A71C73E7-BDEF-430C-BE2B-73E35D00A542">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A71C73E7-BDEF-430C-BE2B-73E35D00A542"/>
    <ao:exact>Fexofenadine</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 20:07:07 -0400</pav:createdOn>
    <ao:suffix> has been shown to exhibit minimal (ca. 5%) metabolism. However, coadministration of fexofenadine hydrochloride with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects. Fexofenadine had no</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A71C73E7-BDEF-430C-BE2B-73E35D00A542</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7B5E0E2-9287-47B6-9135-34CE522BE395">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> resulted in increased </ao:prefix>
    <pav:createdOn>2014-07-24 20:14:43 -0400</pav:createdOn>
    <ao:exact>azithromycin</ao:exact>
    <domeo:uuid>E7B5E0E2-9287-47B6-9135-34CE522BE395</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-161.txt.html</ao:hasSource>
    <ao:suffix> serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E7B5E0E2-9287-47B6-9135-34CE522BE395"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E76D782E-ADBF-42D0-9CCA-8944F07D22DA">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:D0DD21B4-2DEA-49DA-B4BC-07501CC0DD24</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-07 11:23:25 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B98C3482-C44D-4C61-ACC3-D277890BCE91"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3EA9FD84-7972-4F14-ACAC-44E7B91CD0C2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E0188B4-6C70-41E7-B903-5A68F972FC55"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:43:06 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71CADA90-E1E5-4B50-9394-FDFC0B1512B0">
    <pav:lastSavedOn>2014-07-13 11:02:33 -0400</pav:lastSavedOn>
    <permissions:permissions rdf:nodeID="Nbb23a965649b4da59283f66205750358"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-4.txt.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:390CA5FE-7939-4F69-B612-7F5C21A06481"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2014-07-13 11:02:05 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:BA49274C-11BD-499C-B6F3-8E9B55B40E77</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79F49E5C-6D04-4116-8E54-1C6470AEB616">
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> may increase the serum levels of tacrolimus. </ao:suffix>
    <domeo:uuid>79F49E5C-6D04-4116-8E54-1C6470AEB616</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:79F49E5C-6D04-4116-8E54-1C6470AEB616"/>
    <ao:exact>tacrolimus</ao:exact>
    <pav:createdOn>2014-09-02 19:19:41 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C4061A3-979D-486B-9CDA-1CFF771CCB5B">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:ABF527C0-D635-49E4-BC45-911EBB72D2E8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:10:47 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:67C400B9-D19B-4746-9FE2-12A58EE79507</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F95A684-4F34-42D2-8F26-ACB40DD06487">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5F95A684-4F34-42D2-8F26-ACB40DD06487"/>
    <pav:createdOn>2014-07-21 21:26:56 -0400</pav:createdOn>
    <ao:exact>phenytoin </ao:exact>
    <domeo:uuid>5F95A684-4F34-42D2-8F26-ACB40DD06487</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of phenytoin. (See PRECAUTIONS.)</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>(oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6887274E-F614-42FD-904F-B7E202949297">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix>, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in th</ao:suffix>
    <pav:createdOn>2014-07-13 11:11:10 -0400</pav:createdOn>
    <domeo:uuid>6887274E-F614-42FD-904F-B7E202949297</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6887274E-F614-42FD-904F-B7E202949297"/>
    <ao:prefix> is 90%, and that of its major metabolite, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B61CCD79-538E-42B4-8232-5A3A92F4AC3F">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:38:56 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A97D0542-D1E0-45E8-A59A-491B0F6B5ABF"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3802033-7DB0-4AE2-833F-5EF306928ABF">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3802033-7DB0-4AE2-833F-5EF306928ABF"/>
    <ao:exact>propranolol</ao:exact>
    <pav:createdOn>2014-07-24 19:54:37 -0400</pav:createdOn>
    <ao:suffix> at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased thioridazine metabolite (mesoridazine) concentrations ranging from 33% to 209%.</ao:suffix>
    <ao:prefix>Co-administration of long-acting </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A3802033-7DB0-4AE2-833F-5EF306928ABF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-133.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4302BBE9-CEFD-4D9A-8509-E48CACB9AAC3">
    <ao:prefix>, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4302BBE9-CEFD-4D9A-8509-E48CACB9AAC3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <ao:exact>paroxetine</ao:exact>
    <ao:suffix> may significantly inhibit the activity of this isozyme. In most patients (&gt;90%), this CYP2D6 isozyme is saturated early during paroxetine dosing. In 1 study, daily dosing of immediate-release paroxetine  (20 mg once daily) under steady-state conditions </ao:suffix>
    <pav:createdOn>2014-09-02 11:56:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4302BBE9-CEFD-4D9A-8509-E48CACB9AAC3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5672F5D0-071A-4DE9-9A98-BD20431A00C2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5672F5D0-071A-4DE9-9A98-BD20431A00C2"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 09:34:12 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Sildenafil </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE5) in the smooth muscle of the pulmonary vasculature, where PDE5 is responsible for degradation of cGMP. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells res</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/C98F4F9C-3452-4547-9D59-858A821616E1">
    <rdfs:label>methadone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6813</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07FAC59A-4DB3-40BE-8ADC-7231ECC711EF">
    <domeo:uuid>07FAC59A-4DB3-40BE-8ADC-7231ECC711EF</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:07FAC59A-4DB3-40BE-8ADC-7231ECC711EF"/>
    <pav:createdOn>2014-09-02 11:30:33 -0400</pav:createdOn>
    <ao:prefix>,</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:exact> theophylline</ao:exact>
    <ao:suffix>, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48081C9F-3CDC-436C-888F-B763536ACD92">
    <ao:exact>Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites. Diazepam does not alter the pharmacokinetics of propranolol</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:48081C9F-3CDC-436C-888F-B763536ACD92"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>48081C9F-3CDC-436C-888F-B763536ACD92</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-07-24 19:44:48 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-128.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08F7FCFD-3C5E-46FE-8EDA-8ED22CA77882">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:08F7FCFD-3C5E-46FE-8EDA-8ED22CA77882"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:13:55 -0400</pav:createdOn>
    <ao:suffix> exposure. Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses up to 240 mg/day, dose adjustment may be considered. When voriconazole (400 mg Q12h x 1 day, then 200 mg</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>08F7FCFD-3C5E-46FE-8EDA-8ED22CA77882</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>omeprazole</ao:exact>
    <ao:prefix>(a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7359157D-6F7C-43D2-9127-08D4CCFA7E1A">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-24 20:07:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:31A6BF79-BBAC-479E-B954-4B14FED74D2E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2537CEFB-4053-4AC9-8731-C65B1AC5D0F9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 11:15:55 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:F1E65BAF-B906-4702-93F2-2AB99EAC8EC2</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D526C276-CAAE-4E9B-8038-08BB2FB8FBBD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A268B82-4B69-4D00-A6E9-95F225012877">
    <domeo:uuid>4A268B82-4B69-4D00-A6E9-95F225012877</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> to the enzyme suggests this is unlikely [see 7 DRUG INTERACTIONS].</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:16:15 -0400</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix> to interfere with metabolism of other drugs metabolized by CYP 2D6. Relatively weak binding of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4A268B82-4B69-4D00-A6E9-95F225012877"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFB9988E-CEA1-4326-AC04-4DC5F728B495">
    <pav:createdOn>2014-07-22 19:38:33 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EFB9988E-CEA1-4326-AC04-4DC5F728B495"/>
    <domeo:uuid>EFB9988E-CEA1-4326-AC04-4DC5F728B495</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>rosiglitazone</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B803E851-5AD5-4741-B1B9-1CBAED597E18">
    <ao:item rdf:resource="urn:domeoclient:uuid:1FE8E158-755A-4E57-81FB-928873E93B12"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <permissions:permissions rdf:nodeID="N39d343c1c8ea42c296642f02570456f8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:EDF86F62-D99C-4656-9677-171A5B522535"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-54.txt.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-21 21:49:33 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:E60C908C-8168-4614-80BA-973B0DEE03B0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FE17741D-F10F-4662-94F4-BB9A69F3D7F4"/>
    <pav:createdOn>2014-07-21 21:47:18 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:905FFDFF-C273-410A-BE8E-A56C8BC94629"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:F1EC2D5D-E8AA-4BAB-8BCE-D86C722E5855"/>
    <pav:lineageUri>urn:domeoserver:annotationset:B796714B-4414-4CA1-8F35-70E7AD530AE1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97D1DB41-3631-4DF4-AC28-E9932F707785">
    <ao:suffix>therapy. Repeat doses of </ao:suffix>
    <domeo:uuid>97D1DB41-3631-4DF4-AC28-E9932F707785</domeo:uuid>
    <pav:createdOn>2014-07-22 19:50:12 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:97D1DB41-3631-4DF4-AC28-E9932F707785"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>glyburide </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix> (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CD89FD03-D99F-41BD-9614-0F760DFF0EFC">
    <pav:createdOn>2014-07-24 20:07:14 -0400</pav:createdOn>
    <domeo:uuid>CD89FD03-D99F-41BD-9614-0F760DFF0EFC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> has been shown to exhibit minimal (ca. 5%) metabolism. However, coadministration of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CD89FD03-D99F-41BD-9614-0F760DFF0EFC"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:exact>fexofenadine hydrochloride</ao:exact>
    <ao:suffix> with either ketoconazole or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects. Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole. In two separate studies in healthy adul</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A5583BB-B797-401F-B398-564C65590C7B">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-56.txt.html</ao:hasSource>
    <ao:suffix> </ao:suffix>
    <pav:createdOn>2014-07-21 21:53:30 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A5583BB-B797-401F-B398-564C65590C7B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7A5583BB-B797-401F-B398-564C65590C7B</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Zonisamide</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4CEC1749-9AA0-4FDA-B649-6B3CDED4298A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4CEC1749-9AA0-4FDA-B649-6B3CDED4298A"/>
    <domeo:uuid>4CEC1749-9AA0-4FDA-B649-6B3CDED4298A</domeo:uuid>
    <ao:exact>fluconazole</ao:exact>
    <pav:createdOn>2014-07-13 12:56:07 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> AUC and a significant increase in apparent oral clearance of </ao:prefix>
    <ao:suffix>. There was a mean ± SD reduction in fluconazole AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTI</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E7D289E-0E68-4A95-9CAF-BA6B4026295E">
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:DB9F8CF3-932C-4B62-8B9D-7E4C3E1A4FF6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 12:03:00 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB06C7B2-447E-44A6-9D7B-F5BB28ED6AB3">
    <pav:createdOn>2014-07-22 19:36:30 -0400</pav:createdOn>
    <ao:suffix>. Since metformin is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EB06C7B2-447E-44A6-9D7B-F5BB28ED6AB3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>EB06C7B2-447E-44A6-9D7B-F5BB28ED6AB3</domeo:uuid>
    <ao:exact>AVANDIA</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function. No dosage adjustment is therefore required in such patients receiving </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7176E11-44D4-4336-A0B0-21D16F8910C5">
    <pav:createdOn>2014-07-24 19:54:46 -0400</pav:createdOn>
    <ao:prefix> at doses greater than or equal to 160 mg/day resulted in increased thioridazine plasma concentrations ranging from 55% to 369% and increased </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E7176E11-44D4-4336-A0B0-21D16F8910C5"/>
    <ao:suffix> metabolite (mesoridazine) concentrations ranging from 33% to 209%.</ao:suffix>
    <ao:exact>thioridazine</ao:exact>
    <domeo:uuid>E7176E11-44D4-4336-A0B0-21D16F8910C5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-133.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16BAA0E0-EEEC-4785-9C63-DBB8909400D3">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:suffix> was given without voriconazole.</ao:suffix>
    <domeo:uuid>16BAA0E0-EEEC-4785-9C63-DBB8909400D3</domeo:uuid>
    <ao:exact>omeprazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16BAA0E0-EEEC-4785-9C63-DBB8909400D3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when </ao:prefix>
    <pav:createdOn>2014-09-02 19:16:32 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/903A96DD-5D24-4703-BA4D-F99711E452A7">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6809</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>metformin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA692151-6A7E-43FA-8077-22E490457CAD">
    <ao:suffix> on phenobarbital pharmacokinetics was not studied. Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustment with Paroxetine </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FA692151-6A7E-43FA-8077-22E490457CAD"/>
    <pav:createdOn>2014-09-01 16:21:59 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-45.txt.html</ao:hasSource>
    <ao:prefix>ose of immediate-release paroxetine  was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone. The effect of </ao:prefix>
    <ao:exact>paroxetine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>FA692151-6A7E-43FA-8077-22E490457CAD</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0643518-055A-42DE-BA98-B5C01760828C">
    <pav:createdOn>2014-07-24 19:42:43 -0400</pav:createdOn>
    <ao:exact>Propranolol</ao:exact>
    <ao:suffix> does not affect the pharmacokinetics of verapamil and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D0643518-055A-42DE-BA98-B5C01760828C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-127.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D0643518-055A-42DE-BA98-B5C01760828C</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89F35E49-064B-44B8-B2CE-6FDE26A34AC7">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:89F35E49-064B-44B8-B2CE-6FDE26A34AC7"/>
    <pav:createdOn>2014-09-02 11:44:17 -0400</pav:createdOn>
    <ao:prefix>:</ao:prefix>
    <ao:exact> Tryptophan</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>89F35E49-064B-44B8-B2CE-6FDE26A34AC7</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:851EB41C-687B-464B-9105-16513BFE3A24">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:19DF8C99-A2F9-40E1-9BC9-0D4A0531A57A"/>
    <pav:createdOn>2014-07-22 19:24:53 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6279850D-A32F-4EDB-A281-0BC6CBECE7F7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6279850D-A32F-4EDB-A281-0BC6CBECE7F7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other. As with other psychotropic medications, patients should be advised to avoid alcohol while taking </ao:prefix>
    <ao:suffix> maleate tablets.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:39:16 -0400</pav:createdOn>
    <domeo:uuid>6279850D-A32F-4EDB-A281-0BC6CBECE7F7</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7ACE5CBD-6F8F-4F53-8756-2657011A4A35">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:290AF144-A2E1-407F-983D-E11E6DCD09ED</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 15:04:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:60E67041-A9C9-414B-A575-799C5BAFAF37"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nce246f50d23749a28b4722f4dc20cb1b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B51833F-74F3-4AB3-A6D0-CD524F9F3140">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1B51833F-74F3-4AB3-A6D0-CD524F9F3140"/>
    <ao:exact>fluvoxamine</ao:exact>
    <domeo:uuid>1B51833F-74F3-4AB3-A6D0-CD524F9F3140</domeo:uuid>
    <ao:suffix> maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decre</ao:suffix>
    <pav:createdOn>2014-09-02 11:38:06 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix>Lorazepam: A study of multiple doses of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1C706B9-7F27-4C22-8F0D-E46B96B35A86">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C1C706B9-7F27-4C22-8F0D-E46B96B35A86"/>
    <domeo:uuid>C1C706B9-7F27-4C22-8F0D-E46B96B35A86</domeo:uuid>
    <ao:suffix> increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
    <pav:createdOn>2014-07-13 12:56:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0CDA62F-9ACD-470D-B0EC-F331BF018B09">
    <pav:lineageUri>urn:domeoserver:annotation:673E0CDF-7F39-4F2D-B468-96E8A768435F</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:B394B422-1AAF-4ED4-A3BB-3FB13E961EEA</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:28:32 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:32AF5202-FB01-4507-AD10-D10F0C16E37A"/>
    <pav:lastSavedOn>2014-07-21 21:30:23 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6588D45E-2F4C-40CF-8AF4-0CD621F484E1">
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:905A65BE-2FB4-442E-92C6-EA5747341AA6</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:58:43 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:FAD17173-A1D3-4A24-A29E-5999F0DFA8F4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F6275ED-13B1-45BE-8276-90A65C4C4506">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:39B82E57-92E3-4322-A8E6-A3AFF215F02C</domeo:belongsToSet>
    <pav:createdOn>2014-09-01 15:57:28 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4515CD24-4667-47E1-80AE-FBC3F30BFD11"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-01 15:57:39 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:E3D5CDD5-71A5-456B-B855-A9AA17258416</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEC761C8-1050-4E1A-A450-D460F8514160">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:984E4D2D-A998-4068-9BF7-F709348DD1B2"/>
    <pav:lineageUri>urn:domeoserver:annotation:FE75629E-FE6A-4361-BE28-79148B042D27</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:18:21 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F9653C29-A4D2-424D-A8FE-3DDBAC24C18C">
    <pav:createdOn>2014-09-02 19:17:54 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:9FB8A434-B2A7-4CA1-A629-583CC07853C3"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:164A1C02-147C-4620-8927-26251560C2C2">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 20:02:13 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F4BA9A75-9ED6-4A34-AD9F-D5874AACDFF0"/>
    <pav:lastSavedOn>2014-07-24 20:02:49 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:56C2F38D-C848-4229-BC11-951066231DC2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:189A8E0E-67D6-4C53-A96E-CB48A3B4B2E9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40918124-C290-4DAB-B23D-F9B3E387A308">
    <ao:exact>antacids</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>40918124-C290-4DAB-B23D-F9B3E387A308</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>). In the clinical trials, </ao:prefix>
    <pav:createdOn>2014-09-02 19:12:24 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:40918124-C290-4DAB-B23D-F9B3E387A308"/>
    <ao:suffix> were used concomitantly with the administration of omeprazole delayed-release capsules USP.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6EE25330-67E2-4BE9-AB27-EB9F40763AA3">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6EE25330-67E2-4BE9-AB27-EB9F40763AA3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-53.txt.html</ao:hasSource>
    <ao:suffix> </ao:suffix>
    <ao:exact>ketoconazole</ao:exact>
    <domeo:uuid>6EE25330-67E2-4BE9-AB27-EB9F40763AA3</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-21 21:46:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE7465D0-1375-484E-9391-EFB42F00FC99">
    <pav:createdOn>2014-09-02 15:04:25 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:4AF93FFE-AF2A-4091-98AF-CE5D00B15BB0"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:E6F20489-F8CB-4779-81D4-E9901F37C4BA</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/56DDE847-8CB1-4471-8B16-A24584A6647C">
    <rdfs:label>trazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10737</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:954496DB-A54A-496F-92B2-F690C8B1E299">
    <ao:prefix>Results of a population pharmacokinetic analysis including subjects of Caucasian, black, and other ethnic origins indicate that race has no influence on the pharmacokinetics of</ao:prefix>
    <pav:createdOn>2014-07-22 19:38:52 -0400</pav:createdOn>
    <domeo:uuid>954496DB-A54A-496F-92B2-F690C8B1E299</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:954496DB-A54A-496F-92B2-F690C8B1E299"/>
    <ao:exact> rosiglitazone.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/E8F2CA32-13F5-477A-BE7F-DE4F66964CFD">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdfs:label>carbamazepine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F9A7B706-7816-4689-A106-0C28124DEA2F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>atomoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/38400</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76B68D47-1D9C-4B2A-B9A6-CFE359C93E64">
    <ao:exact>fluconazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76B68D47-1D9C-4B2A-B9A6-CFE359C93E64"/>
    <pav:createdOn>2014-07-13 12:56:09 -0400</pav:createdOn>
    <ao:prefix>. There was a mean ± SD reduction in </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <domeo:uuid>76B68D47-1D9C-4B2A-B9A6-CFE359C93E64</domeo:uuid>
    <ao:suffix> AUC of 23% ± 9% (range: -13 to -42%). Apparent oral clearance of fluconazole increased 32% ± 17% (range: 16 to 72%). Fluconazole half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DE707944-9AAF-45E4-85A6-2EA10D365226">
    <ao:body rdf:nodeID="N322aa55f0f7f42f183db8d95465c3b0e"/>
    <pav:lastSavedOn>2014-07-24 20:10:48 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:8D86A4AC-54BD-4BB3-8B58-AB55DEC01A88</pav:previousVersion>
    <pav:createdOn>2014-07-24 20:11:05 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D87DBE9A-311B-4697-A944-4490E16F4680"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1F1125BC-11EF-427A-9581-C05D50951446">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4ABC712B-B1B6-46E9-80C3-428EA00FAEEF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57242808-9748-4ED3-908E-E0054E0C8BBE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:57242808-9748-4ED3-908E-E0054E0C8BBE"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <domeo:uuid>57242808-9748-4ED3-908E-E0054E0C8BBE</domeo:uuid>
    <ao:prefix> 200 mg) did not affect the bioavailability or pharmacokinetics of </ao:prefix>
    <pav:createdOn>2014-07-13 12:46:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> in 24 healthy male volunteers.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluconazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:364EB4BF-76FF-46DE-8F92-5E5F5D0222E7">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-28 17:00:48 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:4FC315CC-8F6D-4166-AEB6-FBF9CF2FA510</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:1DEA14EB-D88E-4D43-BAE8-FC44C4169F4A</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:D96F23AA-C203-4EA6-BA78-F8249D904C85"/>
    <pav:lastSavedOn>2014-07-28 17:00:29 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70919722-5B5F-4E86-A52F-8A64A1EFDA72">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:34E978B5-2DD2-44FE-B1ED-248C51C20EC2</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 12:56:11 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C1C706B9-7F27-4C22-8F0D-E46B96B35A86"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15DA0901-8237-4923-B2A0-A784328F0684">
    <domeo:uuid>15DA0901-8237-4923-B2A0-A784328F0684</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-01 16:07:51 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:15DA0901-8237-4923-B2A0-A784328F0684"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluconazole</ao:exact>
    <ao:suffix> administration was 56.9% (range: 35 to 81).</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-40.txt.html</ao:hasSource>
    <ao:prefix> as a single daily oral dose for 7 days. The mean percentage increase in the glipizide AUC after </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8BB0D7D8-E6FC-43D6-A047-53DA7C4A005E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8BB0D7D8-E6FC-43D6-A047-53DA7C4A005E"/>
    <ao:exact>The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours. (See PRECAUTIONS.)</ao:exact>
    <domeo:uuid>8BB0D7D8-E6FC-43D6-A047-53DA7C4A005E</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-21 21:34:52 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FCB07677-3685-4C25-935B-67786B32E56B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FCB07677-3685-4C25-935B-67786B32E56B"/>
    <pav:createdOn>2014-07-21 21:33:53 -0400</pav:createdOn>
    <ao:exact>theophylline </ao:exact>
    <domeo:uuid>FCB07677-3685-4C25-935B-67786B32E56B</domeo:uuid>
    <ao:suffix>AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <ao:prefix>200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7A327F1B-E170-41D6-BEC1-65E5D1CB43B8">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:62EE12D9-5314-4E3B-81A5-6CC4F5785F46"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78619284-035D-4B46-89AF-54BD7FF23461">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:78619284-035D-4B46-89AF-54BD7FF23461"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-21 21:54:37 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-56.txt.html</ao:hasSource>
    <domeo:uuid>78619284-035D-4B46-89AF-54BD7FF23461</domeo:uuid>
    <ao:exact>Zonisamide had no appreciable effect on the steady-state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20B4F69C-E14E-46A0-8FCE-6AAC4D5EF0B0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:20B4F69C-E14E-46A0-8FCE-6AAC4D5EF0B0"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-07 09:40:23 -0400</pav:createdOn>
    <ao:prefix>After chronic dosing of 80 mg </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>TID </ao:exact>
    <ao:suffix>sildenafil to patients with pulmonary arterial hypertension, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F7832F9-F40E-4E9B-917C-25342C417D3F">
    <domeo:uuid>7F7832F9-F40E-4E9B-917C-25342C417D3F</domeo:uuid>
    <pav:createdOn>2014-09-02 19:17:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F7832F9-F40E-4E9B-917C-25342C417D3F"/>
    <ao:suffix> has been reported to interact with some antiretroviral drugs. The clinical importance and the mechanisms behind these interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the antiretroviral dru</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:exact>Omeprazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E67991C8-7BD1-474A-98AE-6F58A72C0A35">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
    <ao:exact>cyclosporine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of fluconazole. The mean ± SD increase in AUC was 92% ± 43% (range: 18 to 147%). The Cmax increased 60% ± 48% (range: -5 to 133%)</ao:suffix>
    <pav:createdOn>2014-07-21 21:28:38 -0400</pav:createdOn>
    <domeo:uuid>E67991C8-7BD1-474A-98AE-6F58A72C0A35</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E67991C8-7BD1-474A-98AE-6F58A72C0A35"/>
    <ao:prefix>dose for at least 6 weeks. There was a significant increase in </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A41AFCF-E95D-4B06-B213-C3D7AC444FB8">
    <pav:lineageUri>urn:domeoserver:annotation:34AB49DC-0AB4-455F-A582-7E3D626DD866</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:150123D0-F340-48A6-8FF1-AE43891B6007"/>
    <pav:lastSavedOn>2014-09-01 16:12:36 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-01 16:12:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:5D381360-05CD-407C-BAB9-6496A42C73E4</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF9C19C8-A145-4276-833C-C3641196A24F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FF9C19C8-A145-4276-833C-C3641196A24F"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-21 21:35:21 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <domeo:uuid>FF9C19C8-A145-4276-833C-C3641196A24F</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>The pharmacokinetics of theophylline were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours. (See PRECAUTIONS.)</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:876DAFB7-BB08-4119-BA16-59187031D7BB">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:F60474E5-A763-40B4-B547-A0BB4FA6BDEF</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6BC9135A-65A9-4BB2-A462-DD73D14C286B"/>
    <permissions:permissions rdf:nodeID="Nafea1009a07848c5ac88ffeeae566862"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6E8F08BA-7079-4216-9618-95A54B886D84"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-53.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:C5974F18-7052-426D-A45F-D129E2BC7FB8"/>
    <pav:lastSavedOn>2014-07-21 21:46:47 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-21 21:45:44 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC73A4DB-52A1-428E-A3E7-50DAC49D6A5A">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:DBA2FBEC-FB21-4B1E-AFD1-05AF52CBAB09</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 19:38:18 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C9F22978-089A-4215-9421-19B4E3E4358A"/>
    <pav:lineageUri>urn:domeoserver:annotation:B9E6F388-F6BA-4A6D-95DF-40A9E25BB859</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 19:38:41 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6062d078326342bea09692e19a8080f2">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71244950-C950-47EB-A32B-D2748E51EF60">
    <pav:createdOn>2014-07-22 19:39:28 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1504073B-965A-43C5-A889-0D6EA22F08A0"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:443354CF-9409-4015-81BA-17601E505BAB">
    <ao:item rdf:resource="urn:domeoclient:uuid:0F10F658-B658-4FA9-8235-47BB00E1C0A0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D6A30BCE-90A8-4548-B78C-7949C0F059D0"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E9BC3D72-DC81-43AF-974C-F7283BF4A096</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:A2CCEA97-69CF-4E75-83A2-17A2D250C5C4"/>
    <permissions:permissions rdf:nodeID="N9258e03bec2c4f3abb8b2cb3a8ba3554"/>
    <pav:createdOn>2014-09-02 15:05:19 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 15:06:18 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:0A5A79F0-6C01-40CE-B775-CC68C1268935"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5B5C139F-AE11-4B67-AB76-74B91C6DD60D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-70.txt.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE0574D5-7BB9-4BA6-A291-C37F1314832B">
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 11:57:27 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:B1FA2934-6D08-45C1-9A5C-A76136C211CF</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C42C067D-4201-4F47-96EA-FFFFA5B4C4AB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FAD17173-A1D3-4A24-A29E-5999F0DFA8F4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FAD17173-A1D3-4A24-A29E-5999F0DFA8F4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-07 09:58:43 -0400</pav:createdOn>
    <ao:exact>REVATIO </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>Injection: The pharmacokinetic profile of REVATIO has been characterized following intravenous administration. A 10 mg dose of REVATIO Injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to t</ao:suffix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/C17461FE-A35A-4C0A-940B-01CB796E4877">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3443</dailymed:activeMoietyRxCUI>
    <rdfs:label>diltiazem</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C77DFAE-836C-475E-BE78-637BCFAAA992">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A49EC3D-7C54-46A7-831E-A352B5A1B081"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 19:49:16 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A95F4FE2-696A-4769-8ED1-FC8F49B83876">
    <ao:prefix> does not alter the pharmacokinetics of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A95F4FE2-696A-4769-8ED1-FC8F49B83876</domeo:uuid>
    <ao:exact>propranolol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A95F4FE2-696A-4769-8ED1-FC8F49B83876"/>
    <pav:createdOn>2014-07-24 19:44:25 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-128.txt.html</ao:hasSource>
    <ao:suffix>.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72C81315-5D14-41CA-AEB9-E23AC335F4C3">
    <ao:prefix> compared to similar placebo dosing. The mean AUCs of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:38:31 -0400</pav:createdOn>
    <ao:suffix> and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compar</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:72C81315-5D14-41CA-AEB9-E23AC335F4C3"/>
    <ao:exact>ethinyl estradiol</ao:exact>
    <domeo:uuid>72C81315-5D14-41CA-AEB9-E23AC335F4C3</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00C24F6A-259C-4CD5-BB57-3231935B23AE">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 19:17:56 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:3801AFB1-E917-4E09-8201-F7DFAAAD30AC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DE725ECB-6E8C-4D1C-9EE0-A969014D8035">
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DE725ECB-6E8C-4D1C-9EE0-A969014D8035"/>
    <ao:suffix>, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone. If co-administration is necessary, caution is advised when initiating therapy with, curre</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>carbamazepine</ao:exact>
    <domeo:uuid>DE725ECB-6E8C-4D1C-9EE0-A969014D8035</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 19:09:57 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F47F11AD-A4E0-4F3C-B00C-4BAD618B41C3">
    <pav:lineageUri>urn:domeoserver:annotation:8117623B-4BF0-4517-82B6-2304B430DF21</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:F2788742-3226-4BFB-9D85-2FC7211066F7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="N253bf09e590c4e1294545cf518145765"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-22 18:59:42 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 18:59:41 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E8525C10-3E49-4039-8E81-69ACBAC8A16F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5BA6BC8B-1F30-4288-9D03-060F552BAA12">
    <pav:lineageUri>urn:domeoserver:annotation:DDA9B5AE-040F-439A-82F9-BF46844F39FC</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1BF82CCC-CD60-4AB5-8C1B-4176DC1A85F3"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:16:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6FD9D48D-F639-4F09-ABA6-F4B259681453">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:50649F2A-1F77-4AC3-AA05-9C465AAF3D79"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:59:10 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:BCAC0F86-EF1B-48A6-B71C-46750D478032</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7086D655-845E-4135-B24F-75B4FFD47BD0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:514BA51B-D734-4003-A7C3-F03C0F95833A</pav:previousVersion>
    <pav:createdOn>2014-07-22 19:41:37 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:44:46 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:69C6BE85-B8AD-457C-8581-67B0BD3C4802"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC83EF48-BF8E-4B34-9782-4DFBE01FA8AA">
    <ao:suffix>esters, and iron salts). In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.</ao:suffix>
    <domeo:uuid>DC83EF48-BF8E-4B34-9782-4DFBE01FA8AA</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DC83EF48-BF8E-4B34-9782-4DFBE01FA8AA"/>
    <ao:prefix>, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:12:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>ampicillin </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0FC34074-15F7-4C00-87F2-8D4B6F9B8889">
    <domeo:belongsToSet>urn:domeoclient:uuid:F70AB841-7C14-48D1-B543-A45EA067C642</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-24 20:03:53 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2C43BBB-3043-4AE4-89EE-69DCE07C3309"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-24 20:04:12 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:65C4C1CA-156F-4826-A9A8-AA28011A9F9E</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9019660D-1815-46EC-A26A-41E87A114AA7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9019660D-1815-46EC-A26A-41E87A114AA7"/>
    <pav:createdOn>2014-09-02 19:08:19 -0400</pav:createdOn>
    <domeo:uuid>9019660D-1815-46EC-A26A-41E87A114AA7</domeo:uuid>
    <ao:suffix> with caution and in reduced dosages in patients taking these agents.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <ao:exact>oxycodone hydrochloride</ao:exact>
    <ao:prefix>Other central nervous system (CNS) depressants including sedatives, hypnotics, general anesthetics, antiemetics, phenothiazines, or other tranquilizers or alcohol increases the risk of respiratory depression, hypotension, profound sedation, or coma. Use </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4EEAF739-3D04-465D-8AC0-35EAE4B00AE0">
    <pav:createdOn>2014-07-13 12:35:54 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:3D8D67C2-6E18-4F0E-AEDD-1DFCE48220A1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3FEE8D2-9817-490A-AF14-CC53E5ADFBF2"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60F0E01C-50AF-48FD-82F1-C840D5A8FDDD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, a substrate for  CYP3A4, revealed no effect of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>paroxetine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:60F0E01C-50AF-48FD-82F1-C840D5A8FDDD"/>
    <pav:createdOn>2014-09-02 15:04:06 -0400</pav:createdOn>
    <ao:suffix> on terfenadine pharmacokinetics. In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for this enzyme, </ao:suffix>
    <domeo:uuid>60F0E01C-50AF-48FD-82F1-C840D5A8FDDD</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B1EDC65E-7D2E-4E9E-9D08-0D72BD366C29">
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:97B4DA35-A3A0-41E4-9927-06388A15995F"/>
    <pav:createdOn>2014-07-22 19:26:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3ED57AC4-296D-4C8D-9873-49C193F69BBA">
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:CE972F8D-C1AD-46A9-B34B-1D883FDAF1EC"/>
    <pav:createdOn>2014-07-07 09:40:14 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:631995B6-520A-4B5F-B283-0557077A8B49">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 15:04:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
    <ao:suffix>, triazolam, and cyclosporine. Based on the assumption that the relationship between paroxetine’s in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, paroxetine’s extent of inhibition of C</ao:suffix>
    <ao:exact>cisapride</ao:exact>
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:631995B6-520A-4B5F-B283-0557077A8B49"/>
    <domeo:uuid>631995B6-520A-4B5F-B283-0557077A8B49</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E4C91349-DA7A-412B-B58B-E0D1EEF83781">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:346407F0-F265-40E8-A6A0-BB0525152D4E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3778184B-7478-42AC-8128-7363E5970F00">
    <ao:prefix> (4 mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of </ao:prefix>
    <pav:createdOn>2014-07-22 19:42:20 -0400</pav:createdOn>
    <ao:exact>rosiglitazone</ao:exact>
    <ao:suffix> may be needed when </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3778184B-7478-42AC-8128-7363E5970F00"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>3778184B-7478-42AC-8128-7363E5970F00</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04AF0456-B803-4275-972A-36BD0F6352B7">
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 11:41:00 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E17E51AB-6385-4BD7-89B1-ABDDA504EE2C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FD9D4BD5-A390-4CD6-8FF4-21ABE76D596A">
    <pav:createdOn>2014-07-13 11:17:12 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:4B02B1E0-9F20-40AA-9E20-12AD253C4462</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CB01A892-8D67-4A38-8CA4-2D230875A1F6"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6A5356C-B181-4F61-AEF2-74464A340D7F">
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5FBE9544-4653-482C-B065-70CA3AA07309"/>
    <pav:createdOn>2014-07-13 11:15:53 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:C5FD329C-F801-4589-8147-439BFA776D12</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AEC296E5-554D-42F1-BF6A-CA09B038958F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9.0 mmHg and 8.4 mmHg, respectively.</ao:suffix>
    <ao:exact>sildenafil </ao:exact>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>After chronic dosing of 80 mg TID </ao:prefix>
    <pav:createdOn>2014-07-07 09:39:24 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AEC296E5-554D-42F1-BF6A-CA09B038958F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F010F0A-45BC-4132-A685-857F72A4DCEC">
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9B40D027-2C99-4AA7-A143-A35EFB743189"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:46:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D17A3686-1703-468A-9054-837449C245F1">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFAB29CD-3C49-4713-BDAE-478181F5EB8F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:43:52 -0400</pav:createdOn>
    <ao:exact>fluvoxamine</ao:exact>
    <domeo:uuid>CFAB29CD-3C49-4713-BDAE-478181F5EB8F</domeo:uuid>
    <ao:suffix>, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CFAB29CD-3C49-4713-BDAE-478181F5EB8F"/>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47CAE4AD-FEB1-437D-9ADB-758C9BEBE377">
    <pav:createdOn>2014-07-24 20:07:48 -0400</pav:createdOn>
    <ao:suffix> 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study). No differences in adverse events or QTc interval were observed when subjects were administered fexofenadine hydrochlorid</ao:suffix>
    <ao:exact>erythromycin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:prefix> 120 mg twice daily (240 mg total daily dose) was coadministered with either </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>47CAE4AD-FEB1-437D-9ADB-758C9BEBE377</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:47CAE4AD-FEB1-437D-9ADB-758C9BEBE377"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B332456-24D5-452E-8A10-14D40375ED79">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:5D381360-05CD-407C-BAB9-6496A42C73E4</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:5FD35D8D-0021-4DC8-9F96-6883D484A470</pav:lineageUri>
    <pav:createdOn>2014-09-01 16:11:59 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5A04C3C3-B677-4732-87D0-83C03497D24C"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-01 16:12:36 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76258D2D-1630-4254-82ED-C3434163EAE3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>76258D2D-1630-4254-82ED-C3434163EAE3</domeo:uuid>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:15:09 -0400</pav:createdOn>
    <ao:prefix> pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:76258D2D-1630-4254-82ED-C3434163EAE3"/>
    <ao:suffix> in patients receiving quinidine have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given risperidone do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known e</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BAF53035-A41C-4F81-96B6-41B0D9633025">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-128.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BAF53035-A41C-4F81-96B6-41B0D9633025"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Propranolol can inhibit the metabolism of diazepam, resulting in increased concentrations of diazepam and its metabolites. Diazepam does not alter the pharmacokinetics of propranolol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>BAF53035-A41C-4F81-96B6-41B0D9633025</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-24 19:45:14 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F83742D9-BF1E-4B6B-9F1C-2CC08800D877">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>gemfibrozil</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4719</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e143046812afe0146812eda990003">
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:email>nonexpert2@gmail.com</foafx:email>
    <foafx:firstname>nonexpert</foafx:firstname>
    <foafx:title>nonexpert2</foafx:title>
    <rdfs:label>nonexpert2</rdfs:label>
    <foafx:name>nonexpert2</foafx:name>
    <foafx:lastname>2</foafx:lastname>
    <foafx:homepage></foafx:homepage>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:middlename></foafx:middlename>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E50BE5A6-0C68-4839-AB64-4D7AED50EDAC">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:1BD555DB-DE08-478A-98FE-8A631606CA83"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:49:08 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8543469A-E725-45C1-A0A3-93FAB55D1DD5">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:13:40 -0400</pav:createdOn>
    <ao:suffix> concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
    <domeo:uuid>8543469A-E725-45C1-A0A3-93FAB55D1DD5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and higher </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8543469A-E725-45C1-A0A3-93FAB55D1DD5"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2CEE4B1-2371-4B8E-B2D2-F9EED99532CB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>atazanavir</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 19:18:40 -0400</pav:createdOn>
    <ao:suffix> and nelfinavir is therefore not recommended. For other antiretroviral drugs, such as saquinavir, elevated serum levels have been reported with an increase in AUC by 82%, in Cmax by 75% and in Cmin by 106% following multiple dosing of saquinavir/ritonavi</ao:suffix>
    <domeo:uuid>F2CEE4B1-2371-4B8E-B2D2-F9EED99532CB</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F2CEE4B1-2371-4B8E-B2D2-F9EED99532CB"/>
    <ao:prefix> (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%. Concomitant administration with omeprazole and drugs such as </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C45EB527-9AC4-4005-86AF-8EEB1D4B88FA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> in combination with other hypoglycemic agents were generally similar to those seen with </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>C45EB527-9AC4-4005-86AF-8EEB1D4B88FA</domeo:uuid>
    <ao:exact>AVANDIA</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C45EB527-9AC4-4005-86AF-8EEB1D4B88FA"/>
    <pav:createdOn>2014-07-22 19:22:31 -0400</pav:createdOn>
    <ao:suffix> in monotherapy.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8621DC71-D1C0-4E5B-97BA-B7275B47A413">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:18:51 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:2025A1F1-3A58-4E3E-A4B7-739A783D52BB"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/B9254794-2257-403D-AD8D-D269CBB2679F">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/39998</dailymed:activeMoietyRxCUI>
    <rdfs:label>Zonisamide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E804A110-85A5-4650-B960-F11AB9FD25A2">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E804A110-85A5-4650-B960-F11AB9FD25A2"/>
    <domeo:uuid>E804A110-85A5-4650-B960-F11AB9FD25A2</domeo:uuid>
    <ao:suffix> (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
    <pav:createdOn>2014-07-13 11:11:36 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> (10 mcg/mL), and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>carbamazepine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E65733E-5455-4115-AFE9-BA2E1EB6BB2F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E65733E-5455-4115-AFE9-BA2E1EB6BB2F"/>
    <ao:suffix>. If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS AND PRECAUTIONS [5.3]).</ao:suffix>
    <ao:exact>triptan</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7E65733E-5455-4115-AFE9-BA2E1EB6BB2F</domeo:uuid>
    <pav:createdOn>2014-09-02 11:43:18 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix>Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F79885A8-4CEA-4ACB-9EC1-9EB939A385DE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-21 21:32:58 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F79885A8-4CEA-4ACB-9EC1-9EB939A385DE"/>
    <ao:exact>Plasma zidovudine concentrations were determined on two occasions (before and following fluconazole 200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6 ± 3.6 to 5.7 ± 2.2</ao:exact>
    <domeo:uuid>F79885A8-4CEA-4ACB-9EC1-9EB939A385DE</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92530361-A562-40CE-942A-CC181EBE7AD7">
    <pav:lineageUri>urn:domeoserver:annotation:FB9B5330-BB9D-4DA0-8780-703069BE2890</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 12:34:35 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:6A05795B-B1AB-4DB3-A12F-2765CBCC2FED</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A22D7450-FC77-45A4-B835-3948870AD344"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 12:34:42 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nef31c47169944e18a0a65df627ee2d9f">
    <domeo:sets rdf:resource="urn:pddi:uuid:9B027AFC-3BAE-4FDC-889F-813F2AD35C5A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3DAB1A6-C48D-422B-A0D0-776352B4CC3F">
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 11:36:19 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:38A85164-B87B-441D-87CB-0E3B5B67551D"/>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B30D95E2-6A9C-41B9-A6BC-823FD4639E01">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 19:10:13 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B30D95E2-6A9C-41B9-A6BC-823FD4639E01"/>
    <ao:prefix>, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <ao:exact>oxycodone</ao:exact>
    <domeo:uuid>B30D95E2-6A9C-41B9-A6BC-823FD4639E01</domeo:uuid>
    <ao:suffix>. If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inducers. Evaluate these patients at frequent intervals and consider dose adjustments until stable drug effects are achieved. </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53200B7D-3B88-4C24-827A-DE552ED1B23F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A2B398FC-383E-4A71-A215-EA4AD0E5C9DA"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 19:13:05 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:150123D0-F340-48A6-8FF1-AE43891B6007">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-42.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-01 16:12:22 -0400</pav:createdOn>
    <ao:suffix> for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeu</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>allopurinol sodium</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:150123D0-F340-48A6-8FF1-AE43891B6007"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>150123D0-F340-48A6-8FF1-AE43891B6007</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69C6BE85-B8AD-457C-8581-67B0BD3C4802">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:69C6BE85-B8AD-457C-8581-67B0BD3C4802"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>69C6BE85-B8AD-457C-8581-67B0BD3C4802</domeo:uuid>
    <pav:createdOn>2014-07-22 19:41:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Concomitant administration of </ao:prefix>
    <ao:exact>gemfibrozi</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>l (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone. Given the potential for dose-related adverse even</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12ACDF1A-FCDF-42E9-A413-FB39FC095FFC">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-24 20:04:12 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-24 20:03:50 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:F70AB841-7C14-48D1-B543-A45EA067C642</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:7F6AD967-0ADD-47B3-9A57-B98BAD421735</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8A17CFA1-4C14-4F96-911E-3EB707629E7A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BFF65D4B-C4C0-4D4B-82C1-14B60D53FB1D">
    <pav:lineageUri>urn:domeoserver:annotation:DCA20857-B042-41C0-8F2D-DFF85B6A4526</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 19:55:21 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:06416843-5F84-4886-A5D4-559FA1082541"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:346B16C2-85FF-42F8-A3AB-6C7DEBB418C7">
    <pav:createdOn>2014-09-01 16:12:31 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1459510A-C593-4CF2-959E-F68381AB3C04"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-01 16:12:36 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:27512628-B2FB-4020-B711-A78AA2E6DE2F</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:5D381360-05CD-407C-BAB9-6496A42C73E4</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA479503-5E2B-4688-851D-61C9DCC47907">
    <ao:suffix>resulted in a 70% increase in propranolol plasma level.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AA479503-5E2B-4688-851D-61C9DCC47907"/>
    <ao:prefix>Co-administration of chlorpromazine with </ao:prefix>
    <pav:createdOn>2014-07-24 19:55:03 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>AA479503-5E2B-4688-851D-61C9DCC47907</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>propranolol </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-134.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:98C6E110-7293-43BC-967C-E828D967CC54">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:98C6E110-7293-43BC-967C-E828D967CC54"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:39:37 -0400</pav:createdOn>
    <ao:exact>carbamazepine</ao:exact>
    <ao:suffix>.</ao:suffix>
    <domeo:uuid>98C6E110-7293-43BC-967C-E828D967CC54</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> maleate and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6E3CCB3A-24FB-48E1-AC28-838B1ACF54A3">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2F9FC4A6-CD86-434B-9237-24FD478F9ECA"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A17CFA1-4C14-4F96-911E-3EB707629E7A">
    <pav:createdOn>2014-07-24 20:03:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A17CFA1-4C14-4F96-911E-3EB707629E7A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> 100 mg to 300 mg daily, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-137.txt.html</ao:hasSource>
    <ao:suffix> reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.</ao:suffix>
    <domeo:uuid>8A17CFA1-4C14-4F96-911E-3EB707629E7A</domeo:uuid>
    <ao:exact>carbamazepine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B6E9A08-C112-4656-8901-F8802CD64317">
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:body rdf:nodeID="N427a12adf2ba42a687e0b8d9875bb02b"/>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2BF9F224-82C0-470E-9645-8A6965E66A04"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:B0DBD770-879A-4A78-90BD-890A235DEC8D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-07-13 12:45:35 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/8E677686-F1A8-4E2D-A503-156B748361AB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/39998</dailymed:activeMoietyRxCUI>
    <rdfs:label>Zonisamide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:338E8B18-C7D9-423A-ACA5-3E11D88F42E9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, a substrate for  CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics. In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibito</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:338E8B18-C7D9-423A-ACA5-3E11D88F42E9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>338E8B18-C7D9-423A-ACA5-3E11D88F42E9</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 15:04:01 -0400</pav:createdOn>
    <ao:prefix> and </ao:prefix>
    <ao:exact>terfenadine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0BD5D38-FA1E-4B14-9F0A-76765ADF5FEE">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D09BF05F-7BD7-4E57-A285-8CF1F5BA4395"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-21 21:42:43 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:BD4B7475-BD13-46C4-932F-139564A0063D</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:42:10 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:C02BB3CE-597B-4042-8BE4-2FEACC94E100</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CAB91F57-2F70-4DDB-9BF8-A50167C8BBCE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CAB91F57-2F70-4DDB-9BF8-A50167C8BBCE"/>
    <pav:createdOn>2014-07-13 12:40:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>CAB91F57-2F70-4DDB-9BF8-A50167C8BBCE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:190DDFDA-8456-4B27-972C-5E815FA29EBD">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:5039F6DC-F654-4E38-8762-0E1BD92F058C"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="N789923a2d6ed4cccbf7d6ab76045a416"/>
    <pav:createdOn>2014-07-13 12:47:19 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:6778C161-ADEE-4D2A-83DD-90876C90F77A</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F33CE913-7DCE-473E-810F-A9B07CED9081">
    <domeo:uuid>F33CE913-7DCE-473E-810F-A9B07CED9081</domeo:uuid>
    <pav:createdOn>2014-07-24 19:47:18 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F33CE913-7DCE-473E-810F-A9B07CED9081"/>
    <ao:exact>Co-administration of metoclopramide with the long-acting propranolol did not have a significant effect on propranolol’s pharmacokinetics</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-130.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EF07060-EF5D-42BC-87F0-3EFC38B56BAA">
    <pav:createdOn>2014-07-24 20:01:41 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:816C98CB-228B-41B9-9F5B-78D35D300142"/>
    <pav:lastSavedOn>2014-07-24 20:02:49 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:4A688FF7-D55F-411D-A8EF-DDA813F95C96</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:189A8E0E-67D6-4C53-A96E-CB48A3B4B2E9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F63A36F-F819-4E40-9C8A-C518B5519787">
    <domeo:uuid>7F63A36F-F819-4E40-9C8A-C518B5519787</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F63A36F-F819-4E40-9C8A-C518B5519787"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>albumin</ao:exact>
    <pav:createdOn>2014-07-13 11:17:56 -0400</pav:createdOn>
    <ao:prefix> in plasma was increased by about 35% because of the diminished concentration of both </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> and α1-acid glycoprotein. Risperidone doses should be reduced in patients with liver disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C7A86B1F-FEF9-4500-AC47-4A4949A51ABD">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:47D86654-5774-44C8-91EF-5162D998152D</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:A54DB360-9E9B-4E55-AC79-A80E321825D3"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:38:35 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:833A5FDE-B0F0-4E66-B232-68839CFE44D9">
    <pav:lineageUri>urn:domeoserver:annotation:ADF29A86-5F3A-4560-8B26-F1E831392AF3</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:A52F0287-AD68-4755-8E11-75217CD4FED8</domeo:belongsToSet>
    <pav:createdOn>2014-07-21 21:38:40 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-21 21:38:46 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0546F8AF-C9DB-4EB6-A2C6-2FB5CABD510D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1584C65E-C32D-42F5-A725-32DCDF671F11">
    <pav:lineageUri>urn:domeoserver:annotation:17F7A9E9-6742-46E5-B13E-47EE41D9F8C1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:B63FFC37-B751-48F0-8F6D-DC3232F9B394"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:6C727003-BB8F-45A8-BBAC-ACBE1D4D132E</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-24 19:47:46 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-24 19:51:13 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:10BB95F9-1856-4D70-9976-235CE8AD3D39">
    <pav:createdOn>2014-07-07 11:36:13 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:8F3CF3D9-AADE-4A86-BD42-2924B3D6A406</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 11:36:14 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <ao:body rdf:nodeID="N8dac255a5a144042a2ebae3b495b5fe2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:2D04CBBE-379A-4D9F-BDD4-AA3663CD4669"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21ABBCD8-EA84-4836-B499-F6A002CF43B9">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:21ABBCD8-EA84-4836-B499-F6A002CF43B9"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>21ABBCD8-EA84-4836-B499-F6A002CF43B9</domeo:uuid>
    <pav:createdOn>2014-07-22 20:17:59 -0400</pav:createdOn>
    <ao:exact> AVANDIA</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Repeat dosing with</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/851B37FE-C029-42CD-9AFE-2CD0906FA393">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluconazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:669918DD-5E01-4F63-9C3C-FB4172F004FB">
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:0323018B-085E-4636-9195-1B6FDC9A582D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:48:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64792593-BEAB-4B65-88FB-A2254663F469">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:DFB0D433-995A-4EB5-B9CC-EAE5A0C16DEA"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:C65DDEB0-B97A-4B57-9CA0-73F44448001C</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:12:29 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:532BC8DC-5349-4E14-AC6A-60B992104491">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-22 18:44:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:8A0A9901-A1C2-4230-8BC1-B758AADE7F4C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0054F81-6A9B-4AF0-9DCB-962A6FC1C418</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 18:46:52 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:8192878E-B1B0-4825-8F66-9102938DC568</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EBA2A42-43E7-40EC-B69A-A8622A20C1FD">
    <ao:prefix>metabolism can be inhibited by the CYP3A4 inhibitors ketoconazole, ritonavir, and indinavir.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7EBA2A42-43E7-40EC-B69A-A8622A20C1FD"/>
    <pav:createdOn>2014-07-24 20:03:04 -0400</pav:createdOn>
    <ao:suffix> Adverse effects including nausea, hypotension, and syncope were observed when</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-136.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7EBA2A42-43E7-40EC-B69A-A8622A20C1FD</domeo:uuid>
    <ao:exact> The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) has been studied in 10 healthy subjects. The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD70C5DB-2834-4A85-B530-F776A208FB2C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AD70C5DB-2834-4A85-B530-F776A208FB2C"/>
    <ao:exact>cisapride</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <ao:suffix>. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (ci</ao:suffix>
    <ao:prefix>, or </ao:prefix>
    <pav:createdOn>2014-09-01 15:57:33 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AD70C5DB-2834-4A85-B530-F776A208FB2C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC4F7D99-8435-471D-98FA-12D2364884E1">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-118.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>EC4F7D99-8435-471D-98FA-12D2364884E1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EC4F7D99-8435-471D-98FA-12D2364884E1"/>
    <pav:createdOn>2014-07-22 18:46:07 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB1EE25E-5302-4609-9598-C6AFBB42CB9A">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-136.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-24 20:02:33 -0400</pav:createdOn>
    <ao:prefix> and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DB1EE25E-5302-4609-9598-C6AFBB42CB9A"/>
    <domeo:uuid>DB1EE25E-5302-4609-9598-C6AFBB42CB9A</domeo:uuid>
    <ao:exact>trazodone</ao:exact>
    <ao:suffix> were coadministered.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3801AFB1-E917-4E09-8201-F7DFAAAD30AC">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3801AFB1-E917-4E09-8201-F7DFAAAD30AC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>3801AFB1-E917-4E09-8201-F7DFAAAD30AC</domeo:uuid>
    <ao:exact>nelfinavir</ao:exact>
    <ao:prefix>and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:suffix>, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively </ao:suffix>
    <pav:createdOn>2014-09-02 19:17:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35CDD6FE-B2DA-45B7-836A-B05452D0DAB8">
    <ao:exact>voriconazole </ao:exact>
    <domeo:uuid>35CDD6FE-B2DA-45B7-836A-B05452D0DAB8</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:13:49 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:35CDD6FE-B2DA-45B7-836A-B05452D0DAB8"/>
    <ao:prefix>and </ao:prefix>
    <ao:suffix>(a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure. Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses up to 240 m</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A033E70-6D84-4601-985E-2D559145926B">
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1B51833F-74F3-4AB3-A6D0-CD524F9F3140"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 11:38:06 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BCC3E44B-0E96-41D5-AB03-A4CC9A1EB653">
    <ao:prefix>time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>BCC3E44B-0E96-41D5-AB03-A4CC9A1EB653</domeo:uuid>
    <ao:suffix>may need to be monitored for increases in INR and prothrombin time.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BCC3E44B-0E96-41D5-AB03-A4CC9A1EB653"/>
    <ao:exact>warfarin </ao:exact>
    <pav:createdOn>2014-09-02 19:12:54 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46780EA4-462F-4B55-AB22-23CB7FC82C80">
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> tablets.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46780EA4-462F-4B55-AB22-23CB7FC82C80"/>
    <ao:prefix> oral solution is bioequivalent to </ao:prefix>
    <pav:createdOn>2014-07-13 11:09:25 -0400</pav:createdOn>
    <domeo:uuid>46780EA4-462F-4B55-AB22-23CB7FC82C80</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA680547-50B2-43E1-8768-6007654CDEF9">
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EFB9988E-CEA1-4326-AC04-4DC5F728B495"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-22 19:38:33 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A624918-A90F-4845-8DFE-C35AFD8B0B68">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 11:43:38 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A16A73F6-04A0-4350-B482-E365FE1CCB81"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3A2D166B-BD0B-4C2A-9E40-D07C3CE85DBC">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9639DF56-3E53-4998-9064-63357AB54862"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F46BEE2C-B82E-4386-96D7-C74221898C04">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:90D2913F-1AFA-432E-968A-2D879173B288</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:15:12 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B951EF5-B48C-4B58-B273-480990730DEA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92AF00E3-613A-4E27-ACAC-A744AA15CCB8">
    <ao:suffix> (7.5 mg/kg q12h intravenously [iv]) in the treatment of complicated skin and skin structure infections were performed. The comparator drug was oxacillin (2g q6h iv) in the first study (JRV 304) and cefazolin (1g q8h iv) in the second study (JRV 305); ho</ao:suffix>
    <ao:exact>Synercid</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:92AF00E3-613A-4E27-ACAC-A744AA15CCB8"/>
    <ao:prefix>Two randomized, open-label, controlled clinical trials of </ao:prefix>
    <domeo:uuid>92AF00E3-613A-4E27-ACAC-A744AA15CCB8</domeo:uuid>
    <pav:createdOn>2014-07-22 18:51:22 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-119.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30818391-5098-4A86-BF01-5AB0C0597335">
    <ao:prefix> displaces each other from plasma binding sites. High therapeutic concentrations of </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>s</ao:exact>
    <domeo:uuid>30818391-5098-4A86-BF01-5AB0C0597335</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:11:27 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:30818391-5098-4A86-BF01-5AB0C0597335"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9AF0B949-C133-4703-9F65-362D4B5B4494">
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6887274E-F614-42FD-904F-B7E202949297"/>
    <pav:lineageUri>urn:domeoserver:annotation:C0DB2807-8137-4A89-A166-930A58544F71</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:11:10 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F9B083BB-350D-424C-ABD3-5F63B771A9A9">
    <pav:createdOn>2014-07-28 17:00:46 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:AE31FB45-DE35-4E4D-B623-72AA865505E0"/>
    <pav:lastSavedOn>2014-07-28 17:00:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:4FC315CC-8F6D-4166-AEB6-FBF9CF2FA510</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:3571BBB6-88DC-455D-8449-2369BE0EA051</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4599F40B-EE74-4C90-A4C8-716EBE52CAA7">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 11:58:35 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:9CD077F0-DA16-4E30-8E10-EF64E4D50B64</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:977500EC-B7B9-4889-A108-85D25AA19BE0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31254608-CDC4-4553-A278-115226EC9264">
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:EE0F6228-C669-47FF-9D22-04B7A608D69E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:38:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D555A94C-D1DE-4B5C-B227-8172F8605613">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D555A94C-D1DE-4B5C-B227-8172F8605613"/>
    <pav:createdOn>2014-09-02 19:09:20 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>erythromycin</ao:exact>
    <ao:prefix>. Inhibition of CYP3A4 activity by its inhibitors, such as macrolide antibiotics (e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may prolong opioid effects. If co-administration is necessary, caution is advised when initiating therapy with, currently taking, or discontinuing CYP3A4 inhibito</ao:suffix>
    <domeo:uuid>D555A94C-D1DE-4B5C-B227-8172F8605613</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C5170BD-B57E-4757-B143-AE7F2FE21CCC">
    <pav:createdOn>2014-09-02 19:10:58 -0400</pav:createdOn>
    <ao:suffix>and monoamine oxidase inhibitors has been observed, but caution in the use of any opioid in patients taking this class of drugs is appropriate.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C5170BD-B57E-4757-B143-AE7F2FE21CCC"/>
    <ao:exact>oxycodone </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>No specific interaction between </ao:prefix>
    <domeo:uuid>9C5170BD-B57E-4757-B143-AE7F2FE21CCC</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C13FD629-159C-4DA7-9B01-A5B3536DF254">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C13FD629-159C-4DA7-9B01-A5B3536DF254"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>sertraline </ao:exact>
    <pav:createdOn>2014-09-01 16:06:11 -0400</pav:createdOn>
    <ao:prefix>extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that </ao:prefix>
    <ao:suffix>200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>C13FD629-159C-4DA7-9B01-A5B3536DF254</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18E928D8-1D25-4E2F-BBD0-E7B1E4E45799">
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:808DC7C6-B4BD-432C-A6A2-0F47B3206319"/>
    <pav:lineageUri>urn:domeoserver:annotation:44433A89-79F3-4B05-802D-4636E2FBCB70</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 19:10:00 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89155DC0-3493-4590-8DD7-44717F141C27">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:09:15 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:0A1E742B-4ABE-40BF-84E5-2A5F57F232F2"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:94085E4A-F1A0-40E6-8805-C846AF27EEDD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0569E8E5-928F-4D8D-93AE-056F350503EF">
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:0C6FF426-D0F6-4DFE-8C13-8BD0EAA98C6F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:46:15 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:FC7F51C8-D140-4695-B609-DCDA64270F6D</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04DF851F-404D-44D4-A74D-22017210AF9A">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 12:03:29 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:23EBC507-A336-4506-9D28-78F1ECDFDF8B"/>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FADFAA32-BB4A-4542-AEFD-2B7D80177234">
    <ao:exact>risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FADFAA32-BB4A-4542-AEFD-2B7D80177234"/>
    <domeo:uuid>FADFAA32-BB4A-4542-AEFD-2B7D80177234</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:10:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Food Effect: Food does not affect either the rate or extent of absorption of </ao:prefix>
    <ao:suffix>. Thus, risperidone can be given with or without meals.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2AC08E4-8A5F-4E68-B2F1-20AFB690BAC7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E2AC08E4-8A5F-4E68-B2F1-20AFB690BAC7"/>
    <pav:createdOn>2014-07-07 11:22:40 -0400</pav:createdOn>
    <ao:exact>Sildenafil </ao:exact>
    <ao:suffix>exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg TID compared to its exposure at a dose of 20 mg TID. This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug int</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>clearance when it was co-administered with CYP3A inhibitors. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:194B637B-12E0-40F8-A961-33C50074CD18">
    <domeo:belongsToSet>urn:domeoclient:uuid:69C22FA1-8D50-4AA7-ACD8-8F71E69BB8AC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:1F8915F4-D391-48E0-8456-40C2A2D6DC05</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F0271A3E-BA13-45E3-87AB-B8C1F9BB72CC"/>
    <pav:createdOn>2014-09-02 19:41:42 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 19:42:49 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8EA1563F-47E7-4983-918E-643A5D2021DC">
    <ao:suffix>on Vision</ao:suffix>
    <ao:exact>REVATIO </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Effects of </ao:prefix>
    <pav:createdOn>2014-07-07 09:40:48 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8EA1563F-47E7-4983-918E-643A5D2021DC"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB79C29A-687E-46A8-AEEA-C0F67E49EB97">
    <pav:createdOn>2014-09-01 15:59:50 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-17.txt.html</ao:hasSource>
    <ao:suffix>for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose. Sertraline administration did not noticeably change either the p</ao:suffix>
    <domeo:uuid>DB79C29A-687E-46A8-AEEA-C0F67E49EB97</domeo:uuid>
    <ao:prefix>In a placebo-controlled trial in normal volunteers, administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>sertraline </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DB79C29A-687E-46A8-AEEA-C0F67E49EB97"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E595AA2-A52D-41DE-BC69-4125AE10A552">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>’s in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
    <domeo:uuid>3E595AA2-A52D-41DE-BC69-4125AE10A552</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E595AA2-A52D-41DE-BC69-4125AE10A552"/>
    <ao:exact>paroxetine</ao:exact>
    <ao:suffix>’s extent of inhibition of CYP3A4 activity is not likely to be of clinical significance.</ao:suffix>
    <pav:createdOn>2014-09-02 15:04:34 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34A39B5E-1BC8-4028-8390-448D67AF41F6">
    <ao:body rdf:nodeID="Nc5cfc25b89d84d0894f03f046c415d78"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:57110ED0-1E32-4464-B810-CBC16353C315</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 20:03:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:7EBA2A42-43E7-40EC-B69A-A8622A20C1FD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:189A8E0E-67D6-4C53-A96E-CB48A3B4B2E9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 20:02:49 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd510f773a9bd439e9a515be564d4c7c7">
    <domeo:sets rdf:resource="urn:pddi:uuid:96647834-C481-4294-B866-A481E00D4F42"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E766D1AC-45BC-4579-89AD-BE0DEC69FC35">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>N</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E766D1AC-45BC-4579-89AD-BE0DEC69FC35"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>-</ao:suffix>
    <pav:createdOn>2014-07-07 09:42:25 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix>and its major circulating </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7292F6B8-8DF2-4158-91E5-6FA4A069D796">
    <pav:lastSavedOn>2014-09-02 11:54:50 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 11:53:27 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:body rdf:nodeID="N8cd98dbf60b94c1b8dea50213566da16"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:C5C09821-2ECD-424B-9FA4-FD278FE901F2</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C94B4C4D-E742-4102-A342-E2728F29088D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7DCD6738-9404-46BB-A758-BDDEB41B4565">
    <ao:item rdf:resource="urn:domeoclient:uuid:81F0286A-7D44-49B2-9EF8-817CDCC20940"/>
    <permissions:permissions rdf:nodeID="N1430fb2af07e42b49ff933d500b0c0b2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:60DE0286-3CA3-49E7-8170-0F036F3F13E2"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-160.txt.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2014-07-24 20:13:52 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-24 20:14:00 -0400</pav:lastSavedOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:D2CDA065-14B9-49F3-B117-09FCBF86485A</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:A6FD6D5D-B7A2-423B-8A6B-8CCFD72983C1"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:856ADB71-F8FC-4B9D-8651-B139286C3B33">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:856ADB71-F8FC-4B9D-8651-B139286C3B33"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-07-22 18:54:36 -0400</pav:createdOn>
    <domeo:uuid>856ADB71-F8FC-4B9D-8651-B139286C3B33</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-119.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Two randomized, open-label, controlled clinical trials of Synercid (7.5 mg/kg q12h intravenously [iv]) in the treatment of complicated skin and skin structure infections were performed. The comparator drug was oxacillin (2g q6h iv) in the first study (JRV 304) and cefazolin (1g q8h iv) in the second study (JRV 305); however, in both studies vancomycin (1g q12h iv) could be substituted for the specified comparator if the causative pathogen was suspected or confirmed methicillin-resistant staphylococcus or if the patient was allergic to penicillins, cephalosporins or carbapenems. Study JRV 304 enrolled 450 patients (n = 229 Synercid; n= 221 Comparator) and Study JRV 305 enrolled 443 patients (n = 221 Synercid; n = 222 Comparator)</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AFC067D9-3DC4-4FB0-B028-1D222EE28907">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AFC067D9-3DC4-4FB0-B028-1D222EE28907"/>
    <ao:suffix>, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for this enzyme, including terfenadine, astemizole, cisapride, triazolam, and cyclosporine. Based on the</ao:suffix>
    <pav:createdOn>2014-09-02 15:04:18 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
    <ao:exact>ketoconazole</ao:exact>
    <ao:prefix> pharmacokinetics. In addition, in vitro studies have shown </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AFC067D9-3DC4-4FB0-B028-1D222EE28907</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:789A1E1D-CA44-4410-B654-F6392AB94EDC">
    <ao:exact>albumin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:789A1E1D-CA44-4410-B654-F6392AB94EDC"/>
    <pav:createdOn>2014-07-13 11:10:54 -0400</pav:createdOn>
    <domeo:uuid>789A1E1D-CA44-4410-B654-F6392AB94EDC</domeo:uuid>
    <ao:prefix> is bound to </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> and α1-acid glycoprotein. The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic con</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:697447CC-E28E-42D6-889F-E4B9D46954FC">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/C17461FE-A35A-4C0A-940B-01CB796E4877"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F66BC8F5-49B9-4B6B-9972-D0A9AFB6AF18"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A810EBBA-9C6C-4A0D-9FD2-AFA2874096F5">
    <pav:createdOn>2014-07-13 12:38:23 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <domeo:uuid>A810EBBA-9C6C-4A0D-9FD2-AFA2874096F5</domeo:uuid>
    <ao:exact>norethindrone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A810EBBA-9C6C-4A0D-9FD2-AFA2874096F5"/>
    <ao:suffix> compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in t</ao:suffix>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFD62BB2-11C8-4215-B304-C5A0146A8A66">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CFD62BB2-11C8-4215-B304-C5A0146A8A66"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>; n= 221 Comparator) and Study JRV 305 enrolled 443 patients (n = 221 </ao:suffix>
    <ao:exact>Synercid</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-119.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 18:52:22 -0400</pav:createdOn>
    <ao:prefix>substituted for the specified comparator if the causative pathogen was suspected or confirmed methicillin-resistant staphylococcus or if the patient was allergic to penicillins, cephalosporins or carbapenems. Study JRV 304 enrolled 450 patients (n = 229 </ao:prefix>
    <domeo:uuid>CFD62BB2-11C8-4215-B304-C5A0146A8A66</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35CE9A7F-F23D-4EBE-B09F-02A153717FBA">
    <ao:prefix>. Thus, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>35CE9A7F-F23D-4EBE-B09F-02A153717FBA</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:35CE9A7F-F23D-4EBE-B09F-02A153717FBA"/>
    <ao:suffix> can be given with or without meals.</ao:suffix>
    <pav:createdOn>2014-07-13 11:10:38 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C48F039A-1F94-471B-9DF9-0D4E6B99DA14">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C48F039A-1F94-471B-9DF9-0D4E6B99DA14"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, a non-specific CYP450 inhibitor, increased propranolol AUC and Cmax by 46% and 35%, respectively. Co-administration with aluminum hydroxide gel (1200 mg) may result in a decrease in propranolol concentrations.</ao:suffix>
    <pav:createdOn>2014-07-24 19:45:35 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-129.txt.html</ao:hasSource>
    <ao:prefix>Co-administration of propranolol with </ao:prefix>
    <domeo:uuid>C48F039A-1F94-471B-9DF9-0D4E6B99DA14</domeo:uuid>
    <ao:exact>cimetidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1EC2D5D-E8AA-4BAB-8BCE-D86C722E5855">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-21 21:47:22 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-21 21:49:33 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:C0CA1D7A-A6F3-4B33-A548-FEE27A93C15D</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:805A260D-8C6D-4764-98FF-7A828A5A8A65"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:B803E851-5AD5-4741-B1B9-1CBAED597E18</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B017829-D9F5-484A-8F49-2CBAD935419D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:338E8B18-C7D9-423A-ACA5-3E11D88F42E9"/>
    <pav:createdOn>2014-09-02 15:04:01 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:801D52C5-A4A0-4C8E-873C-878BAB088D1F</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A04C3C3-B677-4732-87D0-83C03497D24C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5A04C3C3-B677-4732-87D0-83C03497D24C"/>
    <domeo:uuid>5A04C3C3-B677-4732-87D0-83C03497D24C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-01 16:11:59 -0400</pav:createdOn>
    <ao:prefix>In patients receiving </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-42.txt.html</ao:hasSource>
    <ao:suffix>or azathioprine, the concomitant administration of 300 to 600 mg of allopurinol sodium for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of mercaptopurine or azathioprine. Subsequent adjustm</ao:suffix>
    <ao:exact>mercaptopurine </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84F2753B-0F8B-4975-8EFA-3A99E0B82A50">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:84F2753B-0F8B-4975-8EFA-3A99E0B82A50"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-09-02 11:44:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <domeo:uuid>84F2753B-0F8B-4975-8EFA-3A99E0B82A50</domeo:uuid>
    <ao:exact>Tryptophan</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:270BC940-6C4E-4F0E-91AB-DAC2FC78E847">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:2C994664-AD86-4E78-8F09-1465E29593D8</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:57:31 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:C3030391-F9A1-49F9-B8E8-7E56658D5BF2"/>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82628688-78B9-45FB-8BED-8C81D7B2F03E">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-22 19:42:20 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 19:44:46 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:3778184B-7478-42AC-8128-7363E5970F00"/>
    <pav:previousVersion>urn:domeoserver:annotationset:514BA51B-D734-4003-A7C3-F03C0F95833A</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1EB12059-BBA2-4D0D-8E36-2569CD51DC88">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1EB12059-BBA2-4D0D-8E36-2569CD51DC88"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>A published study showed that the co-administration of </ao:prefix>
    <pav:createdOn>2014-09-02 19:09:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>1EB12059-BBA2-4D0D-8E36-2569CD51DC88</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <ao:suffix>, a drug metabolizing enzyme inducer, significantly decreased plasma oxycodone concentrations. Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an ab</ao:suffix>
    <ao:exact>rifampin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71E5047C-5690-4D45-9A6E-FB1384C14928">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:DFC21707-69A6-4E64-9438-1D6C69F0352F</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 11:16:15 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:4A268B82-4B69-4D00-A6E9-95F225012877"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B951EF5-B48C-4B58-B273-480990730DEA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B951EF5-B48C-4B58-B273-480990730DEA"/>
    <ao:prefix> in patients receiving </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>quinidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given risperidone do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g., carbamazep</ao:suffix>
    <domeo:uuid>2B951EF5-B48C-4B58-B273-480990730DEA</domeo:uuid>
    <pav:createdOn>2014-07-13 11:15:12 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C335096-224E-43D5-B91F-473E8217B098">
    <ao:prefix> added to </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5C335096-224E-43D5-B91F-473E8217B098"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluvoxamine</ao:exact>
    <domeo:uuid>5C335096-224E-43D5-B91F-473E8217B098</domeo:uuid>
    <ao:suffix> 100 mg/day administered at steady-state was associated with five- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea followi</ao:suffix>
    <pav:createdOn>2014-09-02 11:41:14 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17E64297-0A57-4C9B-94C4-18ED1956FCF7">
    <pav:lineageUri>urn:domeoserver:annotation:2F1405B4-F41E-4809-AC54-DA4B296E83DB</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:51:17 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:7950DCED-7411-4B59-B629-CB1341A53897"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/5F00796E-B959-488F-969F-87505727DC32">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>cimetidine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB7CDA28-9814-4B6E-95D0-E4733B2DD0B9">
    <domeo:uuid>FB7CDA28-9814-4B6E-95D0-E4733B2DD0B9</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-119.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 18:51:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>(2g q6h iv) in the first study (JRV 304) and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FB7CDA28-9814-4B6E-95D0-E4733B2DD0B9"/>
    <ao:suffix> (1g q8h iv) in the second study (JRV 305); however, in both studies vancomycin (1g q12h iv) could be substituted for the specified comparator if the causative pathogen was suspected or confirmed methicillin-resistant staphylococcus or if the patient was</ao:suffix>
    <ao:exact>cefazolin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A7AE105-ADC2-416B-AD5B-0B0B1DB2A2E2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A7AE105-ADC2-416B-AD5B-0B0B1DB2A2E2"/>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> decreased very slightly (&lt;5%) in 3 of the 21 subjects after </ao:prefix>
    <domeo:uuid>8A7AE105-ADC2-416B-AD5B-0B0B1DB2A2E2</domeo:uuid>
    <ao:suffix> treatment.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 12:38:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53C71D4E-A625-4012-ABC4-932105C30699">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:38:27 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9E6E80C9-FE56-4016-839A-ADB4FEFC8C55"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:657DCEFF-DA71-40A0-8E23-F90A79E8F3B2">
    <pav:createdOn>2014-09-02 11:58:26 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5B60DE0C-DAD3-497E-B767-27CC4F4AA306"/>
    <pav:lineageUri>urn:domeoserver:annotation:23A6B85A-8C04-4B54-AC49-8D72F071AD15</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E854201F-10EB-4992-8353-B60276384931">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:1DA34422-734D-46B1-AB2C-C1CABCA4C26C</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-01 16:07:52 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BE7787BA-2717-4D64-BE0B-A188784B75CE"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-01 16:07:12 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:5DA1738B-3B14-48F7-9099-42BBEE0E2846</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3F94F7A-3299-4ECD-8A0C-54D9B0E17A6D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:13:30 -0400</pav:createdOn>
    <ao:suffix>, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone co</ao:suffix>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3F94F7A-3299-4ECD-8A0C-54D9B0E17A6D"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>F3F94F7A-3299-4ECD-8A0C-54D9B0E17A6D</domeo:uuid>
    <ao:prefix> rapidly into </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F04829AF-C604-411D-8F92-B9DB45D4050E">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/135097</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Synercid</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62667796-1E15-449B-8175-6954CB53F6DF">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:62667796-1E15-449B-8175-6954CB53F6DF"/>
    <domeo:uuid>62667796-1E15-449B-8175-6954CB53F6DF</domeo:uuid>
    <ao:suffix> with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.</ao:suffix>
    <pav:createdOn>2014-09-02 11:38:20 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> alone and </ao:prefix>
    <ao:exact>lorazepam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C42C067D-4201-4F47-96EA-FFFFA5B4C4AB">
    <domeo:uuid>C42C067D-4201-4F47-96EA-FFFFA5B4C4AB</domeo:uuid>
    <ao:prefix> with </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C42C067D-4201-4F47-96EA-FFFFA5B4C4AB"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone conc</ao:suffix>
    <pav:createdOn>2014-09-02 11:57:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E9300CC-A667-49A8-AD8F-115AE6705100">
    <ao:context rdf:resource="urn:domeoclient:uuid:3B160A10-3999-44C9-A9E0-AB903EF4E9F4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:BA436780-411D-4925-859C-E7850751624C</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-28 17:01:58 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-28 17:01:39 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:05CE82A3-E1C6-497A-B0B0-31DD508C02A1</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:77F990A5-C7A6-4873-A32F-AD9607EFDE51">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>77F990A5-C7A6-4873-A32F-AD9607EFDE51</domeo:uuid>
    <ao:suffix> occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabol</ao:suffix>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:prefix> occurred at about 1 hour. Peak concentrations of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:77F990A5-C7A6-4873-A32F-AD9607EFDE51"/>
    <pav:createdOn>2014-07-13 11:10:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/7C1B3FD3-CA8D-4D2F-B094-F0DB74BF2108">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4124</dailymed:activeMoietyRxCUI>
    <rdfs:label>ethinyl estradiol</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A119113-824F-4EAE-B66E-B060687F0A7E">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A119113-824F-4EAE-B66E-B060687F0A7E"/>
    <pav:createdOn>2014-07-21 21:47:28 -0400</pav:createdOn>
    <domeo:uuid>6A119113-824F-4EAE-B66E-B060687F0A7E</domeo:uuid>
    <ao:exact>diltiazem</ao:exact>
    <ao:prefix>does not alter the kinetics of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-54.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0323018B-085E-4636-9195-1B6FDC9A582D">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>0323018B-085E-4636-9195-1B6FDC9A582D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Rifampin</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0323018B-085E-4636-9195-1B6FDC9A582D"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-22 19:48:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3030391-F9A1-49F9-B8E8-7E56658D5BF2">
    <pav:createdOn>2014-09-02 11:57:31 -0400</pav:createdOn>
    <ao:suffix> 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C3030391-F9A1-49F9-B8E8-7E56658D5BF2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>paroxetine</ao:exact>
    <domeo:uuid>C3030391-F9A1-49F9-B8E8-7E56658D5BF2</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:371BCC12-3242-4854-9882-2DB2B2EE1A70">
    <pav:createdOn>2014-07-13 12:38:53 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:371BCC12-3242-4854-9882-2DB2B2EE1A70"/>
    <ao:suffix> decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatment.</ao:suffix>
    <ao:prefix> AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>norethindrone</ao:exact>
    <domeo:uuid>371BCC12-3242-4854-9882-2DB2B2EE1A70</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41AFFAD3-B330-44BA-91A6-EFE69C07C0A2">
    <pav:createdOn>2014-09-02 11:40:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:8A0FA947-246E-4008-87C0-91C5CA96E875"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB5170BC-470C-4927-94E9-76D8F5299B74">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 19:55:03 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-24 19:54:45 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:F87D2273-7E05-4F58-B46E-DA5B9D8816DE</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:AA479503-5E2B-4688-851D-61C9DCC47907"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:85A49C92-4B0E-4688-B7A9-F420702DEF48</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31F715F6-A269-43C4-9AA2-9270BCFEF7C0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:71782464-053E-46F0-8930-DB2CDA0F1338"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:CD9F9CAF-F87E-49CF-A73B-3ED9BCBF0A03</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-24 20:11:41 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:875A1582-88A4-40A2-9290-112578B609F1">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:C4DA9FCE-B7DB-4AB2-8187-C60945E96A8D"/>
    <pav:createdOn>2014-07-24 20:07:18 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A49EC3D-7C54-46A7-831E-A352B5A1B081">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> (2 mg twice daily) taken concomitantly with </ao:prefix>
    <domeo:uuid>7A49EC3D-7C54-46A7-831E-A352B5A1B081</domeo:uuid>
    <pav:createdOn>2014-07-22 19:49:16 -0400</pav:createdOn>
    <ao:suffix> (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy. Repeat doses of AVANDIA (8 mg once daily) for 8 days in healthy adult Caucasian subjects cause</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A49EC3D-7C54-46A7-831E-A352B5A1B081"/>
    <ao:exact>glyburide</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF1FC131-57E9-4A89-8FBF-B786D1543F24">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:6C37E9D5-F4A3-4CDB-AE4B-E46CCA6F2A60"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:createdOn>2014-07-22 19:16:20 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2932281-71AF-4D8C-BFA1-44627891CD3C">
    <pav:lineageUri>urn:domeoserver:annotationset:092451F5-B0C0-430C-8896-07F81D33F9E1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40007BD9-0869-48CF-A8F2-BAD26AE3E6E1</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-21 21:31:15 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-21 21:31:54 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:02D77FC0-6DA3-45AA-9C58-66539927EF97"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B40A6C2-C532-4FE1-9D1E-96A1576E7CC1">
    <pav:createdOn>2014-09-02 19:11:00 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:BB9A9C70-7859-46AE-887F-B9F2CBDE39DB"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:C437B730-34CD-4CA8-A3D5-EEB1FCE27C9A</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96E66F0D-E214-4562-BC8C-77A59132E471">
    <ao:exact>Paroxetine </ao:exact>
    <pav:createdOn>2014-07-21 21:44:28 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:96E66F0D-E214-4562-BC8C-77A59132E471"/>
    <domeo:uuid>96E66F0D-E214-4562-BC8C-77A59132E471</domeo:uuid>
    <ao:suffix>produced no genotoxic effects in a battery of 5 in vitro and 2 in vivo assays that included the following: Bacterial mutation assay, mouse lymphoma mutation assay, unscheduled DNA synthesis assay, and tests for cytogenetic aberrations in vivo in mouse bo</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-52.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6EB0C05E-6581-4241-B07F-CF48B6405DC1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>6EB0C05E-6581-4241-B07F-CF48B6405DC1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6EB0C05E-6581-4241-B07F-CF48B6405DC1"/>
    <ao:suffix>200 mg daily for 15 days) in 13 volunteers with AIDS or ARC who were on a stable zidovudine dose for at least two weeks. There was a significant increase in zidovudine AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20%</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluconazole </ao:exact>
    <pav:createdOn>2014-07-21 21:31:10 -0400</pav:createdOn>
    <ao:prefix>concentrations were determined on two occasions (before and following </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:001ECFA6-B086-4B2B-977E-41F4C9DE054B">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-132.txt.html</ao:hasSource>
    <ao:prefix> or </ao:prefix>
    <ao:exact>pravastatin</ao:exact>
    <pav:createdOn>2014-07-24 19:52:46 -0400</pav:createdOn>
    <ao:suffix>, decreased 18% to 23% the AUC of both, but did not alter their pharmacodynamics. Propranolol did not have an effect on the pharmacokinetics of fluvastatin.</ao:suffix>
    <domeo:uuid>001ECFA6-B086-4B2B-977E-41F4C9DE054B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:001ECFA6-B086-4B2B-977E-41F4C9DE054B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:883BB188-A483-4C32-85F5-63D2C4B33561">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:28368420-4E42-4D08-91FB-67DAADA661EC"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:18:57 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:787692CD-0BB7-4EBC-B1EB-B839CB0674FF">
    <ao:context rdf:resource="urn:domeoclient:uuid:E7B5E0E2-9287-47B6-9135-34CE522BE395"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:15178808-6677-451C-9986-6BBD161C3567</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-24 20:14:43 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:2BAA59CB-3862-4A98-8A6C-AA14E82983DC</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 20:14:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:143E0873-3AEC-4273-B2E8-23467A7C6978">
    <domeo:uuid>143E0873-3AEC-4273-B2E8-23467A7C6978</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:43:53 -0400</pav:createdOn>
    <ao:exact>paroxetine</ao:exact>
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:143E0873-3AEC-4273-B2E8-23467A7C6978"/>
    <ao:suffix>, sertraline) is clinically warranted, appropriate observation of the patient is advised.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D1D462E-3009-4EB1-A982-ED88FF1CE34A">
    <pav:createdOn>2014-09-02 11:38:45 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D5584BFA-AB83-49EE-A2F1-68159AD3AEAC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA428F64-D782-46F5-B866-2FBC24D3F4F8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:9F3CAE5F-12DF-463B-A0AD-4F223784EC31</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:EA1C9791-9797-4F15-A767-767B900E9B87"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-07 09:58:58 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:977500EC-B7B9-4889-A108-85D25AA19BE0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:977500EC-B7B9-4889-A108-85D25AA19BE0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a red</ao:suffix>
    <domeo:uuid>977500EC-B7B9-4889-A108-85D25AA19BE0</domeo:uuid>
    <ao:prefix> every 12 hours. This resulted in increases in steady state </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <ao:exact>atomoxetine</ao:exact>
    <pav:createdOn>2014-09-02 11:58:35 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6D8B558-463C-428A-82F9-861E7A7AA7AC">
    <pav:lineageUri>urn:domeoserver:annotation:73DB93B0-36EA-401A-A4D9-8296CC5688CC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-24 20:02:07 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-24 20:02:49 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EACE427F-1066-4C2C-B450-F3CF99633404"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:189A8E0E-67D6-4C53-A96E-CB48A3B4B2E9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB317DCF-ED84-480E-92AF-867EFA3D6E76">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-21 21:42:16 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:87DA7BB9-8F52-460F-B488-90DD6AC36EFF"/>
    <pav:lastSavedOn>2014-07-21 21:42:43 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:BD4B7475-BD13-46C4-932F-139564A0063D</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:5826AA0F-B3D5-46C2-99FF-C0761E3C5E0D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E89967E-ADD7-495C-B4F3-72B05A30FE8E">
    <ao:suffix>. This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis. The size of wheal and flare were significantly larger when fexofenadine hydrochloride was administ</ao:suffix>
    <pav:createdOn>2014-07-24 20:12:29 -0400</pav:createdOn>
    <ao:exact>fexofenadine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8E89967E-ADD7-495C-B4F3-72B05A30FE8E"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <domeo:uuid>8E89967E-ADD7-495C-B4F3-72B05A30FE8E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Fruit juices such as grapefruit, orange and apple may reduce the bioavailability and exposure of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC0DA7A3-93CD-44F0-B862-95BDA351400D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:58:42 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:702E239E-7D5E-4778-8584-0516BA254DC8"/>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:67EF776C-169B-4458-8DD4-A843EBC79870</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2DE3872D-3935-4824-AF9D-DBFF26D2588F">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:E960F182-0178-48DA-9F6A-A1F40CDC1A1D"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 19:12:33 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8794C27-AB48-4247-A5DC-F99E0DB48B2D">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-28 17:08:37 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-28 17:04:52 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EE9D00B3-F511-4E8E-BFBF-A30D7A5C5F82"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:88D4AAD7-575C-4C65-A82F-5671A64A4763</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:48D839E5-6B0A-4EC3-B64A-E3E20E06246A</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:518CD4C6-1719-48AB-B300-84A10DEACB68">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:35CE9A7F-F23D-4EBE-B09F-02A153717FBA"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:10:38 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:01596A5C-8D3C-4B38-BEFB-CD0AFC09802B</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A676ABAB-01BC-4D19-9DA7-5CF8687711A8">
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:58:39 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:F9808DBF-4E74-434F-AD39-3686E0AF3378</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:5488F065-12C7-4BC6-B53E-99FE4483B13A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D37AF6F7-4BC0-4394-A3CE-386E408720C1">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D37AF6F7-4BC0-4394-A3CE-386E408720C1"/>
    <domeo:uuid>D37AF6F7-4BC0-4394-A3CE-386E408720C1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 20:19:23 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Concurrent administration of AVANDIA (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9D2EDEBD-1223-4650-A96C-6AA36F00C854">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/964F2661-87EF-4D00-87C8-D1C5E12C0ECB"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/7C1B3FD3-CA8D-4D2F-B094-F0DB74BF2108"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nafea1009a07848c5ac88ffeeae566862">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC9FB0B5-1564-4BF2-A4E4-4D05B0A1AB86">
    <ao:context rdf:resource="urn:domeoclient:uuid:F353BFC5-D6B5-4819-8EA8-0A44F2223E3B"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-07 09:37:19 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B604E28-4F1B-4B10-A878-DE6620893CDB">
    <pav:lineageUri>urn:domeoserver:annotation:3843036B-6944-4AF6-BA4D-F08B2E58FE59</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:B57AEEF2-0F0B-4E76-9F59-DBC483D6322C"/>
    <pav:createdOn>2014-07-24 20:14:32 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-24 20:14:43 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:2BAA59CB-3862-4A98-8A6C-AA14E82983DC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F55A562-8BC3-4202-8F0A-0D9AD00722CD">
    <domeo:uuid>5F55A562-8BC3-4202-8F0A-0D9AD00722CD</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 19:44:10 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5F55A562-8BC3-4202-8F0A-0D9AD00722CD"/>
    <ao:exact>Rifampin administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease rosiglitazone AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E221E79-602A-4812-8488-538D6506C879">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 11:17:48 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:99FCA5E3-D174-4EE6-A00A-E8CEB0ED9FB4</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:AD57239D-3225-4F0C-8054-FBD32976EE0C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16E9C8A9-8DAA-4EB9-8859-7C353FD7C273">
    <pav:createdOn>2014-07-21 21:53:44 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-56.txt.html</ao:hasSource>
    <domeo:uuid>16E9C8A9-8DAA-4EB9-8859-7C353FD7C273</domeo:uuid>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Zonisamide</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16E9C8A9-8DAA-4EB9-8859-7C353FD7C273"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35CD1CDB-7257-43BB-BB56-7A444AAF4BA3">
    <pav:createdOn>2014-07-24 20:05:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:CC1D209A-F362-4FEA-ABD5-96B660CE4A7A"/>
    <pav:lastSavedOn>2014-07-24 20:04:50 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:07539CCF-9ED2-4C02-AC53-CD1CF6713CB3</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:CB9DE49D-2EBB-4CA3-BC80-5D2A9373C00A</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6ECE2E9A-54C4-4507-95A6-2F4053719529">
    <pav:createdOn>2014-07-13 11:09:51 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:CF873305-5222-4D37-9C71-925D3C390B7A"/>
    <pav:lineageUri>urn:domeoserver:annotation:D829A856-ADE0-4E82-B940-6DE74589EFC8</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3DCB5ACD-9F2E-46B4-98D0-F1D2BD3C8EE7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:A3D04FE1-598A-407B-A69E-44B383594D74</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:DB1EE25E-5302-4609-9598-C6AFBB42CB9A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-24 20:02:33 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-24 20:02:49 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:189A8E0E-67D6-4C53-A96E-CB48A3B4B2E9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53FAB419-4FF7-440E-89DD-64411826800A">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 11:30:35 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3B66F49-9D04-482E-BF7F-722441E81595"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A29DA787-54E3-4422-B166-2BA6676BC91D">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A29DA787-54E3-4422-B166-2BA6676BC91D"/>
    <ao:suffix> at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
    <ao:prefix> at 10 ng/mL and </ao:prefix>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A29DA787-54E3-4422-B166-2BA6676BC91D</domeo:uuid>
    <pav:createdOn>2014-07-13 11:11:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5DD6E78-70E1-4015-8485-53B5D56072C0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A5DD6E78-70E1-4015-8485-53B5D56072C0"/>
    <domeo:uuid>A5DD6E78-70E1-4015-8485-53B5D56072C0</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-54.txt.html</ao:hasSource>
    <ao:exact>Diltiazem significantly decreases the clearance and increases the t1/2 of quinidine, but quinidine does not alter the kinetics of diltiazem.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-21 21:49:21 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DB19655-BFA0-4BCE-93AA-DD6B932E259B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5DB19655-BFA0-4BCE-93AA-DD6B932E259B"/>
    <domeo:uuid>5DB19655-BFA0-4BCE-93AA-DD6B932E259B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:43:51 -0400</pav:createdOn>
    <ao:suffix>, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.</ao:suffix>
    <ao:prefix> have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with sumatriptan and an SSRI (e.g., </ao:prefix>
    <ao:exact>fluoxetine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE1FD7C4-2F16-4751-88A8-4F0AA6A4450A">
    <ao:exact>fexofenadine</ao:exact>
    <domeo:uuid>BE1FD7C4-2F16-4751-88A8-4F0AA6A4450A</domeo:uuid>
    <ao:prefix> gastrointestinal absorption. This observed increase in the bioavailability of </ao:prefix>
    <ao:suffix> may be due to transport-related effects, such as p-glycoprotein. In vivo animal studies also suggest that in addition to enhancing absorption, ketoconazole decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary e</ao:suffix>
    <pav:createdOn>2014-07-24 20:11:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BE1FD7C4-2F16-4751-88A8-4F0AA6A4450A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6950FFA4-1583-4644-99BE-7BD0F0C06B95">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 11:42:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:0A4B6E36-A9AC-4581-A4CD-969904241345"/>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84AD1907-FCD9-44ED-A2B9-CE7DA4A1A9AA">
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:55:23 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:99D19A33-63BB-4F24-96F1-57FE6B759A48"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:F59033EF-A957-4A73-82F8-005781304BC2</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44246EE4-6542-429C-AE56-DA84A2FDC57F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 11:40:12 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:26DA75B4-1584-4219-A170-BBFBF5DAB037"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33BB0EA3-00A7-4E9A-8406-1B489BED52FB">
    <pav:createdOn>2014-09-02 19:32:05 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>33BB0EA3-00A7-4E9A-8406-1B489BED52FB</domeo:uuid>
    <ao:prefix>. </ao:prefix>
    <ao:exact>Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Following multiple doses of</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:33BB0EA3-00A7-4E9A-8406-1B489BED52FB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A68BF389-96D4-4F16-BF9D-C1BF35E3CE01">
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A9F3E7CF-7FCB-472F-9AC5-B1BE53CD842F"/>
    <pav:createdOn>2014-07-22 19:26:02 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4019A76A-1D16-4F04-8CBF-FF855DD2A7A2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:07:17 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:09B51181-CF5C-416F-839B-FE6DF66105EA</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:636BB7C2-294D-452D-967D-461DEF7A510A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C00A54D-2DAC-4CE9-9A86-5591EF7E3323">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2C00A54D-2DAC-4CE9-9A86-5591EF7E3323"/>
    <domeo:uuid>2C00A54D-2DAC-4CE9-9A86-5591EF7E3323</domeo:uuid>
    <ao:suffix>) may increase the AUC of </ao:suffix>
    <pav:createdOn>2014-07-22 19:07:10 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-122.txt.html</ao:hasSource>
    <ao:exact>gemfibrozil</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>An inhibitor of CYP2C8 (e.g., </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0EC2FB2-F825-49D1-A3E4-EA98B976BFED">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C0EC2FB2-F825-49D1-A3E4-EA98B976BFED"/>
    <ao:suffix>e increase in a dose-proportional manner over the therapeutic dose range (Table 8). The elimination half-life is 3 to 4 hours and is independent of dose.</ao:suffix>
    <pav:createdOn>2014-07-22 19:22:52 -0400</pav:createdOn>
    <ao:exact>rosiglitazon</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Maximum plasma concentration (Cmax) and the area under the curve (AUC) of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>C0EC2FB2-F825-49D1-A3E4-EA98B976BFED</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84B56A7B-030D-4746-A4B2-C5097E07099C">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 20:01:45 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 20:02:49 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:28CDC6CA-725A-4228-B269-418A74B1E75D</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:30044970-A8CB-42F8-A59C-789340FE24AC"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:189A8E0E-67D6-4C53-A96E-CB48A3B4B2E9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:62EE12D9-5314-4E3B-81A5-6CC4F5785F46">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/4E62726A-262F-4A69-83FB-3965D3CD27BD"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/5AD16038-68DB-4293-9251-D5A275F9AB73"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/BB75F5EA-3BE0-4FC8-9344-269517A2A6EE">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>diazepam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3322</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4558C3C-CC16-4A44-85EC-2AB4969F8A0D">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:createdOn>2014-07-22 19:34:31 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:7E80543E-BF76-4514-92A9-91458DCB802B</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-22 19:35:16 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BD65EDB0-5E4A-430E-B9C2-3D953A7DE94C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DD1327AF-4B75-4BEA-B917-539687934A1F">
    <pav:createdOn>2014-09-02 12:03:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <domeo:uuid>DD1327AF-4B75-4BEA-B917-539687934A1F</domeo:uuid>
    <ao:exact>atomoxetine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DD1327AF-4B75-4BEA-B917-539687934A1F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA4737DB-0EF5-4431-A3C1-AB7A8F5E730A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AA4737DB-0EF5-4431-A3C1-AB7A8F5E730A"/>
    <pav:createdOn>2014-07-22 19:56:13 -0400</pav:createdOn>
    <ao:prefix>Coadministration of </ao:prefix>
    <ao:suffix> (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.</ao:suffix>
    <domeo:uuid>AA4737DB-0EF5-4431-A3C1-AB7A8F5E730A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:exact>acarbose</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA839309-7C8B-4446-A5C1-08694E7B8482">
    <domeo:uuid>FA839309-7C8B-4446-A5C1-08694E7B8482</domeo:uuid>
    <ao:exact>9-</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>, its major metabolite, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FA839309-7C8B-4446-A5C1-08694E7B8482"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:09:57 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF657FF8-3529-4A9B-9294-13C604834E0A">
    <pav:createdOn>2014-07-13 12:56:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="Nc5a300787b694f07bda1103a56b5759d"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:AB1C3D00-CC4C-4CA3-B347-69BA6BFE0FBF</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:211F5FD6-FC29-4AC5-96E1-14E088108ABB"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5841BCC9-42A5-4486-AA8B-635392DB4438">
    <ao:exact>fluvoxamine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5841BCC9-42A5-4486-AA8B-635392DB4438"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <domeo:uuid>5841BCC9-42A5-4486-AA8B-635392DB4438</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.</ao:suffix>
    <ao:prefix>: Administration of </ao:prefix>
    <pav:createdOn>2014-09-02 11:44:39 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D2E5F5D-2D44-4EC9-93CD-D558EE6CAD75">
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3D2E5F5D-2D44-4EC9-93CD-D558EE6CAD75"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-07 09:40:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>to patients with pulmonary arterial hypertension, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg).</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E4B6A541-B29F-419F-88B1-22F770341BFA">
    <ao:context rdf:resource="urn:domeoclient:uuid:265209EB-0CE8-478A-9C0E-59E0095E0A6B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 11:41:26 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E456854E-5580-4BC4-A878-DCBA76DC28FA">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:8C807E9A-52F6-4F5A-9553-5D4EB47525AC"/>
    <pav:createdOn>2014-07-24 19:44:10 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:511EDFA9-5A42-4340-9D4A-CBF6EDD9185C</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 19:44:56 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:AE9EE81B-F1E8-4623-B34F-44165AD48CDE</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC569F9C-8D7B-414A-9059-EDFAE9A86040">
    <domeo:uuid>EC569F9C-8D7B-414A-9059-EDFAE9A86040</domeo:uuid>
    <ao:exact>Nifedipine</ao:exact>
    <ao:suffix> is a peripheral arterial vasodilator which acts directly on vascular smooth muscle. The binding of nifedipine to voltage-dependent and possibly receptor-operated channels in vascular smooth muscle results in an inhibition of calcium influx through these</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-117.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EC569F9C-8D7B-414A-9059-EDFAE9A86040"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-09-02 19:46:24 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50649F2A-1F77-4AC3-AA05-9C465AAF3D79">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:exact>sildenafil </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-07 09:59:10 -0400</pav:createdOn>
    <ao:suffix> pharmacokinetics in patients with PAH.</ao:suffix>
    <ao:prefix> in patients with PAH. The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function. None of these factors had a significant impact on </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:50649F2A-1F77-4AC3-AA05-9C465AAF3D79"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E24CDAFA-738D-436F-8EA5-33584022000D">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 11:54:18 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:F5584C7B-8E90-4E9E-952C-B4931C5A6238</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 11:54:50 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:body rdf:nodeID="N0d48e2646a8a4bce8372d7a86920d7ca"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F263AADA-7E42-4AA1-B33C-9D0E2B21A723"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6DEBCD8F-80B7-4229-A275-28C4CFF1B5A0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6DEBCD8F-80B7-4229-A275-28C4CFF1B5A0"/>
    <pav:createdOn>2014-07-22 20:18:04 -0400</pav:createdOn>
    <ao:prefix>had no clinically relevant effect on the steady-state pharmacokinetics of </ao:prefix>
    <ao:exact>warfarin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:suffix> enantiomers.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>6DEBCD8F-80B7-4229-A275-28C4CFF1B5A0</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:167FB68A-5943-4F0E-8CC6-C6BAB7625E4F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 12:38:47 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:A6AB8619-AAFD-4D65-8839-376407154A96</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F5A4FF79-C22B-475D-8775-B7CA929DA67C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B1C7E3B-0E62-4AAE-9A68-874D098352C2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Pretreatment with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>ranitidine</ao:exact>
    <ao:suffix> (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers. These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanie</ao:suffix>
    <pav:createdOn>2014-07-22 20:18:32 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B1C7E3B-0E62-4AAE-9A68-874D098352C2"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>2B1C7E3B-0E62-4AAE-9A68-874D098352C2</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A67B256-CA48-48CA-B584-DB13E0D52B58">
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2014-07-22 19:37:28 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:C3E38D47-25A8-4196-B6ED-8D47D85B5D94"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:340175F1-825F-4D60-A67E-F61F27C225F8">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-24 19:43:34 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:ADF65F0E-08FD-4ECE-88A1-9CD46724D710</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEB6848-E3C6-4761-8965-41F19EE5D781</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:015BF3DA-12CC-44A1-9B13-94A006D56307"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-24 19:42:48 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07539CCF-9ED2-4C02-AC53-CD1CF6713CB3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-07-24 20:04:50 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:964473A2-5981-4815-94A0-CEAF4A357060"/>
    <pav:lineageUri>urn:domeoserver:annotationset:73DB6DC7-9F44-4798-8BE5-917866542E6C</pav:lineageUri>
    <pav:createdOn>2014-07-24 20:05:02 -0400</pav:createdOn>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:35CD1CDB-7257-43BB-BB56-7A444AAF4BA3"/>
    <permissions:permissions rdf:nodeID="N2bdd44e75a0e4177a23d455c3f4dbde7"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-138.txt.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D6A80456-C24A-4B51-9FF1-54B2442E9245">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-28 17:08:37 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:5FB651AA-4C9C-42E4-94BA-0C38AC19F913</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-28 17:04:20 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:E61B11CA-1C13-4025-B813-17930363237F"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:48D839E5-6B0A-4EC3-B64A-E3E20E06246A</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2A93D3C-935C-417F-BE1B-282EDBEB8D85">
    <ao:context rdf:resource="urn:domeoclient:uuid:56FE6B9A-96B3-43BC-A4E1-A9AFE78680CE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:12676179-27AE-44BF-86DE-5AE7A37D1457</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 11:14:04 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2CF891F7-2E96-4382-8EDB-5C061E8E1AFA">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-07 09:42:06 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8F1DD8EF-72E2-425B-B98B-233F1591A13F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69354CBD-D372-4AD9-A6F1-93E07CA4D048">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:FF8F1249-3CE1-41AF-B118-1647BE5597AF"/>
    <pav:createdOn>2014-09-02 11:45:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E69A980E-DFDE-46F6-BAC1-FFD29BDCB6F5">
    <pav:lineageUri>urn:domeoserver:annotation:10225704-623F-4ACB-82E2-8720FFAEF850</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:190E7AE8-2ACF-42E2-AE00-E433EEA9737C</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 19:38:22 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:34C208E6-0FE1-4394-8496-13F4C10CB492"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:38:39 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B664870-D5A4-43DD-8990-228B68AA60AA">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 11:43:36 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:257F4F5D-CCED-4AAD-9504-4A9F1A855C69"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00672751-8DEF-4963-8AA5-6205618296C1">
    <ao:context rdf:resource="urn:domeoclient:uuid:ED5A7142-16C6-4FE6-8733-C955CEF7A376"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:43:54 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D94A3BF4-A374-449F-9330-5C3F983FC929">
    <ao:item rdf:resource="urn:domeoclient:uuid:704A238F-4D41-41C0-AEE2-EF49045B60D6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-01 16:02:32 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-18.txt.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N7f04182c6d404dcba0f1e9f8c1f6c785"/>
    <pav:lineageUri>urn:domeoserver:annotationset:5EC8F086-573B-4106-ABC5-394EC3185A72</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-09-01 16:02:33 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:15AF1994-00EF-4BF7-9C44-C16149A1F769">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A87B61D2-D72C-42FD-B166-A4440E8574B1"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56AEEC1F-6F5E-4CAD-A96A-7EC09CB365C8">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-01 15:59:54 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:6341241A-9991-4CE8-B771-4A2513B1FF21"/>
    <pav:lineageUri>urn:domeoserver:annotation:0946B8FF-FE7F-4B36-A972-249F2756BCEC</pav:lineageUri>
    <pav:lastSavedOn>2014-09-01 16:00:14 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:659ED9DF-77DA-41F2-B123-6E455B4F2385</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9E86ADEB-E76E-4255-8364-3D0CF7C52E24">
    <domeo:uuid>9E86ADEB-E76E-4255-8364-3D0CF7C52E24</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> is predominantly metabolized by CYP2C8, and to a lesser extent, 2C9. AVANDIA (4 mg twice daily) was shown to have no clinically relevant effect on the pharmacokinetics of nifedipine and oral contraceptives (ethinyl estradiol and norethindrone), which ar</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9E86ADEB-E76E-4255-8364-3D0CF7C52E24"/>
    <ao:prefix>rate that </ao:prefix>
    <pav:createdOn>2014-07-22 19:39:44 -0400</pav:createdOn>
    <ao:exact>rosiglitazone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA208444-D170-43D4-B1EB-ED24016D3210">
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:9019660D-1815-46EC-A26A-41E87A114AA7"/>
    <pav:createdOn>2014-09-02 19:08:19 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:84CCDE46-BE0B-4763-B442-1C17B49D1114</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76ADDE4C-05F0-4C9D-B547-37B2AA813054">
    <ao:context rdf:resource="urn:domeoclient:uuid:0129AA9B-FCF1-4926-ABF4-20D80C13A55D"/>
    <pav:lineageUri>urn:domeoserver:annotation:93675D22-5FCD-4C8A-8A2D-BB6E7CF53E25</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:10:32 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABD16F80-DE85-4E62-8A97-6477F60FC07D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ABD16F80-DE85-4E62-8A97-6477F60FC07D"/>
    <ao:exact>fluvoxamine</ao:exact>
    <pav:createdOn>2014-09-02 11:30:22 -0400</pav:createdOn>
    <ao:suffix> inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., om</ao:suffix>
    <domeo:uuid>ABD16F80-DE85-4E62-8A97-6477F60FC07D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix> with certain of these drugs (see later parts of this section and also WARNINGS AND PRECAUTIONS [5]) and limited in vitro data for CYP3A4, it appears that </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87DA7BB9-8F52-460F-B488-90DD6AC36EFF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-21 21:42:16 -0400</pav:createdOn>
    <ao:prefix>alone at steady state. If anticholinergic effects are seen, the dose of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87DA7BB9-8F52-460F-B488-90DD6AC36EFF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>should be reduced.</ao:suffix>
    <domeo:uuid>87DA7BB9-8F52-460F-B488-90DD6AC36EFF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-50.txt.html</ao:hasSource>
    <ao:exact>procyclidine </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E08DAB4-201F-48CD-8ACA-375750DA65B1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>concentrations when co-administered with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>(50 mg) to healthy volunteers.</ao:suffix>
    <ao:exact>sildenafil </ao:exact>
    <pav:createdOn>2014-07-07 11:22:56 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E08DAB4-201F-48CD-8ACA-375750DA65B1"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/C3802543-BD64-4421-A632-BFDE8408A954">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7417</dailymed:activeMoietyRxCUI>
    <rdfs:label>nifedipine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E36FB611-A4C3-4DBB-9B86-FD93883853AE">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E36FB611-A4C3-4DBB-9B86-FD93883853AE"/>
    <domeo:uuid>E36FB611-A4C3-4DBB-9B86-FD93883853AE</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Phenytoin AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volunteers. There was a significant increase in phenytoin AUC. The mean ± SD increase in phenytoin AUC was 88% ± 68% (range: 16 to 247%). The absolute magnitude of this interaction is unknown because of the intrinsically nonlinear disposition of phenytoin. (See PRECAUTIONS.)</ao:exact>
    <pav:createdOn>2014-07-21 21:28:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBA2FBEC-FB21-4B1E-AFD1-05AF52CBAB09">
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:56885854-DBBA-451C-B531-1D54B8C98A0B"/>
    <pav:createdOn>2014-07-24 19:38:05 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:0ABA0AC7-182A-406C-840C-4443E197D138"/>
    <domeo:deleted>false</domeo:deleted>
    <pav:lineageUri>urn:domeoserver:annotationset:5B223E53-D0BF-4E3A-9D17-4CDE219FA974</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-125.txt.html</ao:annotatesResource>
    <permissions:permissions rdf:nodeID="N0865f61584144d27a0073f432cc57231"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-24 19:38:40 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DC73A4DB-52A1-428E-A3E7-50DAC49D6A5A"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79016A6C-CD48-4680-8D24-28567975EAC5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> exposure and withdrawal symptoms occurred concurrently. Upon discontinuation of </ao:prefix>
    <ao:suffix>, the incidence of withdrawal symptoms decreased and methadone exposure increased to a level comparable to that prior to phenytoin administration.</ao:suffix>
    <ao:exact>phenytoin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-201.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:79016A6C-CD48-4680-8D24-28567975EAC5"/>
    <pav:createdOn>2014-07-28 17:04:42 -0400</pav:createdOn>
    <domeo:uuid>79016A6C-CD48-4680-8D24-28567975EAC5</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:709146DB-F43F-4A5F-B3FB-C395469E387B">
    <pav:createdOn>2014-07-22 19:12:50 -0400</pav:createdOn>
    <domeo:uuid>709146DB-F43F-4A5F-B3FB-C395469E387B</domeo:uuid>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:709146DB-F43F-4A5F-B3FB-C395469E387B"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>AVANDIA</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A97D0542-D1E0-45E8-A59A-491B0F6B5ABF">
    <ao:exact>lorazepam</ao:exact>
    <pav:createdOn>2014-09-02 11:38:56 -0400</pav:createdOn>
    <ao:suffix> alone.</ao:suffix>
    <domeo:uuid>A97D0542-D1E0-45E8-A59A-491B0F6B5ABF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A97D0542-D1E0-45E8-A59A-491B0F6B5ABF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> did not produce larger mean decrements compared to </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F5A32BEB-91E7-4E38-9495-09168C9EA7B8">
    <pav:lastSavedOn>2014-07-22 18:36:37 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:040380DC-30D6-454D-ACD7-489B2130A9CC</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-22 18:36:48 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Na556a10ed80a4e0bb3b6d69492073e1f"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:72EBC805-5C38-43F6-B5A7-655F7D1D8C4C</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:CDDC5F6F-E40F-4F4A-BB7A-C77A3A968B0B"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:292BF8EC-0E65-4E33-A331-3D217DD6B134">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 19:37:19 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B2987A9F-B765-4C33-B2FF-1E55869E162F"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1AECF5B-0B80-4F34-AE54-273DA1B3D41A">
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E51D112-F22F-4792-B99B-6D615797BAEB"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:4ADEE51B-1E69-45C2-A11C-A971981D4762</pav:lineageUri>
    <pav:createdOn>2014-09-02 19:09:15 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04984965-B2D0-4ECE-8862-143E95A2279E">
    <domeo:uuid>04984965-B2D0-4ECE-8862-143E95A2279E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (ci</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:04984965-B2D0-4ECE-8862-143E95A2279E"/>
    <ao:prefix>, or </ao:prefix>
    <pav:createdOn>2014-09-01 16:06:03 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <ao:exact>cisapride</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6EAB4BAE-C8C3-48B7-AC36-EFE4C7088448">
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 11:38:17 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C72F4C30-BFCD-4714-88DE-DBF33CE067AD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BD9047F-C1DA-4B64-92B7-4D031972C9CF">
    <ao:context rdf:resource="urn:domeoclient:uuid:AEC296E5-554D-42F1-BF6A-CA09B038958F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-07 09:39:24 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D704B671-5676-476E-BB75-84893439C054">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D704B671-5676-476E-BB75-84893439C054"/>
    <pav:createdOn>2014-09-02 19:42:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>nifedipine</ao:exact>
    <ao:prefix>lts in an inhibition of calcium influx through these channels. Stores of intracellular calcium in vascular smooth muscle are limited and thus dependent upon the influx of extracellular calcium for contraction to occur. The reduction in calcium influx by </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D704B671-5676-476E-BB75-84893439C054</domeo:uuid>
    <ao:suffix> causes arterial vasodilation and decreased peripheral vascular resistance which results in reduced arterial blood pressure.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-117.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:01D05C1E-36FA-4699-B134-4F8E31F1B1CA">
    <domeo:belongsToSet>urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:11C5CA3C-71F0-4F5E-9925-04242D1BFA4A</pav:lineageUri>
    <pav:createdOn>2014-09-01 16:05:52 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:93C83EDE-36D5-4436-B242-D2D391BA499C"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-01 16:06:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:43E08535-8340-472C-92D9-100ECFA2CB93">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/CE1B6F16-57BD-40EB-AB83-B1A40576F8C0"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/AFDFD2C0-7545-4E19-ABAA-7E48CFD82223"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF3A4E4B-56B2-47CF-B174-C006C3954623">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-01 16:19:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:082BC34B-E2CB-4EAD-908C-433213A92A0D"/>
    <pav:lineageUri>urn:domeoserver:annotation:B604BC28-04F3-406B-BA4D-891CD1698D81</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-01 16:20:01 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:94DCE217-B72B-4727-9783-98D7EFCB02E6</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:093D643B-E7AF-49BD-BBEA-F13CDCDAD6C4">
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-09-02 11:53:56 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:41A41E41-EEC5-49D6-81A5-A1C7FAE7676D</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:ACE53139-5B8B-4FB2-8940-338C5989D498"/>
    <ao:body rdf:nodeID="N671af0b91e8043ec90327a6b48661eae"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 11:54:50 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:838A3F9E-0F12-46F7-B6B3-FFABDE022693">
    <pav:lineageUri>urn:domeoserver:annotation:3BA6C4A7-55CD-4101-A138-60C934E15A12</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-24 20:00:43 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-24 20:00:35 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:D6C4080C-5AC3-402F-9359-F2135366B16E"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0050ED6-BE4F-4871-9847-FC4493F22447</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:11E26B74-9DE2-4B10-A8C9-A250D2747B3E">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:74A8BD59-3770-4E00-8C04-C4D9A82E8F47</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:EBCFB082-4C3F-4C27-B1B4-7DE7E01178ED"/>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 12:55:59 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D0EF2EA1-1BE2-4B9B-8114-37709CA5774E">
    <rdfs:label>sotalol</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F941BEEC-394B-4F88-B13F-E8C0361B2C8D">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:exact>fexofenadine hydrochloride</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F941BEEC-394B-4F88-B13F-E8C0361B2C8D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-24 20:08:12 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>F941BEEC-394B-4F88-B13F-E8C0361B2C8D</domeo:uuid>
    <ao:suffix> alone or in combination with either erythromycin or ketoconazole. The findings of these studies are summarized in the following table</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7059CDB-FD5F-4D07-9802-7905CA2F92BA">
    <pav:lastSavedOn>2014-07-22 18:54:35 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:FB7CDA28-9814-4B6E-95D0-E4733B2DD0B9"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:3D195979-3E82-427D-95B8-F50F48DB4AA7</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:B12DFBA5-C6D2-4173-89F1-D7B5DBF95B30</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 18:51:35 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A374628-9340-4980-A329-4E957642EBA7">
    <domeo:uuid>7A374628-9340-4980-A329-4E957642EBA7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A374628-9340-4980-A329-4E957642EBA7"/>
    <ao:exact>tacrolimus</ao:exact>
    <ao:prefix> may increase the serum levels of </ao:prefix>
    <ao:suffix>. </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:19:46 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:176AA3EF-BFBB-48D5-8C72-B5138286D455">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:176AA3EF-BFBB-48D5-8C72-B5138286D455"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>176AA3EF-BFBB-48D5-8C72-B5138286D455</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-07-22 20:21:31 -0400</pav:createdOn>
    <ao:exact>Repeat dosing with AVANDIA had no clinically relevant effect on the steady-state pharmacokinetics of warfarin enantiomers.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39C2E9DA-729E-466D-9F16-3F254B23A03C">
    <domeo:uuid>39C2E9DA-729E-466D-9F16-3F254B23A03C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Propranolol and Other Beta-Blockers: Coadministration of </ao:prefix>
    <ao:suffix> maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. In this study, there was a slight potentiation of the propranolol-induced redu</ao:suffix>
    <ao:exact>fluvoxamine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 11:44:56 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:39C2E9DA-729E-466D-9F16-3F254B23A03C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F702DA3-314E-4514-A96E-ADDF64264F59">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:36:37 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A3A7600E-EE05-47D1-8823-CA504866B3BD"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F8EAE386-C8C4-4874-BD9D-09F2FAF602D8">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:4F81F868-415D-4A79-8A62-6366850D49AA"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 20:20:26 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:BAE27596-EB60-4361-9A9F-1417E09C1460</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA587655-D235-49D2-9724-0AEBB3E5E13B">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 11:39:02 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AC27080F-C738-4176-9E15-7672938F5DF3"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18F9EC5C-6A37-4A41-85DF-87BCEB900110">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-24 19:55:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:F87D2273-7E05-4F58-B46E-DA5B9D8816DE</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:EDFB18D2-D8A0-44B9-8E84-FD352C6F84E0</pav:lineageUri>
    <pav:lastSavedOn>2014-07-24 19:54:45 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4E6639F4-F4C8-45C0-82E0-34A805D7B468"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/3FCE39BA-811B-456A-83F4-652EA5B4F4FC">
    <rdfs:label>trazodone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10737</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58BF67B8-BDBC-4A81-816F-832DAD1FC0F8">
    <pav:createdOn>2014-07-21 21:52:26 -0400</pav:createdOn>
    <domeo:uuid>58BF67B8-BDBC-4A81-816F-832DAD1FC0F8</domeo:uuid>
    <ao:exact>phenytoin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>had no appreciable effect on the steady-state plasma concentrations of </ao:prefix>
    <ao:suffix>, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabo</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:58BF67B8-BDBC-4A81-816F-832DAD1FC0F8"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-56.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35B88B08-A82B-4D65-B565-57DA9528E578">
    <ao:context rdf:resource="urn:domeoclient:uuid:285AE4B3-9649-4D7B-A540-9B1BE0CD0CDA"/>
    <pav:lastSavedOn>2014-07-24 19:37:34 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="N05000c6dc1d84f2ea8d5f53710f6a69c"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:F409994B-1EBD-49AA-BBB6-E27FBBC16767</pav:lineageUri>
    <pav:createdOn>2014-07-24 19:37:50 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:079AA7B9-9BE4-4706-A20A-5848B50272B5</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2CEC4DC-B35C-4F1A-8ACA-017FE944131C">
    <pav:createdOn>2014-09-02 11:44:48 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1AD84D60-1A25-43EF-A981-A873C4F1D40E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D19C185B-AB58-4956-9871-777E207AC825">
    <ao:exact>Tryptophan</ao:exact>
    <ao:suffix> </ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-09-02 11:44:09 -0400</pav:createdOn>
    <domeo:uuid>D19C185B-AB58-4956-9871-777E207AC825</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D19C185B-AB58-4956-9871-777E207AC825"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FF394C23-B19D-4287-8ACE-54167C17E2D1">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AB5CE3C5-4CFD-489B-9021-04685E6B310D"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC9F95A3-1FEE-4EEA-8C1A-39DFE96EBAB8">
    <pav:createdOn>2014-09-02 11:42:53 -0400</pav:createdOn>
    <ao:prefix>Tricyclic Antidepressants (TCAs): Significantly increased plasma TCA levels have been reported with the coadministration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FC9F95A3-1FEE-4EEA-8C1A-39DFE96EBAB8"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:suffix> maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.</ao:suffix>
    <ao:exact>fluvoxamine</ao:exact>
    <domeo:uuid>FC9F95A3-1FEE-4EEA-8C1A-39DFE96EBAB8</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55A5D871-82BA-4D87-A1EA-62DCA1BF358F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> rosiglitazone</ao:exact>
    <ao:suffix> is predominantly metabolized by Cytochrome P450 (CYP) isoenzyme 2C8, with CYP2C9 contributing as a minor pathway.</ao:suffix>
    <pav:createdOn>2014-07-22 19:28:13 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55A5D871-82BA-4D87-A1EA-62DCA1BF358F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>In vitro data demonstrate that</ao:prefix>
    <domeo:uuid>55A5D871-82BA-4D87-A1EA-62DCA1BF358F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55C36B4E-CDCE-4B16-94D5-178014A48A7F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix>, its major metabolite, 9-hydroxyrisperidone, and risperidone plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma conce</ao:suffix>
    <ao:prefix>Plasma concentrations of </ao:prefix>
    <domeo:uuid>55C36B4E-CDCE-4B16-94D5-178014A48A7F</domeo:uuid>
    <pav:createdOn>2014-07-13 11:09:28 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55C36B4E-CDCE-4B16-94D5-178014A48A7F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/5F10CADF-C9DD-4270-A5C5-81DBB003F49D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/84108</dailymed:activeMoietyRxCUI>
    <rdfs:label>rosiglitazone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F4C5D67-B302-4D5E-86D3-E308EE0C607E">
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:B06BD29E-2481-4EA0-885B-420749EBE703"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 12:46:20 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:044837BF-E4FA-4C9D-8EA0-E23B27E2EC72</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3469EEA4-696B-455B-896A-1006CE93364D">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-01 16:00:14 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-01 15:59:56 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6F243BA5-FCEC-4956-AF25-0E751A006E5C"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:659ED9DF-77DA-41F2-B123-6E455B4F2385</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:2307DB07-8B9A-4D0C-B0D0-0E14E0095777</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5139C7C3-ACE5-4F03-BC84-8DD2AF187DDB">
    <ao:suffix>(800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma sildenafil concentrations when co-administered with sildenafil (50 mg) to healthy volunteers.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5139C7C3-ACE5-4F03-BC84-8DD2AF187DDB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-07 11:22:50 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Cimetidine </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/3C01338E-7E0D-4BD8-B48B-5D14379A445C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>propranolol</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7950DCED-7411-4B59-B629-CB1341A53897">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Effects of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7950DCED-7411-4B59-B629-CB1341A53897"/>
    <ao:exact>REVATIO </ao:exact>
    <pav:createdOn>2014-07-07 09:51:17 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>on Blood Pressure</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0AC894E-27E2-43D9-BFEB-167E8117247A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B0AC894E-27E2-43D9-BFEB-167E8117247A"/>
    <ao:prefix> hydrochloride is supplied for oral administration as scored tablets containing </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>sertraline</ao:exact>
    <ao:suffix> hydrochloride equivalent to 25, 50, 100, 150 and 200 mg of sertraline and the following inactive ingredients: dibasic calcium phosphate dihydrate, hydroxypropyl cellulose, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol</ao:suffix>
    <pav:createdOn>2014-07-13 12:34:38 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-20.txt.html</ao:hasSource>
    <domeo:uuid>B0AC894E-27E2-43D9-BFEB-167E8117247A</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76D2A20E-E18E-4676-958D-12D182D20430">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:575F0CD0-2CEC-4594-9019-B1A6C8BA5D55"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:B2317F54-7476-4D82-9C44-76D503E6DA71</pav:lineageUri>
    <pav:createdOn>2014-07-13 12:37:40 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CBB863B4-0141-4362-8357-0FD5A3909A10">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-07 11:23:07 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:23A67AAE-576A-4FB5-8468-E2C34B2748CB</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:098AA784-6695-4935-9450-C87D502EDBCD"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F45CCE04-9C17-4AB6-BF4A-23A94A70AB21">
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdOn>2014-09-02 19:13:24 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:713FC0EF-F420-4182-BCC3-9D97A1296B91"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBA99B4F-F7DB-4460-981A-81817F4BFE98">
    <pav:createdOn>2014-09-02 11:38:20 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:62667796-1E15-449B-8175-6954CB53F6DF"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F652E827-5625-4F3B-BD53-6EF8860F2CDE">
    <ao:exact>AVANDIA</ao:exact>
    <domeo:uuid>F652E827-5625-4F3B-BD53-6EF8860F2CDE</domeo:uuid>
    <pav:createdOn>2014-07-22 19:35:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F652E827-5625-4F3B-BD53-6EF8860F2CDE"/>
    <ao:suffix> should not be initiated if the patient exhibits clinical evidence of active liver disease or increased serum transaminase levels (ALT &gt;2.5X upper limit of normal) at baseline [see Warnings and Precautions (5.6)].</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix>Therapy with </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BD5228B-2C30-4C04-8347-5E28492ED531">
    <ao:suffix>prazole and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure. Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0BD5228B-2C30-4C04-8347-5E28492ED531"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>0BD5228B-2C30-4C04-8347-5E28492ED531</domeo:uuid>
    <ao:exact>e</ao:exact>
    <pav:createdOn>2014-09-02 19:13:48 -0400</pav:createdOn>
    <ao:prefix>Concomitant administration of om</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93AEC1F9-3191-4D73-8BB9-21EE50636AB5">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-21 21:43:22 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-21 21:44:00 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:42248733-4719-42F4-8132-866191F8E708</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:056787DE-BFEB-4038-A418-CB53FF7030DC"/>
    <pav:lineageUri>urn:domeoserver:annotation:F0A0304E-D86D-4C10-B359-4A808EF0B94F</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C988966D-DF06-4093-9B27-77BEB9FDE53C">
    <pav:createdOn>2014-09-02 19:32:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Concomitant administration with omeprazole and drugs such as</ao:suffix>
    <ao:exact>Following multiple doses of atazanavir (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%.</ao:exact>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>C988966D-DF06-4093-9B27-77BEB9FDE53C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C988966D-DF06-4093-9B27-77BEB9FDE53C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/43BF860F-DF76-4336-A687-956DE41661F4">
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44D9A897-A866-42BB-8DD9-A376BF8D1B3E">
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:31:30 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:7E80543E-BF76-4514-92A9-91458DCB802B</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 19:35:16 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:74381157-1392-49DE-BD6B-8C71824715BF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C94B4C4D-E742-4102-A342-E2728F29088D">
    <ao:exact> Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other. As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C94B4C4D-E742-4102-A342-E2728F29088D"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix>Alcohol:</ao:prefix>
    <pav:createdOn>2014-09-02 11:53:27 -0400</pav:createdOn>
    <domeo:uuid>C94B4C4D-E742-4102-A342-E2728F29088D</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B49DFB13-7D38-41A6-989C-F0F22BFBCA7D">
    <ao:prefix> have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B49DFB13-7D38-41A6-989C-F0F22BFBCA7D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:15:18 -0400</pav:createdOn>
    <ao:suffix> do not suggest important differences between poor and extensive metabolizers. Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma c</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>B49DFB13-7D38-41A6-989C-F0F22BFBCA7D</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F34547B1-36EF-43A2-81A9-922401A6E906">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:prefix>. In two separate studies in healthy adult subjects, </ao:prefix>
    <pav:createdOn>2014-07-24 20:07:44 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions to healthy adult subjects (n = 24, each study). No differences in adverse event</ao:suffix>
    <ao:exact>fexofenadine hydrochloride</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F34547B1-36EF-43A2-81A9-922401A6E906"/>
    <domeo:uuid>F34547B1-36EF-43A2-81A9-922401A6E906</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CAEF4002-AC71-41B3-AB37-783C0F6D54AB">
    <domeo:uuid>CAEF4002-AC71-41B3-AB37-783C0F6D54AB</domeo:uuid>
    <ao:exact>Concomitant administration of Synercid and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine and midazolam, respectively.</ao:exact>
    <pav:createdOn>2014-07-22 18:46:46 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-118.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CAEF4002-AC71-41B3-AB37-783C0F6D54AB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:918A8BC4-10A8-4ADA-9C87-87BCD441E2ED">
    <ao:prefix>200 mg (q.d.) induces the metabolism of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:918A8BC4-10A8-4ADA-9C87-87BCD441E2ED"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-01 15:57:38 -0400</pav:createdOn>
    <ao:suffix>(cisapride AUC and Cmax were reduced by about 35%).</ao:suffix>
    <ao:exact>cisapride </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <domeo:uuid>918A8BC4-10A8-4ADA-9C87-87BCD441E2ED</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BA34B2D-02C3-4A53-9C4E-833C005A5CBE">
    <pav:createdOn>2014-09-01 16:06:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces th</ao:suffix>
    <ao:prefix>did not increase plasma concentrations of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <ao:exact>terfenadine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9BA34B2D-02C3-4A53-9C4E-833C005A5CBE"/>
    <domeo:uuid>9BA34B2D-02C3-4A53-9C4E-833C005A5CBE</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D41F6EB4-7428-411F-9159-905789D6B7B0">
    <domeo:belongsToSet>urn:domeoclient:uuid:C988D053-7CF3-4C50-BDB6-7C2B20B837B9</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-21 21:55:00 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A9F403B-F60E-4954-9EEE-BB0C7DAD583B"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:53:39 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:36367788-6B4F-48D5-ACBF-69147D22E350</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:788F9802-1A2C-4B8B-958F-27977AB9BE1B">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9C71E884-F7BA-41EE-A3DD-8DAE2AB3D4C0"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23AC6809-BABB-405A-80DE-630CA211B109">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 19:26:11 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:A4B2C542-4FBC-4849-8602-BB3245792CC3"/>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8916B040-D309-4348-A145-26FC08137345">
    <ao:exact>paroxetine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8916B040-D309-4348-A145-26FC08137345"/>
    <domeo:uuid>8916B040-D309-4348-A145-26FC08137345</domeo:uuid>
    <ao:prefix>may significantly inhibit the activity of this isozyme. In most patients (&gt;90%), this CYP2D6 isozyme is saturated early during paroxetine dosing. In 1 study, daily dosing of immediate-release </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>  (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also b</ao:suffix>
    <pav:createdOn>2014-09-02 12:02:48 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0ECD29D-DAB1-4D63-85F1-1839E3B04BF6">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E0ECD29D-DAB1-4D63-85F1-1839E3B04BF6"/>
    <domeo:uuid>E0ECD29D-DAB1-4D63-85F1-1839E3B04BF6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:11:19 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10 mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydro</ao:suffix>
    <ao:prefix> nor </ao:prefix>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0CCA954-EB0E-4D16-9B00-C1E4BE4A989D">
    <ao:suffix>AUC.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F0CCA954-EB0E-4D16-9B00-C1E4BE4A989D"/>
    <pav:createdOn>2014-07-07 11:24:14 -0400</pav:createdOn>
    <ao:prefix>Cmax and a 210% increase in </ao:prefix>
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BB40EDC-DE0E-4B5E-AEE3-DCE89148115F">
    <pav:createdOn>2014-07-22 19:37:25 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:06403BE6-A661-445F-882B-070BE1039BE5"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CAC294B3-5790-4488-B65C-CB3269F765C6">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:366925ED-C6A8-41CA-97EB-602399B8DB72"/>
    <pav:createdOn>2014-07-13 11:16:30 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:E7F026CF-6162-4445-A7F9-6B029DDC6F96</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5039F6DC-F654-4E38-8762-0E1BD92F058C">
    <domeo:uuid>5039F6DC-F654-4E38-8762-0E1BD92F058C</domeo:uuid>
    <ao:exact>After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14% (range: -5 to -40%).</ao:exact>
    <ao:prefix> 400 mg to six healthy male volunteers. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5039F6DC-F654-4E38-8762-0E1BD92F058C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:47:19 -0400</pav:createdOn>
    <ao:suffix> However, the administration of</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93DAC455-F057-464E-B0F5-494B00341776">
    <ao:context rdf:resource="urn:domeoclient:uuid:0F9E744D-C586-43FA-AB0E-FF3294D6D12E"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-21 21:33:59 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-21 21:35:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:6034386E-A439-4FD9-A50D-3EFD1BBB961F</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:B61F1A9B-4696-4ED0-80AA-4FE2E9016966</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21A6A401-CC93-4E3D-8008-3C8347574A85">
    <ao:exact> allopurinol sodium</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-43.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:21A6A401-CC93-4E3D-8008-3C8347574A85"/>
    <ao:suffix> for injection in the U.S. Of these patients, 411 had established hyperuricemia and 307 had normal serum urate levels at the time that treatment was initiated. Normal serum uric acid levels were achieved in 68% (reduction of serum uric acid was documente</ao:suffix>
    <domeo:uuid>21A6A401-CC93-4E3D-8008-3C8347574A85</domeo:uuid>
    <pav:createdOn>2014-09-01 16:19:43 -0400</pav:createdOn>
    <ao:prefix>A compassionate plea trial was conducted from 1977 through 1989 in which 718 evaluable patients with malignancies requiring treatment with cytotoxic chemotherapy, but who were unable to ingest or retain oral medication, received i.v.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBBBE91C-3E2F-469A-9254-58328E372FEA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Single oral doses of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 09:37:41 -0400</pav:createdOn>
    <ao:exact>sildenafil </ao:exact>
    <ao:suffix>100 mg administered to healthy volunteers produced decreases in supine blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8/5 mmHg). The decrease in blood pressure was most notable approximately 1–2 hours after dosing, and was </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DBBBE91C-3E2F-469A-9254-58328E372FEA"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8BA43995-3A5A-44A6-AEC6-73AB1675E1DE">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:C91B79D0-C0A0-4540-8068-2730CADBF44E</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:4B7476C3-D9FB-4C21-AF95-2B4CD2143061"/>
    <pav:createdOn>2014-09-02 19:10:44 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDE42D33-6312-4DF8-AF70-310C20268892">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CDE42D33-6312-4DF8-AF70-310C20268892"/>
    <domeo:uuid>CDE42D33-6312-4DF8-AF70-310C20268892</domeo:uuid>
    <pav:createdOn>2014-09-02 19:12:46 -0400</pav:createdOn>
    <ao:suffix> concomitantly. Increases in INR and prothrombin time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and prothrombin time.</ao:suffix>
    <ao:prefix>, and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>warfarin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0CD4EB6E-420B-4F8E-802C-4BC8BDD384E4">
    <pav:lastSavedOn>2014-07-24 19:43:34 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-24 19:42:58 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEB6848-E3C6-4761-8965-41F19EE5D781</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:20733A72-ADFB-4446-B449-BD9E22203676</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6E7448AD-8A84-4C38-A84C-AA12E07DD681"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8D8724AE-D8FE-4EA2-BC2B-883652CC6520">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/3FCE39BA-811B-456A-83F4-652EA5B4F4FC"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/E8F2CA32-13F5-477A-BE7F-DE4F66964CFD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1DCA5297-1C05-4654-AADE-90A7C81DD992">
    <pav:createdOn>2014-09-02 12:01:08 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D390D1C1-F946-4B8E-A2EB-3CBC7637D30E"/>
    <pav:lineageUri>urn:domeoserver:annotation:A7BFA862-67B8-4B4D-A2A5-B578E891D1E6</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="N75616d180bd341b0985aad6a6cd844b8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02D92735-6D44-4DFA-A2E9-75A5A3D4DCF9">
    <pav:createdOn>2014-07-07 09:42:51 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:DC34C3D8-C58F-483B-80DB-B65FEBB2EC20"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9C2359BE-4DCE-4088-A5EE-19EA356FF32D">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:36209E50-DEE4-4172-A9EA-98FA4D4477D3"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6D31780D-83B2-4F04-8282-BA0D62D2F386">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/46FB1ED5-40B7-4788-9A91-7689FC73A793"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/56DDE847-8CB1-4471-8B16-A24584A6647C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E2360A5-44FC-4633-8B3E-758DB777C4E6">
    <ao:context rdf:resource="urn:domeoclient:uuid:98937C65-C245-4875-B071-CCFF5209C083"/>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 19:12:16 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:137CD66C-79A5-4DE2-BF83-E1E083B1F26F">
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:65F0E5B5-1315-4738-B18A-166E4145A2DF</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:6E924DBB-A7DD-4939-9801-279C7188D87E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 20:17:56 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9517CDA-E201-4D75-90EA-09D040EC5F9E">
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:08:35 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:A4CF10B8-6217-4E35-AA5B-2F2FD2C31E87</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:28F0EB50-7D95-4C50-8040-47E337110AC7"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C9FE015-E10A-4124-9250-BA73B7E52470">
    <pav:previousVersion>urn:domeoserver:annotationset:7E80543E-BF76-4514-92A9-91458DCB802B</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:6E817E52-FC9C-4090-86D7-ADDBC13CA122"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 19:28:50 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 19:35:16 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FD421B20-B74E-481A-8077-F6D9C42943B8">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:861C11A2-8AEA-4CD2-AC61-355B6002E25D"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50CB810E-E5CE-4D21-8703-B10F04053C7D">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:19AF6A28-5E1F-4E38-963D-A9F4633CDDE9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:19:04 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/5AC4FDB3-99BB-4CC2-9A03-87893DB04756">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/61AE2D64-FCA3-4A33-91AF-196E90750A35">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Propranolol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9FB8A434-B2A7-4CA1-A629-583CC07853C3">
    <ao:suffix>and nelfinavir, decreased serum levels have been reported when given together with omeprazole. Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75%</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:prefix> treatment may change the absorption of the antiretroviral drug. Other possible interaction mechanisms are via CYP2C19. For some antiretroviral drugs, such as </ao:prefix>
    <domeo:uuid>9FB8A434-B2A7-4CA1-A629-583CC07853C3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9FB8A434-B2A7-4CA1-A629-583CC07853C3"/>
    <pav:createdOn>2014-09-02 19:17:54 -0400</pav:createdOn>
    <ao:exact>atazanavir </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36B5198A-3542-4C86-BF30-6375D3BC2CDB">
    <domeo:uuid>36B5198A-3542-4C86-BF30-6375D3BC2CDB</domeo:uuid>
    <ao:prefix>, </ao:prefix>
    <pav:createdOn>2014-09-01 15:57:27 -0400</pav:createdOn>
    <ao:exact>carbamazepine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:36B5198A-3542-4C86-BF30-6375D3BC2CDB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A355239-7CF3-43F5-B979-1B59EE6C6121">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 11:45:38 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:465EEACA-9FFE-4F82-9410-36A29C720187"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D83441D-0916-4D83-A136-CA26588E67D0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and </ao:prefix>
    <domeo:uuid>0D83441D-0916-4D83-A136-CA26588E67D0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0D83441D-0916-4D83-A136-CA26588E67D0"/>
    <pav:createdOn>2014-07-13 11:13:49 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:suffix> combined, after single and multiple doses, are similar in extensive and poor metabolizers.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB4AA59B-BD34-4506-A617-157D639949C4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:12FF752F-ABCD-4F14-B2B9-41A0476FEF33</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 12:44:29 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:EBDA4EF3-E793-47E4-9F6F-74592DE48307"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N77b8670d22b2476490296e0bca826d6f">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F52690C8-04C0-4A9E-B719-C8C7578F5CA8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>theophylline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C624C116-E8F0-4A10-B8B2-BC8AA88D6B11">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C624C116-E8F0-4A10-B8B2-BC8AA88D6B11"/>
    <ao:prefix>Triptans: There have been rare postmarketing reports of </ao:prefix>
    <ao:exact>serotonin</ao:exact>
    <domeo:uuid>C624C116-E8F0-4A10-B8B2-BC8AA88D6B11</domeo:uuid>
    <ao:suffix> syndrome with use of an SSRI and a </ao:suffix>
    <pav:createdOn>2014-09-02 11:43:24 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/E4072F00-AC18-479B-BBF5-FE87E12CA45B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>cimetidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F989B861-2D11-4383-83FA-D6724A4DE400">
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:BCC3E44B-0E96-41D5-AB03-A4CC9A1EB653"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 19:12:54 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BD1E279-39ED-4853-AF2E-BE56BEB4AF03">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:7687B2A2-948F-4E07-9BC1-43216AD31878</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:11:31 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:159DCA30-3727-4241-9440-301E40381956"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:083AD66D-BAA3-4731-A45A-FB051CF3619F">
    <ao:context rdf:resource="urn:domeoclient:uuid:D555A94C-D1DE-4B5C-B227-8172F8605613"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:6DB697AB-44ED-459A-BF85-DA145CBA7F25</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:09:20 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B40D027-2C99-4AA7-A143-A35EFB743189">
    <pav:createdOn>2014-09-02 11:46:26 -0400</pav:createdOn>
    <ao:exact>propranolol</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9B40D027-2C99-4AA7-A143-A35EFB743189"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix> maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol. Unlike </ao:prefix>
    <domeo:uuid>9B40D027-2C99-4AA7-A143-A35EFB743189</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B768EBB-3E7D-4144-B911-6362101E6343">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-01 16:06:18 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:7FAAF035-8612-4FF2-9CCE-2560955AB943</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:9BA34B2D-02C3-4A53-9C4E-833C005A5CBE"/>
    <pav:createdOn>2014-09-01 16:06:01 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC1D209A-F362-4FEA-ABD5-96B660CE4A7A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CC1D209A-F362-4FEA-ABD5-96B660CE4A7A"/>
    <ao:suffix> hydrochloride tablets should be taken shortly after a meal or light snack. Symptomatic relief may be seen during the first week, with optimal antidepressant effects typically evident within two weeks. Twenty-five percent of those who respond to trazodon</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>CC1D209A-F362-4FEA-ABD5-96B660CE4A7A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>e should be initiated at a low level and increased gradually, noting the clinical response and any evidence of intolerance. Occurrence of drowsiness may require the administration of a major portion of the daily dose at bedtime or a reduction of dosage. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-138.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 20:05:02 -0400</pav:createdOn>
    <ao:exact>Trazodone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:584B0A9B-8106-4A13-BCCB-4DD9957E0EF1">
    <ao:exact>rosiglitazone</ao:exact>
    <pav:createdOn>2014-07-22 19:28:27 -0400</pav:createdOn>
    <ao:prefix>Following oral or intravenous administration of [14C]</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> maleate, approximately 64% and 23% of the dose was eliminated in the urine and in the feces, respectively. The plasma half-life of [14C]related material ranged from 103 to 158 hours.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:584B0A9B-8106-4A13-BCCB-4DD9957E0EF1"/>
    <domeo:uuid>584B0A9B-8106-4A13-BCCB-4DD9957E0EF1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8AA02101-5E16-4D28-B719-8FAC66F7E101">
    <ao:exact>disulfiram</ao:exact>
    <ao:prefix> was found, there have been clinical reports of interaction with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>8AA02101-5E16-4D28-B719-8FAC66F7E101</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8AA02101-5E16-4D28-B719-8FAC66F7E101"/>
    <pav:createdOn>2014-09-02 19:13:15 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2DFE50C-520B-4A09-83FE-8498F429017C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>mexiletine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-160.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E2DFE50C-520B-4A09-83FE-8498F429017C"/>
    <ao:suffix> therapy has not been established. In addition, there have been isolated reports of drowsiness, nystagmus, ataxia, dyspepsia, hypersensitivity reaction, and exacerbation of congestive heart failure in patients with pre-existing compromised ventricular fu</ao:suffix>
    <ao:prefix>have been isolated, spontaneous reports of pulmonary changes including pulmonary infiltration and pulmonary fibrosis during mexiletine therapy with or without other drugs or diseases that are known to produce pulmonary toxicity. A causal relationship to </ao:prefix>
    <pav:createdOn>2014-07-24 20:13:52 -0400</pav:createdOn>
    <domeo:uuid>E2DFE50C-520B-4A09-83FE-8498F429017C</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:170D0DFA-5641-4603-80E1-C79ED18CB7D8">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0054F81-6A9B-4AF0-9DCB-962A6FC1C418</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-22 18:46:29 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 18:46:52 -0400</pav:lastSavedOn>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:0AE29601-35D4-4744-B1F3-9C7B8DC9B20B</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C6A356B7-0DEE-4744-8B2D-DDF0B281AC9B"/>
    <ao:body rdf:nodeID="N1861f1d417844b00a0bbe52ebc792108"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nedafe03b7c9b4388b0c59e9c8aa32636">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7BE43707-1914-4E31-AAC1-03F035925C89">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A3AF38F3-51D7-4A66-84B7-21A51A8CE79F"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:060B4AD5-C06D-4579-9AB3-F6932ED1425B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>060B4AD5-C06D-4579-9AB3-F6932ED1425B</domeo:uuid>
    <pav:createdOn>2014-07-24 20:01:38 -0400</pav:createdOn>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>trazodone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:060B4AD5-C06D-4579-9AB3-F6932ED1425B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-136.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1085914C-2530-49EB-92B4-1E4BC17AEBAC">
    <ao:suffix> is 400 mg daily given as 200 mg b.i.d. Dosage should be increased gradually until an optimal clinical response is obtained, generally at 600 to 1200 mg per day. If treatment is to be discontinued, the dosage should be reduced gradually over a period of </ao:suffix>
    <ao:prefix>The usual initial dosage of </ao:prefix>
    <pav:createdOn>2014-07-13 11:02:05 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1085914C-2530-49EB-92B4-1E4BC17AEBAC"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-4.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>acebutolol</ao:exact>
    <domeo:uuid>1085914C-2530-49EB-92B4-1E4BC17AEBAC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:796FE422-C147-4AA7-A57F-067429194AA4">
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:7E80543E-BF76-4514-92A9-91458DCB802B</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-22 19:35:16 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:584B0A9B-8106-4A13-BCCB-4DD9957E0EF1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:28:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2FF47DA5-4366-4BC2-AA71-7E8F63D7F2AA">
    <ao:prefix> on </ao:prefix>
    <ao:suffix> pharmacokinetics. In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for this enzyme, including terfe</ao:suffix>
    <domeo:uuid>2FF47DA5-4366-4BC2-AA71-7E8F63D7F2AA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>terfenadine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2FF47DA5-4366-4BC2-AA71-7E8F63D7F2AA"/>
    <pav:createdOn>2014-09-02 15:04:10 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBFA7BB9-378D-445C-9A8F-2DF6D035AC7D">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:E0BA7513-EC9D-435D-8BE2-617311ADA2D8"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 19:53:55 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-24 19:53:06 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:FCB9971B-E34D-4290-8946-8F66C9B4F25A</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0863579-8D19-4B30-ADD6-2A5BDBC2F482</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0FEC326D-6B98-40B2-8D49-7B4318AEB3B8">
    <ao:prefix>may enhance the serotonergic effects of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>0FEC326D-6B98-40B2-8D49-7B4318AEB3B8</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0FEC326D-6B98-40B2-8D49-7B4318AEB3B8"/>
    <pav:createdOn>2014-09-02 11:44:20 -0400</pav:createdOn>
    <ao:suffix>, and the combination should, therefore, be used with caution. Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).</ao:suffix>
    <ao:exact>fluvoxamine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:01E43715-3610-4176-8FB9-E2D7C94F6C63">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:181381FE-800A-4970-81D8-2B14B7735770"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/4E62726A-262F-4A69-83FB-3965D3CD27BD">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Synercid</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/135097</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A332788B-8D94-435B-A2BD-5419224AC500">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A332788B-8D94-435B-A2BD-5419224AC500"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (2 mg twice daily) taken concomitantly with glyburide (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy. Repeat doses of AVANDIA (8 mg once daily</ao:suffix>
    <pav:createdOn>2014-07-22 19:48:47 -0400</pav:createdOn>
    <domeo:uuid>A332788B-8D94-435B-A2BD-5419224AC500</domeo:uuid>
    <ao:exact>AVANDIA</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EEF7294-F55C-48E2-8A50-69D9A3726172">
    <pav:createdOn>2014-07-24 20:03:38 -0400</pav:createdOn>
    <domeo:uuid>7EEF7294-F55C-48E2-8A50-69D9A3726172</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-137.txt.html</ao:hasSource>
    <ao:prefix>Carbamazepine induces CYP3A4. Following coadministration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> 400 mg/day with trazodone 100 mg to 300 mg daily, carbamazepine reduced plasma concentrations of trazodone (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.</ao:suffix>
    <ao:exact>carbamazepine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7EEF7294-F55C-48E2-8A50-69D9A3726172"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84BD0311-11DD-4CCD-B082-CEE1C8BAAD37">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:8D86A4AC-54BD-4BB3-8B58-AB55DEC01A88</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:CB138E02-5A43-4D20-A598-828A1F13AC26"/>
    <pav:createdOn>2014-07-24 20:07:52 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-24 20:10:48 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9011E52E-6FAE-42BF-913B-D3EF952E8A2B">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:B9422143-55C7-4DC9-89FD-1C96FFB68383</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:04:07 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3D2A83E-9B62-495D-A7E7-A17FEF5E2561"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35E17DFA-B3B8-4521-B986-4AC98CC81C96">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:C988D053-7CF3-4C50-BDB6-7C2B20B837B9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:AE683DEB-803C-4D4C-BDAB-800593153F2E</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A5583BB-B797-401F-B398-564C65590C7B"/>
    <pav:lastSavedOn>2014-07-21 21:55:00 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-21 21:53:30 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4BA9A75-9ED6-4A34-AD9F-D5874AACDFF0">
    <ao:prefix> (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of </ao:prefix>
    <domeo:uuid>F4BA9A75-9ED6-4A34-AD9F-D5874AACDFF0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F4BA9A75-9ED6-4A34-AD9F-D5874AACDFF0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> (50 mg) has been studied in 10 healthy subjects. The Cmax of trazodone increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%. Adverse effects including nausea, hypotension, and syncope were</ao:suffix>
    <ao:exact>trazodone</ao:exact>
    <pav:createdOn>2014-07-24 20:02:13 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-136.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/EA8D118F-5115-426B-8423-6A5269AC5A4A">
    <rdfs:label>phenytoin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:23B46B7B-627E-4D42-A5FF-1DBE8AB466EF">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5A32BB60-7D2B-448B-A3EB-21F28A75BB33"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0863579-8D19-4B30-ADD6-2A5BDBC2F482">
    <ao:item rdf:resource="urn:domeoclient:uuid:EBFA7BB9-378D-445C-9A8F-2DF6D035AC7D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:84794CD6-2D7E-423B-92EC-B0CDCB2CF050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4C303406-873F-442A-82D7-9FA28371D696"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AA6CCDE1-25E7-45C1-9526-49B0190E1EC2"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-07-24 19:53:55 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N10b60bd7938c48b7b6ed8b046e5a9a9e"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:4BBBCCF7-77AF-4B32-B246-8C1032EB3DF0"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-132.txt.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:0498601E-1695-4042-B282-36B6420F06B7</pav:lineageUri>
    <pav:createdOn>2014-07-24 19:52:41 -0400</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:9207210A-6F7A-4F79-BDF9-A1A2BE0D055E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CE82B7F1-A555-4EA6-BB43-259D94DCEA76"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F9E744D-C586-43FA-AB0E-FF3294D6D12E">
    <ao:suffix>clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours. (See PRECAUTIONS.)</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). </ao:prefix>
    <ao:exact>Theophylline </ao:exact>
    <domeo:uuid>0F9E744D-C586-43FA-AB0E-FF3294D6D12E</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0F9E744D-C586-43FA-AB0E-FF3294D6D12E"/>
    <pav:createdOn>2014-07-21 21:33:59 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21C1BD16-9B1B-4BDA-B036-93523B41DFDF">
    <pav:lineageUri>urn:domeoserver:annotationset:13565436-2280-4488-95B4-68368AB28E9D</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:2254AD70-D7DF-48C1-827C-280B109CF542"/>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="Nfcf7dae047b740818bb2e4a71a46ec2d"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2014-07-24 19:46:59 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-24 19:46:59 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143046812afe0146812eda990003"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-130.txt.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:D77CF944-3EF8-45F2-9976-BAD4E451F994"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E9C5B173-AFE1-44E0-A146-6AEBE6A982AB"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CCA3540C-4A74-4782-9325-18A999F61C75">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> was shown to be mediated by increased sensitivity to insulin’s action in the liver, muscle, and adipose tissues. Pharmacological studies in animal models indicate that </ao:prefix>
    <domeo:uuid>CCA3540C-4A74-4782-9325-18A999F61C75</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:11:48 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CCA3540C-4A74-4782-9325-18A999F61C75"/>
    <ao:suffix> inhibits hepatic gluconeogenesis. The expression of the insulin-regulated glucose transporter GLUT-4 was increased in adipose tissue. Rosiglitazone did not induce hypoglycemia in animal models of type 2 diabetes and/or impaired glucose tolerance.</ao:suffix>
    <ao:exact>rosiglitazone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9174469-54E0-4FAB-8165-210C50F1F809">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 12:37:33 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2CE66065-C68D-4E90-911C-F8B5E04B3813"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:2051B080-40BC-4A2C-B53F-A08613EB9C84</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/90DF0B47-DCBB-4EEC-BC07-A4A1FACD692F">
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <foafx:homepage></foafx:homepage>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <foafx:build>050</foafx:build>
    <foafx:version>2.1alpha</foafx:version>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70E66A8A-36A7-4A61-AFC4-4E0A6DF9B0BC">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:74C12A9B-7A11-44EB-A829-30F93AA6ADCF"/>
    <pav:createdOn>2014-07-28 17:04:24 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:8A1382BC-E89F-4716-8CE8-1B58C9B713DC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-28 17:08:37 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:48D839E5-6B0A-4EC3-B64A-E3E20E06246A</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79293219-D172-4E27-A045-D16B4F539C60">
    <ao:context rdf:resource="urn:domeoclient:uuid:E2AC08E4-8A5F-4E68-B2F1-20AFB690BAC7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:A98BA61A-C2C5-4182-B0E9-6095CE94E0D1</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-07 11:22:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:082BC34B-E2CB-4EAD-908C-433213A92A0D">
    <domeo:uuid>082BC34B-E2CB-4EAD-908C-433213A92A0D</domeo:uuid>
    <ao:exact>hyperuricemia</ao:exact>
    <ao:prefix> for injection in the U.S. Of these patients, 411 had established </ao:prefix>
    <ao:suffix> and 307 had normal serum urate levels at the time that treatment was initiated. Normal serum uric acid levels were achieved in 68% (reduction of serum uric acid was documented in 93%) of the former, and were maintained throughout chemotherapy in 97% of </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-43.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:082BC34B-E2CB-4EAD-908C-433213A92A0D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-01 16:19:52 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34472B29-EA4E-45E5-84B2-2EEE556610B6">
    <pav:createdOn>2014-07-13 11:29:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="Na0c1c81902814ffeb9ff4fba3348b2c8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:B294F73B-169E-4106-90EF-3C87099953E8"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:29BBE1A3-B55A-462F-A387-1BC5EE901EF7</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42814771-C705-49EC-A4A8-3257DD3ADB49">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:42814771-C705-49EC-A4A8-3257DD3ADB49"/>
    <pav:createdOn>2014-09-02 11:53:02 -0400</pav:createdOn>
    <ao:prefix>Lorazepam: </ao:prefix>
    <ao:suffix>. On average, bot</ao:suffix>
    <ao:exact>A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>42814771-C705-49EC-A4A8-3257DD3ADB49</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C00C0C31-D3ED-43CE-8CB0-398EA275616B">
    <pav:createdOn>2014-09-02 19:18:20 -0400</pav:createdOn>
    <ao:suffix> (400 mg, qd) and omeprazole (40 mg, qd, 2 hr before atazanavir), AUC was decreased by 94%, Cmax by 96%, and Cmin by 95%. Concomitant administration with omeprazole and drugs such as atazanavir and nelfinavir is therefore not recommended. For other antir</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>C00C0C31-D3ED-43CE-8CB0-398EA275616B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>atazanavir</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C00C0C31-D3ED-43CE-8CB0-398EA275616B"/>
    <ao:prefix> (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B743E18-8323-4761-B0A4-3B200C16F9BE">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:16FE2F0D-3BF4-4708-9147-BD5159B47059"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:9644563B-1E1E-4AF0-871E-E395B93BB653</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:14:31 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99838144-4399-4843-860D-C565071F0347">
    <pav:createdOn>2014-09-02 11:39:30 -0400</pav:createdOn>
    <ao:suffix> maleate and carbamazepine.</ao:suffix>
    <domeo:uuid>99838144-4399-4843-860D-C565071F0347</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:99838144-4399-4843-860D-C565071F0347"/>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:prefix>Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0926D3D-98EA-4A7F-A9B4-EC238004514E">
    <ao:prefix>The pharmacokinetics of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E0926D3D-98EA-4A7F-A9B4-EC238004514E</domeo:uuid>
    <pav:createdOn>2014-07-21 21:33:41 -0400</pav:createdOn>
    <ao:exact>theophylline </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E0926D3D-98EA-4A7F-A9B4-EC238004514E"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <ao:suffix>were determined from a single intravenous dose of aminophylline (6 mg/kg) before and after the oral administration of fluconazole 200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na7e3c681a1ac497892fc55d801d39f0d">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E8F08BA-7079-4216-9618-95A54B886D84">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:B81F177E-80FA-4C7E-AD7A-4FA9D5D95A8B</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8F192869-CBB9-4ECB-A4F1-F621F322E7E6"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-21 21:46:36 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:876DAFB7-BB08-4119-BA16-59187031D7BB</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-21 21:46:47 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68293B6C-C124-4A8B-AD38-563F597E9486">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:68293B6C-C124-4A8B-AD38-563F597E9486"/>
    <ao:prefix>ed or confirmed methicillin-resistant staphylococcus or if the patient was allergic to penicillins, cephalosporins or carbapenems. Study JRV 304 enrolled 450 patients (n = 229 Synercid; n= 221 Comparator) and Study JRV 305 enrolled 443 patients (n = 221 </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 18:52:17 -0400</pav:createdOn>
    <ao:suffix>; n = 222 Comparator). </ao:suffix>
    <domeo:uuid>68293B6C-C124-4A8B-AD38-563F597E9486</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-119.txt.html</ao:hasSource>
    <ao:exact>Synercid</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FBE8BF3F-CF31-4746-AE08-52B8B70D3AA7">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 19:50:12 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:97D1DB41-3631-4DF4-AC28-E9932F707785"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A444D2E-FB37-4D42-8D22-19CAC1F671D0">
    <ao:suffix> (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized o</ao:suffix>
    <domeo:uuid>5A444D2E-FB37-4D42-8D22-19CAC1F671D0</domeo:uuid>
    <pav:createdOn>2014-09-02 12:02:51 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5A444D2E-FB37-4D42-8D22-19CAC1F671D0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>  (20 mg once daily) under steady-state conditions increased single-dose </ao:prefix>
    <ao:exact>desipramine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF3F948A-978C-448B-972C-FC7423B8770D">
    <ao:exact>propranolol</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AF3F948A-978C-448B-972C-FC7423B8770D"/>
    <ao:prefix> with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> resulted in up to 50% decrease in propranolol concentrations.</ao:suffix>
    <domeo:uuid>AF3F948A-978C-448B-972C-FC7423B8770D</domeo:uuid>
    <pav:createdOn>2014-07-24 19:51:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-131.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:31A6A7B0-3980-4B84-A4E6-68B8A08EC05D">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A250DA9B-BB28-425B-B634-A002C82007BD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1184FE6-5357-43C5-BB6C-87EC586C8468">
    <pav:lineageUri>urn:domeoserver:annotation:2ABACF29-D8D4-48D6-8FEC-7F26497385EC</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:404B1852-88F6-45BB-8C18-358B3A408485</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-21 21:50:30 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:35FBCEB9-D10F-4DB4-8F8D-DB121D785B9B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-21 21:50:34 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:67CFE2D6-F2AA-4465-A433-B26BEA64FB5E">
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C5023B49-22AF-4880-9F9A-B1FCB16EAE71"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:2B2D2409-EC63-45B4-9720-BB70CEBD3CE2</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-13 12:42:01 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74981A52-DA21-4061-9DF7-E2A73DB55601">
    <ao:suffix>glucuronide, naphthyloxylactic acid and glucuronic acid, and sulfate conjugates of 4-hydroxy propranolol.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> oxidation, and direct glucuronidation. It has been estimated that the percentage contributions of these routes to total metabolism are 42%, 41% and 17%, respectively, but with considerable variability between individuals. The four major metabolites are </ao:prefix>
    <pav:createdOn>2014-07-24 20:00:56 -0400</pav:createdOn>
    <ao:exact>propranolol </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-135.txt.html</ao:hasSource>
    <domeo:uuid>74981A52-DA21-4061-9DF7-E2A73DB55601</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:74981A52-DA21-4061-9DF7-E2A73DB55601"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72843AE3-90CC-43FD-BCEC-E83B4E3A7EDF">
    <pav:lineageUri>urn:domeoserver:annotation:7D999E14-4D2E-4EE2-945B-2011BD864F5E</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 11:10:19 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:77F990A5-C7A6-4873-A32F-AD9607EFDE51"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16C89EA1-7173-40AF-99E3-B5CF422C3FBB">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:5183CA14-21F4-45E0-840D-A1DC67564C1F</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7EB0AC81-B2FD-4D6F-8BAC-50662A16D4C6"/>
    <pav:createdOn>2014-09-02 11:57:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6B6560EB-DD3A-4FD9-ACE8-690CA260DD8B">
    <pav:createdOn>2014-07-13 11:15:09 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:76258D2D-1630-4254-82ED-C3434163EAE3"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:45DFA268-E20B-41A7-BE0C-703868597D0E</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:464ED203-77EC-4EFC-873A-7853A308DCA5">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:A434E784-EF19-4D9F-9D9A-D71E320A8599</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:17:56 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F63A36F-F819-4E40-9C8A-C518B5519787"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C5969D2-1348-44AF-8DA9-7B96D70B4770">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:464E41DE-27DF-4413-A7E6-C191985E633B"/>
    <pav:createdOn>2014-09-02 11:44:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ACECEC3-3253-49CC-B7BF-D586E8F2D7A4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0ACECEC3-3253-49CC-B7BF-D586E8F2D7A4"/>
    <pav:createdOn>2014-07-22 20:19:56 -0400</pav:createdOn>
    <ao:suffix>.</ao:suffix>
    <domeo:uuid>0ACECEC3-3253-49CC-B7BF-D586E8F2D7A4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:exact>AVANDIA</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03FCDCDD-B854-48FC-9FD5-39AD4A15667C">
    <ao:suffix> was administered with either grapefruit or orange juices compared to water. Based on the literature reports, the same effects may be extrapolated to other fruit juices such as apple juice. The clinical significance of these observations is unknown. In a</ao:suffix>
    <ao:prefix>. This is based on the results from three clinical studies using histamine induced skin wheals and flares coupled with population pharmacokinetic analysis. The size of wheal and flare were significantly larger when </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:03FCDCDD-B854-48FC-9FD5-39AD4A15667C"/>
    <ao:exact>fexofenadine hydrochloride</ao:exact>
    <pav:createdOn>2014-07-24 20:12:42 -0400</pav:createdOn>
    <domeo:uuid>03FCDCDD-B854-48FC-9FD5-39AD4A15667C</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D6854021-6829-4D54-8ADE-ADC84C0AF5B8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D6854021-6829-4D54-8ADE-ADC84C0AF5B8</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>carbamazepine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D6854021-6829-4D54-8ADE-ADC84C0AF5B8"/>
    <ao:prefix>, </ao:prefix>
    <ao:suffix>, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A</ao:suffix>
    <pav:createdOn>2014-09-01 16:05:57 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DEE6C6F-A6F1-480F-B422-0E55E610EAAB">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 11:43:30 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:BFF92609-A328-4612-927E-6F35023B6FC8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E17F3ACA-8486-4702-886B-6FA2562FDEFF">
    <ao:prefix> AUC was 6% (range: -47 to 108%) and </ao:prefix>
    <ao:exact>levonorgestrel</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:44:35 -0400</pav:createdOn>
    <ao:suffix> AUC increased 17% (range: -33 to 141%).</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E17F3ACA-8486-4702-886B-6FA2562FDEFF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E17F3ACA-8486-4702-886B-6FA2562FDEFF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:65F441ED-AF61-4AE3-8365-8ABE9FA557A2">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:65F441ED-AF61-4AE3-8365-8ABE9FA557A2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>65F441ED-AF61-4AE3-8365-8ABE9FA557A2</domeo:uuid>
    <ao:prefix>A clinically significant </ao:prefix>
    <ao:suffix> interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminat</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:35:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E202AAE6-7DCA-486D-9C29-8CB3B82CFECF">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-13 11:09:35 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:30903A1B-437C-4ABA-B24D-6148F07F178D"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:70E60126-522D-4A50-BCBB-D49738745AFC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C47D157-D8A4-4053-B2C7-7ECD1B16B721">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:createdOn>2014-07-22 19:12:50 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 19:15:50 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:BE4B86AC-FE5F-4543-A713-EC5B852A5A2A</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:709146DB-F43F-4A5F-B3FB-C395469E387B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A0256F1-F31A-4A0C-BA59-EC817B22A85D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0A0256F1-F31A-4A0C-BA59-EC817B22A85D"/>
    <domeo:uuid>0A0256F1-F31A-4A0C-BA59-EC817B22A85D</domeo:uuid>
    <ao:prefix> (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of </ao:prefix>
    <pav:createdOn>2014-07-22 19:41:54 -0400</pav:createdOn>
    <ao:suffix> (4 mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced [see Drug Interactions (7.1)].</ao:suffix>
    <ao:exact>rosiglitazone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72594949-CA92-4CEF-8CB6-0072661759A0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:72C81315-5D14-41CA-AEB9-E23AC335F4C3"/>
    <pav:createdOn>2014-07-13 12:38:31 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:4A02C183-A585-4567-848A-3878478E06F5</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B572D091-3712-43AD-B485-3E1311449FAA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:54E3B0B5-2096-41BF-BC0D-256928923869"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:32:43 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75348A1F-6A84-4B07-BE23-172E91593A8D">
    <pav:createdOn>2014-07-22 18:44:30 -0400</pav:createdOn>
    <ao:prefix>Concomitant administration of </ao:prefix>
    <domeo:uuid>75348A1F-6A84-4B07-BE23-172E91593A8D</domeo:uuid>
    <ao:suffix> and nifedipine (repeated oral doses) and midazolam (intravenous bolus dose) in healthy volunteers led to elevated plasma concentrations of these drugs. The Cmax increased by 18% and 14% (median values) and the AUC increased by 44% and 33% for nifedipine</ao:suffix>
    <ao:exact>Synercid</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:75348A1F-6A84-4B07-BE23-172E91593A8D"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-118.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFBF6FAC-1B25-458D-A6E1-4DFEB8A3FAC9">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:5DBA32DA-F1E7-4F9E-AD15-D58983A11DB9</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:53:02 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:42814771-C705-49EC-A4A8-3257DD3ADB49"/>
    <pav:lastSavedOn>2014-09-02 11:54:50 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="N6d8c93370944406db8f7d570f9c5d643"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/5AD16038-68DB-4293-9251-D5A275F9AB73">
    <rdfs:label>oxacillin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F55B6524-A848-4FBC-99DB-A1B22E5FCA28">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F55B6524-A848-4FBC-99DB-A1B22E5FCA28"/>
    <domeo:uuid>F55B6524-A848-4FBC-99DB-A1B22E5FCA28</domeo:uuid>
    <ao:prefix> for injection per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>or azathioprine. Subsequent adjustment of doses of mercaptopurine or azathioprine should be made on the basis of therapeutic response and the appearance of toxic effects (see PRECAUTIONS- Drug Interactions).</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-42.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-01 16:12:26 -0400</pav:createdOn>
    <ao:exact>mercaptopurine </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F31EE1EC-A22F-4FE9-8763-7C623AD7B0BE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> results from the combined concentrations of </ao:prefix>
    <ao:suffix> and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY]. Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>F31EE1EC-A22F-4FE9-8763-7C623AD7B0BE</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F31EE1EC-A22F-4FE9-8763-7C623AD7B0BE"/>
    <pav:createdOn>2014-07-13 11:08:54 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/6FD42917-DF6A-4B72-83EF-A23E155102AF">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <rdfs:label>theophylline</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C14E39F-8619-4318-B524-D5D59AE2A868">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1C14E39F-8619-4318-B524-D5D59AE2A868"/>
    <pav:createdOn>2014-07-22 20:17:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1C14E39F-8619-4318-B524-D5D59AE2A868</domeo:uuid>
    <ao:exact>AVANDIA</ao:exact>
    <ao:suffix> </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE69196D-B8BA-4576-AC08-BEA775939851">
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:EDE878E4-C5E0-46C3-B925-8B3825F4CA93"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-24 20:07:21 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6FE6875-950C-46F9-801E-FB47AB83A2ED">
    <ao:exact>nelfinavir</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E6FE6875-950C-46F9-801E-FB47AB83A2ED"/>
    <ao:prefix> is not recommended when administered in combination with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E6FE6875-950C-46F9-801E-FB47AB83A2ED</domeo:uuid>
    <ao:suffix>, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted (see ADVERSE REACTIONS).</ao:suffix>
    <pav:createdOn>2014-07-24 20:14:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-161.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/EF2D99E6-548C-4F7E-82EC-A1FF35F17CB0">
    <rdfs:label>procyclidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7650976-DBE7-4CD9-8158-46355CF2F821">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:B61F1A9B-4696-4ED0-80AA-4FE2E9016966</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-21 21:35:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:F6DD78C2-91A0-422A-808B-1666B89DB3EF</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-21 21:34:27 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:FAA92561-4F1F-46DE-9C0F-2783EAC09CFA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E17E51AB-6385-4BD7-89B1-ABDDA504EE2C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E17E51AB-6385-4BD7-89B1-ABDDA504EE2C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:suffix>: See WARNINGS AND PRECAUTIONS (5.8).</ao:suffix>
    <domeo:uuid>E17E51AB-6385-4BD7-89B1-ABDDA504EE2C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:41:00 -0400</pav:createdOn>
    <ao:exact>Ramelteon</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A412DBFC-2FE0-43FA-A538-B84D822A5BFD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-07 09:44:07 -0400</pav:createdOn>
    <ao:suffix>pharmacologic effects. In patients with pulmonary arterial hypertension, however, the ratio of the metabolite to sildenafil is higher. Both sildenafil and the active metabolite have terminal half-lives of about 4 hours.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A412DBFC-2FE0-43FA-A538-B84D822A5BFD"/>
    <ao:exact>sildenafil's </ao:exact>
    <ao:prefix>, so that the metabolite accounts for about 20% of </ao:prefix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F442DD1F-67E3-41D3-92CB-9048022BDFCC">
    <ao:suffix> is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses up to 240 mg/day, dose adjustment may be considered. When voriconazole (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with omeprazole (40</ao:suffix>
    <ao:prefix> exposure. Dose adjustment of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F442DD1F-67E3-41D3-92CB-9048022BDFCC"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:15:59 -0400</pav:createdOn>
    <domeo:uuid>F442DD1F-67E3-41D3-92CB-9048022BDFCC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>omeprazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F5EB55C-E7E1-447C-B54E-5F02D52FA3AE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 20:22:47 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6F5EB55C-E7E1-447C-B54E-5F02D52FA3AE"/>
    <domeo:uuid>6F5EB55C-E7E1-447C-B54E-5F02D52FA3AE</domeo:uuid>
    <ao:exact>Pretreatment with ranitidine (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of rosiglitazone in healthy volunteers. These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9ee8aa4820bf401195da3129ee623636">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/8CED9A21-7623-4055-94D4-793400BC8FD1">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/84108</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>rosiglitazone</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C44A8620-423F-46B3-A5AA-096744C9A1FF">
    <domeo:belongsToSet>urn:domeoclient:uuid:39B82E57-92E3-4322-A8E6-A3AFF215F02C</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:024DA998-8A48-48B5-83FB-3E3328F234D5"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-01 15:57:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:E6595957-5AB4-48D0-BA7E-DA2D008F36BF</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-01 15:57:39 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B45944E-9180-4FB2-9DC0-7DC156F7508B">
    <ao:exact>Lithium</ao:exact>
    <pav:createdOn>2014-09-02 11:39:51 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1B45944E-9180-4FB2-9DC0-7DC156F7508B"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <domeo:uuid>1B45944E-9180-4FB2-9DC0-7DC156F7508B</domeo:uuid>
    <ao:suffix>: As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution. Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03ABEF2C-055A-4C30-91E7-3717F41B4C84">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D6854021-6829-4D54-8ADE-ADC84C0AF5B8"/>
    <pav:lastSavedOn>2014-09-01 16:06:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-01 16:05:57 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:97CCDA9F-F14E-48A6-A583-AA3AB41BA52E</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23CAE79F-92D8-407B-BE7A-4BCA038E20F4">
    <domeo:belongsToSet>urn:domeoclient:uuid:4C207F47-3585-4A4F-A5A4-245A1F19DF8E</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:00:28 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 19:00:38 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:319A061D-1A35-4E08-859B-F39DA704D1B4"/>
    <pav:lineageUri>urn:domeoserver:annotation:B1F452A5-D9B4-427C-B59B-814D4EF0510B</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6b6f7ee80a86438c83cd8cf5e9d44d18">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3967C16-EC04-423B-908A-CF2BC1EC4011">
    <domeo:uuid>F3967C16-EC04-423B-908A-CF2BC1EC4011</domeo:uuid>
    <pav:createdOn>2014-07-13 11:04:27 -0400</pav:createdOn>
    <ao:exact>serotonin</ao:exact>
    <ao:suffix> Type 2 (5HT2) receptor antagonism.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3967C16-EC04-423B-908A-CF2BC1EC4011"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> Type 2 (D2) and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23D9C242-E097-43FB-88F0-20E20588FBFC">
    <ao:context rdf:resource="urn:domeoclient:uuid:D7A544C2-F82A-49C9-83A0-D19D9DDF7E00"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:nodeID="N1d9e4ff74e94474a8a976734e86a154d"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 20:20:12 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:7186BD4F-BACE-424E-B322-19883E2F77B1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE2369F6-B30D-45B8-9655-5079A35C9D6D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BE2369F6-B30D-45B8-9655-5079A35C9D6D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>atomoxetine</ao:exact>
    <ao:prefix>ely 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold. The effect of paroxetine on the pharmacokinetics of </ao:prefix>
    <ao:suffix> has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state a</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>BE2369F6-B30D-45B8-9655-5079A35C9D6D</domeo:uuid>
    <pav:createdOn>2014-09-02 11:58:19 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/5E9DF383-ABD6-4F64-BB57-8EF69FDE4C64">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>ketoconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF4B8408-EC34-4E9C-A970-D7F98CF2EEE1">
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:19:31 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:3CDFB7B3-F366-4F19-B27E-4B00DC64BA96"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndc58ef98dfa545569fd00d795b381bfd">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B5C139F-AE11-4B67-AB76-74B91C6DD60D">
    <pav:lastSavedOn>2014-09-02 15:06:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:443354CF-9409-4015-81BA-17601E505BAB</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:E9D6FD85-CFBF-4435-A027-4008AB18DB92</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 15:05:47 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:5DC04223-08C0-4FC9-9E10-75D588673E2D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2CF4DD8F-BE67-4B73-8082-A0A474C61D19">
    <pav:createdOn>2014-07-24 19:39:23 -0400</pav:createdOn>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>2CF4DD8F-BE67-4B73-8082-A0A474C61D19</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2CF4DD8F-BE67-4B73-8082-A0A474C61D19"/>
    <ao:exact>propranolol</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-126.txt.html</ao:hasSource>
    <ao:prefix> are increased by 64% and 79%, respectively, by co-administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC193B15-53DF-4479-BA9B-BCE880C4232C">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:98202FCE-E474-49D7-9BB0-19337824E18A</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:04984965-B2D0-4ECE-8862-143E95A2279E"/>
    <pav:lastSavedOn>2014-09-01 16:06:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-01 16:06:03 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:224F94C2-6E6D-4C8D-9B6C-9E8B442425A3">
    <ao:context rdf:resource="urn:domeoclient:uuid:3DFC0290-B79C-492E-A5DB-32EF23C9B433"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEB6848-E3C6-4761-8965-41F19EE5D781</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:A1618A56-31FE-4CA0-8501-AA51FFFC9A40</pav:lineageUri>
    <pav:createdOn>2014-07-24 19:43:03 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-24 19:43:34 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:856332C7-36D0-4788-B89D-FC8E3A9C55D9">
    <pav:lastSavedOn>2014-07-22 18:37:42 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 18:37:56 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:9FA29E53-6B1B-4856-B5BD-22A93164E58E</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:7323A4E6-9262-4C31-906F-6A9D2369FE37</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B12E6D2-E83F-42E5-821A-DFDAD994F783"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C2471146-B114-47FF-BB78-F58B6158FB99">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DC200567-4E8F-495B-9D13-A2A04A7A47EC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB3EAD78-45A5-439B-B26A-FE0BB9EDCBD0">
    <domeo:uuid>AB3EAD78-45A5-439B-B26A-FE0BB9EDCBD0</domeo:uuid>
    <ao:exact>Fluconazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB3EAD78-45A5-439B-B26A-FE0BB9EDCBD0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:56:13 -0400</pav:createdOn>
    <ao:prefix> increased 32% ± 17% (range: 16 to 72%). </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-24.txt.html</ao:hasSource>
    <ao:suffix> half-life decreased from 33.4 ± 4.4 hours to 26.8 ± 3.9 hours. (See PRECAUTIONS.)</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8EAC93E7-05D8-439B-86B4-7B47CB07E8D8">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:12670ED8-C472-4DF9-A553-567C7F4720E9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:17:15 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:70B9E8E9-06ED-4420-9CDE-4E0F36F57CC9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BAD39B9-2A3E-47D0-84C7-BB409378B51D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdOn>2014-09-02 11:44:36 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C970223A-AA7A-4283-8B0C-B1F7B0A1261F"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:72BE2161-391C-488C-B44D-F6CF16588EAC">
    <ao:prefix> effects on lipids. At baseline, week 26, and week 52, mean LDL/HDL ratios were 3.1, 3.2, and 3.0, respectively, for AVANDIA 4 mg twice daily. The corresponding values for glyburide were 3.2, 3.1, and 2.9. The differences in change from baseline between </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 19:22:07 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> and glyburide at week 52 were statistically significant.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:exact>AVANDIA</ao:exact>
    <domeo:uuid>72BE2161-391C-488C-B44D-F6CF16588EAC</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:72BE2161-391C-488C-B44D-F6CF16588EAC"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/77D06206-6695-47A2-961A-30BA8D501FA5">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/84108</dailymed:activeMoietyRxCUI>
    <rdfs:label>rosiglitazone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1230CFBE-6F41-4107-8D50-5F5A730D40C5">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1230CFBE-6F41-4107-8D50-5F5A730D40C5"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-13 11:07:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-sensitive sigma site, and no affinity (when tested at concentrations &gt;10-5 M) </ao:suffix>
    <ao:prefix> acts as an antagonist at other receptors, but with lower potency. </ao:prefix>
    <domeo:uuid>1230CFBE-6F41-4107-8D50-5F5A730D40C5</domeo:uuid>
    <ao:exact>Risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9AD8A1AA-8615-46DA-AE55-BBCBAC221CBF">
    <pav:createdOn>2014-07-22 18:52:22 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:3D195979-3E82-427D-95B8-F50F48DB4AA7</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-22 18:54:35 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:46500A6E-E71E-4137-BEB6-043CBB4397F1</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:CFD62BB2-11C8-4215-B304-C5A0146A8A66"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9273B7AD-9357-4702-9126-48471F347ED0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-24 20:05:44 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2342B6D8-C79F-4015-BB88-4C2608E0EBC6"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-24 20:07:19 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1956FA88-0DCF-4091-9E82-114782E551B6">
    <domeo:belongsToSet>urn:domeoclient:uuid:B6F745E6-5734-4636-A383-683BA4C79E38</domeo:belongsToSet>
    <pav:createdOn>2014-07-21 21:26:46 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:819F1E61-50CC-41FC-9596-57CE5DC96A2C"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:01711B7F-9102-4563-BBBC-CEC29491356C</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-21 21:27:51 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ECBE6688-F3FC-4F3A-AB24-57398C040B44">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2A2B8454-0B34-43FC-8C83-D2580B9D07B1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C2CFA62-3DF2-413F-9AE0-376E0D06DC3C">
    <ao:prefix>Smokers had a 25% increase in the metabolism of </ao:prefix>
    <ao:suffix> compared to nonsmokers.</ao:suffix>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5C2CFA62-3DF2-413F-9AE0-376E0D06DC3C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>5C2CFA62-3DF2-413F-9AE0-376E0D06DC3C</domeo:uuid>
    <pav:createdOn>2014-09-02 11:49:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D6127232-F0FF-46A9-830F-67E3832E779A">
    <ao:context rdf:resource="urn:domeoclient:uuid:41C681E8-1D19-42FD-B50F-1189BEEA2B54"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 15:08:17 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:C4E518E3-AA88-46AF-85A6-8C02ABD7AB1D</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:E40335DD-BC65-49CD-BC0F-8BBE782D757E</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 15:08:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ECE7CA77-7E57-44B0-89AE-B78915FEC8C2">
    <ao:body rdf:nodeID="N2c54d7c3b3e746aa853ae0a181ca0c5c"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-22 19:43:29 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lastSavedOn>2014-07-22 19:44:46 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:2490C71A-5328-4CD0-A630-7A3E5DC56DAB"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:514BA51B-D734-4003-A7C3-F03C0F95833A</pav:previousVersion>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55F0E65E-65B9-4FEF-9D48-18521D03D3DC">
    <pav:createdOn>2014-09-02 19:08:48 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:0B3AC343-21C5-41C7-88CD-1F70840866D0</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:3E420EBD-D4BF-4705-A9AE-EDDA116820D1"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7956E8A3-C5E3-47AD-A166-8DD4306EBB1D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-28 17:01:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7956E8A3-C5E3-47AD-A166-8DD4306EBB1D</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7956E8A3-C5E3-47AD-A166-8DD4306EBB1D"/>
    <ao:prefix> is contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitors or those who have recently received such agents. Therapeutic doses of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-165.txt.html</ao:hasSource>
    <ao:suffix> have occasionally precipitated unpredictable, severe, and occasionally fatal reactions in patients who have received such agents within 14 days. The mechanism of these reactions is unclear, but may be related to a preexisting hyperphenylalaninemia. Some</ao:suffix>
    <ao:exact>meperidine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C5023B49-22AF-4880-9F9A-B1FCB16EAE71">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C5023B49-22AF-4880-9F9A-B1FCB16EAE71"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or </ao:suffix>
    <ao:prefix>Oral contraceptives were administered as a single dose both before and after the oral administration of </ao:prefix>
    <pav:createdOn>2014-07-13 12:42:01 -0400</pav:createdOn>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C5023B49-22AF-4880-9F9A-B1FCB16EAE71</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E6639F4-F4C8-45C0-82E0-34A805D7B468">
    <ao:suffix>with </ao:suffix>
    <ao:prefix>Co-administration of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-134.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 19:55:04 -0400</pav:createdOn>
    <domeo:uuid>4E6639F4-F4C8-45C0-82E0-34A805D7B468</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4E6639F4-F4C8-45C0-82E0-34A805D7B468"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>chlorpromazine </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6793D5D8-D5E4-4015-B012-93740E224E6E">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 11:46:17 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:95CC663C-8F74-4A62-BE19-7170368BDA5F"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8ED4F58C-10A8-4F3A-8776-FD6D08A25610">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:11:00 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%. Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites. High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), an</ao:suffix>
    <domeo:uuid>8ED4F58C-10A8-4F3A-8776-FD6D08A25610</domeo:uuid>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> and α1-acid glycoprotein. The plasma protein binding of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8ED4F58C-10A8-4F3A-8776-FD6D08A25610"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E420EBD-D4BF-4705-A9AE-EDDA116820D1">
    <ao:suffix>. In these patients, mixed agonist/antagonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <ao:exact>oxycodone hydrochloride</ao:exact>
    <pav:createdOn>2014-09-02 19:08:48 -0400</pav:createdOn>
    <ao:prefix>) to patients who have received or are receiving a course of therapy with a pure opioid agonist analgesic such as </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E420EBD-D4BF-4705-A9AE-EDDA116820D1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>3E420EBD-D4BF-4705-A9AE-EDDA116820D1</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nec26fd5ce7aa49f289371fa49a428476">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5CFC30D6-1C24-402D-845E-93F7BF5F0922">
    <pav:createdOn>2014-09-02 12:02:37 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BFB51383-F8CA-4B7D-AF51-8BC2302A8276"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:67B51F20-AA33-44F4-AC6E-1115C0BA7889">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:67B51F20-AA33-44F4-AC6E-1115C0BA7889"/>
    <ao:prefix> hydrochloride tablets should be taken shortly after a meal or light snack. Symptomatic relief may be seen during the first week, with optimal antidepressant effects typically evident within two weeks. Twenty-five percent of those who respond to </ao:prefix>
    <ao:suffix> require more than two weeks (up to four weeks) of drug administration.</ao:suffix>
    <domeo:uuid>67B51F20-AA33-44F4-AC6E-1115C0BA7889</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-138.txt.html</ao:hasSource>
    <ao:exact>trazodone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-24 20:05:09 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B0374C4-A360-43F1-A6B7-10442B0A8905">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8B0374C4-A360-43F1-A6B7-10442B0A8905"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> is reduced by co-administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, leading to a two-three fold increased blood concentration and greater degrees of clinical beta-blockade.</ao:suffix>
    <ao:exact>quinidine</ao:exact>
    <pav:createdOn>2014-07-24 19:38:25 -0400</pav:createdOn>
    <domeo:uuid>8B0374C4-A360-43F1-A6B7-10442B0A8905</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-125.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A960BCB-9A9F-4998-9418-33D622C35F7C">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 19:24:47 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7FB9730F-B82C-4408-87AE-CE704E2BFD12"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7882D277-8513-479D-B463-EFE36E633410">
    <ao:prefix>Concomitant administration of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7882D277-8513-479D-B463-EFE36E633410"/>
    <domeo:uuid>7882D277-8513-479D-B463-EFE36E633410</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:suffix>and voriconazole (a combined inhibitor of CYP2C19 and CYP3A4) resulted in more than doubling of the omeprazole exposure. Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 19:13:48 -0400</pav:createdOn>
    <ao:exact>omeprazole </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20DF2C21-448E-4857-BAE0-83C2A6124710">
    <pav:createdOn>2014-07-24 19:47:04 -0400</pav:createdOn>
    <domeo:uuid>20DF2C21-448E-4857-BAE0-83C2A6124710</domeo:uuid>
    <ao:suffix> did not have a significant effect on propranolol’s pharmacokinetics.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-130.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:20DF2C21-448E-4857-BAE0-83C2A6124710"/>
    <ao:prefix> with the long-acting </ao:prefix>
    <ao:exact>propranolol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/B6FF0814-E04F-4FA2-8963-BC913DC8898E">
    <rdfs:label>antacid</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D39A9499-CCA7-4666-A0EC-BE7D45405E91">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D39A9499-CCA7-4666-A0EC-BE7D45405E91"/>
    <ao:prefix> administration (250 mg b.i.d. initially for 1 day followed by 300 mg QD for 3 to 4 days) resulted in an approximately 50% reduction in </ao:prefix>
    <domeo:uuid>D39A9499-CCA7-4666-A0EC-BE7D45405E91</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-201.txt.html</ao:hasSource>
    <ao:exact>methadone</ao:exact>
    <pav:createdOn>2014-07-28 17:04:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> exposure and withdrawal symptoms occurred concurrently. Upon discontinuation of phenytoin, the incidence of withdrawal symptoms decreased and methadone exposure increased to a level comparable to that prior to phenytoin administration.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE0F6228-C669-47FF-9D22-04B7A608D69E">
    <ao:exact>orazepam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:38:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EE0F6228-C669-47FF-9D22-04B7A608D69E"/>
    <ao:prefix> maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of l</ao:prefix>
    <ao:suffix> (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam</ao:suffix>
    <domeo:uuid>EE0F6228-C669-47FF-9D22-04B7A608D69E</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4515CD24-4667-47E1-80AE-FBC3F30BFD11">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4515CD24-4667-47E1-80AE-FBC3F30BFD11"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is n</ao:suffix>
    <pav:createdOn>2014-09-01 15:57:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4515CD24-4667-47E1-80AE-FBC3F30BFD11</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <ao:exact>cisapride </ao:exact>
    <ao:prefix>, or </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC27080F-C738-4176-9E15-7672938F5DF3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AC27080F-C738-4176-9E15-7672938F5DF3"/>
    <pav:createdOn>2014-09-02 11:39:02 -0400</pav:createdOn>
    <domeo:uuid>AC27080F-C738-4176-9E15-7672938F5DF3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix>Alcohol: Studies involving single 40 g doses of </ao:prefix>
    <ao:suffix> (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other. As with other psychotropic medication</ao:suffix>
    <ao:exact>ethanol</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/4B3161A8-052C-446A-A771-EB9186F64AD8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7646</dailymed:activeMoietyRxCUI>
    <rdfs:label>omeprazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F81F868-415D-4A79-8A62-6366850D49AA">
    <ao:exact>digoxin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>(8 mg once daily) for 14 days did not alter the steady-state pharmacokinetics of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:suffix> (0.375 mg once daily) in healthy volunteers.</ao:suffix>
    <pav:createdOn>2014-07-22 20:20:26 -0400</pav:createdOn>
    <domeo:uuid>4F81F868-415D-4A79-8A62-6366850D49AA</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4F81F868-415D-4A79-8A62-6366850D49AA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF3DBDD7-1816-4E91-BF27-7D21BEF67A06">
    <pav:createdOn>2014-07-07 11:37:21 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor saquinavir, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CF3DBDD7-1816-4E91-BF27-7D21BEF67A06"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>CF3DBDD7-1816-4E91-BF27-7D21BEF67A06</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D05E9B7E-AE50-4FCD-BC2D-B3A39CEF8396">
    <pav:createdOn>2014-07-24 19:54:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-24 19:54:28 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E7176E11-44D4-4336-A0B0-21D16F8910C5"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:A8E97F89-BD6B-481E-9E5B-A03025E04E7D</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:8AA46BC0-EA66-4E73-81A9-6463BB4DE15B</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:807433B2-EB3F-4CEF-824C-1D71920A4C22">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:08F7FCFD-3C5E-46FE-8EDA-8ED22CA77882"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 19:13:55 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CF243312-0709-454B-9D42-8D2FEDA95D55">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6D31780D-83B2-4F04-8282-BA0D62D2F386"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F044222C-AB83-4B62-B72A-FD9B65C89DD6">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>AVANDIA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/261455</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4C6E4A21-6D29-4DFC-BCC7-71D10F66BA88">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-21 21:28:38 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:D9B4B7F7-2711-4353-9C2F-C940C1013315</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:B394B422-1AAF-4ED4-A3BB-3FB13E961EEA</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E67991C8-7BD1-474A-98AE-6F58A72C0A35"/>
    <pav:lastSavedOn>2014-07-21 21:30:24 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:390CA5FE-7939-4F69-B612-7F5C21A06481">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:1085914C-2530-49EB-92B4-1E4BC17AEBAC"/>
    <pav:lastSavedOn>2014-07-13 11:02:34 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71CADA90-E1E5-4B50-9394-FDFC0B1512B0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:9CBDBE67-2211-4254-BEF8-DDC84C5BB035</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:02:05 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DDEC112C-9331-4573-8A13-ED3D4798FE89">
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:8D86A4AC-54BD-4BB3-8B58-AB55DEC01A88</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:5701D17C-4067-47BA-ACBD-ED6053F1DE96"/>
    <pav:lastSavedOn>2014-07-24 20:10:48 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="N08de9a9d680b428bb076db7cf6b2b9e4"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-07-24 20:10:51 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:4A88D0A6-E9B6-4E7F-955F-3692600C178C</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5FBE9544-4653-482C-B065-70CA3AA07309">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other drugs meta</ao:suffix>
    <pav:createdOn>2014-07-13 11:15:53 -0400</pav:createdOn>
    <ao:exact>rifampin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>5FBE9544-4653-482C-B065-70CA3AA07309</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5FBE9544-4653-482C-B065-70CA3AA07309"/>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:346407F0-F265-40E8-A6A0-BB0525152D4E">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/60730FAE-AD66-492F-8E58-7FE659B7159F"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/DABEA160-744E-4F3F-99D1-342761D8E356"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/DF818BD4-17A0-4731-84D5-207257326816">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>propranolol</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9C71E884-F7BA-41EE-A3DD-8DAE2AB3D4C0">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/20398182-F09D-4166-8536-A74DA8BDB5D5"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/692FB180-95F1-4EAA-88D0-82BF4B541921"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F8E4E79-C59A-410E-ACD6-41B9C532F968">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-13 11:14:57 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:806597EC-5BAB-46E0-96D6-B25563A80A8C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:FDE2CC52-F5FC-4C63-AEAD-C53C36960021</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9AE25ABB-CFC2-479D-B1B0-184576D49108">
    <domeo:belongsToSet>urn:domeoclient:uuid:42248733-4719-42F4-8132-866191F8E708</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:8834E508-3DB6-40D4-997D-4BC1EFD12E61</pav:lineageUri>
    <pav:createdOn>2014-07-21 21:43:20 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:846B6C02-30BD-4750-BAD3-4CC242462EE4"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-21 21:44:00 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DFF0F114-795C-4A7F-B8CF-1A970C7B1D1A">
    <pav:createdOn>2014-09-02 15:05:19 -0400</pav:createdOn>
    <ao:prefix>Administration of </ao:prefix>
    <domeo:uuid>DFF0F114-795C-4A7F-B8CF-1A970C7B1D1A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-70.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DFF0F114-795C-4A7F-B8CF-1A970C7B1D1A"/>
    <ao:suffix> within 2 hours of antacids containing aluminum oxide and magnesium hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Admin</ao:suffix>
    <ao:exact>sotalol</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:735CA4BD-A16D-4729-BFC3-96D72BFE5B0B">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:007F6835-1CAF-4F0B-8BFD-311D8BFD8926"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:996DAC66-98E7-4BAE-90CA-B2474D43F8E1</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-07 11:23:01 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42B2FE1C-E6AF-411B-A916-428E36F4B282">
    <ao:exact>trazodone </ao:exact>
    <ao:prefix> (50 mg) has been studied in 10 healthy subjects. The Cmax of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> increased by 34%, the AUC increased 2.4 fold, the half-life increased by 2.2 fold, and the clearance decreased by 52%. Adverse effects including nausea, hypotension, and syncope were observed when ritonavir and trazodone were coadministered.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:42B2FE1C-E6AF-411B-A916-428E36F4B282"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>42B2FE1C-E6AF-411B-A916-428E36F4B282</domeo:uuid>
    <pav:createdOn>2014-07-24 20:02:19 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-136.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD52F407-3F2E-43FA-A8DA-659510309A62">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A4CCAADB-C549-4258-8D06-8971C53D94D8"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:778C0BF9-5A4D-40AD-B741-BA2E9EEA8CD8</pav:lineageUri>
    <pav:createdOn>2014-09-01 16:22:20 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:215CE713-9F50-45C2-808D-0725CC11DF6D</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-01 16:22:41 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N10b60bd7938c48b7b6ed8b046e5a9a9e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57427A36-AF04-4B9A-A5C2-85D0AE5CA845">
    <domeo:uuid>57427A36-AF04-4B9A-A5C2-85D0AE5CA845</domeo:uuid>
    <ao:suffix>, ampicillin esters, and iron salts). In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.</ao:suffix>
    <pav:createdOn>2014-09-02 19:12:09 -0400</pav:createdOn>
    <ao:prefix>Because of its profound and long lasting inhibition of gastric acid secretion, it is theoretically possible that omeprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (e.g., </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:57427A36-AF04-4B9A-A5C2-85D0AE5CA845"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>ketoconazole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:095C4B55-33C1-4413-83DF-963BC2158506">
    <pav:lineageUri>urn:domeoserver:annotation:390EB652-B284-46B4-B184-503F54659708</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:08:37 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:3D56C301-550F-4FAE-8357-941B7D128A4B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/830A06B9-325D-4AF2-8757-EF2CC57EB2F9">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>desipramine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:01B5F725-B643-43F6-B470-6409EC7AE08D">
    <ao:context rdf:resource="urn:domeoclient:uuid:B4A07D2A-59AD-4845-9180-9D26F251F26E"/>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:60CFA2CD-757B-43D2-A98C-0ED2D3BDE041</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-09-02 11:58:55 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CDF62581-CF1E-49F8-8077-2328677F5CAD">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DFEFC5E6-CD9E-430A-AB17-673B60C626A3"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60E67041-A9C9-414B-A575-799C5BAFAF37">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>60E67041-A9C9-414B-A575-799C5BAFAF37</domeo:uuid>
    <ao:exact>astemizole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 15:04:23 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
    <ao:prefix>, </ao:prefix>
    <ao:suffix>, cisapride, triazolam, and cyclosporine. Based on the assumption that the relationship between paroxetine’s in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, paroxetine’s extent of inhi</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:60E67041-A9C9-414B-A575-799C5BAFAF37"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3558088E-2467-4C3A-87EA-D9EA80C217D1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>plasma oxycodone</ao:exact>
    <ao:prefix>, a drug metabolizing enzyme inducer, significantly decreased </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3558088E-2467-4C3A-87EA-D9EA80C217D1"/>
    <pav:createdOn>2014-09-02 19:09:44 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <ao:suffix> concentrations. Induction of CYP3A4 activity by its inducers, such as rifampin, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycod</ao:suffix>
    <domeo:uuid>3558088E-2467-4C3A-87EA-D9EA80C217D1</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AB3B0778-C37A-4D38-B2AC-7049DC5E2EE9">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D8D922B0-F01D-471E-B5F5-F72185F3B01C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F1ACE0D3-FA23-46EC-ACAA-40836B0D32A9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:326B6DC1-778C-4951-9B8A-4B76A407BA1D">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2CD22D95-BDF9-4FBD-98F2-9CC6023043DD"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6D3CB53E-CF58-4136-8B4C-980888C68920">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:697447CC-E28E-42D6-889F-E4B9D46954FC"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47492213-15E8-4498-83DF-D443A77CE0C4">
    <ao:exact>Rosiglitazone</ao:exact>
    <domeo:uuid>47492213-15E8-4498-83DF-D443A77CE0C4</domeo:uuid>
    <pav:createdOn>2014-07-22 19:08:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:47492213-15E8-4498-83DF-D443A77CE0C4"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix>, a member of the thiazolidinedione class of antidiabetic agents, improves glycemic control by improving insulin sensitivity. </ao:prefix>
    <ao:suffix> is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-gamma (PPARγ). In humans, PPAR receptors are found in key target tissues for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPA</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F243BA5-FCEC-4956-AF25-0E751A006E5C">
    <ao:suffix> administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug. The clinical significance of thi</ao:suffix>
    <domeo:uuid>6F243BA5-FCEC-4956-AF25-0E751A006E5C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-01 15:59:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>following an intravenous 1000 mg dose. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6F243BA5-FCEC-4956-AF25-0E751A006E5C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-17.txt.html</ao:hasSource>
    <ao:exact>Sertraline</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D32DB27C-3D8E-46AF-87F9-8A3307B5D13B">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:2FF47DA5-4366-4BC2-AA71-7E8F63D7F2AA"/>
    <pav:lastSavedOn>2014-09-02 15:04:32 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:32CAAE58-D8E1-40B0-8139-A1D54B51BEEE</pav:lineageUri>
    <pav:createdOn>2014-09-02 15:04:10 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:C4B80A95-F569-4ED4-84D1-6796B53A580C</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83CCA675-BEDD-43C9-AB17-7E503848F851">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:39:08 -0400</pav:createdOn>
    <domeo:uuid>83CCA675-BEDD-43C9-AB17-7E503848F851</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> (oral administration in one study and intravenous in the other) and multiple dosing with </ao:prefix>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83CCA675-BEDD-43C9-AB17-7E503848F851"/>
    <ao:suffix> maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other. As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CEE8C6E7-92B6-4611-A8A6-213D50A907B1">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CEE8C6E7-92B6-4611-A8A6-213D50A907B1"/>
    <ao:exact>An inhibitor of CYP2C8 (e.g., gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (e.g., rifampin) may decrease the AUC of rosiglitazone. Therefore, if an inhibitor or an inducer of CYP2C8 is started or stopped during treatment with rosiglitazone, changes in diabetes treatment may be needed based upon clinical response.</ao:exact>
    <pav:createdOn>2014-07-22 19:08:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> [See Clinical Pharmacology (12.4).]</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-122.txt.html</ao:hasSource>
    <domeo:uuid>CEE8C6E7-92B6-4611-A8A6-213D50A907B1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B7317CD-AFB7-45AB-8141-DD5FD3B899F5">
    <pav:createdOn>2014-07-24 20:11:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>ketoconazole</ao:exact>
    <domeo:uuid>5B7317CD-AFB7-45AB-8141-DD5FD3B899F5</domeo:uuid>
    <ao:suffix> or erythromycin coadministration enhances fexofenadine gastrointestinal absorption. This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. In vivo animal studies also suggest that i</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5B7317CD-AFB7-45AB-8141-DD5FD3B899F5"/>
    <ao:prefix>The mechanism of these interactions has been evaluated in in vitro, in situ, and in vivo animal models. These studies indicate that </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3A608F7-C1CD-4106-B1C6-F80BB86494C0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E3A608F7-C1CD-4106-B1C6-F80BB86494C0"/>
    <ao:prefix>In vitro data suggest that </ao:prefix>
    <ao:suffix> is a relatively weak inhibitor of CYP2D6.</ao:suffix>
    <pav:createdOn>2014-09-02 11:30:53 -0400</pav:createdOn>
    <domeo:uuid>E3A608F7-C1CD-4106-B1C6-F80BB86494C0</domeo:uuid>
    <ao:exact>fluvoxamine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:985C3233-0D87-48CA-9DDA-A1D83B9FCA6D">
    <ao:exact>paroxetine</ao:exact>
    <ao:prefix>An in vivo interaction study involving the coadministration under steady-state conditions of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:985C3233-0D87-48CA-9DDA-A1D83B9FCA6D"/>
    <pav:createdOn>2014-09-02 15:03:58 -0400</pav:createdOn>
    <domeo:uuid>985C3233-0D87-48CA-9DDA-A1D83B9FCA6D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> and terfenadine, a substrate for  CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics. In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetin</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc9aeff62f6cd48a09527e42e3bd3c5ea">
    <domeo:sets rdf:resource="urn:pddi:uuid:2FB03C2F-1973-4F66-AF66-7DEAA97D5719"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A95EA236-59E2-47FB-878A-81116D82930F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A95EA236-59E2-47FB-878A-81116D82930F</domeo:uuid>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> occurred at about 1 hour. Peak concentrations of 9-hydroxyrisperidone occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and w</ao:suffix>
    <pav:createdOn>2014-07-13 11:10:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A95EA236-59E2-47FB-878A-81116D82930F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0CE6C620-40B4-4E55-8185-8A319ECD6D71">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:553A6608-733A-477E-BDCB-F0D16F1054E3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78A5F631-80CE-4FB1-974D-F82BE8D8E584">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CCA3540C-4A74-4782-9325-18A999F61C75"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-22 19:11:48 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-22 19:11:40 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EB7D7E2-B15C-4936-A208-A041FD22D74F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
    <domeo:uuid>2EB7D7E2-B15C-4936-A208-A041FD22D74F</domeo:uuid>
    <pav:createdOn>2014-07-21 21:31:24 -0400</pav:createdOn>
    <ao:exact>fluconazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2EB7D7E2-B15C-4936-A208-A041FD22D74F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, from 7.6 ± 3.6 to 5.7 ± 2.2.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8E504B5-222C-4BAE-88E1-E79A32308174">
    <pav:lastSavedOn>2014-07-24 20:04:12 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-24 20:03:38 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:F70AB841-7C14-48D1-B543-A45EA067C642</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:16C3044F-D627-4305-8565-E4F15BE17B40</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:7EEF7294-F55C-48E2-8A50-69D9A3726172"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EAE18A28-D547-4A0F-951B-598FF59A2D26">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-07-22 18:54:36 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:D2959471-DB15-4D27-9C9C-2AEF6BC7E79F</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:856ADB71-F8FC-4B9D-8651-B139286C3B33"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 18:54:35 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N8de555767fe64ef08c999345c83bdc4a"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:3D195979-3E82-427D-95B8-F50F48DB4AA7</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:806597EC-5BAB-46E0-96D6-B25563A80A8C">
    <domeo:uuid>806597EC-5BAB-46E0-96D6-B25563A80A8C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have not been evaluated, but observations in a modest number (N≅70) of poor metabolizers given risperidone </ao:suffix>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:806597EC-5BAB-46E0-96D6-B25563A80A8C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a </ao:prefix>
    <pav:createdOn>2014-07-13 11:14:57 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/9C6B1447-979C-42A2-8477-0513E82FA0CC">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Synercid</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/135097</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/10A838C4-49F6-43A9-A4D2-77899C57569E">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/261455</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>AVANDIA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:265209EB-0CE8-478A-9C0E-59E0095E0A6B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:265209EB-0CE8-478A-9C0E-59E0095E0A6B"/>
    <ao:exact>tacrine</ao:exact>
    <pav:createdOn>2014-09-02 11:41:26 -0400</pav:createdOn>
    <ao:suffix>.</ao:suffix>
    <domeo:uuid>265209EB-0CE8-478A-9C0E-59E0095E0A6B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix>e- and eight-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3EE823B0-79E2-43AF-B47E-C72BE189895E">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-21 21:35:10 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:B61F1A9B-4696-4ED0-80AA-4FE2E9016966</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:6055A20F-073A-4F5E-A069-540422439AFA</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:33:53 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:FCB07677-3685-4C25-935B-67786B32E56B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BAFAC6A6-4A37-498B-BA86-449A697DAA80">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:70094340-3BB3-42EB-8579-D2FEE274AB33"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF575835-131F-4DD9-876A-6D2B6D7A7744">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>atomoxetine</ao:exact>
    <ao:prefix> 20 mg daily was given in combination with 20 mg </ao:prefix>
    <pav:createdOn>2014-09-02 11:58:31 -0400</pav:createdOn>
    <domeo:uuid>BF575835-131F-4DD9-876A-6D2B6D7A7744</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BF575835-131F-4DD9-876A-6D2B6D7A7744"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <ao:suffix> every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of atomoxetine may be</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9B027AFC-3BAE-4FDC-889F-813F2AD35C5A">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D318A30A-F708-43F6-AB5B-A9D659E063BF"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08D219B2-A0EC-49C7-A943-47EE7CE4B542">
    <domeo:belongsToSet>urn:domeoclient:uuid:94DCE217-B72B-4727-9783-98D7EFCB02E6</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:21A6A401-CC93-4E3D-8008-3C8347574A85"/>
    <pav:lastSavedOn>2014-09-01 16:20:01 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-01 16:19:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:F08B1EA8-F65C-40FB-B1FA-F3BC3C80E89D</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/E2F95CEA-24A5-407F-856C-8C142EEA5626">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F9EAA1C1-5B83-488C-8314-2E971233350A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-51.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F9EAA1C1-5B83-488C-8314-2E971233350A"/>
    <pav:createdOn>2014-07-21 21:44:10 -0400</pav:createdOn>
    <domeo:uuid>F9EAA1C1-5B83-488C-8314-2E971233350A</domeo:uuid>
    <ao:exact>Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy). </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7AD1296-3138-4E05-ACC3-466E8259339A">
    <ao:exact> In 1 study, daily dosing of immediate-release paroxetine (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. </ao:exact>
    <ao:prefix> dosing.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E7AD1296-3138-4E05-ACC3-466E8259339A</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E7AD1296-3138-4E05-ACC3-466E8259339A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Concomitant use of</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 12:00:11 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2D1A706-CE7E-4379-97CF-4EE9CA384DB2">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:createdOn>2014-07-22 19:31:11 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:7E80543E-BF76-4514-92A9-91458DCB802B</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:04B30485-E368-4D5D-ABB9-17EBA8B817CD"/>
    <pav:lastSavedOn>2014-07-22 19:35:16 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62CEF929-8FCC-4F3F-8B23-F0215966A438">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>62CEF929-8FCC-4F3F-8B23-F0215966A438</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:62CEF929-8FCC-4F3F-8B23-F0215966A438"/>
    <ao:exact>Glimepiride</ao:exact>
    <pav:createdOn>2014-07-22 19:53:07 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D555EE88-9218-4AF9-81CC-40D543746D77">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-07-22 19:12:55 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:097BBD64-4910-4F32-9440-9A37CCEA09F8"/>
    <pav:previousVersion>urn:domeoclient:uuid:BE4B86AC-FE5F-4543-A713-EC5B852A5A2A</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 19:15:50 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD929BB0-93FC-4E77-9CA8-72C96F88EBB3">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:A2F4B6D6-7CF7-42D6-A019-60A8CCB4F364"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:FBC12C20-ABFB-48FF-87DF-D79ED53A9F20</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:55:29 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/C9B2FC03-3B32-472D-B469-B9F86400F4C6">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <rdfs:label>risperidone</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38A0F3BF-9F6A-4A3D-89AB-BD75B2AC4CE8">
    <domeo:uuid>38A0F3BF-9F6A-4A3D-89AB-BD75B2AC4CE8</domeo:uuid>
    <ao:suffix> in patients with mild to severe renal impairment or in hemodialysis-dependent patients compared to subjects with normal renal function. No dosage adjustment is therefore required in such patients receiving AVANDIA. Since metformin is contraindicated in </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 19:36:20 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:38A0F3BF-9F6A-4A3D-89AB-BD75B2AC4CE8"/>
    <ao:exact>rosiglitazone</ao:exact>
    <ao:prefix>There are no clinically relevant differences in the pharmacokinetics of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4683A379-9BF3-47AD-B269-BF50998FE88B">
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:52AE2649-A143-4E37-A21D-82019096A697"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:B8091647-B5DD-4576-A186-2BCF2E1FA6BF</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:08:35 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C53D58B-D2A3-4A8C-9924-E26E43A59105">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:7E80543E-BF76-4514-92A9-91458DCB802B</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:35:16 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-22 19:35:05 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:5C74E3FF-0F23-47DF-BFE0-C6FFA3577DFE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05003F42-3401-4DB3-B275-544005230F77">
    <ao:prefix>. Based on the assumption that the relationship between </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:05003F42-3401-4DB3-B275-544005230F77"/>
    <domeo:uuid>05003F42-3401-4DB3-B275-544005230F77</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>’s in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, paroxetine’s extent of inhibition of CYP3A4 activity is not likely to be of clinical significance.</ao:suffix>
    <pav:createdOn>2014-09-02 15:04:30 -0400</pav:createdOn>
    <ao:exact>paroxetine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:581B1F88-8814-40C0-9F72-77FEA7E30122">
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 11:49:28 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5C2CFA62-3DF2-413F-9AE0-376E0D06DC3C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 11:49:17 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:3F546823-204F-4F9B-9006-3DC526C56931</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na0c1c81902814ffeb9ff4fba3348b2c8">
    <domeo:sets rdf:resource="urn:pddi:uuid:C2471146-B114-47FF-BB78-F58B6158FB99"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:34C208E6-0FE1-4394-8496-13F4C10CB492">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. </ao:prefix>
    <ao:suffix> did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known.</ao:suffix>
    <ao:exact>Citalopram</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-78.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:38:22 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:34C208E6-0FE1-4394-8496-13F4C10CB492"/>
    <domeo:uuid>34C208E6-0FE1-4394-8496-13F4C10CB492</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3FDC3F96-3CFF-46A2-ABE6-20195EB336B0">
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:9BDFA0ED-9096-4328-B514-6A94D7426FE7"/>
    <pav:lastSavedOn>2014-07-24 19:43:34 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:D828BA61-D00D-4D81-84AD-C53D822CACC1</pav:lineageUri>
    <ao:body rdf:nodeID="N6caa0159f543400998e47aec2eeb1674"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:7DEB6848-E3C6-4761-8965-41F19EE5D781</domeo:belongsToSet>
    <pav:createdOn>2014-07-24 19:43:48 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38A85164-B87B-441D-87CB-0E3B5B67551D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:38A85164-B87B-441D-87CB-0E3B5B67551D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:36:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>38A85164-B87B-441D-87CB-0E3B5B67551D</domeo:uuid>
    <ao:suffix>. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at </ao:suffix>
    <ao:exact>phenytoin</ao:exact>
    <ao:prefix> and </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DDFAFFA-5DE6-4D3B-BC30-6421E6531AD8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:41:59 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>levonorgestrel</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0DDFAFFA-5DE6-4D3B-BC30-6421E6531AD8"/>
    <ao:suffix> AUC after the administration of 50 mg of fluconazole. The mean increase in ethinyl estradiol AUC was 6% (range: -47 to 108%) and levonorgestrel AUC increased 17% (range: -33 to 141%).</ao:suffix>
    <domeo:uuid>0DDFAFFA-5DE6-4D3B-BC30-6421E6531AD8</domeo:uuid>
    <ao:prefix>Oral contraceptives were administered as a single dose both before and after the oral administration of fluconazole 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in ethinyl estradiol or </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:19EC0F23-10DE-4B34-BA59-B2E33CFE1030">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/25CF5D55-E18C-41A3-8548-34F37BD2A10A"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/E5F7CCC2-0F44-40A0-87D9-225E3A4EAC91"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4EA61C9-E628-4806-856F-9D86959C5B20">
    <ao:exact>cisapride </ao:exact>
    <pav:createdOn>2014-09-01 16:05:58 -0400</pav:createdOn>
    <ao:suffix>under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertraline’s extent of inhibition of P450 3A4 activity is n</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4EA61C9-E628-4806-856F-9D86959C5B20"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, or </ao:prefix>
    <domeo:uuid>D4EA61C9-E628-4806-856F-9D86959C5B20</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40F97AE4-1A18-4FD3-B30C-9226F8465F7B">
    <ao:suffix>200 mg daily for 14 days in 16 normal male volunteers. There were significant increases in theophylline AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD theophylline AUC increased 21% ± 16% (range: -5 to 48%). The Cmax i</ao:suffix>
    <ao:exact>fluconazole </ao:exact>
    <domeo:uuid>40F97AE4-1A18-4FD3-B30C-9226F8465F7B</domeo:uuid>
    <pav:createdOn>2014-07-21 21:33:50 -0400</pav:createdOn>
    <ao:prefix>(6 mg/kg) before and after the oral administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:40F97AE4-1A18-4FD3-B30C-9226F8465F7B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA8C16C4-EEEA-4E22-BEA7-98D738176A08">
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:D87F2CD3-CBAA-4935-84B1-F85E0D5E7632</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:BF575835-131F-4DD9-876A-6D2B6D7A7744"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-02 11:58:31 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2490C71A-5328-4CD0-A630-7A3E5DC56DAB">
    <domeo:uuid>2490C71A-5328-4CD0-A630-7A3E5DC56DAB</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Concomitant administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and rosiglitazone (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when gemfibrozil is introduced</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 19:44:51 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2490C71A-5328-4CD0-A630-7A3E5DC56DAB"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95AEC430-A2F4-4B0D-B623-70050D7B891E">
    <ao:context rdf:resource="urn:domeoclient:uuid:CC861D6D-4076-4F69-B134-B404C685F91A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:EB8C6594-359A-42D0-A03E-A9374296DDDA</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-13 11:18:24 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:58965DB7-A15D-49D8-BC77-60DF512B6132">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:72D01271-A1C0-4012-BD2D-70CB0846FFF5"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A87B61D2-D72C-42FD-B166-A4440E8574B1">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/8F36BE9D-F662-4788-A209-5115C542C5AE"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/4BCAA30A-4939-4A50-A548-16A452EDFC69"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2C43BBB-3043-4AE4-89EE-69DCE07C3309">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>trazodone</ao:exact>
    <domeo:uuid>D2C43BBB-3043-4AE4-89EE-69DCE07C3309</domeo:uuid>
    <pav:createdOn>2014-07-24 20:03:53 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2C43BBB-3043-4AE4-89EE-69DCE07C3309"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-137.txt.html</ao:hasSource>
    <ao:prefix> reduced plasma concentrations of </ao:prefix>
    <ao:suffix> (as well as mCPP) by 76 and 60%, respectively, compared to pre-carbamazepine values.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B60DE0C-DAD3-497E-B767-27CC4F4AA306">
    <pav:createdOn>2014-09-02 11:58:26 -0400</pav:createdOn>
    <domeo:uuid>5B60DE0C-DAD3-497E-B767-27CC4F4AA306</domeo:uuid>
    <ao:prefix> has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, </ao:prefix>
    <ao:suffix> 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxet</ao:suffix>
    <ao:exact>paroxetine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5B60DE0C-DAD3-497E-B767-27CC4F4AA306"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F3D5E3DD-A431-4A01-92CB-C01ED4EF9988">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4A35ABC4-4C04-40DD-A14B-E710CC4288AE"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6F0B480-ABD4-436B-8A6F-A4BD34827F73">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:11:27 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:945BD1E4-DE7D-4DBC-804B-A4E048F20780</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:30818391-5098-4A86-BF01-5AB0C0597335"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/DBA1F413-B42A-40DE-B1F5-8527CD8BE365">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>norverapamil</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N170f06b4eb99445f825536b64dc09b0c">
    <domeo:sets rdf:resource="urn:pddi:uuid:BC114E92-ED59-4D14-B788-57030FC75EBC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D7F3CF4B-F577-4BF7-B88B-B5D04D01A04A">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9A220CC1-B0E4-46E3-92ED-BA102CB9A99F"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1262FCE3-53B9-497A-AB5D-DA122BFC8786">
    <pav:lastSavedOn>2014-07-24 20:00:43 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-24 20:00:44 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0050ED6-BE4F-4871-9847-FC4493F22447</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:A8719BF8-41F7-424F-A7E0-D2E9708465A5</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:762110B9-8FE2-4631-8D47-86C30D8D9102"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D7A544C2-F82A-49C9-83A0-D19D9DDF7E00">
    <pav:createdOn>2014-07-22 20:20:12 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>D7A544C2-F82A-49C9-83A0-D19D9DDF7E00</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:exact>Coadministration of acarbose (100 mg three times daily) for 7 days in healthy volunteers had no clinically relevant effect on the pharmacokinetics of a single oral dose of AVANDIA.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D7A544C2-F82A-49C9-83A0-D19D9DDF7E00"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/B92741C4-FB91-4395-8B40-7C9F2438DDA0">
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/E02048B2-A2E1-475E-9345-1FE9194336FD">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9143</dailymed:activeMoietyRxCUI>
    <rdfs:label>ranitidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A2643B5-4BD1-4161-8CBE-473EFB4DDFC8">
    <pav:createdOn>2014-07-21 21:34:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="N3182aa97ea6247b4ad9b341aabfc05b9"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:B61F1A9B-4696-4ED0-80AA-4FE2E9016966</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:8BB0D7D8-E6FC-43D6-A047-53DA7C4A005E"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-21 21:35:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:06B071FC-227B-4B3A-85BA-6720A021449E</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC416A29-1315-42C5-90FA-652412A6AD12">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:8EA1563F-47E7-4983-918E-643A5D2021DC"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 09:40:48 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DC04223-08C0-4FC9-9E10-75D588673E2D">
    <pav:createdOn>2014-09-02 15:05:47 -0400</pav:createdOn>
    <domeo:uuid>5DC04223-08C0-4FC9-9E10-75D588673E2D</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-70.txt.html</ao:hasSource>
    <ao:prefix> result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the antacid two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5DC04223-08C0-4FC9-9E10-75D588673E2D"/>
    <ao:suffix>.</ao:suffix>
    <ao:exact>sotalol</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3762570C-CF43-4DB9-B163-FAA6DAE60017">
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:28EA3105-DAE4-4248-8C5A-EACDF44B4680"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-07 09:39:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6FF44D67-C048-4D48-95BC-9CAC7BF5E54F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-21 21:55:00 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:58BF67B8-BDBC-4A81-816F-832DAD1FC0F8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-21 21:52:26 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:C988D053-7CF3-4C50-BDB6-7C2B20B837B9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:5D24394F-4462-424E-8BC2-BB9AC13FAFF6</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfcf7dae047b740818bb2e4a71a46ec2d">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4FEA5923-D748-4E87-8041-D8BE9DFF7EAA">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-28 17:04:35 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:48D839E5-6B0A-4EC3-B64A-E3E20E06246A</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-28 17:08:37 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:D2F7CB67-D160-465A-9A39-FCF7F38FFD34</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D39A9499-CCA7-4666-A0EC-BE7D45405E91"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A30DCF7F-AD5F-403E-9FF6-A1CEC51B4252">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:16BAA0E0-EEEC-4785-9C63-DBB8909400D3"/>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:16:32 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N03320dcbcf444f378f68cdf86d042a09">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D10C9054-F924-40A5-9EDB-304BEF56C148">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Propranolol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/161695D1-EF44-45A7-B41B-A52C6CD2F783">
    <rdfs:label>midazolam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6960</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2F7D256-D331-45B3-9459-089EEB530262">
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:56C7D107-DA52-4259-9BBA-41DB4C5FB13D"/>
    <pav:createdOn>2014-07-22 19:38:28 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F230A2C-E15E-41D9-8781-4AF5CA3E381E">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:6DC77E85-D03E-4E33-9B0F-4B8826F63FA7</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 12:46:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C0DCB0F4-61CC-48CE-8688-567F2327B321"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C5BA635-EF8B-4165-A2A6-5832D61A15BF">
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 11:35:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:body rdf:nodeID="Nd3d447e214954d1e998f88bc7ff94378"/>
    <pav:lastSavedOn>2014-07-07 11:35:31 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:7AACEF8D-2EBC-4F0B-94B2-190650E562F6</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:5F97F910-5C88-42D5-BF36-6EFC8C9A3DD1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5B6732B-67A7-4A25-9BC2-70185A35217F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:601A10D5-2B9E-4942-8107-15DFA9C70ACF"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 19:13:08 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CA65F737-1E98-4A37-A7F1-220396E99856">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1BC59DC6-C39B-4F32-9DCC-98000370046A"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF8F1249-3CE1-41AF-B118-1647BE5597AF">
    <ao:exact>fluvoxamine</ao:exact>
    <domeo:uuid>FF8F1249-3CE1-41AF-B118-1647BE5597AF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> maleate and metoprolol.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FF8F1249-3CE1-41AF-B118-1647BE5597AF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of </ao:prefix>
    <pav:createdOn>2014-09-02 11:45:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N253bf09e590c4e1294545cf518145765">
    <domeo:sets rdf:resource="urn:pddi:uuid:FF394C23-B19D-4287-8ACE-54167C17E2D1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ECF8E578-9A91-41E0-91AC-502E097E5A11">
    <pav:createdOn>2014-07-07 11:23:40 -0400</pav:createdOn>
    <ao:suffix>administration.</ao:suffix>
    <ao:exact>sildenafil </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ECF8E578-9A91-41E0-91AC-502E097E5A11"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:43D41023-3393-411C-B3B2-FDFDACB25B35">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D47C4E1D-3FAD-4BB4-842A-3B71726A722C"/>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 11:30:03 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F9DA591-B9E4-4841-9D52-F5DDC170AE85">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <ao:prefix> (400 mg Q12h x 1 day, then 200 mg x 6 days) was given with </ao:prefix>
    <ao:suffix> (40 mg once daily x 7 days) to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times (90% CI: 1.8, 2.6) and 4 times (90% CI: 3.3, 4.4) respectively as compared to when omeprazole was given wi</ao:suffix>
    <ao:exact>omeprazole</ao:exact>
    <domeo:uuid>5F9DA591-B9E4-4841-9D52-F5DDC170AE85</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5F9DA591-B9E4-4841-9D52-F5DDC170AE85"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:16:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55E92945-9B4A-406D-8BFF-54471B2E432E">
    <ao:suffix> was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers. The pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, were similar in extensive and poor metabolizers, wi</ao:suffix>
    <pav:createdOn>2014-07-13 11:17:02 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55E92945-9B4A-406D-8BFF-54471B2E432E"/>
    <domeo:uuid>55E92945-9B4A-406D-8BFF-54471B2E432E</domeo:uuid>
    <ao:prefix> was 3 hours (CV=30%) in extensive metabolizers and 20 hours (CV=40%) in poor metabolizers. The apparent half-life of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1d9e4ff74e94474a8a976734e86a154d">
    <domeo:sets rdf:resource="urn:pddi:uuid:3A2D166B-BD0B-4C2A-9E40-D07C3CE85DBC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:257F4F5D-CCED-4AAD-9504-4A9F1A855C69">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:257F4F5D-CCED-4AAD-9504-4A9F1A855C69"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-09-02 11:43:36 -0400</pav:createdOn>
    <domeo:uuid>257F4F5D-CCED-4AAD-9504-4A9F1A855C69</domeo:uuid>
    <ao:suffix>- There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan. If concomitant treatment with sumatriptan and an SSRI </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:exact>Sumatriptan </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:797E523C-94FC-4569-A544-1F1C2179E9C1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> AUC and Cmax slightly increased following coadministration of AVANDIA.</ao:suffix>
    <ao:exact>glyburide</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 19:49:34 -0400</pav:createdOn>
    <ao:prefix> (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%. In Japanese subjects, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:797E523C-94FC-4569-A544-1F1C2179E9C1"/>
    <domeo:uuid>797E523C-94FC-4569-A544-1F1C2179E9C1</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:986D80D9-D47C-41ED-95FE-F55B1AE2AC9D">
    <pav:createdOn>2014-07-24 20:11:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:00F781B7-912F-4DC4-ACCE-83BA41B12A3F</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:5B7317CD-AFB7-45AB-8141-DD5FD3B899F5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8186AE14-85DE-4E1A-B5F4-BC58233DC47B">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:43E08535-8340-472C-92D9-100ECFA2CB93"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:22A46207-521A-4D8F-8D17-31F7E25F3B95">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DFE53F7D-4938-4208-8BAE-E74CAD65CFE9"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A16A73F6-04A0-4350-B482-E365FE1CCB81">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Tryptophan</ao:exact>
    <ao:suffix>: Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution. Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan (see WARNINGS AND PRECAUTIONS</ao:suffix>
    <pav:createdOn>2014-09-02 11:43:38 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A16A73F6-04A0-4350-B482-E365FE1CCB81"/>
    <domeo:uuid>A16A73F6-04A0-4350-B482-E365FE1CCB81</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6681C81-EA03-49F0-8187-EF5752C9D126">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-22 19:11:40 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:9ED864DE-C2BC-4B14-881F-AFD561FC58D1"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 19:11:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0CD8B93-AF6F-43D3-99AB-2252325772E9">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D0CD8B93-AF6F-43D3-99AB-2252325772E9"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-70.txt.html</ao:hasSource>
    <domeo:uuid>D0CD8B93-AF6F-43D3-99AB-2252325772E9</domeo:uuid>
    <pav:createdOn>2014-09-02 15:05:52 -0400</pav:createdOn>
    <ao:exact>antacid</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> hydroxide should be avoided because it may result in a reduction in Cmax and AUC of 26% and 20%, respectively and consequently in a 25% reduction in the bradycardic effect at rest. Administration of the </ao:prefix>
    <ao:suffix> two hours after sotalol has no effect on the pharmacokinetics or pharmacodynamics of </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3F1A48F-9525-4CA3-8022-C7885849CBC2">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 12:34:41 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:0EB4AE1F-6DB3-497B-AAE0-DD8E03C51D30</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 12:34:42 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:4FCA7E7B-CC82-4455-94C0-73C09ED070C1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:6A05795B-B1AB-4DB3-A12F-2765CBCC2FED</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3347F4AE-F668-4910-8729-7775D7697AD7">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-01 16:07:51 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-09-01 16:07:52 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:15DA0901-8237-4923-B2A0-A784328F0684"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:1DA34422-734D-46B1-AB2C-C1CABCA4C26C</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:1B6E2F8D-4A01-45E3-957A-F3F5793AA559</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C84DD53D-5B64-47C5-92EE-E2D0E78BD754">
    <ao:exact>Risperidone</ao:exact>
    <ao:prefix>Metabolism and Drug Interactions: </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C84DD53D-5B64-47C5-92EE-E2D0E78BD754"/>
    <ao:suffix> is extensively metabolized in the liver. The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, h</ao:suffix>
    <domeo:uuid>C84DD53D-5B64-47C5-92EE-E2D0E78BD754</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:11:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BFE9EAEF-FFFF-446F-B84E-D50E1FB72CA0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 19:22:42 -0400</pav:createdOn>
    <ao:suffix> were variable and were generally not statistically different from placebo or glyburide controls.</ao:suffix>
    <domeo:uuid>BFE9EAEF-FFFF-446F-B84E-D50E1FB72CA0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>The changes in triglycerides during therapy with </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BFE9EAEF-FFFF-446F-B84E-D50E1FB72CA0"/>
    <ao:exact>AVANDIA</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D7B822C5-ED4F-4553-B7A4-E4C2A921922B">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:C45C4490-8CED-42E2-B469-10CCB87DB2EB</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:21ABBCD8-EA84-4836-B499-F6A002CF43B9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 20:17:59 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/BAE41BF7-CAA3-4865-832D-24EB9699E14C">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4053</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>erythromycin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/FA86A8F3-C1E5-4301-8EE4-2F312AEF69D5">
    <rdfs:label>atazanavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/343047</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9D4D6AE-7491-4219-BCFA-453D4DA5FF99">
    <ao:prefix>. No clinically significant reductions in glimepiride AUC and Cmax were observed after repeat doses of </ao:prefix>
    <ao:suffix> (8 mg once daily) for 8 days in healthy adult subjects.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E9D4D6AE-7491-4219-BCFA-453D4DA5FF99"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 19:53:25 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:exact>AVANDIA</ao:exact>
    <domeo:uuid>E9D4D6AE-7491-4219-BCFA-453D4DA5FF99</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D77CF944-3EF8-45F2-9976-BAD4E451F994">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdOn>2014-07-24 19:47:18 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F33CE913-7DCE-473E-810F-A9B07CED9081"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:7996706F-8826-48E3-A9EE-7A3F64D946D8</pav:lineageUri>
    <ao:body rdf:nodeID="N505e48cb1778457da65484f26e8f6be0"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lastSavedOn>2014-07-24 19:46:59 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:21C1BD16-9B1B-4BDA-B036-93523B41DFDF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52224847-1B69-4520-9514-0282DC403A76">
    <domeo:uuid>52224847-1B69-4520-9514-0282DC403A76</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:exact>Theophylline</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>: See WARNINGS AND PRECAUTIONS (5.8).</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-09-02 11:46:37 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:52224847-1B69-4520-9514-0282DC403A76"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:960E16A3-CF0E-48BD-8B23-ACD869DFB214">
    <pav:createdOn>2014-09-02 19:09:44 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:17DC0692-91CE-41C4-B801-A31BD19A01C7</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:3558088E-2467-4C3A-87EA-D9EA80C217D1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3B6634D-5A1F-4C6F-AF5E-421854DA709D">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-21 21:26:48 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-21 21:27:51 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:3D34B51E-FCA2-43A6-B868-09CC77429F93</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:B6F745E6-5734-4636-A383-683BA4C79E38</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:9FBD505E-822F-4348-AFE5-73B2A9104B24"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF969EAD-2CD7-4039-AD45-C2D98B79E3B0">
    <pav:createdOn>2014-07-21 21:28:35 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:CFC97B98-DBD4-41F9-A8AC-EE259873DFA7</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:B394B422-1AAF-4ED4-A3BB-3FB13E961EEA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-21 21:30:23 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F2BC4367-94B2-4BA7-AAA4-DA34C58B02C3"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02D77FC0-6DA3-45AA-9C58-66539927EF97">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>AUC following the administration of fluconazole. The mean ± SD increase in AUC was 20% ± 32% (range: -27 to 104%). The metabolite, GZDV, to parent drug ratio significantly decreased after the administration of fluconazole, from 7.6 ± 3.6 to 5.7 ± 2.2.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>02D77FC0-6DA3-45AA-9C58-66539927EF97</domeo:uuid>
    <ao:exact>zidovudine </ao:exact>
    <ao:prefix>dose for at least two weeks. There was a significant increase in </ao:prefix>
    <pav:createdOn>2014-07-21 21:31:15 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:02D77FC0-6DA3-45AA-9C58-66539927EF97"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-27.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D6809060-E4EB-4D01-8BD0-6671105C2ACF">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:217FEFFB-6BFC-422A-B88B-75EE70185C1C"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BB31731-2995-4E32-A961-91EF24F0EEE7">
    <pav:createdOn>2014-07-22 18:47:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="Nc89bb9886cd046d2be16de9629514d11"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0054F81-6A9B-4AF0-9DCB-962A6FC1C418</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-22 18:46:52 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F9271EC-A8D0-45D0-9412-2C40F45D0D4B"/>
    <pav:lineageUri>urn:domeoserver:annotation:033DECA4-8588-431F-BA99-F93BE3AFFA0D</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:693EEFEC-7BCC-4823-A86C-533B31687EFA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>AVANDIA</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>693EEFEC-7BCC-4823-A86C-533B31687EFA</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:693EEFEC-7BCC-4823-A86C-533B31687EFA"/>
    <pav:createdOn>2014-07-22 19:49:22 -0400</pav:createdOn>
    <ao:suffix> (8 mg once daily) for 8 days in healthy adult Caucasian subjects caused a decrease in glyburide AUC and Cmax of approximately 30%. In Japanese subjects, glyburide AUC and Cmax slightly increased following coadministration of AVANDIA.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix> (3.75 to 10 mg/day) for 7 days did not alter the mean steady-state 24-hour plasma glucose concentrations in diabetic patients stabilized on glyburide therapy. Repeat doses of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:398266C6-18B2-479E-8C00-4B3F67E7DB6D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:82B114B4-DF8C-4358-AB9B-8EBA4957BC3F"/>
    <pav:createdOn>2014-07-22 19:50:53 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:047EE665-B8C6-4153-96F1-5D2C3C08A276">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8916B040-D309-4348-A145-26FC08137345"/>
    <pav:createdOn>2014-09-02 12:02:48 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:454E7688-A4B1-42BF-86B5-6E1A3C88986A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:EEDA4663-FBED-4C68-848C-30943B88C061"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:B5E9E5D3-CEDE-43AC-A6D0-E7513DB65222</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-13 11:10:25 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92436D94-1FB4-49B2-B20D-385CA961A940">
    <pav:createdOn>2014-07-13 11:13:53 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1E6C968E-32AF-45A2-96F3-10B3A640C99F"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:19D86C58-A255-44F5-87D8-8E8795312D29</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15CCD695-F33B-4A85-9FD0-BAFCB7975EAB">
    <ao:suffix>: Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of </ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Carbamazepine</ao:exact>
    <domeo:uuid>15CCD695-F33B-4A85-9FD0-BAFCB7975EAB</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:15CCD695-F33B-4A85-9FD0-BAFCB7975EAB"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:39:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1CF0856D-0878-41B0-8A05-7007C19C91DB">
    <pav:lastSavedOn>2014-07-24 19:39:23 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:2CF4DD8F-BE67-4B73-8082-A0A474C61D19"/>
    <pav:createdOn>2014-07-24 19:39:23 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:CE5AF44C-D211-4F33-A502-2B4C37E2ACFC</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:3D46B0B0-9486-45F5-8735-D5E5F3EE9D5D</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3CF71FFB-73DC-483D-B743-8D191F63D01D">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D907D608-9F35-4208-BA27-EE0CA65B1AE3"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/5E9DF383-ABD6-4F64-BB57-8EF69FDE4C64"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6644A5F-920F-4CAA-86BD-086A69F19FA5">
    <domeo:uuid>F6644A5F-920F-4CAA-86BD-086A69F19FA5</domeo:uuid>
    <ao:suffix> AUC by 66%, compared to the administration of rosiglitazone (8 mg) alone [see Drug Interactions (7.1)].4</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F6644A5F-920F-4CAA-86BD-086A69F19FA5"/>
    <ao:prefix> administration (600 mg once a day), an inducer of CYP2C8, for 6 days is reported to decrease </ao:prefix>
    <ao:exact>rosiglitazone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 19:43:42 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E76B5D64-7248-4EBD-A023-3820BFDEFD26">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C0F812BF-119E-4BE1-AAA3-BF2DAE39B76F"/>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdOn>2014-07-07 09:36:31 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A2265F0-B7D6-4A47-834F-F540E39BE257">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1A2265F0-B7D6-4A47-834F-F540E39BE257"/>
    <domeo:uuid>1A2265F0-B7D6-4A47-834F-F540E39BE257</domeo:uuid>
    <pav:createdOn>2014-07-24 20:14:49 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-161.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> serum concentrations. Although a dose adjustment of </ao:prefix>
    <ao:suffix> is not recommended when administered in combination with nelfinavir, close monitoring for known side effects of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted (see ADVERSE REACTIONS).</ao:suffix>
    <ao:exact>azithromycin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35FBCEB9-D10F-4DB4-8F8D-DB121D785B9B">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-55.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:35FBCEB9-D10F-4DB4-8F8D-DB121D785B9B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Extended-release Tablet contains 300 mg of quinidine sulfate (249 mg of quinidine base) in a formulation to provide extended release; the inactive ingredients are: fumaric acid, hypromellose, lactose monohydrate, magnesium stearate, polydextrose, polyet</ao:suffix>
    <ao:exact>Quinidine Sulfate</ao:exact>
    <ao:prefix>Each </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>35FBCEB9-D10F-4DB4-8F8D-DB121D785B9B</domeo:uuid>
    <pav:createdOn>2014-07-21 21:50:34 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56FE6B9A-96B3-43BC-A4E1-A9AFE78680CE">
    <ao:prefix> to </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <pav:createdOn>2014-07-13 11:14:04 -0400</pav:createdOn>
    <ao:suffix> [see 7 DRUG INTERACTIONS]. This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers. The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:56FE6B9A-96B3-43BC-A4E1-A9AFE78680CE"/>
    <domeo:uuid>56FE6B9A-96B3-43BC-A4E1-A9AFE78680CE</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E0188B4-6C70-41E7-B903-5A68F972FC55">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E0188B4-6C70-41E7-B903-5A68F972FC55"/>
    <ao:suffix> maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluvoxamine</ao:exact>
    <domeo:uuid>7E0188B4-6C70-41E7-B903-5A68F972FC55</domeo:uuid>
    <pav:createdOn>2014-09-02 11:43:06 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEDA4663-FBED-4C68-848C-30943B88C061">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers. Steady-state concentrations of </ao:prefix>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabolizers. Steady-state concentrations of 9-hydroxyrisperidone are reached in 5 to 6 days (measured in extensive metabolizers).</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:10:25 -0400</pav:createdOn>
    <domeo:uuid>EEDA4663-FBED-4C68-848C-30943B88C061</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EEDA4663-FBED-4C68-848C-30943B88C061"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:19DF8C99-A2F9-40E1-9BC9-0D4A0531A57A">
    <domeo:uuid>19DF8C99-A2F9-40E1-9BC9-0D4A0531A57A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix> is 99%. Peak plasma concentrations are observed about 1 hour after dosing. Administration of </ao:prefix>
    <ao:suffix> with food resulted in no change in overall exposure (AUC), but there was an approximately 28% decrease in Cmax and a delay in Tmax (1.75 hours). These changes are not likely to be clinically significant; therefore, AVANDIA may be administered with or wi</ao:suffix>
    <ao:exact>rosiglitazone</ao:exact>
    <pav:createdOn>2014-07-22 19:24:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:19DF8C99-A2F9-40E1-9BC9-0D4A0531A57A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8de555767fe64ef08c999345c83bdc4a">
    <domeo:sets rdf:resource="urn:pddi:uuid:CDF62581-CF1E-49F8-8077-2328677F5CAD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5BCF5967-ADD0-4798-B754-B12D230BDBFA">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:0498CEC9-6EEB-4566-BE56-E8A1249425AB</pav:lineageUri>
    <pav:createdOn>2014-09-02 19:11:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:AFAC33CD-2472-4FC2-BA17-FF7F45039527"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:846B6C02-30BD-4750-BAD3-4CC242462EE4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>with </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-51.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:846B6C02-30BD-4750-BAD3-4CC242462EE4"/>
    <ao:exact>paroxetine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>846B6C02-30BD-4750-BAD3-4CC242462EE4</domeo:uuid>
    <pav:createdOn>2014-07-21 21:43:20 -0400</pav:createdOn>
    <ao:suffix>significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy). </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/27D0B4AA-F7F1-4B7F-ADC9-3414612394E8">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Fexofenadine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/87636</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E4954BA3-FA9C-4983-8CA9-D8BA258D2881">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:2EE2832E-F77B-407B-AD3C-39A564CB31D3</pav:lineageUri>
    <pav:lastSavedOn>2014-07-21 21:27:51 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:B6F745E6-5734-4636-A383-683BA4C79E38</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-21 21:26:56 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5F95A684-4F34-42D2-8F26-ACB40DD06487"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB66F52A-826A-4B19-9DAB-4F305456531E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:40519342-F06B-41D2-A39A-795BA218AF7B"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:48:45 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:EC9B90D7-F9B5-4E51-94E2-878FAA06F611</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 12:46:18 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:A5C90995-9DDD-408E-A19C-6AA024D77686</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7907DD5-4FA4-4B5A-99D9-9D24B76931C6">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-07 11:22:37 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:4A784235-A949-4FFD-9438-52955B529B7A</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:1D92FA7B-3CB7-4C89-9E21-9980B649BC2E"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D87DBE9A-311B-4697-A944-4490E16F4680">
    <domeo:uuid>D87DBE9A-311B-4697-A944-4490E16F4680</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D87DBE9A-311B-4697-A944-4490E16F4680"/>
    <pav:createdOn>2014-07-24 20:11:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6E87B62-FE76-4230-92AF-6FD2DBA966AD">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E6E87B62-FE76-4230-92AF-6FD2DBA966AD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>E6E87B62-FE76-4230-92AF-6FD2DBA966AD</domeo:uuid>
    <ao:exact>Glyburide</ao:exact>
    <pav:createdOn>2014-07-22 19:48:54 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2987A9F-B765-4C33-B2FF-1E55869E162F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B2987A9F-B765-4C33-B2FF-1E55869E162F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix>. Since </ao:prefix>
    <ao:suffix> is contraindicated in patients with renal impairment, coadministration of metformin with AVANDIA is contraindicated in these patients.</ao:suffix>
    <domeo:uuid>B2987A9F-B765-4C33-B2FF-1E55869E162F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 19:37:19 -0400</pav:createdOn>
    <ao:exact>metformin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/AFDFD2C0-7545-4E19-ABAA-7E48CFD82223">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9FAFF1D3-9F76-4586-93FE-52B6168FFC14">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-21 21:35:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:D0A27279-F905-4F2D-9872-52DD6349DF41</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:B61F1A9B-4696-4ED0-80AA-4FE2E9016966</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:40F97AE4-1A18-4FD3-B30C-9226F8465F7B"/>
    <pav:createdOn>2014-07-21 21:33:50 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:464DEB11-7E78-4A1A-BC27-EFBA56EDF6A6">
    <ao:suffix> to voltage-dependent and possibly receptor-operated channels in vascular smooth muscle results in an inhibition of calcium influx through these channels. Stores of intracellular calcium in vascular smooth muscle are limited and thus dependent upon the i</ao:suffix>
    <ao:exact>nifedipine</ao:exact>
    <pav:createdOn>2014-09-02 19:46:36 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:464DEB11-7E78-4A1A-BC27-EFBA56EDF6A6"/>
    <ao:prefix> is a peripheral arterial vasodilator which acts directly on vascular smooth muscle. The binding of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-117.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>464DEB11-7E78-4A1A-BC27-EFBA56EDF6A6</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0a93cde7037a4766b6ff21e60fdfe160">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E2ABCCE-5CA9-4636-B0AA-BA504DC9879E">
    <pav:createdOn>2014-07-21 21:33:56 -0400</pav:createdOn>
    <ao:suffix>AUC increased 21% ± 16% (range: -5 to 48%). The Cmax increased 13% ± 17% (range: -13 to 40%). Theophylline clearance decreased 16% ± 11 % (range: -32 to 5%). The half-life of theophylline increased from 6.6 ± 1.7 hours to 7.9 ± 1.5 hours. (See PRECAUTION</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0E2ABCCE-5CA9-4636-B0AA-BA504DC9879E"/>
    <ao:prefix>AUC, Cmax, and half-life with a corresponding decrease in clearance. The mean ± SD </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <ao:exact>theophylline </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>0E2ABCCE-5CA9-4636-B0AA-BA504DC9879E</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1A9D1840-CE0D-486B-A233-984C10D2DFDC">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6C2517B0-E801-41F8-8917-AC00583F30D9"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1459510A-C593-4CF2-959E-F68381AB3C04">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1459510A-C593-4CF2-959E-F68381AB3C04"/>
    <domeo:uuid>1459510A-C593-4CF2-959E-F68381AB3C04</domeo:uuid>
    <ao:prefix>or </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-42.txt.html</ao:hasSource>
    <ao:exact>azathioprine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-01 16:12:31 -0400</pav:createdOn>
    <ao:suffix>should be made on the basis of therapeutic response and the appearance of toxic effects (see PRECAUTIONS- Drug Interactions).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41C681E8-1D19-42FD-B50F-1189BEEA2B54">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:41C681E8-1D19-42FD-B50F-1189BEEA2B54"/>
    <pav:createdOn>2014-09-02 15:08:17 -0400</pav:createdOn>
    <domeo:uuid>41C681E8-1D19-42FD-B50F-1189BEEA2B54</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Sotalol </ao:exact>
    <ao:suffix>hydrochloride tablets USP, 80 mg are available as light blue, oval-shaped tablets that are scored on one side and debossed with the numbers “93” and “61” on each side of the score, and plain on the other side. They are available in bottles of 100.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-71.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0D94D28F-90BB-4AF1-9CBD-EC4DB10359AA">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E3F718F3-CFE3-42BB-856E-B673538F448A"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:04931205-C053-487C-8E10-4A1A8F38120C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, astemizole, cisapride, triazolam, and cyclosporine. Based on the assumption that the relationship between paroxetine’s in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, paroxetine’s ex</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>04931205-C053-487C-8E10-4A1A8F38120C</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-48.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:04931205-C053-487C-8E10-4A1A8F38120C"/>
    <ao:exact>terfenadine</ao:exact>
    <ao:prefix>, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for this enzyme, including </ao:prefix>
    <pav:createdOn>2014-09-02 15:04:22 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED359A65-2894-4EE7-9430-453B2C8C6D26">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:40:24 -0400</pav:createdOn>
    <ao:exact>In this placebo-controlled, double-blind, randomized, two-way crossover study carried out over three cycles of oral contraceptive treatment, fluconazole dosing resulted in small increases in the mean AUCs of ethinyl estradiol and norethindrone compared to similar placebo dosing. The mean AUCs of ethinyl estradiol and norethindrone increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ED359A65-2894-4EE7-9430-453B2C8C6D26"/>
    <domeo:uuid>ED359A65-2894-4EE7-9430-453B2C8C6D26</domeo:uuid>
    <ao:prefix>. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/A11930F7-6D95-4B60-BEDF-64A102BE527C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:019F3E7A-E338-4B52-B537-D71474689AD1">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:58E427EC-D7E5-4793-B477-C5BA94E35E63</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:FA7A671D-A8CF-4ED4-9A82-73178DBED757"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-01 16:06:18 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-01 16:06:00 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:A84DE8F6-26B7-471D-8309-4E7CC2994FDF</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A54DB360-9E9B-4E55-AC79-A80E321825D3">
    <ao:suffix> increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. Fluconazole treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosi</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:exact>norethindrone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A54DB360-9E9B-4E55-AC79-A80E321825D3"/>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 12:38:35 -0400</pav:createdOn>
    <domeo:uuid>A54DB360-9E9B-4E55-AC79-A80E321825D3</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B787EC6-4A3E-44EC-8288-875426F19CB3">
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>propranolol</ao:exact>
    <domeo:uuid>5B787EC6-4A3E-44EC-8288-875426F19CB3</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5B787EC6-4A3E-44EC-8288-875426F19CB3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-124.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 19:37:23 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFBA3663-4C52-45BA-895B-7EB3C0A4DA3A">
    <ao:context rdf:resource="urn:domeoclient:uuid:1B4D9B85-636E-45EE-9796-1A7AE7E45DCF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:createdOn>2014-07-13 11:11:43 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:03C6457D-A506-405A-9290-D5818D79A053</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30CD6C3F-1B6D-4C66-B96F-A460B56D3480">
    <ao:exact>metformin</ao:exact>
    <domeo:uuid>30CD6C3F-1B6D-4C66-B96F-A460B56D3480</domeo:uuid>
    <pav:createdOn>2014-07-22 19:55:33 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:prefix> (2 mg twice daily) and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:30CD6C3F-1B6D-4C66-B96F-A460B56D3480"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0F812BF-119E-4BE1-AAA3-BF2DAE39B76F">
    <pav:createdOn>2014-07-07 09:36:31 -0400</pav:createdOn>
    <ao:prefix>Studies in vitro have shown that </ao:prefix>
    <ao:suffix>is selective for PDE5. Its effect is more potent on PDE5 than on other known phosphodiesterases (10-fold for PDE6, &gt; 80-fold for PDE1, &gt; 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The approximately 4,000-fold selectivity for PDE5</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C0F812BF-119E-4BE1-AAA3-BF2DAE39B76F"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/7BF23512-3FBF-4262-B453-848863F44618">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Rifampin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B94C34A7-F932-4189-9935-D5DEEC3449E4">
    <ao:prefix>The AUC of </ao:prefix>
    <ao:suffix> is increased by more than 200% by co-administration of propranolol.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-124.txt.html</ao:hasSource>
    <domeo:uuid>B94C34A7-F932-4189-9935-D5DEEC3449E4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B94C34A7-F932-4189-9935-D5DEEC3449E4"/>
    <pav:createdOn>2014-07-24 19:36:31 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>propafenone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:762110B9-8FE2-4631-8D47-86C30D8D9102">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:762110B9-8FE2-4631-8D47-86C30D8D9102"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-135.txt.html</ao:hasSource>
    <ao:suffix> is metabolized through three primary routes: aromatic hydroxylation (mainly 4-hydroxylation), N-dealkylation followed by further side-chain oxidation, and direct glucuronidation. It has been estimated that the percentage contributions of these routes to</ao:suffix>
    <pav:createdOn>2014-07-24 20:00:44 -0400</pav:createdOn>
    <domeo:uuid>762110B9-8FE2-4631-8D47-86C30D8D9102</domeo:uuid>
    <ao:exact>Propranolol</ao:exact>
    <ao:prefix> is extensively metabolized with most metabolites appearing in the urine. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/94DFD21D-D749-4F5E-AE57-CF5CE30BA0D9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:311508D9-4E16-476A-B489-8598869EEF79">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/314A940A-9CA5-4B7A-B433-2AECFF25EFA4"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/0A6A30F9-53A5-47E7-B0BA-25617EEE3E7A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00CDF4D6-2271-4B2A-9836-98BD00E7E952">
    <pav:createdOn>2014-07-13 12:42:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> or </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:00CDF4D6-2271-4B2A-9836-98BD00E7E952"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-22.txt.html</ao:hasSource>
    <ao:exact>ethinyl estradiol</ao:exact>
    <ao:prefix> 50 mg once daily for 10 days in 10 healthy women. There was no significant difference in </ao:prefix>
    <domeo:uuid>00CDF4D6-2271-4B2A-9836-98BD00E7E952</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:465EEACA-9FFE-4F82-9410-36A29C720187">
    <pav:createdOn>2014-09-02 11:45:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>465EEACA-9FFE-4F82-9410-36A29C720187</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended. No dosage adjustment is required for fluvoxamine maleate tablets.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:465EEACA-9FFE-4F82-9410-36A29C720187"/>
    <ao:prefix>If </ao:prefix>
    <ao:exact>propranolol</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D8D922B0-F01D-471E-B5F5-F72185F3B01C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6809</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>metformin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/46FB1ED5-40B7-4788-9A91-7689FC73A793">
    <rdfs:label>ritonavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N97cc11880a0f4d699e83bbe3398d069f">
    <domeo:sets rdf:resource="urn:pddi:uuid:CA65F737-1E98-4A37-A7F1-220396E99856"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/B959D351-8EA8-4A27-AEBB-7E2C63519031">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ethanol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/448</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B9978DD-BF7E-4B48-BA74-826CB1EA9750">
    <pav:createdOn>2014-07-24 19:54:37 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:8AA46BC0-EA66-4E73-81A9-6463BB4DE15B</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:924923B4-F032-417D-AA15-AA656F363BB9</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A3802033-7DB0-4AE2-833F-5EF306928ABF"/>
    <pav:lastSavedOn>2014-07-24 19:54:28 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1FA6545E-180C-46D2-A000-88AB02BD37E4">
    <ao:exact>cimetidine</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1FA6545E-180C-46D2-A000-88AB02BD37E4"/>
    <domeo:uuid>1FA6545E-180C-46D2-A000-88AB02BD37E4</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-57.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 18:36:25 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:015BF3DA-12CC-44A1-9B13-94A006D56307">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:015BF3DA-12CC-44A1-9B13-94A006D56307"/>
    <ao:prefix> does not affect the pharmacokinetics of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-127.txt.html</ao:hasSource>
    <domeo:uuid>015BF3DA-12CC-44A1-9B13-94A006D56307</domeo:uuid>
    <ao:suffix> and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol.</ao:suffix>
    <pav:createdOn>2014-07-24 19:42:48 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>verapamil</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95CC663C-8F74-4A62-BE19-7170368BDA5F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:95CC663C-8F74-4A62-BE19-7170368BDA5F"/>
    <ao:suffix> maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol. Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.</ao:suffix>
    <pav:createdOn>2014-09-02 11:46:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>95CC663C-8F74-4A62-BE19-7170368BDA5F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:prefix>Coadministration of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CE3E7D7-79CE-4BA9-8CA0-7B7A05D77AFC">
    <pav:lineageUri>urn:domeoserver:annotation:746D73EB-609F-4ABC-8FAC-F496DCDBACDA</pav:lineageUri>
    <pav:createdOn>2014-07-13 12:38:04 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5C901133-925A-4BA8-947F-0FE9FB6D60DB"/>
    <pav:lastSavedOn>2014-07-13 12:41:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:4F872953-6D19-4809-9285-FCCF2FF54315</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70B9E8E9-06ED-4420-9CDE-4E0F36F57CC9">
    <pav:createdOn>2014-07-13 11:17:15 -0400</pav:createdOn>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:70B9E8E9-06ED-4420-9CDE-4E0F36F57CC9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and </ao:prefix>
    <domeo:uuid>70B9E8E9-06ED-4420-9CDE-4E0F36F57CC9</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> combined, after single and multiple doses, were similar in extensive and poor metabolizers, with an overall mean elimination half-life of about 20 hours.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:010AF63D-C71E-4A93-9F41-8E5764F068ED">
    <pav:lineageUri>urn:domeoserver:annotation:451E9FBF-CD25-4B95-963D-2A293790A1B4</pav:lineageUri>
    <pav:createdOn>2014-07-13 12:42:05 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:23567EF7-7482-444A-B1F6-5AAA9D43E54A</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-13 12:45:54 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:00CDF4D6-2271-4B2A-9836-98BD00E7E952"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:140EFF4D-9D91-427D-B48B-7B1FAFA2E5CF">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:5841BCC9-42A5-4486-AA8B-635392DB4438"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 11:44:39 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55590627-6DCB-46F4-B196-1032E6ECA077">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55590627-6DCB-46F4-B196-1032E6ECA077"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-01 16:06:05 -0400</pav:createdOn>
    <domeo:uuid>55590627-6DCB-46F4-B196-1032E6ECA077</domeo:uuid>
    <ao:prefix>. These data indicate that </ao:prefix>
    <ao:suffix>extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by abo</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <ao:exact>sertraline’s </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE31FB45-DE35-4E4D-B623-72AA865505E0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AE31FB45-DE35-4E4D-B623-72AA865505E0"/>
    <pav:createdOn>2014-07-28 17:00:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Cimetidine</ao:exact>
    <domeo:uuid>AE31FB45-DE35-4E4D-B623-72AA865505E0</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-164.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/C5B717C7-A880-452E-91DB-A2F2F96090B8">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7417</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nifedipine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7FD7602A-D05F-4BEA-AC56-67DE4BF0AB32">
    <ao:suffix> decreases fexofenadine gastrointestinal secretion, while erythromycin may also decrease biliary excretion.</ao:suffix>
    <ao:prefix> may be due to transport-related effects, such as p-glycoprotein. In vivo animal studies also suggest that in addition to enhancing absorption, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7FD7602A-D05F-4BEA-AC56-67DE4BF0AB32"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:exact>ketoconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-24 20:11:57 -0400</pav:createdOn>
    <domeo:uuid>7FD7602A-D05F-4BEA-AC56-67DE4BF0AB32</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd4361df8c29b49b2b7fef99f73cb3033">
    <domeo:sets rdf:resource="urn:pddi:uuid:171C7925-6F8E-4017-8743-473B0DE0C8C1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F12731E-6D41-4E27-83E3-C87822424FCA">
    <pav:createdOn>2014-07-07 09:59:05 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F14E8BB4-85EC-49A7-B9E5-8976B448D19D"/>
    <pav:lineageUri>urn:domeoserver:annotation:35639159-ED9C-4B53-8BA3-5D1C355CF374</pav:lineageUri>
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0B3096F2-9B83-424A-BCB8-CF996BA224AC">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:B434A8E1-DA82-459A-AAAF-E55806E0A976"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:16:55 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:67967D27-75AF-4745-A665-F0AE8B4677A2">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:311508D9-4E16-476A-B489-8598869EEF79"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86768360-42DE-4CD0-A167-0F5E6C6CAE55">
    <domeo:belongsToSet>urn:domeoclient:uuid:3D195979-3E82-427D-95B8-F50F48DB4AA7</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 18:51:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:92AF00E3-613A-4E27-ACAC-A744AA15CCB8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:FD0778DC-BD38-42CF-98CE-AFBBDCFDFFB7</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-22 18:54:35 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A7382E8-45D1-4872-98EA-20455089A06B">
    <pav:createdOn>2014-07-07 11:23:45 -0400</pav:createdOn>
    <ao:prefix>In a study performed in healthy volunteers, co-administration of the HIV protease inhibitor </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>saquinavir</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>, a CYP3A inhibitor, at steady state (1200 mg TID) with sildenafil (100 mg single dose) resulted in a 140% increase in sildenafil Cmax and a 210% increase in sildenafil AUC.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1A7382E8-45D1-4872-98EA-20455089A06B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:464E41DE-27DF-4413-A7E6-C191985E633B">
    <ao:suffix> maleate and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).</ao:suffix>
    <ao:prefix>, and the combination should, therefore, be used with caution. Severe vomiting has been reported with the coadministration of </ao:prefix>
    <domeo:uuid>464E41DE-27DF-4413-A7E6-C191985E633B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:464E41DE-27DF-4413-A7E6-C191985E633B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluvoxamine </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:44:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7ED86B3-B970-41BF-B468-D38526646742">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> concentrations. Induction of CYP3A4 activity by its inducers, such as </ao:prefix>
    <domeo:uuid>F7ED86B3-B970-41BF-B468-D38526646742</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-72.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F7ED86B3-B970-41BF-B468-D38526646742"/>
    <ao:exact>rifampin</ao:exact>
    <ao:suffix>, carbamazepine, and phenytoin, may lead to a lack of efficacy or, possibly, development of an abstinence syndrome in a patient who had developed physical dependence to oxycodone. If co-administration is necessary, caution is advised when initiating ther</ao:suffix>
    <pav:createdOn>2014-09-02 19:09:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4746991B-1E22-4518-B0DA-6C25E8605F5D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 12:02:39 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:D52DFD7B-BDDF-488F-B339-B1BC641E50E9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:166C20E9-1B4C-47D1-982D-922E2E5ACFF2</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 12:03:47 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:40158315-C4E3-4EA7-89A6-6D4031E7590C"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3612760-5AFD-415B-8269-F1483D859C5D">
    <pav:createdOn>2014-07-07 09:37:58 -0400</pav:createdOn>
    <ao:prefix>iastolic blood pressure of 8/5 mmHg). The decrease in blood pressure was most notable approximately 1–2 hours after dosing, and was not different from placebo at 8 hours. Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg doses of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:exact>sildenafil</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, therefore the effects are not related to dose or plasma levels within this dosage range. Larger effects were recorded among patients receiving concomitant nitrates [see Contraindications (4)].</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3612760-5AFD-415B-8269-F1483D859C5D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B3F6AB4E-3B37-4465-8CFC-119F30A661AA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FA48E451-6066-4222-B6F6-48D1739BF14F"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE73B237-E7E7-49DE-9295-FF17AED8776B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AE73B237-E7E7-49DE-9295-FF17AED8776B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-19.txt.html</ao:hasSource>
    <ao:exact>sertraline </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AE73B237-E7E7-49DE-9295-FF17AED8776B</domeo:uuid>
    <pav:createdOn>2014-09-01 16:04:28 -0400</pav:createdOn>
    <ao:prefix>In a placebo-controlled trial in normal volunteers, administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09E68084-B057-4315-B5D2-BAB13980BCAE">
    <ao:prefix> has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluvoxamine</ao:exact>
    <pav:createdOn>2014-09-02 11:35:42 -0400</pav:createdOn>
    <ao:suffix> metabolism have not been studied.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:09E68084-B057-4315-B5D2-BAB13980BCAE"/>
    <domeo:uuid>09E68084-B057-4315-B5D2-BAB13980BCAE</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:032977FB-2362-4162-8691-DC921A41219C">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/77D06206-6695-47A2-961A-30BA8D501FA5"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F83742D9-BF1E-4B6B-9F1C-2CC08800D877"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97BD942B-FE8A-49D9-A08D-AF25357CEE2D">
    <ao:context rdf:resource="urn:domeoclient:uuid:F1920C60-E3BB-461B-89EC-34061357C4C7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:3B2612E2-2F1F-4406-B35F-844C79D86AEE</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 20:18:44 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF4B56FC-1048-4C85-AD05-E8D9C4F159CF">
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 19:44:46 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 19:43:42 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:F6644A5F-920F-4CAA-86BD-086A69F19FA5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:514BA51B-D734-4003-A7C3-F03C0F95833A</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B3FBAFB-BA3F-4404-86D8-EB3FEBC44D50">
    <ao:context rdf:resource="urn:domeoclient:uuid:9C474000-EB80-4F4E-8C99-0066BDF22196"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0054F81-6A9B-4AF0-9DCB-962A6FC1C418</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:737BF383-2E27-497C-B02E-98A51537FC3A</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 18:46:52 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-22 18:44:50 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:097BBD64-4910-4F32-9440-9A37CCEA09F8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 19:12:55 -0400</pav:createdOn>
    <ao:prefix>. In all 26-week controlled trials, across the recommended dose range, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>097BBD64-4910-4F32-9440-9A37CCEA09F8</domeo:uuid>
    <ao:exact>AVANDIA</ao:exact>
    <ao:suffix> as monotherapy was associated with increases in total cholesterol, LDL, and HDL and decreases in free fatty acids. These changes were statistically significantly different from placebo or glyburide controls (Table 7).</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:097BBD64-4910-4F32-9440-9A37CCEA09F8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71782464-053E-46F0-8930-DB2CDA0F1338">
    <ao:exact>erythromycin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-24 20:11:41 -0400</pav:createdOn>
    <ao:suffix> coadministration enhances fexofenadine gastrointestinal absorption. This observed increase in the bioavailability of fexofenadine may be due to transport-related effects, such as p-glycoprotein. In vivo animal studies also suggest that in addition to en</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:71782464-053E-46F0-8930-DB2CDA0F1338"/>
    <domeo:uuid>71782464-053E-46F0-8930-DB2CDA0F1338</domeo:uuid>
    <ao:prefix> or </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E2C79BAB-965C-479E-824A-F2884B348419">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E2C79BAB-965C-479E-824A-F2884B348419"/>
    <ao:prefix> increased by 24% (95% C.I. range 18 to 31%) and 13% (95% C.I. range 8 to 18%), respectively relative to placebo. </ao:prefix>
    <domeo:uuid>E2C79BAB-965C-479E-824A-F2884B348419</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Fluconazole</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-21.txt.html</ao:hasSource>
    <ao:suffix> treatment did not cause a decrease in the ethinyl estradiol AUC of any individual subject in this study compared to placebo dosing. The individual AUC values of norethindrone decreased very slightly (&lt;5%) in 3 of the 21 subjects after fluconazole treatm</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 12:38:39 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5488F065-12C7-4BC6-B53E-99FE4483B13A">
    <ao:exact>atomoxetine</ao:exact>
    <ao:suffix> Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.</ao:suffix>
    <ao:prefix> AUC values that were 6- to 8-fold greater and in </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:58:39 -0400</pav:createdOn>
    <domeo:uuid>5488F065-12C7-4BC6-B53E-99FE4483B13A</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5488F065-12C7-4BC6-B53E-99FE4483B13A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4779D2E6-DE3C-43C7-BA5C-2FB2261F8E92">
    <ao:suffix> and its metabolites. Diazepam does not alter the pharmacokinetics of propranolol.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4779D2E6-DE3C-43C7-BA5C-2FB2261F8E92</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4779D2E6-DE3C-43C7-BA5C-2FB2261F8E92"/>
    <ao:exact>diazepam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-24 19:44:17 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-128.txt.html</ao:hasSource>
    <ao:prefix>, resulting in increased concentrations of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52B64BE2-7636-4E5D-B162-D84F2D892E3D">
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:7E80543E-BF76-4514-92A9-91458DCB802B</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 19:35:16 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:DCEF4B50-19DE-4DDE-ADB0-22E897CE8FC1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 19:31:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2254AD70-D7DF-48C1-827C-280B109CF542">
    <domeo:belongsToSet>urn:domeoclient:uuid:21C1BD16-9B1B-4BDA-B036-93523B41DFDF</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-24 19:46:59 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-24 19:46:59 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:271B21A2-D2A2-4C95-8E2C-A3C373B06A45"/>
    <pav:lineageUri>urn:domeoserver:annotation:C9F9D68A-23F7-4F74-B839-0E2A5A0613D8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25B50478-76B9-41F0-8556-A8AEB125E61E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:25B50478-76B9-41F0-8556-A8AEB125E61E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> or ketoconazole. In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-s</ao:suffix>
    <ao:exact>erythromycin</ao:exact>
    <ao:prefix> had no effect on the pharmacokinetics of either </ao:prefix>
    <domeo:uuid>25B50478-76B9-41F0-8556-A8AEB125E61E</domeo:uuid>
    <pav:createdOn>2014-07-24 20:07:33 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:01CABF7B-5601-4091-B27B-BB36CCDE1151">
    <pav:lastSavedOn>2014-09-02 19:11:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:3966BCFB-CA02-4053-828D-3860558E7BE8</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:61EC9BF9-7DCF-4DC4-A685-81B401973EA5</pav:lineageUri>
    <pav:createdOn>2014-09-02 19:08:36 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:3CB57EB2-8A93-411F-AFE4-75EE6C88177B"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CDFB7B3-F366-4F19-B27E-4B00DC64BA96">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3CDFB7B3-F366-4F19-B27E-4B00DC64BA96"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:19:31 -0400</pav:createdOn>
    <ao:prefix>Concomitant administration of </ao:prefix>
    <ao:suffix> and tacrolimus may increase the serum levels of tacrolimus. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>3CDFB7B3-F366-4F19-B27E-4B00DC64BA96</domeo:uuid>
    <ao:exact>omeprazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EB0AC81-B2FD-4D6F-8BAC-50662A16D4C6">
    <ao:suffix> (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized o</ao:suffix>
    <ao:prefix>  (20 mg once daily) under steady-state conditions increased single-dose </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7EB0AC81-B2FD-4D6F-8BAC-50662A16D4C6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7EB0AC81-B2FD-4D6F-8BAC-50662A16D4C6</domeo:uuid>
    <ao:exact>desipramine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 11:57:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16D91D82-D12B-41E8-A218-F336224CF507">
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:689B7657-F3FC-48C0-A564-2904140C7D29"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:createdOn>2014-09-02 19:16:36 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4DA9FCE-B7DB-4AB2-8187-C60945E96A8D">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C4DA9FCE-B7DB-4AB2-8187-C60945E96A8D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> with either </ao:prefix>
    <pav:createdOn>2014-07-24 20:07:18 -0400</pav:createdOn>
    <ao:exact>ketoconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> or erythromycin led to increased plasma concentrations of fexofenadine in healthy adult subjects. Fexofenadine had no effect on the pharmacokinetics of either erythromycin or ketoconazole. In two separate studies in healthy adult subjects, fexofenadine </ao:suffix>
    <domeo:uuid>C4DA9FCE-B7DB-4AB2-8187-C60945E96A8D</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/A3E00879-812C-4400-97F2-AF59166DF8BB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>phenytoin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37E9FF1C-D06E-42C3-944C-482813D8E38E">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:55A5D871-82BA-4D87-A1EA-62DCA1BF358F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 19:28:13 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62F3C932-C305-4581-AA4E-BB34C6D0F7D4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:62F3C932-C305-4581-AA4E-BB34C6D0F7D4"/>
    <ao:suffix>compared to its exposure at a dose of 20 mg </ao:suffix>
    <pav:createdOn>2014-07-07 11:22:45 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:prefix>exposure without concomitant medication is shown to be 5-fold higher at a dose of 80 mg </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>TID </ao:exact>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF43541C-6D0C-436D-805F-CCE8AF9ED52C">
    <ao:prefix> (150 mg twice daily for 4 days) did not alter the pharmacokinetics of either single oral or intravenous doses of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>CF43541C-6D0C-436D-805F-CCE8AF9ED52C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 20:18:40 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:suffix> in healthy volunteers. These results suggest that the absorption of oral rosiglitazone is not altered in conditions accompanied by increases in gastrointestinal pH.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CF43541C-6D0C-436D-805F-CCE8AF9ED52C"/>
    <ao:exact>rosiglitazone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F0EB30BB-0A91-4488-BC91-DB2E42B74BC6">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>lithium</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/BB10D5C0-6D53-40A0-8A2D-D31E8D5FA6E1">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Zonisamide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/39998</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E13A2A1-DB0E-49CA-8B2D-2D7FD2760FEC">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E13A2A1-DB0E-49CA-8B2D-2D7FD2760FEC"/>
    <ao:exact>Maalox®1</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>3E13A2A1-DB0E-49CA-8B2D-2D7FD2760FEC</domeo:uuid>
    <pav:createdOn>2014-07-24 20:06:30 -0400</pav:createdOn>
    <ao:prefix> containing antacid (</ao:prefix>
    <ao:suffix>) decreased fexofenadine AUC by 41% and Cmax by 43%.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/04BE103D-A7ED-4289-9B72-CCC97FDE114E">
    <rdfs:label>warfarin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/EAC1688B-D768-4B56-8D0E-B9D5F8FC7164">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3322</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Diazepam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30903A1B-437C-4ABA-B24D-6148F07F178D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:30903A1B-437C-4ABA-B24D-6148F07F178D"/>
    <pav:createdOn>2014-07-13 11:09:35 -0400</pav:createdOn>
    <ao:exact>risperidone</ao:exact>
    <ao:prefix>, its major metabolite, 9-hydroxyrisperidone, and </ao:prefix>
    <ao:suffix> plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily). Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour. Peak conce</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <domeo:uuid>30903A1B-437C-4ABA-B24D-6148F07F178D</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/CE20B5C0-36BB-4878-B0C9-3069561D06F7">
    <rdfs:label>lorazepam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/5A962BFF-E73B-4290-B642-C49A7EBCD1B8">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/1311214</dailymed:activeMoietyRxCUI>
    <rdfs:label>serotonin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EF32B76C-C252-4DA7-9AC6-7FCD32EE9F83">
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:254E1933-56AE-4110-9A6C-715CC58538B6"/>
    <pav:createdOn>2014-07-22 19:38:22 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D98E97B5-BA28-4298-8921-05B56B7A1166">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D98E97B5-BA28-4298-8921-05B56B7A1166"/>
    <ao:exact>oxacillin </ao:exact>
    <pav:createdOn>2014-07-22 18:51:31 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> (2g q6h iv) in the first study (JRV 304) and cefazolin (1g q8h iv) in the second study (JRV 305); however, in both studies vancomycin (1g q12h iv) could be substituted for the specified comparator if the causative pathogen was suspected or confirmed met</ao:suffix>
    <domeo:uuid>D98E97B5-BA28-4298-8921-05B56B7A1166</domeo:uuid>
    <ao:prefix> (7.5 mg/kg q12h intravenously [iv]) in the treatment of complicated skin and skin structure infections were performed. The comparator drug was </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-119.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F0238CB-D573-4236-AA09-42BC8251946C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:AFB9CA92-A9E3-4B4C-83E2-8651E1485BD5</pav:lineageUri>
    <pav:createdOn>2014-07-24 19:39:41 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:nodeID="Nfb621328581d481090095b9cd99d3a31"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:CE5AF44C-D211-4F33-A502-2B4C37E2ACFC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:B383ED3F-1A7B-49EF-9DAD-049AD0F927DE"/>
    <pav:lastSavedOn>2014-07-24 19:39:23 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FAA92561-4F1F-46DE-9C0F-2783EAC09CFA">
    <pav:createdOn>2014-07-21 21:34:27 -0400</pav:createdOn>
    <ao:exact>theophylline</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FAA92561-4F1F-46DE-9C0F-2783EAC09CFA"/>
    <domeo:uuid>FAA92561-4F1F-46DE-9C0F-2783EAC09CFA</domeo:uuid>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-28.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nae46eb0195924ed0be40a050e70705a9">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F14E8BB4-85EC-49A7-B9E5-8976B448D19D">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F14E8BB4-85EC-49A7-B9E5-8976B448D19D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-07 09:59:05 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>pharmacokinetics in patients with PAH. The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function. None of these factors had a signif</ao:suffix>
    <ao:exact>sildenafil </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Age, gender, race, and renal and hepatic function were included as factors assessed in the population pharmacokinetic model to evaluate </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2632D1DD-2AAF-40EA-9A99-DCA6352518F5">
    <pav:lastSavedOn>2014-09-02 19:46:58 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:35B3106D-87ED-421E-904D-19B280409F61</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:1285AF18-3541-4E0D-9BAA-DDBC5E9C152C</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:464DEB11-7E78-4A1A-BC27-EFBA56EDF6A6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 19:46:36 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3406496-29A1-41A2-B195-BAD281E72E4B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C3406496-29A1-41A2-B195-BAD281E72E4B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 11:40:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> may enhance the serotonergic effects of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:suffix> and, therefore, the combination should be used with caution. Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.</ao:suffix>
    <domeo:uuid>C3406496-29A1-41A2-B195-BAD281E72E4B</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C6D1C88-D003-4F29-8AF2-F22A03983530">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:907AD9A7-E55A-480A-BC73-7429BC2CE1DE"/>
    <pav:createdOn>2014-09-02 11:30:39 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/8F36BE9D-F662-4788-A209-5115C542C5AE">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>tacrine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10318</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B5E75366-F0BF-442F-852E-19C5EDDC84EE">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-07 09:42:24 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C4441B5B-C18F-4F66-90A8-3A3306CD1C90"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA1AC920-C96A-453E-A808-BB6D8038B11E">
    <ao:exact>warfarin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CA1AC920-C96A-453E-A808-BB6D8038B11E"/>
    <ao:prefix> inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., </ao:prefix>
    <ao:suffix>, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 11:30:30 -0400</pav:createdOn>
    <domeo:uuid>CA1AC920-C96A-453E-A808-BB6D8038B11E</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B28EDC18-743D-4015-956F-B084F96B3589">
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C0EC2FB2-F825-49D1-A3E4-EA98B976BFED"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-22 19:22:52 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C30455C-E476-4155-9E8E-67570BFAB396">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:0E2ABCCE-5CA9-4636-B0AA-BA504DC9879E"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:B61F1A9B-4696-4ED0-80AA-4FE2E9016966</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:171FCBF8-8AC9-4B78-9E1B-9B6E17C3BC2E</pav:lineageUri>
    <pav:createdOn>2014-07-21 21:33:56 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-21 21:35:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35E50D31-0B97-45CD-9519-3A5F2D6512D3">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:3E53E10A-E533-402B-8239-6CE1B3724B6B</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:42248733-4719-42F4-8132-866191F8E708</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:0D6AEBDD-929E-4D65-B956-E7E552F5D014"/>
    <pav:lastSavedOn>2014-07-21 21:44:00 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-21 21:43:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/504D9B65-0BA3-47AC-BD1D-5D353F912A60">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7417</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>nifedipine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6586910C-89D6-48D4-A5C5-1E4D8CB29677">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-01 16:00:05 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:F05ECB2E-0877-466E-936C-3A60595FD6B9"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:B1FC7631-66BC-44DC-8003-1595B584F6D2</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:659ED9DF-77DA-41F2-B123-6E455B4F2385</domeo:belongsToSet>
    <pav:lastSavedOn>2014-09-01 16:00:14 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F192869-CBB9-4ECB-A4F1-F621F322E7E6">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-53.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F192869-CBB9-4ECB-A4F1-F621F322E7E6"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-21 21:46:36 -0400</pav:createdOn>
    <ao:exact>quinidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>8F192869-CBB9-4ECB-A4F1-F621F322E7E6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0865f61584144d27a0073f432cc57231">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F412DAA-5D4B-4581-AA6A-DB01672CE4BB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-22 18:58:24 -0400</pav:createdOn>
    <ao:exact>warfarin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-120.txt.html</ao:hasSource>
    <ao:prefix> has been reported to potentiate the anticoagulant effect of </ao:prefix>
    <ao:suffix> and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when FLAGYL (metronidazole) is prescribed for patients on this type of anticoagulant therapy.</ao:suffix>
    <domeo:uuid>6F412DAA-5D4B-4581-AA6A-DB01672CE4BB</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6F412DAA-5D4B-4581-AA6A-DB01672CE4BB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C6FF426-D0F6-4DFE-8C13-8BD0EAA98C6F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-23.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> 100 mg was administered as a single oral dose alone and two hours after a single dose of </ao:prefix>
    <ao:exact>cimetidine</ao:exact>
    <pav:createdOn>2014-07-13 12:46:15 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0C6FF426-D0F6-4DFE-8C13-8BD0EAA98C6F"/>
    <ao:suffix> 400 mg to six healthy male volunteers. After the administration of cimetidine, there was a significant decrease in fluconazole AUC and Cmax. There was a mean ± SD decrease in fluconazole AUC of 13% ± 11% (range: -3.4 to -31%) and Cmax decreased 19% ± 14</ao:suffix>
    <domeo:uuid>0C6FF426-D0F6-4DFE-8C13-8BD0EAA98C6F</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62E0CEDC-0C94-4CC8-83F4-85DD741C49B6">
    <domeo:uuid>62E0CEDC-0C94-4CC8-83F4-85DD741C49B6</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:62E0CEDC-0C94-4CC8-83F4-85DD741C49B6"/>
    <ao:suffix>: Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.</ao:suffix>
    <pav:createdOn>2014-09-02 11:44:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Digoxin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4411E759-9248-468B-B2F6-E5A5A8657C4C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:643A5ED0-8507-40E4-BF8F-798721470D41"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <pav:createdOn>2014-07-22 19:28:08 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0025BED1-B4CA-4D8F-9C43-B2F10841CCF4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:15:56 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:F6864EB3-C97B-4F46-976B-E976F8C03348"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:0A047BE5-CEF6-494B-A811-C7F89C6D2A1B</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/3B9DE0DC-8223-4138-A13C-06DB166E9DEF">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Zonisamide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/39998</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C15235C1-3B10-4949-B8E4-1D7FCCD3AC4B">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:89484DAB-0EA9-4ACB-BC2F-9FEC34383940</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1230CFBE-6F41-4107-8D50-5F5A730D40C5"/>
    <pav:createdOn>2014-07-13 11:07:49 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:819F1E61-50CC-41FC-9596-57CE5DC96A2C">
    <pav:createdOn>2014-07-21 21:26:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>AUC was determined after 4 days of phenytoin dosing (200 mg daily, orally for 3 days followed by 250 mg intravenously for one dose) both with and without the administration of fluconazole (oral fluconazole 200 mg daily for 16 days) in 10 normal male volu</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:819F1E61-50CC-41FC-9596-57CE5DC96A2C"/>
    <ao:exact>Phenytoin </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>819F1E61-50CC-41FC-9596-57CE5DC96A2C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-25.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/6C80031B-9390-46A4-B67F-9430DCF128A9">
    <rdfs:label>fluconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4B2C542-4FBC-4849-8602-BB3245792CC3">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A4B2C542-4FBC-4849-8602-BB3245792CC3"/>
    <ao:exact>Rosiglitazone</ao:exact>
    <ao:suffix> is approximately 99.8% bound to plasma proteins, primarily albumin.</ao:suffix>
    <domeo:uuid>A4B2C542-4FBC-4849-8602-BB3245792CC3</domeo:uuid>
    <ao:prefix> is approximately 17.6 (30%) liters, based on a population pharmacokinetic analysis. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 19:26:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50E47850-992D-44A2-BE5F-681487D5414C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:50E47850-992D-44A2-BE5F-681487D5414C"/>
    <pav:createdOn>2014-09-02 19:12:50 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>50E47850-992D-44A2-BE5F-681487D5414C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> concomitantly. Increases in INR and </ao:prefix>
    <ao:exact>prothrombin </ao:exact>
    <ao:suffix>time may lead to abnormal bleeding and even death. Patients treated with proton pump inhibitors and warfarin may need to be monitored for increases in INR and prothrombin time.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B4D9B85-636E-45EE-9796-1A7AE7E45DCF">
    <ao:suffix> at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.</ao:suffix>
    <domeo:uuid>1B4D9B85-636E-45EE-9796-1A7AE7E45DCF</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1B4D9B85-636E-45EE-9796-1A7AE7E45DCF"/>
    <ao:prefix> (10 mcg/mL) caused only a slight increase in the free fraction of </ao:prefix>
    <ao:exact>risperidone</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:11:43 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A617D2E-816A-496B-B5FC-091514B75E33">
    <ao:body rdf:nodeID="N1233caa5f0314501b09bfc3306cf288e"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:46C07518-AE09-4026-8E8F-D159078B10AC</pav:lineageUri>
    <pav:createdOn>2014-09-02 12:00:11 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:4B51141D-C8D2-45DB-8074-74F8D8323E60</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:E7AD1296-3138-4E05-ACC3-466E8259339A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 12:02:18 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62CFF353-D9DB-4975-A77C-87D5AE3C0CCA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> are not influenced by age, race, smoking, or alcohol consumption. Both oral clearance (CL/F) and oral steady-state volume of distribution (Vss/F) were shown to increase with increases in body weight. Over the weight range observed in these analyses (50 </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Population pharmacokinetic analyses from 3 large clinical trials including 642 men and 405 women with type 2 diabetes (aged 35 to 80 years) showed that the pharmacokinetics of </ao:prefix>
    <domeo:uuid>62CFF353-D9DB-4975-A77C-87D5AE3C0CCA</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 19:28:40 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:62CFF353-D9DB-4975-A77C-87D5AE3C0CCA"/>
    <ao:exact>rosiglitazone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F1ACE0D3-FA23-46EC-ACAA-40836B0D32A9">
    <rdfs:label>AVANDIA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/261455</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B3435A02-DBAF-4D33-9A80-3B78037721AE">
    <ao:suffix> acts as an antagonist at other receptors, but with lower potency. Risperidone has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B3435A02-DBAF-4D33-9A80-3B78037721AE"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>Risperidone</ao:exact>
    <domeo:uuid>B3435A02-DBAF-4D33-9A80-3B78037721AE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:07:46 -0400</pav:createdOn>
    <ao:prefix> Type 2 (D2), α1 and α2 adrenergic, and H1 histaminergic receptors. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E1974882-EFE7-48A1-A145-232BC76F5E40">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/8E677686-F1A8-4E2D-A503-156B748361AB"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/506F49B8-922C-4813-A6D3-3A7CFAA9C474"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/31951605-3312-425D-ABB9-1EF6CB9A6AA5">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluconazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15E1712B-2693-4DB6-A2FE-D2F158D3A823">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:467D4F28-D086-4217-9DE0-23E165F30716</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:lastSavedOn>2014-07-22 19:28:02 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C45EB527-9AC4-4005-86AF-8EEB1D4B88FA"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-22 19:22:31 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6198583A-79DD-481E-925D-CD236EDFDC7D">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5FD51EEB-1F14-4FFB-92BE-098757E4ED58"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F69928C-A74C-43BB-99CF-5CCE1F577586">
    <ao:context rdf:resource="urn:domeoclient:uuid:78B644A0-98B2-496A-9F5D-B3073007740E"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:4519FF07-AE90-4478-8B97-B4B2C84457DC</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:lastSavedOn>2014-07-24 19:46:05 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-24 19:46:23 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:91F0A093-3132-4A59-B89C-FC9E8195C30F</pav:lineageUri>
    <ao:body rdf:nodeID="N3b6f5ae3a26645daa88051e6ef52e5ab"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DD06894B-6765-494F-98ED-9B2C217D26FD">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DD06894B-6765-494F-98ED-9B2C217D26FD"/>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly. Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of rispe</ao:suffix>
    <domeo:uuid>DD06894B-6765-494F-98ED-9B2C217D26FD</domeo:uuid>
    <ao:prefix>m (about 6% to 8% of Caucasians, and a very low percentage of Asians, have little or no activity and are “poor metabolizers”) and to inhibition by a variety of substrates and some non-substrates, notably quinidine. Extensive CYP 2D6 metabolizers convert </ao:prefix>
    <pav:createdOn>2014-07-13 11:13:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90D65AEF-2F91-4982-9D2A-D9266BCF827E">
    <pav:createdOn>2014-07-28 17:02:45 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:A0E3203A-2AD3-4045-BAB8-27B340F81B0E</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:0934A57A-D0F5-437D-812B-5E7C1D8E703E</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5F53CA93-4A9A-47DB-B928-A643C66C9223"/>
    <pav:lastSavedOn>2014-07-28 17:02:28 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/B9045C9A-4D72-42C8-90B8-EFC09CB8C259">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9639DF56-3E53-4998-9064-63357AB54862">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/10A838C4-49F6-43A9-A4D2-77899C57569E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/376B1F96-6FA6-4A71-9966-1F46E0D854C7"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86BC1F50-DBC2-4291-BD23-23F4890101B8">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:A6BDBF68-2B8A-4549-9B4E-E673438B46D8</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:39B82E57-92E3-4322-A8E6-A3AFF215F02C</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-09-01 15:57:38 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-01 15:57:39 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:918A8BC4-10A8-4ADA-9C87-87BCD441E2ED"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC13A4FA-8B30-458B-9343-4B48CC945EBF">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdOn>2014-09-02 19:13:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:25585F8F-7F91-467C-B8DE-9153331081D5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:30C6EC33-90D7-4C2C-8AF0-1C1F9C9F0DFD">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/15A5B0E0-F6E2-41DD-B290-4DFF5706433B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/FD1343BF-2E5B-4241-8B0E-0B7BDDB60C21"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/2B0C5D0C-3721-4FB9-8865-41008B332960">
    <rdfs:label>ketoconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5437FEA-0356-41EE-AA7B-C75739F23B59">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:5D381360-05CD-407C-BAB9-6496A42C73E4</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:E8F4B9CE-115D-4AE7-A348-FFA1CBDB2315</pav:lineageUri>
    <pav:createdOn>2014-09-01 16:12:30 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8DA59D18-94D7-4239-958E-D00E6CCD30E7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-01 16:12:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC6345F2-574E-4300-B936-8ED1CC3E2DBC">
    <ao:prefix> (4 mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone may be needed when </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>gemfibrozil</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <domeo:uuid>CC6345F2-574E-4300-B936-8ED1CC3E2DBC</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CC6345F2-574E-4300-B936-8ED1CC3E2DBC"/>
    <pav:createdOn>2014-07-22 19:42:13 -0400</pav:createdOn>
    <ao:suffix> is introduced [see Drug Interactions (7.1)].</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7b38eabe4079490a9efa449a8187eb8e">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:503397EF-2F88-4CC5-9295-97542C30A8DC">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:4C7C4F50-7592-47DB-940D-41FEFF9DF638</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:3A0236F4-5119-432D-9B94-B00A5EEC35E7"/>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 19:55:18 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66EF0F25-8A90-4498-99B4-6985AB481B18">
    <pav:createdOn>2014-09-02 19:33:36 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <ao:body rdf:nodeID="N0e0f5b43049940cf8df3247a0853edc7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 19:33:40 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:AD447610-C9B8-4FFF-AAC8-76E00E96A039</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:87FEE025-38F8-476B-BB04-19AD3D10B07C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B434A8E1-DA82-459A-AAAF-E55806E0A976">
    <ao:suffix>with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect.</ao:suffix>
    <pav:createdOn>2014-09-02 19:16:55 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>B434A8E1-DA82-459A-AAAF-E55806E0A976</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B434A8E1-DA82-459A-AAAF-E55806E0A976"/>
    <ao:exact>atazanavir </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> and proton pump inhibitors is not recommended. Co-administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/6AF445DF-7377-4547-8BE8-05F45AE821E0">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6915</dailymed:activeMoietyRxCUI>
    <rdfs:label>metoclopramide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35685454-E730-4B12-A923-46EE9655234C">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:E89548FF-A4A2-4B87-B1E1-B12E3E255FA1</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB3EAD78-45A5-439B-B26A-FE0BB9EDCBD0"/>
    <pav:createdOn>2014-07-13 12:56:13 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 12:56:57 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:2703BC23-B5BF-482E-A701-F416ADF738D1</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DC200567-4E8F-495B-9D13-A2A04A7A47EC">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F1504F1A-B189-4B6A-9973-4A17775240C5"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/83E9958D-5BAA-415C-B14A-C204CC3ED68C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C91687BB-8074-4878-8273-7F14FC861404">
    <domeo:uuid>C91687BB-8074-4878-8273-7F14FC861404</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.</ao:suffix>
    <ao:exact>metoprolol</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C91687BB-8074-4878-8273-7F14FC861404"/>
    <ao:prefix> and </ao:prefix>
    <pav:createdOn>2014-09-02 11:46:29 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:553A6608-733A-477E-BDCB-F0D16F1054E3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/E4072F00-AC18-479B-BBF5-FE87E12CA45B"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/093D1F2A-587E-4B3C-AAF4-10347561D8A9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:12AC269E-4947-4540-A483-BE43615F8E88">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:suffix> hydrochloride tablets should be taken with water [see Clinical Pharmacology (12.3) and Dosage and Administration (2.1)].</ao:suffix>
    <domeo:uuid>12AC269E-4947-4540-A483-BE43615F8E88</domeo:uuid>
    <ao:exact>fexofenadine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, it is recommended that </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:12AC269E-4947-4540-A483-BE43615F8E88"/>
    <pav:createdOn>2014-07-24 20:13:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DFB0D433-995A-4EB5-B9CC-EAE5A0C16DEA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DFB0D433-995A-4EB5-B9CC-EAE5A0C16DEA"/>
    <domeo:uuid>DFB0D433-995A-4EB5-B9CC-EAE5A0C16DEA</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <ao:suffix> plus 9-hydroxyrisperidone.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:12:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>. Consequently, the clinical effect of the drug results from the combined concentrations of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:816C98CB-228B-41B9-9F5B-78D35D300142">
    <ao:suffix> </ao:suffix>
    <pav:createdOn>2014-07-24 20:01:41 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-136.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:816C98CB-228B-41B9-9F5B-78D35D300142"/>
    <ao:exact>trazodone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>816C98CB-228B-41B9-9F5B-78D35D300142</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9F0C45F-A9FD-47B4-BBF0-2D2F2CBAD8B9">
    <pav:lastSavedOn>2014-07-24 20:12:49 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:1EB77F23-7DD3-4BA6-88CA-34ABC34C90B4</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2014-07-24 20:11:50 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1FC172B8-8AC3-465A-AA69-B73AD9B97CBC</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:BE1FD7C4-2F16-4751-88A8-4F0AA6A4450A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1380C3AE-72EA-44B5-B7B6-5D990055E8E2">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/BD00EF21-094C-47ED-9DFE-B32774923CD1"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/BB10D5C0-6D53-40A0-8A2D-D31E8D5FA6E1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58576832-5E8D-41C1-98BF-9612C4FEA54D">
    <pav:createdOn>2014-09-02 11:40:59 -0400</pav:createdOn>
    <ao:exact>Pimozide</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:58576832-5E8D-41C1-98BF-9612C4FEA54D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <ao:suffix>: See CONTRAINDICATIONS (4) and WARNINGS AND PRECAUTIONS (5.6).</ao:suffix>
    <domeo:uuid>58576832-5E8D-41C1-98BF-9612C4FEA54D</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3d7ab3124abc45b8aa55c787d9f3d744">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F8ED859-2391-4F15-8FA4-EA14374BCE11">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4F8ED859-2391-4F15-8FA4-EA14374BCE11"/>
    <domeo:uuid>4F8ED859-2391-4F15-8FA4-EA14374BCE11</domeo:uuid>
    <ao:suffix> be initiated at a reduced dose when given with paroxetine.</ao:suffix>
    <ao:prefix> may be necessary and it is recommended that </ao:prefix>
    <ao:exact>atomoxetine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 12:03:45 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2bdd44e75a0e4177a23d455c3f4dbde7">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:864B2878-F3F7-49DF-B591-E0E101E10F02">
    <pav:lastSavedOn>2014-07-24 19:44:56 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4779D2E6-DE3C-43C7-BA5C-2FB2261F8E92"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:511EDFA9-5A42-4340-9D4A-CBF6EDD9185C</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-07-24 19:44:17 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:B86683B0-8443-4B4B-BB6E-3E9A3F377B8E</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:62E3DBD7-F876-4CE9-8CED-6955F6A66F76">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D11B175A-9529-45D5-B5B7-A6B7917B6593"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/B7CB635F-4EBF-434B-9159-71DC46A33588">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4124</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>ethinyl estradiol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA9B3930-3D00-45F4-81DF-D789FB3565E3">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:0ACECEC3-3253-49CC-B7BF-D586E8F2D7A4"/>
    <pav:lineageUri>urn:domeoserver:annotation:B613A799-0F9A-4FAC-813B-1B0F1A11F614</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 20:19:56 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68010F53-B903-4110-B73F-5CE843CA2E18">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:68010F53-B903-4110-B73F-5CE843CA2E18"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Sildenafil </ao:exact>
    <pav:createdOn>2014-07-07 09:42:08 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:suffix>and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>is 105 L, indicating distribution into the tissues. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C8D072B3-4844-4132-96FD-1E44EFE7C281">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5A5F8C7B-9705-4277-87C9-38037CFFC534"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9805A65-BB53-4315-AF92-EC703ABB5E61">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:C988D053-7CF3-4C50-BDB6-7C2B20B837B9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-21 21:55:00 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:6F61CF5F-2523-4A70-8E41-8F13894A8AF1</pav:lineageUri>
    <pav:createdOn>2014-07-21 21:52:27 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:A838F94E-4F5C-413B-9E9E-051199F7FC9F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7FE9AC63-C53E-4EF9-AEF0-CC1F82EDA7C3">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D860A1B6-8D5E-4FE4-9EDB-4E1397B29BBD"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/04F5EE18-51BD-4A42-A9E7-52826EE0EA8B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A4653C46-2FC4-4FCC-9060-201662C0BAB0">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3580D7AB-C344-4344-96C6-6C6FF5BA9B3D"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1236F221-49FC-4683-9E78-9A4C14E7DA9F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:39:59 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8AC4DB85-84A2-4639-9224-724D4B50FC4B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BDFA0ED-9096-4328-B514-6A94D7426FE7">
    <ao:exact>Propranolol does not affect the pharmacokinetics of verapamil and norverapamil. Verapamil does not affect the pharmacokinetics of propranolol.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-127.txt.html</ao:hasSource>
    <domeo:uuid>9BDFA0ED-9096-4328-B514-6A94D7426FE7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-24 19:43:48 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9BDFA0ED-9096-4328-B514-6A94D7426FE7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8f4a6a3ce5904118aebc294ee0564492">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D3472C63-0DF1-445A-8D55-A0C2CFC47A4D">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/25789</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>glimepiride</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99E97745-423E-4818-BFC6-3F67C8BF2A87">
    <pav:lineageUri>urn:domeoserver:annotation:EAD485AF-D5DA-435A-B47D-F022CCE0E626</pav:lineageUri>
    <pav:createdOn>2014-07-13 11:11:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:8ED4F58C-10A8-4F3A-8776-FD6D08A25610"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B31DBDC-7235-4CB3-937C-37BEC560A1C4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5B31DBDC-7235-4CB3-937C-37BEC560A1C4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-40.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-01 16:07:25 -0400</pav:createdOn>
    <ao:prefix>and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical, or vaginal preparations of miconazole is not known. The effect of concomitant administration of </ao:prefix>
    <domeo:uuid>5B31DBDC-7235-4CB3-937C-37BEC560A1C4</domeo:uuid>
    <ao:exact>fluconazole </ao:exact>
    <ao:suffix>and glipizide has been demonstrated in a placebo-controlled crossover study in normal volunteers. All subjects received glipizide alone and following treatment with 100 mg of fluconazole as a single daily oral dose for 7 days. The mean percentage increas</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1295B95D-9BC5-45F6-8E74-F4D1E052F64C">
    <pav:createdOn>2014-09-02 11:30:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 11:35:33 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:E3A608F7-C1CD-4106-B1C6-F80BB86494C0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2A6F24F-0266-4E33-86F7-71BB9F9CD038">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 19:38:12 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:190E7AE8-2ACF-42E2-AE00-E433EEA9737C</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 19:38:39 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:0DDAC282-2A1A-42BF-8975-6A46E40E4033</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:D0733D8F-AF43-42E3-B473-28271029CCA5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD57239D-3225-4F0C-8054-FBD32976EE0C">
    <ao:prefix> in subjects with liver disease were comparable to those in young healthy subjects, the mean free fraction of </ao:prefix>
    <domeo:uuid>AD57239D-3225-4F0C-8054-FBD32976EE0C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AD57239D-3225-4F0C-8054-FBD32976EE0C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> in plasma was increased by about 35% because of the diminished concentration of both albumin and α1-acid glycoprotein. Risperidone doses should be reduced in patients with liver disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <pav:createdOn>2014-07-13 11:17:48 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>risperidone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7650C658-240A-439A-9275-FFBCC1902F40">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:19EC0F23-10DE-4B34-BA59-B2E33CFE1030"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B237E79-AEFA-4271-8E72-C8B5A1D78190">
    <ao:prefix>, decreased serum levels have been reported when given together with </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <domeo:uuid>2B237E79-AEFA-4271-8E72-C8B5A1D78190</domeo:uuid>
    <ao:exact>omeprazole</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B237E79-AEFA-4271-8E72-C8B5A1D78190"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:18:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. Following multiple doses of nelfinavir (1250 mg, bid) and omeprazole (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for nelfinavir and M8. Following multiple doses of atazanavir (400 mg, qd) and </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4CA3DCD-82EA-464C-8F9A-1D04DCECE7B6">
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 11:45:59 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:3B8303DC-666E-48AC-A169-56BEAEB6610A"/>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/376B1F96-6FA6-4A71-9966-1F46E0D854C7">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>acarbose</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/16681</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F5662D1-C03B-40DB-AB83-59D0D62748A6">
    <domeo:uuid>4F5662D1-C03B-40DB-AB83-59D0D62748A6</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4F5662D1-C03B-40DB-AB83-59D0D62748A6"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:27:52 -0400</pav:createdOn>
    <ao:prefix> (40 mg, qd), AUC was decreased by 36% and 92%, Cmax by 37% and 89% and Cmin by 39% and 75% respectively for </ao:prefix>
    <ao:suffix> and M8. Following multiple doses of </ao:suffix>
    <ao:exact>nelfinavir</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6C2517B0-E801-41F8-8917-AC00583F30D9">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F044222C-AB83-4B62-B72A-FD9B65C89DD6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D31FCC9E-EA25-4856-B3C1-1712E7892B63"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E3F718F3-CFE3-42BB-856E-B673538F448A">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/AEA0CF77-C0B7-4D4A-ABBA-4F3F58A6C3CA"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/9C6B1447-979C-42A2-8477-0513E82FA0CC"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3B709C4D-773B-4209-8440-63FF184B3636">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/4B3161A8-052C-446A-A771-EB9186F64AD8"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/FA86A8F3-C1E5-4301-8EE4-2F312AEF69D5"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncf7e0af81c5144a5ac15bdb615c11005">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B8A305B-D42C-40FD-B384-05FE89B4ACA4">
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-09-02 19:13:48 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7882D277-8513-479D-B463-EFE36E633410"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6667DCF7-AA10-4999-B062-38650C90AEA5">
    <ao:body rdf:nodeID="N5ee9e48cbcd14b37869fc6f3f1fbef0b"/>
    <pav:lastSavedOn>2014-07-22 19:44:46 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 19:44:10 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:514BA51B-D734-4003-A7C3-F03C0F95833A</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:5F55A562-8BC3-4202-8F0A-0D9AD00722CD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4B76211E-8EB7-4844-9558-2AE555B3F201">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/61AE2D64-FCA3-4A33-91AF-196E90750A35"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/DBA1F413-B42A-40DE-B1F5-8527CD8BE365"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B294F73B-169E-4106-90EF-3C87099953E8">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B294F73B-169E-4106-90EF-3C87099953E8"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> Antagonism at receptors other than D2 and 5HT2 [see 12 CLINICAL PHARMACOLOGY] may explain some of the other effects of risperidone</ao:suffix>
    <domeo:uuid>B294F73B-169E-4106-90EF-3C87099953E8</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-07-13 11:29:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone [see 12 CLINICAL PHARMACOLOGY].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/BB308B9B-CA39-4247-9128-9D19C4C28A67">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05BFBD66-D24D-4F61-89C5-4EDDE7B6040C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:9BB046B1-5949-4043-9525-70D01EC3816C"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:CA7C94FF-7470-4B26-A1E1-5C8247C8F0FC</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 11:10:51 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7616318E-C362-4BC0-B027-F84CBEA6207C">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 19:35:38 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:4588D04A-4EE6-4AEB-8E31-47ECEB3BF1E4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5c71be82559b46e99fc4e32dcaefb89c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78BBB6BD-543C-42F3-B5F5-431ADE5F4D72">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:78BBB6BD-543C-42F3-B5F5-431ADE5F4D72"/>
    <ao:exact>9-hydroxyrisperidone</ao:exact>
    <domeo:uuid>78BBB6BD-543C-42F3-B5F5-431ADE5F4D72</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:12:09 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:suffix> by the enzyme, CYP 2D6. A minor metabolic pathway is through N-dealkylation. The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone. Consequently, the clinical effect of the drug results from the combined concentr</ao:suffix>
    <ao:prefix> to </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A3EAA6A-641B-48C1-A03F-CCA1FF890D64">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-09-02 19:12:29 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:DA838F12-E2BB-4B13-B633-B6F4480341B7"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E22917C-B2E2-46E9-8A17-EDAAF200AA66">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the</ao:suffix>
    <pav:createdOn>2014-09-02 12:03:11 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <domeo:uuid>3E22917C-B2E2-46E9-8A17-EDAAF200AA66</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E22917C-B2E2-46E9-8A17-EDAAF200AA66"/>
    <ao:exact>paroxetine</ao:exact>
    <ao:prefix>, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06403BE6-A661-445F-882B-070BE1039BE5">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:06403BE6-A661-445F-882B-070BE1039BE5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>06403BE6-A661-445F-882B-070BE1039BE5</domeo:uuid>
    <ao:exact>metformin</ao:exact>
    <ao:prefix> is contraindicated in patients with renal impairment, coadministration of </ao:prefix>
    <pav:createdOn>2014-07-22 19:37:25 -0400</pav:createdOn>
    <ao:suffix> with AVANDIA is contraindicated in these patients.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B85AE85-A07C-4614-91F5-52EF7A4737DF">
    <ao:context rdf:resource="urn:domeoclient:uuid:3E08DAB4-201F-48CD-8ACA-375750DA65B1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2014-07-07 11:24:52 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 11:22:56 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:3BDF4B68-5BF9-4914-96AA-D5E7665E8769</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1E635F35-7B6C-49A8-AD29-C3853F8DC576">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2479E0A1-BF58-4BD9-9AB9-45B56AC1BD6A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93764486-40C1-4D42-A6D0-D1FF47D6EC82">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:D37AF6F7-4BC0-4394-A3CE-386E408720C1"/>
    <pav:lineageUri>urn:domeoserver:annotation:7F53CC7E-F810-4069-8FD7-156741906E35</pav:lineageUri>
    <ao:body rdf:nodeID="Nd510f773a9bd439e9a515be564d4c7c7"/>
    <pav:createdOn>2014-07-22 20:19:23 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:171C7925-6F8E-4017-8743-473B0DE0C8C1">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E1974882-EFE7-48A1-A145-232BC76F5E40"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A9F403B-F60E-4954-9EEE-BB0C7DAD583B">
    <ao:suffix> </ao:suffix>
    <pav:createdOn>2014-07-21 21:53:39 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-56.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>6A9F403B-F60E-4954-9EEE-BB0C7DAD583B</domeo:uuid>
    <ao:exact>Zonisamide</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A9F403B-F60E-4954-9EEE-BB0C7DAD583B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79E9E9CE-1D2A-473E-9AED-36041863A42E">
    <pav:createdOn>2014-09-01 16:21:59 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-09-01 16:22:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:215CE713-9F50-45C2-808D-0725CC11DF6D</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:62F4BB2B-6ABB-434D-9DBF-F5176BA6325C</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:FA692151-6A7E-43FA-8077-22E490457CAD"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na25c0f5fb806447eaf0b5fc018bec458">
    <domeo:sets rdf:resource="urn:pddi:uuid:788F9802-1A2C-4B8B-958F-27977AB9BE1B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BFE514C1-B428-49F6-A34E-88C9F7618ABF">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C75F6EFB-5E72-4CF2-9017-B3F8CA0EDE1F"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:12B56AAA-52C8-4D08-9F11-45BACEB9E7C2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdOn>2014-07-22 20:17:52 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 20:22:38 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB40975A-75D0-432E-9BC4-38AE8661FBF6">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CB40975A-75D0-432E-9BC4-38AE8661FBF6"/>
    <ao:prefix>, may be increased by </ao:prefix>
    <pav:createdOn>2014-07-28 17:00:25 -0400</pav:createdOn>
    <domeo:uuid>CB40975A-75D0-432E-9BC4-38AE8661FBF6</domeo:uuid>
    <ao:exact>acyclovir</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-163.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, thus caution should be used with concomitant administration.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BF35833-2A3B-4AAC-BA24-329D7F891DC5">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-26.txt.html</ao:hasSource>
    <ao:prefix>AUC, Cmax, Cmin (24-hour concentration), and a significant reduction in apparent oral clearance following the administration of </ao:prefix>
    <pav:createdOn>2014-07-21 21:28:42 -0400</pav:createdOn>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. The mean ± SD increase in AUC was 92% ± 43% (range: 18 to 147%). The Cmax increased 60% ± 48% (range: -5 to 133%). The Cmin increased 157% ± 96% (range: 33 to 360%). The apparent oral clearance decreased 45% ± 15% (range: -15 to -60%). (See PRECAUTIONS</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2BF35833-2A3B-4AAC-BA24-329D7F891DC5"/>
    <domeo:uuid>2BF35833-2A3B-4AAC-BA24-329D7F891DC5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE717566-90D0-4B59-B00F-B053CAE639C4">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:0D83441D-0916-4D83-A136-CA26588E67D0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:D7AEA2C8-0FF3-482D-BC96-255927C0D5D8</pav:lineageUri>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-13 11:13:49 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:85EED099-46E9-43C2-A412-DB4141880448">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:9BFD55E1-3ADE-4DD6-8289-76C7DC405DE3"/>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-09-02 11:36:10 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3A7600E-EE05-47D1-8823-CA504866B3BD">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3A7600E-EE05-47D1-8823-CA504866B3BD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>. If </ao:prefix>
    <ao:suffix> maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until stea</ao:suffix>
    <ao:exact>fluvoxamine </ao:exact>
    <pav:createdOn>2014-09-02 11:36:37 -0400</pav:createdOn>
    <domeo:uuid>A3A7600E-EE05-47D1-8823-CA504866B3BD</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0024b5e9f27845f9b7061cfd742357bf">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:88D0CD7F-7AEE-47DB-9F13-A8F5D6A36CAB">
    <ao:suffix>(cisapride AUC and Cmax were reduced by about 35%).</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:88D0CD7F-7AEE-47DB-9F13-A8F5D6A36CAB"/>
    <ao:exact>cisapride </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-01 16:06:16 -0400</pav:createdOn>
    <domeo:uuid>88D0CD7F-7AEE-47DB-9F13-A8F5D6A36CAB</domeo:uuid>
    <ao:prefix>200 mg (q.d.) induces the metabolism of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-16.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C446162-FA92-4715-9095-A116DC12F4C8">
    <pav:lineageUri>urn:domeoserver:annotation:22154A78-8E19-4B3A-8326-6AAAB8A19F14</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-07-13 11:15:18 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-13 11:32:29 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:B49DFB13-7D38-41A6-989C-F0F22BFBCA7D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:71191E51-53CB-4FDE-88D0-33C6818E2232</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDCD9DD7-A54D-402A-8BEE-9FE5E515E7D4">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:B94C34A7-F932-4189-9935-D5DEEC3449E4"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:079AA7B9-9BE4-4706-A20A-5848B50272B5</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2014-07-24 19:37:34 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:7B905D92-17B4-4D52-AA01-D27CB223394F</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-07-24 19:36:31 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/4BCAA30A-4939-4A50-A548-16A452EDFC69">
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:098AA784-6695-4935-9450-C87D502EDBCD">
    <ao:suffix>, a CYP3A inhibitor, at steady state (500 mg BID for 5 days), there was a 182% increase in sildenafil systemic exposure (AUC).</ao:suffix>
    <ao:exact>erythromycin</ao:exact>
    <ao:prefix>was co-administered with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-07 11:23:07 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:098AA784-6695-4935-9450-C87D502EDBCD"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AB5CE3C5-4CFD-489B-9021-04685E6B310D">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/A52FAC94-0446-462D-9EE8-53E67CFDFC2E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F027CB1D-7D5A-4ADC-8E54-303492562FCA"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7C69D717-13B9-4E6F-B20D-24925FA1E992">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 18:36:37 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-07-22 18:36:25 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:C250B80E-322B-4526-8087-D8ABAC58D429</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1FA6545E-180C-46D2-A000-88AB02BD37E4"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:040380DC-30D6-454D-ACD7-489B2130A9CC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFAD9029-E218-4465-9975-0A69DA967891">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>TID </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CFAD9029-E218-4465-9975-0A69DA967891"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>After chronic dosing of 80 mg </ao:prefix>
    <ao:suffix>sildenafil to patients with systemic hypertension, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-07 09:40:13 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7DC48B58-6464-4FBE-B643-CA178DD552DB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:createdOn>2014-09-02 11:39:16 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6279850D-A32F-4EDB-A281-0BC6CBECE7F7"/>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BCE3E38-7FC6-48FE-A2E7-EB618F9B1F7F">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:lastSavedOn>2014-09-02 19:33:40 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#expertstudyAnnotation"/>
    <rdfs:label>expertstudy Annotation</rdfs:label>
    <ao:body rdf:nodeID="N6e1ca68f24f040b183c7ab560e446a4e"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C988966D-DF06-4093-9B27-77BEB9FDE53C"/>
    <pav:lineageUri>urn:domeoserver:annotation:E8261332-006B-45FF-A71B-7828DD4D5BE6</pav:lineageUri>
    <pav:createdOn>2014-09-02 19:32:23 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/0FDE0719-4064-4898-AD34-D2D6DF707B50">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>Synercid</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/135097</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E60C908C-8168-4614-80BA-973B0DEE03B0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:AAC67B06-289C-4EF8-9E7D-46A9BC438F20"/>
    <pav:lineageUri>urn:domeoserver:annotation:5862629C-B55B-45E0-8352-762AC58DBF16</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:B803E851-5AD5-4741-B1B9-1CBAED597E18</domeo:belongsToSet>
    <pav:createdOn>2014-07-21 21:47:27 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-07-21 21:49:33 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:799D7550-4333-4600-A69B-DE23093443A4">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F049BA4A-8DAF-49C1-ABA1-6E76A2F6DA6B"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD57075E-3889-44CB-8FF4-EC5663C33AC0">
    <pav:lineageUri>urn:domeoserver:annotation:148E4096-0199-4C34-98AB-FB1EA8CD9625</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-09-02 19:40:44 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 19:40:40 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:05AFE2BC-8117-40BD-BC72-6B1AA0443A12"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:C9195181-C772-4ED4-ADD8-56970C72AD38</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3BA7AB65-2DF7-4BB0-BB24-76AE0AC3003C">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1380C3AE-72EA-44B5-B7B6-5D990055E8E2"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:639E5CAD-4CBF-4CC5-8D9F-6103AC373BA4">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/A11930F7-6D95-4B60-BEDF-64A102BE527C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/EA8D118F-5115-426B-8423-6A5269AC5A4A"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8525C10-3E49-4039-8E81-69ACBAC8A16F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E8525C10-3E49-4039-8E81-69ACBAC8A16F"/>
    <ao:exact>Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when FLAGYL (metronidazole) is prescribed for patients on this type of anticoagulant therapy.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-22 18:59:42 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>E8525C10-3E49-4039-8E81-69ACBAC8A16F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-120.txt.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53840DD5-460C-4E7F-BA1C-65662E771309">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:53840DD5-460C-4E7F-BA1C-65662E771309"/>
    <ao:suffix>and tryptophan (see WARNINGS AND PRECAUTIONS [5.3]).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>maleate </ao:exact>
    <domeo:uuid>53840DD5-460C-4E7F-BA1C-65662E771309</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-09-02 11:44:26 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FA48E451-6066-4222-B6F6-48D1739BF14F">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/19778C35-B5B2-4C65-9F2A-49A170F2C3CF"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/AA628DF4-FFD3-40B4-AF7F-28CD7B682042"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8BC97FA-A136-4744-ADD4-4988FBBA6CCB">
    <pav:createdOn>2014-07-22 19:41:41 -0400</pav:createdOn>
    <ao:prefix>l (600 mg twice daily), an inhibitor of CYP2C8, and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>rosiglitazone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C8BC97FA-A136-4744-ADD4-4988FBBA6CCB"/>
    <domeo:uuid>C8BC97FA-A136-4744-ADD4-4988FBBA6CCB</domeo:uuid>
    <ao:suffix> (4 mg once daily) for 7 days increased rosiglitazone AUC by 127%, compared to the administration of rosiglitazone (4 mg once daily) alone. Given the potential for dose-related adverse events with rosiglitazone, a decrease in the dose of rosiglitazone ma</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84794CD6-2D7E-423B-92EC-B0CDCB2CF050">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:createdOn>2014-07-24 19:52:56 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:E0863579-8D19-4B30-ADD6-2A5BDBC2F482</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:35C90981-123B-4326-86DF-489A6FE9CBFD"/>
    <pav:lineageUri>urn:domeoserver:annotation:C5E7457A-F5FC-4FE3-8A92-FB8C37909455</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-07-24 19:53:55 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/2E502086-B34B-4ECF-A908-98A7B7EF6EA3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>desipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb98092af08f84e3ab4f13089f993ad23">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B77653C9-A978-4DDF-BFD4-9627754056FA">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B6DF21E9-E88D-43B6-BC67-2BA93CF4CFEF"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37752019-6AF8-406B-9C87-6BCEF8ED7AAE">
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:E9D4D6AE-7491-4219-BCFA-453D4DA5FF99"/>
    <pav:createdOn>2014-07-22 19:53:25 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:606A5B3F-B6FB-4279-AA42-7893CFC2D20C</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 19:54:59 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66762812-3E76-4815-AF5C-6E5A2D4739C3">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:66762812-3E76-4815-AF5C-6E5A2D4739C3"/>
    <ao:prefix> did not alter the mean AUC or Cmax of </ao:prefix>
    <domeo:uuid>66762812-3E76-4815-AF5C-6E5A2D4739C3</domeo:uuid>
    <ao:exact>pimozide</ao:exact>
    <ao:suffix>. The mechanism of this pharmacodynamic interaction is not known.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-78.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 19:38:25 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CE16BF01-AD42-444E-9A68-FEF6AED26815">
    <pav:lastSavedOn>2014-07-07 09:44:18 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:39:36 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E5D76E00-F5D9-4E93-B3B6-47859812ACDF"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:76FD4BB5-DE2F-4FCA-B93D-302185B1A381</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5FD51EEB-1F14-4FFB-92BE-098757E4ED58">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/04BE103D-A7ED-4289-9B72-CCC97FDE114E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/B7481A86-7883-4807-96C3-AE9B411B847B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4544b76dc7af44d4b5b4c8ef4c82e633">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/7D37C82A-2E31-4FCE-8C21-50B73E96FF3E">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
    <rdfs:label>saquinavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:29E9C9FA-0648-4564-86E4-3E4F28AF69B7">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/F68E59B2-9C61-4DC7-A6E2-B96F04B0D293"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D3472C63-0DF1-445A-8D55-A0C2CFC47A4D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/60D19F56-D600-4248-96B6-A68AD83F290A">
    <rdfs:label>diltiazem</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3443</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BC898759-CCCD-4E6C-9FBB-4E76A3E8F0BE">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/6C80031B-9390-46A4-B67F-9430DCF128A9"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/31951605-3312-425D-ABB9-1EF6CB9A6AA5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A05276D6-1557-4F87-90F3-A0B48D17A341">
    <domeo:uuid>A05276D6-1557-4F87-90F3-A0B48D17A341</domeo:uuid>
    <ao:prefix>, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of </ao:prefix>
    <ao:suffix>, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectivel</ao:suffix>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A05276D6-1557-4F87-90F3-A0B48D17A341"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-09-02 11:34:59 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D270EDF-E644-45EB-9C94-B02DA5C51002">
    <pav:lineageUri>urn:domeoserver:annotationset:D1715BD2-BD41-46FD-9454-DC7A423A29AC</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:BED41F06-565A-4622-9A88-48810E5A28DE</pav:previousVersion>
    <pav:lastSavedOn>2014-09-02 11:46:58 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-09-02 11:41:11 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:7562C75C-08B1-4D26-BA5E-2C77FA08B4F0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:A3F0B39A-4249-4B63-BB0D-F24A005066AC</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A2F4B6D6-7CF7-42D6-A019-60A8CCB4F364">
    <ao:suffix> (2 mg twice daily) and metformin (500 mg twice daily) in healthy volunteers for 4 days had no effect on the steady-state pharmacokinetics of either metformin or rosiglitazone.</ao:suffix>
    <ao:exact>AVANDIA</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Concurrent administration of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-123.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-22 19:55:29 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A2F4B6D6-7CF7-42D6-A019-60A8CCB4F364"/>
    <domeo:uuid>A2F4B6D6-7CF7-42D6-A019-60A8CCB4F364</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/6C885934-8872-486F-BCF1-97D398581817">
    <rdfs:label>cefazolin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9764c9bb5c364872a521284c7e9117e4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B16948AC-DC5A-471F-B39F-849EE793A353">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A95F4FE2-696A-4769-8ED1-FC8F49B83876"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-07-24 19:44:56 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:511EDFA9-5A42-4340-9D4A-CBF6EDD9185C</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:78BA69B3-6B98-43DC-BD49-8139CC471F72</pav:lineageUri>
    <pav:createdOn>2014-07-24 19:44:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/04F5EE18-51BD-4A42-A9E7-52826EE0EA8B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
    <rdfs:label>saquinavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:702E239E-7D5E-4778-8584-0516BA254DC8">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:702E239E-7D5E-4778-8584-0516BA254DC8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> was given alone. Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.</ao:suffix>
    <pav:createdOn>2014-09-02 11:58:42 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-47.txt.html</ao:hasSource>
    <ao:prefix> Cmax values that were 3- to 4-fold greater than when </ao:prefix>
    <domeo:uuid>702E239E-7D5E-4778-8584-0516BA254DC8</domeo:uuid>
    <ao:exact>atomoxetine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0fda40d7ea8d49f094b68775ed4fba34">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D346F3FB-2896-495E-BF67-B2BC6E8F5714">
    <ao:exact>REVATIO </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D346F3FB-2896-495E-BF67-B2BC6E8F5714"/>
    <ao:suffix>is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (25–63%). Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When REVATIO is taken</ao:suffix>
    <pav:createdOn>2014-07-07 09:41:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B6DF21E9-E88D-43B6-BC67-2BA93CF4CFEF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/C5B717C7-A880-452E-91DB-A2F2F96090B8"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/161695D1-EF44-45A7-B41B-A52C6CD2F783"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5711142-9ABC-4A8E-A6A1-D585CB7190C4">
    <ao:exact>Fluvoxamine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A5711142-9ABC-4A8E-A6A1-D585CB7190C4"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <domeo:uuid>A5711142-9ABC-4A8E-A6A1-D585CB7190C4</domeo:uuid>
    <ao:suffix> Metabolism</ao:suffix>
    <ao:prefix>7.4 Effects of Smoking on </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-09-02 11:46:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1430fb2af07e42b49ff933d500b0c0b2">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:11BCB02F-AC6F-47D4-98D8-4B72C6ED08A2">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/8AB4378A-0391-4B0C-86C1-A8941D0249CB"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/830A06B9-325D-4AF2-8757-EF2CC57EB2F9"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0a8d04ac97be4b7b9850f253c8187cc7">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6981279A-8AEC-4DEB-BDFB-296A4FDF471C">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:AB1741F1-5A5F-4416-AEAC-A544BCBB7D16</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2014-07-22 19:38:52 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:954496DB-A54A-496F-92B2-F690C8B1E299"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:7021B883-FD5C-4083-BD87-DF56D3C87633</pav:previousVersion>
    <pav:lastSavedOn>2014-07-22 19:40:31 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F272A789-69D0-47CC-8CC9-F25C55B91261</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31A6BF79-BBAC-479E-B954-4B14FED74D2E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-139.txt.html</ao:hasSource>
    <ao:suffix>. In two separate studies in healthy adult subjects, fexofenadine hydrochloride 120 mg twice daily (240 mg total daily dose) was coadministered with either erythromycin 500 mg every 8 hours or ketoconazole 400 mg once daily under steady-state conditions </ao:suffix>
    <pav:createdOn>2014-07-24 20:07:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:31A6BF79-BBAC-479E-B954-4B14FED74D2E"/>
    <domeo:uuid>31A6BF79-BBAC-479E-B954-4B14FED74D2E</domeo:uuid>
    <ao:exact>ketoconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> or </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf64d48be91cd446286df97e81b3a67e2">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N812443d2344e4773afdf14af64f54f2c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/FD1343BF-2E5B-4241-8B0E-0B7BDDB60C21">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>pravastatin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42463</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd3042ece2bc14cb4961fbfbe9c2906bd">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DE5C582E-1F4C-478C-9DDC-DAB4C0C1ABFF">
    <pav:lastSavedOn>2014-07-07 10:02:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:131835A3-C655-4F91-97D4-52CAFF7B7CCA</domeo:belongsToSet>
    <pav:createdOn>2014-07-07 09:58:57 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:FFE74587-6133-48F1-B1FA-716CCC2AA2F3</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:AA9BE1F2-854A-4E7D-8C64-DCE1158C5D96"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N288c78171ffa435dbeb0b7195369c3e0">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N480f14c0cdc94b5d9e1c8fe57da8db31">
    <domeo:sets rdf:resource="urn:pddi:uuid:125C14DB-1F35-4667-846F-F789D6D0AFCF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:32B4AA19-CBBE-4BDC-AB2F-037EBB0AE5EB">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:032977FB-2362-4162-8691-DC921A41219C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na556a10ed80a4e0bb3b6d69492073e1f">
    <domeo:sets rdf:resource="urn:pddi:uuid:8844F882-4F5A-460C-9215-039DEB9CB5A2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A3AF38F3-51D7-4A66-84B7-21A51A8CE79F">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/6FD42917-DF6A-4B72-83EF-A23E155102AF"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/6FA2E5AB-9D75-44CD-B064-73797C92A684"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:217FEFFB-6BFC-422A-B88B-75EE70185C1C">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/60D19F56-D600-4248-96B6-A68AD83F290A"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/4BCB725A-6FD9-45A7-A5BE-7BB7C488437E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/F4851EA8-C391-4F16-B8F8-81A3F2688015">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:41533E80-E3DB-4B1A-BC74-31DB2EDCBDFA">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/513340A0-A222-4865-9DAF-1EDDCCCA86A0"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/2E8E0C08-A9A5-4122-9C0E-4594641FBED5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/49D3BE30-05A4-4698-AD40-671451F49C7C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:72D01271-A1C0-4012-BD2D-70CB0846FFF5">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/90DF0B47-DCBB-4EEC-BC07-A4A1FACD692F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/2E502086-B34B-4ECF-A908-98A7B7EF6EA3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2A2B8454-0B34-43FC-8C83-D2580B9D07B1">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/C3802543-BD64-4421-A632-BFDE8408A954"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/0FDE0719-4064-4898-AD34-D2D6DF707B50"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N933161c3cfb9468e9ad8163dadd666cf">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N636bd8627dcd413f9e91686dcc0475cf">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2CDE5DF-B4CC-4374-8C21-8821B6582DB8">
    <ao:exact>atazanavir</ao:exact>
    <domeo:uuid>D2CDE5DF-B4CC-4374-8C21-8821B6582DB8</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2CDE5DF-B4CC-4374-8C21-8821B6582DB8"/>
    <pav:createdOn>2014-09-02 19:16:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> and proton pump inhibitors is not recommended. Co-administration of atazanavir with proton pump inhibitors is expected to substantially decrease atazanavir plasma concentrations and thereby reduce its therapeutic effect.</ao:suffix>
    <ao:prefix>Concomitant use of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8dac255a5a144042a2ebae3b495b5fe2">
    <domeo:sets rdf:resource="urn:pddi:uuid:0CE6C620-40B4-4E55-8185-8A319ECD6D71"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne5ca1c7ee16f4e439b69a0df4c61c0b6">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/D31FCC9E-EA25-4856-B3C1-1712E7892B63">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4815</dailymed:activeMoietyRxCUI>
    <rdfs:label>glyburide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC6949EC-26AB-43DC-8B1B-1401086A35B0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>AC6949EC-26AB-43DC-8B1B-1401086A35B0</domeo:uuid>
    <ao:suffix>, may be increased by acyclovir, thus caution should be used with concomitant administration.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-163.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AC6949EC-26AB-43DC-8B1B-1401086A35B0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> and its metabolite, </ao:prefix>
    <ao:exact>normeperidine</ao:exact>
    <pav:createdOn>2014-07-28 17:00:22 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0BA7513-EC9D-435D-8BE2-617311ADA2D8">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-132.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E0BA7513-EC9D-435D-8BE2-617311ADA2D8</domeo:uuid>
    <ao:exact>lovastatin</ao:exact>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E0BA7513-EC9D-435D-8BE2-617311ADA2D8"/>
    <pav:createdOn>2014-07-24 19:53:06 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5D76E00-F5D9-4E93-B3B6-47859812ACDF">
    <pav:createdOn>2014-07-07 09:39:36 -0400</pav:createdOn>
    <ao:suffix>ildenafil</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>After chronic dosing of 80 mg </ao:prefix>
    <ao:exact>TID s</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E5D76E00-F5D9-4E93-B3B6-47859812ACDF"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7210ECAE-0079-4C21-98CB-EDA94264D7DA">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BC898759-CCCD-4E6C-9FBB-4E76A3E8F0BE"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3580D7AB-C344-4344-96C6-6C6FF5BA9B3D">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/200F7C4A-CD90-46C0-8779-AF63E291B5C6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/066DE754-7246-47EA-9F6B-DB99A3097E26"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D11B175A-9529-45D5-B5B7-A6B7917B6593">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/CE20B5C0-36BB-4878-B0C9-3069561D06F7"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/B4FD0768-DC29-42AD-9E32-079005955FF6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABB70710-CA87-4445-8EB3-1BFDDC4636FE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-07-13 11:17:32 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ABB70710-CA87-4445-8EB3-1BFDDC4636FE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>ABB70710-CA87-4445-8EB3-1BFDDC4636FE</domeo:uuid>
    <ao:exact>Risperidone</ao:exact>
    <ao:suffix> doses should be reduced in patients with renal disease [see 2 DOSAGE AND ADMINISTRATION and 5 WARNINGS AND PRECAUTIONS].</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:prefix> and its active metabolite decreased by 60% compared to young healthy subjects. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED5A7142-16C6-4FE6-8733-C955CEF7A376">
    <ao:exact>sertraline</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>ED5A7142-16C6-4FE6-8733-C955CEF7A376</domeo:uuid>
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ED5A7142-16C6-4FE6-8733-C955CEF7A376"/>
    <ao:suffix>) is clinically warranted, appropriate observation of the patient is advised.</ao:suffix>
    <pav:createdOn>2014-09-02 11:43:54 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B98C3482-C44D-4C61-ACC3-D277890BCE91">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B98C3482-C44D-4C61-ACC3-D277890BCE91"/>
    <pav:createdOn>2014-07-07 11:23:25 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>REVATIO </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/39638090-D8E9-46BA-A5C4-A4210E7F0DCB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>rosiglitazone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/84108</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:968E2714-CEBF-4C37-913F-C2DF10947AB8">
    <pav:createdBy>urn:person:uuid:080e143046812afe0146812eda990003</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F2CEE4B1-2371-4B8E-B2D2-F9EED99532CB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-09-02 19:18:40 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:C5DEBC9B-77EE-4243-88EB-DBC19737ACD2</pav:lineageUri>
    <pav:lastSavedOn>2014-09-02 19:19:47 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E32812A9-205B-4EE1-B488-A1E294EDBFB9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4A35ABC4-4C04-40DD-A14B-E710CC4288AE">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/3C01338E-7E0D-4BD8-B48B-5D14379A445C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/B9045C9A-4D72-42C8-90B8-EFC09CB8C259"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26DA75B4-1584-4219-A170-BBFBF5DAB037">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>maleate</ao:exact>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:26DA75B4-1584-4219-A170-BBFBF5DAB037"/>
    <pav:createdOn>2014-09-02 11:40:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>26DA75B4-1584-4219-A170-BBFBF5DAB037</domeo:uuid>
    <ao:suffix> and lithium.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-9.txt.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N39d343c1c8ea42c296642f02570456f8">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Naadb8920debf48c0ba644812ae753575">
    <domeo:sets rdf:resource="urn:pddi:uuid:58965DB7-A15D-49D8-BC77-60DF512B6132"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6e1ca68f24f040b183c7ab560e446a4e">
    <domeo:sets rdf:resource="urn:pddi:uuid:C97B59CB-4DC7-442A-BF74-3C9020F4F7FA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB359BC3-6C0F-427E-B961-0838B54690D5">
    <ao:exact>sildenafil </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BB359BC3-6C0F-427E-B961-0838B54690D5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Single oral doses of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG. After chronic dosing of 80 mg TID to patients with pulmonary arterial hypertension, no clinically relevant effects on ECG were reported.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-07-07 09:38:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7CE3802C-582C-4A21-83B9-9CF98F3D327C">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:30AC56DD-1608-4DFA-90FC-CCBC462BCAEF"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6f93e46fc7af42179bb2a5e53ae7f08a">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4BE7A024-EE88-4E7C-BCF8-571E06F8C6B1">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D10C9054-F924-40A5-9EDB-304BEF56C148"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/BB75F5EA-3BE0-4FC8-9344-269517A2A6EE"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N94709a13b615484785459852c2a23bcc">
    <domeo:sets rdf:resource="urn:pddi:uuid:1A9D1840-CE0D-486B-A233-984C10D2DFDC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4828a7615acd4c2cbe5689af36560e8e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/E5F7CCC2-0F44-40A0-87D9-225E3A4EAC91">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne52db7e2fde342bf9390f7684d47b628">
    <domeo:sets rdf:resource="urn:pddi:uuid:7210ECAE-0079-4C21-98CB-EDA94264D7DA"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6648e4d88e2c4eca88daa5e9118b3c3c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7eda72905af24be98d5f19cfeffe44b0">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N75df271eb2e047ff9cf0bba6152be3f7">
    <domeo:sets rdf:resource="urn:pddi:uuid:22A46207-521A-4D8F-8D17-31F7E25F3B95"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5BCCF61-F8EE-41B5-8F8E-D5A8F239ED7F">
    <ao:suffix>). In the clinical trials, antacids were used concomitantly with the administration of omeprazole delayed-release capsules USP.</ao:suffix>
    <ao:prefix>, and</ao:prefix>
    <ao:exact> iron salts</ao:exact>
    <domeo:uuid>D5BCCF61-F8EE-41B5-8F8E-D5A8F239ED7F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:12:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D5BCCF61-F8EE-41B5-8F8E-D5A8F239ED7F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:181381FE-800A-4970-81D8-2B14B7735770">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/BAE41BF7-CAA3-4865-832D-24EB9699E14C"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/8FE58707-AFDD-4F32-9EA8-03EC3BF4D67B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N75616d180bd341b0985aad6a6cd844b8">
    <domeo:sets rdf:resource="urn:pddi:uuid:776765AF-5295-4800-809B-C7978354CB7E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:285AE4B3-9649-4D7B-A540-9B1BE0CD0CDA">
    <domeo:uuid>285AE4B3-9649-4D7B-A540-9B1BE0CD0CDA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-124.txt.html</ao:hasSource>
    <pav:createdOn>2014-07-24 19:37:50 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:285AE4B3-9649-4D7B-A540-9B1BE0CD0CDA"/>
    <ao:exact>The AUC of propafenone is increased by more than 200% by co-administration of propranolol.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:991B1A28-CCE6-4672-8304-2C2413DEA09C">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/C4007BE1-F417-40F4-9849-29EA38C247C5"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/DBD9B114-1A26-42A6-8975-25C258D84F84"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EF55F74E-B5B2-4F66-9B6B-11C22CD3DDC4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:30C6EC33-90D7-4C2C-8AF0-1C1F9C9F0DFD"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:713FC0EF-F420-4182-BCC3-9D97A1296B91">
    <ao:suffix> delayed-release capsules USP.</ao:suffix>
    <ao:exact>omeprazole</ao:exact>
    <domeo:uuid>713FC0EF-F420-4182-BCC3-9D97A1296B91</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-74.txt.html</ao:hasSource>
    <pav:createdOn>2014-09-02 19:13:24 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:713FC0EF-F420-4182-BCC3-9D97A1296B91"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>). Patients should be monitored to determine if it is necessary to adjust the dosage of these drugs when taken concomitantly with </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N75cecc01b0984d4599e0e10e2ccb23f5">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/0A6A30F9-53A5-47E7-B0BA-25617EEE3E7A">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>propafenone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1233caa5f0314501b09bfc3306cf288e">
    <domeo:sets rdf:resource="urn:pddi:uuid:04DB6C49-D431-40EA-98E8-D720E8A6787D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5ee9e48cbcd14b37869fc6f3f1fbef0b">
    <domeo:sets rdf:resource="urn:pddi:uuid:FD421B20-B74E-481A-8077-F6D9C42943B8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3b6f5ae3a26645daa88051e6ef52e5ab">
    <domeo:sets rdf:resource="urn:pddi:uuid:F3D5E3DD-A431-4A01-92CB-C01ED4EF9988"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8AF7E41C-63B6-4042-8707-4622E9BC98AA">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/5F10CADF-C9DD-4270-A5C5-81DBB003F49D"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/E02048B2-A2E1-475E-9345-1FE9194336FD"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N608089a516a345d4a44361d1b5bc39fd">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D78CEABF-EE24-4AFF-81A9-B148050EFE16">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D78CEABF-EE24-4AFF-81A9-B148050EFE16"/>
    <ao:suffix>, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone [see 7 DRUG INTERACTIONS]. It would also be possible for risperidone to interfere with metabolism of other </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D78CEABF-EE24-4AFF-81A9-B148050EFE16</domeo:uuid>
    <ao:prefix>, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-07-13 11:15:52 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-8.txt.html</ao:hasSource>
    <ao:exact>phenytoin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2479E0A1-BF58-4BD9-9AB9-45B56AC1BD6A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/7D37C82A-2E31-4FCE-8C21-50B73E96FF3E"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/5224D32E-E4DE-4A9C-B197-4A0F7E4F982D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8896431255c64da18e8b19940edcf181">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/027E2EA7-BD8C-4E55-AE53-75289D2AB62C">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Maalox®1</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne432bd8751914067b2b0e8d76e54ca0b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N702f09942286480888b10c78231d8c59">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3182aa97ea6247b4ad9b341aabfc05b9">
    <domeo:sets rdf:resource="urn:pddi:uuid:7BE43707-1914-4E31-AAC1-03F035925C89"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N69100cd2a5414f258f6511d2eefdaf0a">
    <domeo:sets rdf:resource="urn:pddi:uuid:A3DCC3AB-4469-4227-B682-6E7F65CD2A7A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf230019cb2214378be9f7692c09ea932">
    <domeo:sets rdf:resource="urn:pddi:uuid:6198583A-79DD-481E-925D-CD236EDFDC7D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N789923a2d6ed4cccbf7d6ab76045a416">
    <domeo:sets rdf:resource="urn:pddi:uuid:E8B9127A-D513-4699-BEA0-07E095BADF5D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:36209E50-DEE4-4172-A9EA-98FA4D4477D3">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D356370B-E2E4-45FD-AA2A-DBBBC15D7668"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/FE87FAA2-1979-46D4-90FE-4C8F260790F0"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/DABEA160-744E-4F3F-99D1-342761D8E356">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>verapamil</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11170</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc3612987d6444ddc97bbdd3f2b74b82e">
    <domeo:sets rdf:resource="urn:pddi:uuid:6E3CCB3A-24FB-48E1-AC28-838B1ACF54A3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7bc5dd59ff134e17b222c394bd75c488">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC34C3D8-C58F-483B-80DB-B65FEBB2EC20">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Sildenafil </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DC34C3D8-C58F-483B-80DB-B65FEBB2EC20"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/AnnoStudy/package-insert-section-155.txt.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-desmethylation of sildenafil, and is, itself, further metabolized. This metab</ao:suffix>
    <pav:createdOn>2014-07-07 09:42:51 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9A220CC1-B0E4-46E3-92ED-BA102CB9A99F">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/D17A3686-1703-468A-9054-837449C245F1"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/E2F95CEA-24A5-407F-856C-8C142EEA5626"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4d33327ccf1341f4b3d3ef1545fcbc12">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4bf70699bcb44141aeccce0f4da06ddd">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbb23a965649b4da59283f66205750358">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8EEB8C5F-684D-4C78-B063-32431C5FE74A">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/504D9B65-0BA3-47AC-BD1D-5D353F912A60"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/1D5C7B20-628D-4819-8BB5-5D5207989917"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2E7AB2E6-7FEA-4A78-80FB-CE3FA7ABBCCB">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/78B277CF-FACC-42EA-9594-CD77F7E3193A"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/27D0B4AA-F7F1-4B7F-ADC9-3414612394E8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc5a300787b694f07bda1103a56b5759d">
    <domeo:sets rdf:resource="urn:pddi:uuid:8186AE14-85DE-4E1A-B5F4-BC58233DC47B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N08de9a9d680b428bb076db7cf6b2b9e4">
    <domeo:sets rdf:resource="urn:pddi:uuid:31A6A7B0-3980-4B84-A4E6-68B8A08EC05D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1E16FBF3-81EA-402D-80A2-67FDDDC020EA">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/5F00796E-B959-488F-969F-87505727DC32"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/3B9DE0DC-8223-4138-A13C-06DB166E9DEF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N13a46c5561874dfa93e3ff5c30a6c4da">
    <domeo:sets rdf:resource="urn:pddi:uuid:C8D072B3-4844-4132-96FD-1E44EFE7C281"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0d48e2646a8a4bce8372d7a86920d7ca">
    <domeo:sets rdf:resource="urn:pddi:uuid:15AF1994-00EF-4BF7-9C44-C16149A1F769"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc89bb9886cd046d2be16de9629514d11">
    <domeo:sets rdf:resource="urn:pddi:uuid:B77653C9-A978-4DDF-BFD4-9627754056FA"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1e475d5884324bb6bae01eb347432295">
    <domeo:sets rdf:resource="urn:pddi:uuid:E4C91349-DA7A-412B-B58B-E0D1EEF83781"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc0b0222e27024f76beee60eef89e69c2">
    <domeo:sets rdf:resource="urn:pddi:uuid:6B93EB2B-A516-48C4-A750-602CF9462A88"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6db07ba76ff444be9d2ac66e28011bfe">
    <domeo:sets rdf:resource="urn:pddi:uuid:9A7BCFA2-0D97-4701-B6BB-99407F80BF4B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8235f3e5c30c42d79a037df424a19edd">
    <domeo:sets rdf:resource="urn:pddi:uuid:23B46B7B-627E-4D42-A5FF-1DBE8AB466EF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc1174d054689408ea7ac24af4942a624">
    <domeo:sets rdf:resource="urn:pddi:uuid:D7F3CF4B-F577-4BF7-B88B-B5D04D01A04A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C20ADD05-5DFA-4D15-B8F8-1DD1BE6A5E76">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/39638090-D8E9-46BA-A5C4-A4210E7F0DCB"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/903A96DD-5D24-4703-BA4D-F99711E452A7"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N13d88b318b684685be021a49551b2eb2">
    <domeo:sets rdf:resource="urn:pddi:uuid:7CE3802C-582C-4A21-83B9-9CF98F3D327C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/BD00EF21-094C-47ED-9DFE-B32774923CD1">
    <rdfs:label>phenytoin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0ae4bdc875a4416ab77028b72c909a79">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DFE53F7D-4938-4208-8BAE-E74CAD65CFE9">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/B9254794-2257-403D-AD8D-D269CBB2679F"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/FE6B22BB-D261-488B-A15D-2B75123912F4"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1e1e40a79b134732a76159a7264f0552">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2C22B081-DC6C-4519-BC58-778F31A66BDB">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/089280DB-9E3B-46D1-9448-CA64307E1CBF"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/B959D351-8EA8-4A27-AEBB-7E2C63519031"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne96f1d6348cf4c8da6ada02b64bf08dd">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///home/yin2/python-SPL-connector/AEA0CF77-C0B7-4D4A-ABBA-4F3F58A6C3CA">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7417</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>nifedipine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1861f1d417844b00a0bbe52ebc792108">
    <domeo:sets rdf:resource="urn:pddi:uuid:ECBE6688-F3FC-4F3A-AB24-57398C040B44"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C97B59CB-4DC7-442A-BF74-3C9020F4F7FA">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3B709C4D-773B-4209-8440-63FF184B3636"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ned262ffe895e4d349861bd05bb3f95c1">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N05000c6dc1d84f2ea8d5f53710f6a69c">
    <domeo:sets rdf:resource="urn:pddi:uuid:67967D27-75AF-4745-A665-F0AE8B4677A2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na2864cc8733f48488c44334d82ebb2b4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N478e4ebd309f415696c8b34512e393f2">
    <domeo:sets rdf:resource="urn:pddi:uuid:3BA7AB65-2DF7-4BB0-BB24-76AE0AC3003C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N38dabe368b5e46468e3eacc4953f51b2">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd764c18144dd46df889c525e535f67cd">
    <domeo:sets rdf:resource="urn:pddi:uuid:7650C658-240A-439A-9275-FFBCC1902F40"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd3d447e214954d1e998f88bc7ff94378">
    <domeo:sets rdf:resource="urn:pddi:uuid:01E43715-3610-4176-8FB9-E2D7C94F6C63"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncfb145fdb974485997b36d898fb1f287">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfdf7b4afdbfd41e8ad45338e2d77f07a">
    <domeo:sets rdf:resource="urn:pddi:uuid:6D3CB53E-CF58-4136-8B4C-980888C68920"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb85c2d59ca0b43a7865e0923fbf55525">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfb621328581d481090095b9cd99d3a31">
    <domeo:sets rdf:resource="urn:pddi:uuid:1A79F27D-249B-477A-8F23-ED3A357054B9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:861C11A2-8AEA-4CD2-AC61-355B6002E25D">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/8CED9A21-7623-4055-94D4-793400BC8FD1"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/7BF23512-3FBF-4262-B453-848863F44618"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N38240924dd1e4d7c9794150119568b9b">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne32486d1080a4562b59a22aef1c63dd1">
    <domeo:sets rdf:resource="urn:pddi:uuid:938EFE6C-8A23-4829-AFA7-544CDA08913A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3fc74516d9f647159b7dfadde465bfcd">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6d8c93370944406db8f7d570f9c5d643">
    <domeo:sets rdf:resource="urn:pddi:uuid:62E3DBD7-F876-4CE9-8CED-6955F6A66F76"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9d6a07932077407f97f12ca451cf8c5c">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7fb7b59d697b4b7184c9a03ef68ed812">
    <domeo:sets rdf:resource="urn:pddi:uuid:3010354C-0396-4F68-8730-35FBE74BAACF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N671af0b91e8043ec90327a6b48661eae">
    <domeo:sets rdf:resource="urn:pddi:uuid:1F1125BC-11EF-427A-9581-C05D50951446"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N60eb8cfb63db4e8e95ba2286d666db5e">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N505e48cb1778457da65484f26e8f6be0">
    <domeo:sets rdf:resource="urn:pddi:uuid:326B6DC1-778C-4951-9B8A-4B76A407BA1D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2ea9c4b38a204fb0a2f7f4b68240f2ef">
    <domeo:sets rdf:resource="urn:pddi:uuid:D6809060-E4EB-4D01-8BD0-6671105C2ACF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6caa0159f543400998e47aec2eeb1674">
    <domeo:sets rdf:resource="urn:pddi:uuid:18BE6999-E03C-4FFF-8400-81AB658469AB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N322aa55f0f7f42f183db8d95465c3b0e">
    <domeo:sets rdf:resource="urn:pddi:uuid:F1D81A6A-D89D-4D44-96EB-35FB50C7D732"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8458402d605d4d6c8592ab33c692a49d">
    <domeo:sets rdf:resource="urn:pddi:uuid:BAFAC6A6-4A37-498B-BA86-449A697DAA80"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N54cec6e5108e43acbd7e1ffb67334648">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9dcbdc73f84a423cbd2ef2b7012dbfc1">
    <domeo:sets rdf:resource="urn:pddi:uuid:DDB0C59F-0568-4D74-A9AA-D0E0750F758C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N49b0b28cd9b847a1923f1141acef8370">
    <domeo:sets rdf:resource="urn:pddi:uuid:9C2359BE-4DCE-4088-A5EE-19EA356FF32D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2c54d7c3b3e746aa853ae0a181ca0c5c">
    <domeo:sets rdf:resource="urn:pddi:uuid:32B4AA19-CBBE-4BDC-AB2F-037EBB0AE5EB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7f04182c6d404dcba0f1e9f8c1f6c785">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N65c4633ac4b24dbeb67a22ad3f7e5572">
    <domeo:sets rdf:resource="urn:pddi:uuid:A4653C46-2FC4-4FCC-9060-201662C0BAB0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D318A30A-F708-43F6-AB5B-A9D659E063BF">
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/851B37FE-C029-42CD-9AFE-2CD0906FA393"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///home/yin2/python-SPL-connector/ED3BCC98-B0FE-4421-B54B-7B2414CF4328"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4c1c52171ba14679bcb3d901df1e8607">
    <domeo:sets rdf:resource="urn:pddi:uuid:7A327F1B-E170-41D6-BEC1-65E5D1CB43B8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9e5d3138851c4983b2cd0bd169a7bb7d">
    <domeo:sets rdf:resource="urn:pddi:uuid:6189C7ED-8284-4BC1-8C1D-995A1B9E9199"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc5cfc25b89d84d0894f03f046c415d78">
    <domeo:sets rdf:resource="urn:pddi:uuid:CF243312-0709-454B-9D42-8D2FEDA95D55"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N427a12adf2ba42a687e0b8d9875bb02b">
    <domeo:sets rdf:resource="urn:pddi:uuid:799D7550-4333-4600-A69B-DE23093443A4"/>
  </rdf:Description>
</rdf:RDF>
